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Randomised controlled trials (RCTs) rely on effective recruitment and retention for 
successful completion. Potential trial participants’ preference for a treatment (trial 
intervention) can affect recruitment, post randomisation drop-out and adherence to 
intervention groups in adult RCTs, but little is known about how they may affect 
paediatric trials. Communication of trial information in paediatric trial settings is 
complex as it needs to accommodate the parent’s as well as young person’s 
perspective, whilst at the same time maintaining high standards of trial conduct. This 
PhD explored how treatment preferences influenced recruitment and participation in 
paediatric RCTs by undertaking a systematic review of the literature and embedding 
qualitative research in four paediatric trials.  
 
The systematic literature review focused on paediatric RCTs and qualitative studies 
that reported the treatment preferences of children and young people aged 0-17 
years, and their parents. Fifty-two papers were identified, twelve of which contained 
qualitative data. CONSORT figures reporting decline or withdrawal from trials due to 
treatment preference were tabulated and discussed descriptively. Techniques of 
meta-ethnography were drawn on to evaluate qualitative data. The systematic review 
showed treatment preferences acting as a barrier to recruitment to paediatric RCTs, 
particularly from a parental perspective. Parents’ understanding of trial processes 
and perceptions of the benefits and risks associated with treatments promoted 
discussion of preference. Few RCT papers reported the views of young people in 
relation to preference for treatment.  
 
Qualitative methods were embedded in three chronic fatigue syndrome/myalgic 
encephalomyelitis (CFS/ME) trials, and one surgical trial for acute, uncomplicated 
appendicitis. The QuinteT Recruitment Intervention (QRI) has been embedded 
successfully in adult RCTs to identify and address recruitment difficulties with the 
intention to optimise informed decision-making and recruitment. Methods and 
approaches from the QRI (audio-recorded recruitment consultations, interviews, 
recruiter training) were employed in the present research to explore the treatment 
preferences of young people, their parents, and to discuss issues of equipoise with 
recruiting health professionals. Data analyses drew on techniques of constant 
comparison, content and thematic analysis. All four RCTs were able to successfully 
recruit paediatric participants, but preference for treatment was a consistent reason 
for trial decline, post randomisation drop-out and discontinued treatment in the four 
trials under investigation. Young people and their parents expressed treatment 
preferences when considering RCT participation in all four trials. However, young 
people were less likely to express preferences than their parents. The views and 
equipoise of those recruiting and treating patients influenced families at all stages of 
recruitment, and during trial participation. Providing training for recruiters and wider 
clinical teams that promoted communicating equipoise, and the exploration of 
preference during discussions with families, had a positive effect on observed 
recruitment practices. More efforts are now needed to understand preference for 
treatment in paediatric RCT settings, particularly in relation to the impact on trial 
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 Background – Randomised controlled 
trials, recruitment and treatment preference 
 
1.1 Overview of Chapter 
This chapter includes a comprehensive review of the key research areas relevant to 
this thesis, and acts as a backdrop to the area under investigation - treatment 
preference in paediatric RCTs. Paediatric RCTs are more complex than adult RCTs 
in terms of communication, consent and perhaps recruitment and retention, since the 
views and experiences of parents and young people need to be considered before 
making the decision to participate. In addition to treatment preference and equipoise, 
which are the areas of primary importance to this thesis, several other 
methodological and contextual issues are also discussed. These include an overview 
of: the history of RCTs, facilitators and barriers to RCT recruitment and retention, 
young people, and parents’ motivations for participating in RCT research, ethical 






1.2 Randomised controlled trials and evidence-based 
medicine 
Evidence-based medicine uses numerous different research approaches and 
techniques to gather and analyse data to improve health outcomes for patient 
populations. The randomised controlled trial (RCT) is one such method, and the 
modern-day RCT is defined by the Cochrane community glossary as: 
‘An experiment in which two or more interventions, possibly including a 
control intervention or no intervention, are compared by being randomly 
allocated to participants. In most trials one intervention is assigned to 
each individual but sometimes assignment is to defined groups of 
individuals (for example, in a household) or interventions are assigned 
within individuals (for example, in different orders or to different parts of 
the body).’  [2] 
The hierarchy of evidence (Figure 1:1) has been used to distinguish between the 
levels of bias (risk of error) that a research method is open to when reporting results 
from interventions investigating evidence-based medicine and practice, [3, 4] [5, 6] 
 





Systematic reviews and meta analyses bringing together data from numerous RCTs 
are the most reliable sources of evidence, for establishing an evidence-base for new 
medicines, treatments and interventions that might benefit patients and advance 
medical science. Cochrane Collaboration systematic reviews and meta-analyses sit 
at the top of the hierarchy of evidence, followed by RCTs. [7, 8] Efficacy RCTs 
investigate the performance of interventions under ‘ideal’ conditions, are highly 
controlled, and have strict inclusion and exclusion criteria. Efficacy RCTs often use a 
placebo as a comparator and are double blinded. [9] In contrast, ‘pragmatic’ 
(effectiveness) RCTs are those which incorporate key elements of real-life routine 
clinical practice, whilst applying the rigour of randomisation, (distributing known and 
unknown confounders between groups). [10, 11] Pragmatic RCTs strive to 
incorporate a wide range of the clinical populations using an intervention, in a setting 
such as the NHS. Well-conducted pragmatic RCTs enable health-professionals to 
evaluate the effectiveness of interventions when there is a lack of evidence base in a 
clinical setting and might compare a new intervention with ‘usual’ or ‘routine’ clinical 
care. [3, 12] 
 
RCT research is not carried out in a vacuum, it is conducted in collaboration with 
wider multi-disciplinary teams providing health care for the wider population. 2018 
marked the 70th anniversary of the National Health Service in the UK. The milestone 
establishment of the NHS on the 5th July 1948 paved the way for free healthcare for 
all, with the UK being the first country in the world to provide this to its citizens. 
Women and children were among the most vulnerable groups in UK society who 
stood to benefit most from the establishment of the NHS. Prior to its establishment, 




to contact a doctor because the vast majority were not in paid employment and 





Subsequent important government white papers, such as The Health of the Nation 
[14] in 1992 have been pivotal moments in the evolution of the NHS, with a shift in 
emphasis from ‘sickness’ to the promotion of ‘health’ and the importance of health 
education. [15] The NHS research and development (R&D) strategy was formally 
launched in 1991 [16] and this resulted in the establishment of the Health 
Technology Assessment (HTA) programme, which was set up by the Department of 
Health in 1993. [17] The National Institute for Clinical Excellence (NICE) was created 
in 1999, with the aim of assessing clinical evidence and deciding which new 
treatments should be used by the NHS. [18] NICE has undergone several changes 
since it was established, initially merging with the Health Development Agency and 
renamed as the National Institute for Health and Care Excellence following the 
Health and Social Care Act of 2012. [18] The EU’s 2006 Amendment Regulations 
[19] specifically stated that EU law would support and ensure ‘medicinal products are 





1.3 The history and origin of randomised controlled trials  
Some of the earliest accounts of ‘controlled comparisons of alternative treatments’ 
were carried out in the 16th and 17th centuries by Ambroise Pare [21] and Jan 
Baptista Van Helmont. [22] Van Helmont used the method ‘casting a lot’ to ensure 
that patients were assigned to two equal groups for the treatment of febrile patients 
with and without bloodletting. Dr James Lind, a naval surgeon, performed the first 
‘experimental trial’ in the 18th century when he observed the symptoms of scurvy in 
sailors on long voyages. [23] Lind gave 12 sailors different types of ‘treatment’ in the 
form of ‘drops’ two to three times daily, alongside their ‘usual’ diet. Participants were 
provided with either: cider, elixir vitriol, vinegar, sea-water, citrus fruit or an electuary 
(a drug combined with a more palatable substance such as honey). Those provided 
with citrus fruits recovered fastest. In 1795 the Royal Navy began to provide seamen 
with lemon juice on long voyages to combat scurvy, and this later led to a 
vaccination for the disease. [24] This early account demonstrates an awareness of 
the need to ‘control’ and ‘compare’ treatments between participants, but still lacks 
any formal method in relation to the way in which participants were selected for each 
treatment group. 
 
At the end of the 19th century Fibiger trialled the use of serum to treat diphtheria, 
proposing to treat ‘every second patient with serum’. By separating serum and non-
serum-treated patients by day of patient admittance Fibiger was able to conduct a 
comparison and identify that more ‘non-serum’ patients died from the disease. The 
British Medical Journal cited this as: 
‘the first clinical trial in which random allocation was used and emphasised 




methodology, combined with a large number of patients and rigorous 
planning, conduct, and reporting, makes the trial a milestone in the history 
of clinical trials’ [25] 
 
During the 1940s a series of small scale ‘controlled’ investigations of the potential 
benefits of patulin for the common cold were carried out by the Medical Research 
Council (MRC) and published in The Lancet.  [26, 27]  These small-scale 
investigations produced mixed findings in terms of efficacy, and it was decided that a 
larger ‘multi-centre’, ‘controlled’ trial should take place. The Patulin trial used several 
important RCT features, which although modified, are still used today in modern 
RCT design: unbiased allocation, placebo-control and standardisation of recorded 
symptoms. This early project was innovative and collaborative in nature, despite the 
investigation concluded that patulin had no beneficial effect in comparison to 
placebo: 
‘The MRC trial of patulin, as a possible treatment for the common cold, is 
an exemplar of researchers, research funders, manufacturers, patients 
and government working together with a common purpose to pose and 
answer an important healthcare question. To do this within less than two 
years seems remarkable today, and is something that everyone currently 
involved in healthcare research, policy and decision-making would do well 
to learn from.’ [28] Professor Mike Clarke (Director of the Northern Ireland 
Clinical Trials Unit and Methodology Hub) 
The MRC streptomycin trial investigating treatment options for pulmonary 
tuberculosis is perhaps the most well-known early randomised trial. [29] The trial is 
questionable by modern-day ethical standards since patients didn’t know they were 
enrolled in a research study. The initial trial found that streptomycin was not effective 




tuberculosis RCTs and further investigation of drug resistance which eventually 
resulted in a 100% cure rate for the disease. Previously, around 50% of those who 
developed the disease died. [30] 
 
Ethical issues and RCT research was being debated in the 1950s, with some 
academics questioning the ethical implications of withholding potentially effective 
medication and treatment from those randomised to control, placebo or standard 
care groups. [31] During the 1940s and 50s RCTs were primarily funded by 
government agencies, and the use of RCTs to assess manufacturers’ claims in 
relation to drugs marketed for human use was minimal, [32] with many still relying on 
‘expert opinion’ to approve the use of newly available medications such as antibiotics 
and antipsychotics. [33, 34] A lack of regulation or use of rigorous RCTs to test 
medication before use with the human population led to the thalidomide scandal 
during the early 1960s. Thalidomide was given to pregnant women experiencing 
sleep disturbance or morning sickness and resulted in babies being stillborn or born 
with malformed limbs. In the USA this led to the introduction of regulations which 
resulted in ‘controlled’ investigation of new medications. [35] Similarly in the UK The 
National Institute for Biological Standards and Control (NIBSC) [36] was established 
in 1972 and is now part of the Medicines and Healthcare products Regulatory 
Agency (MHRA). [37] Such bodies ensure that all medicines and medical devices 
are safe for use, with specific information relating to the testing and authorisation of 





RCTs have rapidly increased year on year since the mid-20th century, and the 
location (country) of published RCT research has changed over time, with ‘all other 
world nations combined’ overtaking the UK and USA in terms of published RCT 
research in the late 1990s. [38] Although the modern RCT is frequently referred to as 
the ‘gold standard’ in terms of rigour, the context in which RCTs have been used in 
modern medicine has raised important ethical and social issues. [39] These became 
particularly apparent during the 1990s when RCTs were used to investigate 
treatments for the human immunodeficiency virus (HIV) in developing countries, 
where it was deemed acceptable to use placebo control groups that would not have 
been approved as ethical in European countries and North America. [40, 41]  
 
As the number of RCTs have increased, the funding sources of trials has also 
changed. During the 1960s RCTs were primarily funded by governing bodies or 
agencies such as the medical research council. However, there is now more reliance 
on the pharmaceutical and device manufacturing industries for trial funding. This 
reliance continues to raise questions in relation to conflicts of interest, and the 
registration of RCTs on nationally recognised trial registry sites, (International 
Standard Randomised Controlled Trials Number ISRCTN http://www.isrctn.com/), 
which is now common practice. These sites also encourage those funding RCTs to 
avoid non-publication of trial findings that do not provide evidence to support their 





1.3.1 Trial Phases 
Modern RCTs can be categorised into ‘phases’ 1-4, (see: Table 1:1) and are 
sometimes grouped together into early (1-2) and late (3-4) development phases. [44] 
Early phase trials are usually carried out with adult populations, and only with young 
people if a disease specifically occurs in childhood/adolescence. [45] Feasibility or 
pilot RCTs can be carried out during early and late phases but will typically be 
carried out during phases 3-4. [46, 47] 
Table 1:1 Randomised controlled trial phases 
Phase  Overview 
I - First in human 
 
Assess the safety of a drug, device or intervention, 
including dose-response characteristics in healthy 
volunteers. 
II - Proof of 
concept/efficacy 
 
Test the efficacy of a drug, device or intervention, e.g., 
optimal dose in a population of patients with a 
particular condition. 
III-IV - Effectiveness 
 
Involve randomisation, blinding in a patient population. 
In this phase a new treatment or new way of delivering 
treatment is compared with a standard treatment. 
Different doses or different ways of giving a standard 
treatment(s) may also be compared (or a placebo, if a 
standard treatment does not exist). An evaluation of 
the long-term effects of new drugs and treatments over 
a lengthy period may be carried out to understand 
more about side effects, safety and long-term risks and 
benefits. Phase IV trials will only be carried out after 





A feasibility study is defined by the National Institute for Health Research Trials and 
Studies Coordinating Centre (NETSCC) as ‘research done before a main study’ to 
‘estimate important parameters that are needed to design the main study’. A 
feasibility study aims to establish if it is acceptable to carry out a full study and 
optimise the techniques and interventions that would be used. Typically, the 
objectives of a feasibility study would include establishing the required sample size, 
rates of follow-up, the willingness of participants to be randomised and health 
professionals to recruit participants. 
 
A pilot study is described as being ‘focused on the processes of the main study’ and 
‘to ensure that recruitment, randomisation, treatment, and follow-up assessments all 
run smoothly’. http://www.netscc.ac.uk/glossary/. A major difference between a 
feasibility and pilot study is the latter includes a measure of the primary outcome. 
[47] Pilot studies also have more rigorous methodology (e.g. sample size estimation, 
randomisation and control group selection) than studies that were defined as 
'feasibility studies'. [46] However, a review of published pilot studies from 2007-2008 
in seven popular medical journals (Lancet, BMJ, BJS, BJC, BJOG, JAMA and NEJM 
– see List of Abbreviations) found that most pilot studies reported results as 
inconclusive, and although the majority stated that a larger main trial would be 
conducted, very few main trials were located by the authors (nine of a potential 45). 
[46] 
 
Pilot studies may be stand alone, or internal to the main RCT, i.e. data from the 




However, there is currently a large variation in the way in which progression criteria, 
such as recruitment rates or non-adherence to protocol, are used to determine 
transition to main trial. [48] Avery et al suggest that, instead of simple stop/go 
criteria, internal pilots should use a traffic light system: ‘go, amend or stop’, allowing 
trials which may need ‘modification’ in the amber/amend zone to proceed with some 
degree of caution. 
 
1.3.2 Trial design 
Modern RCTs have several key features, some of which have already been 
mentioned, such as: a comparison of two or more interventions, and an explicit 
method of randomisation is used to ensure equivalence of comparator groups 
resulting in a fair comparison between groups. RCTs also typically involve an 
evaluation of the effectiveness of the interventions under comparison. RCTs can also 
be categorised via the way in which the RCT is ‘designed’ or structured. Participants 
may experience one or more of the interventions offered via groups in the RCT. 
 
 Parallel groups 
In a parallel group design RCT interventions run in parallel, with different groups of 
participants experiencing each individual intervention. RCT interventions are 
assigned between individuals in parallel group designs, and parallel RCTs may be 
fully or partially randomised, whereby some treatment groups include randomised 
participants, and some include participants who have chosen their intervention. (see: 





RCT interventions are assigned within individuals in a cross-over design, which 
allows the participant to act as their own ‘control’, thus reducing between-patient 
variability and allowing a smaller sample size. It is a within-patient design where the 
participant experiences both interventions available in the RCT, e.g. the participant 
receives intervention one then ‘crosses over’ to intervention two (and vice versa). 
Participants may not receive all interventions in RCTs where there are more than two 
intervention groups (partial cross-over or incomplete block). Cross-over designs can 
be used in conditions that are chronic, with relapsing and remitting symptoms such 
as migraine. There will be a ‘wash-out’ period between the interventions to minimise 
carry-over effects.  
 
The N-of-1 RCT design (sometimes referred to as the individualised medication 
effectiveness tests, IMETs) typically involve multiple cross-over trials involving a 
single patient. [49-52] The design allows for an examination of therapeutic benefit, 
and because small patient samples are required, can be of potential value when 
investigating rare conditions, particularly in paediatric medicine. [53] Patient 
feedback from N-of-1-trials has been positive, suggesting that participation can 
provide insight into an illness, and facilitate open discussion between patient and 
clinician. [54] Combined N-of-1 RCTs can be used to determine which patient groups 






However, the cross-over design (including N-of-1) has limitations. It can take longer 
to ‘test’ both treatments in the trial population (N-of-1 design). [49, 55] A cross-over 
design is not suitable for interventions or treatments that have a sustained effect on 
the outcomes under investigation, e.g., the first treatment has a residual effect on the 
second block of treatment. Some conditions and diseases are also not suited to the 
design:  if symptoms are acute, are likely to improve or deteriorate over the course of 
the RCT, if the disease is likely to be cured during the course of treatment, or result 
in death before the end of the trial. [56] Cross-over designs can be useful when 
assessing which treatment ‘outcome’ is preferred by patients or parents, after both 
have been experienced. But, since there is no randomisation in a cross-over design, 
the issues associated with patient preferences ‘between’ treatment groups at 
recruitment to the RCT are not apparent. [57] 
 
Patient Preference Trial  
The Patient Preference Trial (PPT) or Comprehensive Cohort Design (CCD) are 
pragmatic alternatives to the conventional parallel RCT design that uses 
randomisation to all treatment groups. The PPT is partially randomised, whereby 
some treatment groups include randomised participants, and some include 
participants who have chosen their intervention. [58-60] The PPT is an option 
depending on the nature of the population, condition and trial context, and is often 
used where preferences for specific treatments are perceived to be a threat to 
recruitment. [61] The PPT also allows for a comparison between randomised 
participants (who are presumed not to hold strong preferences) and those that opted 
to choose a trial intervention who are followed up via non-randomised groups 




problematic due to uncontrolled confounders in the non-randomised trial groups. [62-
64] 
 
PPT design may be chosen to investigate a patient population where there is a 
perceived lack of ‘collective’ equipoise in the patient community. [10] For example, 
tonsillectomy for recurring and frequent sore throat in children had been a standard 
medical practice for more than 50 years and trialists anticipated that those in the 
clinical and patient community would not be in equipoise, preferring surgical over 
non-surgical management. [65] Trialists used a standard two group RCT design with 
parallel non-randomised cohort groups, so that parents who declined randomisation 
could choose a preferred treatment for their child and be followed up via the 
research protocol. [66]  
 
Comparison of treatment effectiveness in a PPT design will only use data from 
randomised treatment groups, since a comparison between patients who enter 
randomised treatment groups and those who choose treatment is unreliable due to 
unknown confounders. A comparison between randomised and non-randomised 
treatment groups can be useful to establish whether those accepting randomisation 
are similar to the wider clinical cohort as treatment progresses. [67] Because the 
availability of preference groups often results in recruitment to randomised treatment 
groups being slower, the PPT design can result in increased size and costs because 
it takes longer to recruit randomised participants. In addition, these trial designs don’t 
necessarily increase recruitment rates and if there is ‘equipoise’ in the clinical 




treatment preferences that may be based on incorrect or misinterpreted information. 
[68, 69]  
 
Pre-randomisation methods 
Pre-randomisation methods such as the Zelen design involve only those randomised 
to ‘experimental’ trial groups being informed about trial involvement (Figure 1:2). [70]  
 
Figure 1:2 Zelen design 
 
This design results in an increase in the rate of accrual, [71] but given the 
importance of fully informed consent and assent from all those participating in 
research protocols, this design has significant ethical issues. [72]  The Zelen design 
has been considered justifiable to some trialists and acceptable by some parents in 
critical care settings, to avoid unnecessary distress for parents of children 
randomised to ‘standard’ care groups that might be perceived as less intense or 
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Allocation concealment and blinding 
Allocation concealment refers to the method used by trialists to ensure the 
assignment sequence is concealed prior to random allocation, preventing selection 
bias. [75] Blinding is sometimes confused with allocation concealment, but blinding 
occurs post randomisation, and refers to concealment of the intervention or 
treatment from the participant, i.e. they are not told which intervention they are 
receiving during the RCT. Participants will typically be provided information in 
relation to which intervention they received upon trial completion.  
 
Blinding can be used to ensure that participants do not know which intervention they 
have been allocated. An RCT is described as ‘double blinded’ if treating clinicians or 
outcome assessors are also unaware of treatment allocation. Statisticians 
completing analyses are typically unaware of any details of participants’ treatment 
allocation. [76] Blinding is commonly used in drug trials, or if a trial involves similar 
interventions. [77] Blinding is not feasible in all RCTs, for example those comparing 
and evaluating behavioural interventions where participants are asked to follow a 
specific programme of treatment. [78]  
 
Trials that cannot use blinding are referred to as ‘open’ or ‘open label’ trials. Although 
non-blinded trials are considered to be ‘at risk’ of bias, [79] recruitment to open trials 
is 10% higher than blinded trials, i.e., patients like to know which treatment they will 
receive in an RCT. [80-82] Medical versus surgical management of a condition also 
poses a problem where blinding and use of a placebo raise additional ethical issues. 




‘expertise-based’ trial design has been proposed as a solution to the fact that 
surgeons are necessarily unblinded. [86] Participants are randomised to a surgeon 
with expertise in a specific surgical procedure, thus avoiding problems of differential 
expertise. This design also aims to address the issue of ‘subconscious’ bias that 
surgeons may have in relation to a surgical procedure in which they have expertise. 
Surgeons may be more meticulous while performing a procedure in which they 
specialise or prescribe co-interventions differently between trial groups. 
 
A survey of surgeons participating in a ‘nailing tibial fractures’ RCT highlighted that 
surgeons were biased towards one of the procedures under investigation in the trial. 
[87] Before the RCT commenced, 87% rated the ‘reamed’ procedure as superior. 
Later in the trial, after 900 patients had been randomised, 86% still rated this 
procedure as superior with moderate to extreme confidence. Ultimately, trialists must 
be open and transparent in their discussion of the limitations of unblinded RCTs 
when reporting and publishing trial findings. [79, 88] Trialists should always strive to 
ensure that those allocated to different intervention groups are treated as equally as 
possible in all other respects and ensure that interventions are administered as per 
protocol, although this is not always the case. [89] 
 
Trial language and terminology 
Trialists and patients have varied attitudes towards the use of placebos in blinded 
RCTs: an adult trial reported that patients did not mind the use of a placebo, but 
clinicians involved in the study stated this as a reason why they were not happy for 




asked to respond to a survey grading facilitators and barriers to recruitment, a large 
percentage (57%) felt that parent attitudes toward their child taking experimental 
medicine or placebo were among the most influential barriers to participation. [91, 
92] This is also reflected in parent responses to the use of placebo group(s) in RCTs, 
[92-95] in some cases describing it as ‘dummy medicine’ or ‘no treatment’. [96, 97]  
 
Trial language and the way in which interventions are described can also be a barrier 
to recruitment. The term “trial” can be problematic for some participants and parents. 
[72] [pg.157] In the ProtecT study some participants viewed a treatment named 
‘watchful waiting’ as ‘do-nothing’, ‘no treatment’ or in an extreme case there was the 
connotation that clinicians would just “watch while I die”. [98] [pg.22] This was re-
named ‘active monitoring’ to better reflect the way in which patients would be closely 
monitored. A paediatric trial investigating very low risk Wilms tumour reported lower 
than expected participation, with parents and clinicians raising concerns that the 
‘observation alone’ trial group was not sufficient. [99]  
 
Trial design is diverse, and only designs with issues considered relevant to the 
research objectives detailed in this thesis have been discussed. This has largely 
incorporated designs that randomise and recruit at the level of the individual. Ethical 
issues relating to trial acceptability and preferences for treatment will be substantially 
different in other trial designs which recruit at the ‘group’ level (cluster, stepped-
wedge) or modify parameters as the trial progresses (adaptive platform trials). 





Historically it was the clinician who decided which treatment or intervention a patient 
would receive, but in a research context it became apparent that this resulted in 
group assignment being open to ‘bias’ e.g., a doctor may assign patients who have 
been ill for a longer period of time to the ‘experimental’ group. The 1948 MRC article 
‘streptomycin treatment of pulmonary tuberculosis’, (see: Section 1.3: The history 
and origin of randomised controlled trials) stated that a ‘control scheme’ would be 
used to determine treatment allocation ‘made by reference to a statistical series 
based on random sampling numbers’. [29] [pg. 770] Epidemiologist and statistician 
Professor Austin Bradford Hill used the term ‘random allocation of patients’, in an 
article published by the New England Journal of Medicine in 1952, [102] [pg.115] 
randomisation in a controlled trial was born: 
 
Randomisation equally distributes participants between two or more groups to 
ensure a fair comparison of trial interventions, using characteristics such as age and 






Randomisation is generally a poorly understood concept by parents considering trial 
participation for their child, [103-108] although some studies have found that parents 
had a basic understanding of randomisation and why it was used: ‘that’s the thing 
with the randomisations - they don’t have the figures at the moment to say well yes 
this regime does work better than this regime’. [109] [pg.6] [96, 110] One reason for 
parent refusal of ‘randomisation’ is a wish to have ‘decisional control’, [111, 112] 
although parents have retrospectively described randomisation as a process that 
offered protection from responsibility should their child have a poor outcome. [113] 
 
Misunderstandings about the process of randomisation can lead parents who have 
made the decision for their child to participate in an RCT to incorrectly believe their 
child has been allocated a treatment because specific ‘factors’ about their condition 
and/or circumstances have been taken into consideration. This is known as 
therapeutic misconception and can result in the misunderstanding that treatment 
allocated in an RCT has been ‘chosen’ because it will specifically benefit the 
participant. [74, 96, 109, 114-116] Randomisation is also poorly understood by 
young people participating in RCTs. [105, 117] In a recent study, 10-15 year olds 
were asked to consider participation in a ‘hypothetical’ scoliosis RCT involving 
randomisation to an observation or bracing group.  Of those who refused 
participation, six out of 17 (35%) of the young people with a diagnosis of scoliosis, 
and 15 out of 28 (54%) without, stated that they would not want their treatment 





In complex paediatric cancer trials, a staged approach to consent which involved 
multiple and longer consent consultations was compared with trials using a standard 
single consultation approach. Multiple consultations were on average 96 minutes 
long, in comparison to 73 minutes in trials using one consultation. There was an 
increase in the number of health professionals explaining the concept of 
randomisation during longer consent consultations. [119] There was also an increase 
in the number of parents who demonstrated an understanding of the concept of 
randomisation, although when compared to trials using traditional one-stage 
consent, neither of these findings reached statistical significance. However, there 
was a significant difference in the parents’ ‘trust’ scores between the two and one-
staged consent consultations. This suggests that well-developed consent protocols 
that ensure health professionals have adequate time and expertise to provide 
families with detailed research information in trials should be implemented to 
improve the process of informed consent. [105, 111, 119, 120] Health professionals 
have reported discomfort with young people’s treatment being selected via a process 
of randomisation, [121] and concerns about over-burdening families by approaching 
them about research involvement. [96, 122] 
 
Identifying and exploring preferences for treatment has been one way in which 
randomisation has been explained and incorporated into the informed consent 
process by trialists in adult RCTs (see: Section 2.2: Qualitative research and adult 
randomised controlled trials). [123, 124] Participants are more willing to view 
randomisation as an acceptable way of making a decision about treatment 
interventions when they discussed the process with reference to their specific 




RCT intervention options. [125] Discussing the rationale for randomisation, (to 
remove selection bias or why the trial was being conducted) as opposed to the 
‘process’ of randomisation (that it is carried out by a computer) can provide 
participants with a better understanding of the reasons why randomisation is used in 
an RCT setting and improve informed consent. [126, 127] 
 
 
1.4 Randomised controlled trials research in a paediatric 
setting 
Paediatric clinical care suffers from a lack of good quality randomised clinical trials 
[128-132] and, since evidence-based medical progress is reliant upon research to 
find the best treatments for young people experiencing health problems, this poses a 
challenge for health professionals, researchers, and the wider community. [44, 133-
135] Health professionals and policy makers often extrapolate results from adult 
RCTs, [136-140] and many parents are unaware that the majority of medicines used 
to treat children and young people have only been tested in adult populations and 
are prescribed ‘off-label’. [141-144] Research with young people can be delayed or 
not conducted at all for ‘ethical’ reasons when certain interventions (such as 
behavioural interventions), are perceived to be inappropriate for investigation with a 






Illnesses that occur in childhood and adolescence can be different to those that 
occur in adulthood, [147-149] and the way in which young people respond to an 
illness depends upon their developmental stage amongst other factors such as 
gender, family adversity or genetics. [150-152]  For instance, the rate of recurrence 
of appendicitis in the paediatric population may be different from the rate in 
adulthood, since the intra-abdominal inflammatory response is different in children. 
[153, 154] Young people may respond more positively to certain treatment in 
comparison to adults, and vice-versa. [139, 150, 155] If we only carry out research in 
adult populations, many treatments that could potentially be effective for young 
people may be written off as ineffective, limiting positive health outcomes for children 
and young people. Conditions such as type two diabetes are now becoming 
increasingly common in adolescence, and health professionals will be limited in 
terms of available interventions and medicines if research is not carried out with 
young people. [156] The fact that children and adults with the same condition 
respond differently to treatment also has an important implication for the calculation 
of accurate sample sizes for paediatric populations. [139]  
 
Few clinical decisions involving young people are supported by evidence from good 
quality clinical trials. In community paediatric practice, only 40% of clinical decisions 
involving children were evidence-based or supported by good-quality trials, and 
small sample sizes resulted in RCTs that were less likely to reliably report 
generalisable treatment effects .[157] Caldwell et al found that parents and 
paediatricians generally opted for ‘the new intervention or standard care rather than 




Childhood cancer is an area where research with children and young people has 
been particularly successful in terms of establishing a firm evidence base by 
enrolling young patients, testing treatments and improving outcomes. The majority of 
young patients are recruited to trials shortly after diagnosis, [109, 159, 160] and the 
number of children who survive childhood cancers has doubled from 36% to 76% in 
the last 40 years. [161, 162] Although clinical outcomes for young people diagnosed 
with cancer have improved considerably, there is still a lack of older teenagers with 
cancer enrolling on RCTs. [163-165] Participation in fundraising for cancer research 
is now largely considered ‘the norm’ at a wider societal level. There are numerous 
high-profile commercial advertising campaigns and events held nationally every 
year. [166, 167]  
 
Research involving young people and their families is becoming increasingly 
accepted as a ‘normal’ part of clinical care, with the Nuffield Council on Bioethics 
publishing a comprehensive report in 2015 which examined the ways in which 
children and young people could be ethically involved in clinical health research. [44] 
The report included contributions from more than 500 young people, parents and 
professionals, [135] and published material in a variety of formats including an online 





Figure 1:3 Heath research: Making the right decisions 
https://www.nuffieldbioethics.org/publications/children-and-clinical-research 
In 2016 Nuffield bioethics organisation also issued the ‘Statement of aspiration: 
improving research by involving children and young people’, which will be used to 
inform guidance on good practice and the way in which young people can contribute 
to research studies in future. [168] 
 
The Nuffield report also supported steps taken by the EU 2006 Paediatric 
Regulation, [169] but highlighted the fact that there was still much work needed to 
ensure that young people receive fair access to varied high quality research, 
specifically in relation to the current waiver system where certain medicines are 
exempt from the requirement to include children and young people in trials if they are 




and recommendations 10-11 pg. xxviii- xxix] In a press release in 2015 The 
Paediatric Committee (PDCO) revoked eight class waivers because new information 
became available showing that the diseases could occur in children [170] Gamble et 
al have also pointed out the need for continued revision of the regulations so that 
they are fit for purposes of deferred consent in paediatric research. [171]  
 
Young people who have participated in RCTs have clearly stated that they believe 
health professionals should carry out more clinical trials in collaboration with young 
people. [172, 173] Young people have recommended that results from trials should 
be fed back to participants as soon as possible. They have also stated that there 
should be a dedicated secure website where they can show an interest in paediatric 
trials that are open to recruitment, and network with other young people who had 




1.5 Recruitment and retention in randomised controlled 
trials 
Recruitment and retention are of major importance in RCT research. [174-176] 
Activities that aim to improve recruitment processes can include any activity carried 
out before participants consent to RCT involvement. [177] Activities that might 
contribute to improved retention typically occur post recruitment and can be varied. 




Sully et al found that 45% of NIHR and MRC trials recruiting between 1994 and 2002 
required an extension, with just over half recruiting their originally specified sample 
size, (55%). [185] More recently, a review of RCTs funded by the NIHR and HTA 
programmes found wide variability in recruitment and retention rates of RCTs 
published between 2004 and 2016 but reported a similar figure for trials achieving 
their originally specified sample size (56%). [187]  
 
Failure to reach the specified sample size and delays in recruitment have also been 
reported in paediatric RCTs. [184, 188, 189] However, recent findings are more 
optimistic in relation to the number of paediatric trials that succeed to completion, 
with only 8.5% reported as discontinuing prematurely. In contrast 10.2% of adult 
trials and 9.4% of mixed age RCTs (recruiting participants from childhood or 
adolescence into adulthood e.g. 15-25-years) were discontinued prematurely. [190] 
Discontinued RCTs are less likely to be published in peer-reviewed journals. [191] A 
cross-sectional study that compared 173 publications of discontinued RCTs with 
corresponding details on trial registry sites found that less than half of the published 
discontinued trials were accurately labelled as such on the corresponding trial 
registry site. Many discontinued RCTs were labelled as ‘trial completed’, resulting in 
a lack of accurate evidence for trialists developing future trials. [192] Improving the 
conduct of RCTs, [174] particularly in relation to the recruitment and retention of 
participants, can be used to avoid early trial closure and the potential for results to 
remain unpublished. [175, 193-197] Qualitative research methodology is increasingly 
being used to improve trial conduct during the pre-trial [182, 198] and feasibility 
stages of RCTs investigating innovative consenting processes and complex 




preferences for treatment may affect recruitment and retention. [78, 123, 204] 
Qualitative methodology has also been cited as promising in terms of identifying and 
overcoming barriers to recruitment and retention with paediatric and adult 
populations. [205, 206] 
 
Fletcher carried out a systematic review of strategies aimed at improving the 
recruitment activity of clinicians in RCTs. [206] The most successful strategies 
identified by this review were those using embedded qualitative methodology to 
design interventions tailored to the individual RCT to improve recruitment, e.g. 
regular training for recruiters focusing on equipoise, and good practice in relation to 
research and recruitment methods. [123, 207] However, the QUART (QUAlitative 
Research in Trials) study found that between 2008-2010 qualitative research was 
undertaken with only 12% of trials and was infrequent. [208] [209] Research into 
evidence-based interventions that might be used to improve recruitment by 
supporting clinical teams recruiting to RCTs is limited. [206] More recently, the 
Health Research Board Trials Methodology Research Network (HRB-TMRN) and the 
James Lind Alliance (JLA) formed The PRioRiTy Setting Partnership, (Prioritising 
Recruitment in Randomised Trials: PSP) to identify unanswered questions about trial 
recruitment. An online survey yielded 1,693 open-text responses to six questions. 
The number one question posed by those involved directly in any aspect of RCTs 
was: ‘How can randomised trials become part of routine care and best utilise current 
clinical care pathways’. Other relevant trial questions included an analysis of barriers 
and enablers for healthcare professionals in helping conduct RCTs investigating the 





1.5.1 Factors affecting recruitment and retention in adults 
randomised controlled trials 
Factors that influence recruitment and retention during the implementation phase of 
RCTs include; trial design, incentives, patient characteristics, support for recruiters, 
consenting and opt-out strategies. [174, 175, 210-212] Several systematic reviews 
have been conducted across multiple illness domains investigating trial factors (e.g. 
participant blinding) and strategies (e.g. telephone reminders) that influence 
recruitment and retention in adult RCTs. [80, 212, 213] A systematic review of 
strategies for increasing recruitment to RCTs found that unblinded RCTs had higher 
consent rates, and increased education about the health problem or disease 
experienced by participants, as opposed to information provided about trial 
processes (such as additional audio-visual patient information or a booklet explaining 
why the RCT was being conducted) increased RCT recruitment. [213] 
 
A comprehensive Cochrane systematic review identifying evidence from 45 RCTs 
which used a variety of interventions to improve recruitment, was carried out in 2010 
and updated in 2018.  In the original review, open rather than blinded RCTs, (see: 
Allocation concealment and blinding’) opt-out recruitment, (potential participants are 
contacted but can decline further contact from the research team) telephone 
reminders to non-responders and a financial incentive included with the trial 
invitation were the only interventions which improved recruitment. [212] The updated 
review included an additional 24 papers, and the only three recruitment strategies 
which carried a ‘GRADE high certainty of evidence’ were: open trial design, using 




highlighted that more recently published papers were better reported and judged as 
more likely to be at low risk of bias. 
 
Limitations of the original and updated Cochrane reviews (and Caldwell review) were 
highlighted as: the inclusion of ‘hypothetical’ studies, in which participants were 
asked to consider how they would feel if they were asked to participate in an RCT. 
The updated review stated that hypothetical trials would be excluded from future 
versions of the report because they do not provide findings based on ‘real decision 
making’. [80] [pg. 26] None of the RCTs included in either review recruited paediatric 
patients, therefore it is not known if the findings are applicable to paediatric trials. 
The authors highlighted that ‘identifying effective interventions to support recruitment 
to paediatric trials is also a priority’. [80] [pg. 26] A qualitative Cochrane review is 
currently under way. This qualitative synthesis will explore factors that impact 
recruitment to RCTs such as recruiters’ perceptions and participants’ reasons for 
declining or accepting RCT participation. There will also be a qualitative evaluation 
linking the way in which facilitators and barriers to trial participation are addressed by 
the interventions and strategies already evaluated in the previously published 
Cochrane reviews. [210] 
 
1.5.2 Factors affecting recruitment and retention in paediatric 
randomised controlled trials 
Literature reporting factors that act as facilitators and barriers to recruitment and 
retention in paediatric trials can be categorised in the following areas: parent or 




under investigation), trial characteristics and research or clinical team factors. [92, 
172, 188, 205, 214-220] 
 
A recent systematic review cited the parent characteristics - ethnicity, age, education 
and socioeconomic status (SES) - as the most commonly reported predictive 
parental characteristics associated with being barriers to recruitment of children to 
paediatric trials. Older parents who did not identify as being from an ethnic minority 
group, with higher SES and levels of education, were more likely to consent to their 
child being involved in RCT research. [205, 214-216] There were similar findings in 
relation to retention rates, with characteristics such as, unmarried 
parents/caregivers, low SES and ethnic minority status being predictive of lower 
treatment completion and rates of retention in randomised [215] and non-randomised  
[221] clinical research. In contrast, two US-based trials found that parents who 
declined RCT participation had higher levels of education [218] and SES. [111] A 
limitation of focusing on parent characteristics in relation to recruitment and retention 
is the fact that it is unclear whether parents ‘perceived’ to be from lower SES are not 
approached to take part in RCT research, either because health professionals think it 
may be an additional burden, or whether these families are more likely to decline 
when asked to participate. [222, 223] Parent ‘characteristics’ that predict poor 
recruitment and retention do not fully explain the reasons why parents decline or 
accept randomisation and trial participation for their child. 
 
A variety of factors have been reported to influence parental decision-making in 




discussions about trial participation and consent is an important factor, [224-226] 
especially when family members are under considerable stress associated with a 
new diagnosis. [227]  Although some parents will consent to RCTs even when they 
feel the timing of approach is not ideal, [96] others are more likely to give consent if 
approached at a less stressful time, such as an out-patient pre-operative setting as 
opposed to immediately before a surgical-procedure in an in-patient setting. [228] 
 
Other factors that parents have cited as important in terms of being approached 
about RCT involvement and continued participation have included: establishing a 
trusting relationship with the recruiting team with honest discussion of risks and 
benefits of research, [214, 224, 229-232] continuity of care, (speaking to the same 
person on the trial team at various time points during RCT data collection), and  
professionalism of the recruiting team. [189] [218] Reassurance about logistical 
factors, (e.g. the amount of time off work that research participation will involve) and 
personalised discussions, including additional time spent answering questions are 
also considered important by parents. [227, 230] Concern around the type of 
treatment offered in RCTs, e.g. a treatment that is a change from ‘current’ 
recommended treatment [225] or when study groups are perceived as very different 
in terms of effectiveness (placebo versus active treatment), have been cited as 
issues which make decision-making more problematic for parents, particularly when 
a child is seriously ill. [97, 218, 233] Factors associated with disparity between 
treatment groups are linked to a lack of equipoise and preferences for treatment. 
[227] Extended family may also be involved in decisions about treatment and 
research involvement for young people, and the extent to which wider family may 




The importance of gaining assent from young people under the age of 16 years was 
reported as making a difference to engagement in a recent study that required 
participants to undergo general anaesthetic for tooth extraction. [189] Other authors 
have highlighted the importance of young peoples’ motivation to take part in RCTs. 
[214, 224] However, it was parents and researchers – not young people themselves 
– who reported that motivation was a potential barrier to recruitment and retention. 
Mobile and Internet based technologies are increasingly recognised as important 
when engaging and recruiting young people in to RCT research. [238, 239] 
 
A recent systematic review found no association between age of participant and 
recruitment and retention. [205] However, past research has suggested age can be a 
factor when young people consider trial participation, diabetes trials have found that 
older children are more likely to decline RCT involvement using behavioural 
interventions.  [215, 226] Young people who were struggling to manage a chronic 
condition, [227] and had longer duration of illness, [226] were also less likely to 
consent to research involving blood glucose monitoring. In contrast others have 
reported difficulty recruiting and retaining younger children in various RCT and 
observational studies, (specialities included oncology, gastroenterology, internal 
medicine, ophthalmology, and pulmonary disease). [216] Evidence suggests that 
young people pay less attention to the potential harm that research may have on 
their health than parents or caregivers, [229, 240] with young people focusing more 
on potential benefits of research participation. However, these findings were based 
on feedback from healthy young people, or those with an ongoing health conditions 
who were asked to imagine participating in a hypothetical RCT. Such findings may 




the prospect of trial participation in real life situations involving acute illness or 
ongoing health conditions. 
 
Trial related factors associated with successful recruitment and retention included 
having a dedicated trial co-ordinator and having a motivated, experienced, well-
trained trial team with good communication skills. [188, 224, 225, 241, 242] Factors 
such as Clinical Trials Unit (CTU) involvement, being an Investigational Medicinal 
Product (IMP) versus non-IMP RCT, or having a pilot or feasibility stage, were not 
associated with successful recruitment in a paediatric setting. [92, 188] Practices of 
‘patient-centeredness’ [214][pg7] have been found to facilitate retention, including: 
alerting families that calls about the research study would be made from a ‘withheld’ 
number, getting families to commit to a contact time/date and specifying preferred 
modes of follow-up contact. [189, 231] Flexibility in accommodating recruitment and 
data collection outside of ‘normal’ working hours (weekends and evenings) can also 
improve recruitment and retention in paediatric trials, particularly if parents and 
young people are attending full time work, education or college. [189, 224, 238] 
However, clinical teams have reported burden associated with insufficient staffing 
levels [231, 243] and time needed to adequately discuss trial participation with 
parents whilst completing associated research and clinical duties. [214, 242] The 
availability of dedicated research or practice nurses can be key in terms of reducing 
clinician burden and facilitating recruitment to paediatric RCTs. [156, 244] Regular 
monitoring of recruitment figures and frequent opportunities for communication 
between clinical and research teams can be effective in identifying problems with 
recruitment and retention early, so that changes to current trial processes can be 




1.6 Equipoise and uncertainty 
Equipoise is uncertainty about which treatment group is most effective, or about the 
benefits of a new treatment because of the lack of an existing evidence base. [245] 
The acceptance of equipoise between trial treatment groups is essential for clinicians 
and researchers recruiting to RCTs. [125, 197, 246-248]  Lack of equipoise on a 
clinical team recruiting to a trial can lead to the early closure of trials in international 
as well as local settings. [249, 250]  However, health professionals and patients will 
rarely be in a state of ‘perfect’ equipoise or ‘indifference’ (absolute uncertainty) 
before either recruiting to or while participating in an RCT. [251-255]  Freedman 
pointed out that health professionals often have ‘a gut feeling’ or ‘an instinct’ about a 
particular treatment. [251] Freedman also identified the distinction between 
‘individual’ and ‘collective’ (clinical) equipoise, where team members hold varied 
‘individual’ personal beliefs and experiences of treatments, with their perceived 
equipoise depending on a number of factors (e.g. length of service, local availability 
of treatment options or specialty). At the same time there is overall ‘collective’ 
uncertainty within a multi-disciplinary clinical team or the expert medical community 
as a whole.  It could be argued that an effectiveness trial would not be funded if there 
was not a belief (or where possible, preliminary evidence from efficacy trials) that 
‘new’ intervention(s) offered would be more or equally effective. [256, 257]  
 
Many health professionals recruit to RCTs as part of their day-to-day clinical duties. 
This can be challenging since they are forced to re-frame their every-day clinical 
experience. In discussions of ‘routine care’ they might make decisions in relation to 




personal circumstances in collaboration with the patient and their family. [258, 259] 
During RCT recruitment consultations they must instead approach and frame the 
discussion by disclosing to the patient/family that there is uncertainty in terms of 
which treatment might be most effective for ‘eligible’ patients. This will involve the 
health professional taking on a dual role of ‘clinician’ and ‘medical scientist’ or 
'researcher’, depending on clinical experience, their comfort with this dual role may 
vary. [260-262] Accounts from those recruiting to adult trials have highlighted an 
emotional and intellectual burden associated with reconciling the dual roles, required 
when recruiting to trials in addition to providing a more traditional clinical 
consultation. [246] 
 
Theories of equipoise pose an ethical issue, and are problematic when applied to the 
practice of modern clinical care and evidence-based medicine. [263] There has been 
debate and discussion about whether ‘true’ equipoise exists in the context of RCTs, 
where there is conflict between individual patient benefit, [116, 264, 265] and 
developing an evidence-based treatment for future patients and families. [251-255] 
Gifford proposed a ‘sliding scale’ approach to equipoise, highlighting that patients 
and clinicians may be ‘in equipoise’ to different degrees, and at different points in 
time. There is continued fluctuation in personal and collective (clinical) equipoise. 
This will change over time at the individual and group level as trials progress. [255] 
Authors have also incorporated elements of non-exploitation framework to the 
concept of equipoise. [266-269] This approach considers the associated risk/benefit 
ratio of participation for participants. Benefit versus risk may be particularly relevant 
in paediatric research where parents are making decisions on behalf of their child. 




potential opportunity of having the newest treatment available in a trial, (see: Factors 
affecting recruitment and retention in paediatric randomised controlled trials). [270] 
 
Although ethical debates around equipoise continue, [271, 272] the pragmatic issues 
which relate to equipoise, including judgements about eligibility criteria, and the way 
in which equipoise is conveyed and discussed with prospective RCT patients, 
continue to impact recruitment to RCTs. Those recruiting to RCTs have expressed 
the view that patients located in the ‘middle ground’ of the eligibility criteria were 
more readily perceived to be candidates for an RCT. However, those at either end of 
the eligibility spectrum had potential to be excluded on ‘subjective’ grounds based on 
‘hunches’ and ‘bias’. [262] Empirical support for this can be found in other paediatric 
RCTs, [273] [260] and in the wider theoretical literature. [31, 102, 274-277] 
 
Rooshenas drew on evidence from audio-recorded recruitment consultations and 
interviews with clinicians involved in recruitment to six RCTs, finding that clinicians’ 
personal views about trial treatments influenced the way in which they conveyed 
equipoise to prospective participants. Practices that compromised the 
communication of equipoise included: offering treatment recommendations as 
‘expert opinion’, providing imbalanced descriptions of trial treatments (for example, 
by referring to one treatment as ‘traditional’) and disclosing ‘personal opinions’ based 
on intuition. To what extent this resulted in participants declining trial involvement in 
the six trials is less clear. [177] There is also some evidence to suggest that doctors 
and nurses may communicate equipoise differently. Feedback from recruiting nurses 




practicalities of treatment options, families circumstances and their clinical 
background. [262] [278] 
 
 
1.7 Treatment preference and randomised controlled trial 
research 
‘Treatment preference’ can be described as: “any favouring or liking, to any degree, 
towards a particular treatment”. [Mills et al 2014, pg325] [247] It can also be framed 
as a lack of equipoise in a clinical trial setting. Preference for treatment can affect 
RCTs in several different ways. [279] If patients have a preference for treatment 
offered in an RCT they may decline randomisation to access treatment outside the 
trial. [280] If participants with a preference for treatment consent to randomisation 
but withdraw from the trial if they don’t receive their preferred treatment, this will 
result in the loss of statistical power to measure differences between treatment 
groups. [179, 181, 183, 281-283] The external validity of an RCT may be 
compromised if patients with treatment preferences decline to participate, since trial 
results will not be representative of the larger population. [63, 91] 
 
Bias is possible if uneven numbers of participants drop-out or cross to the opposite 
treatment group. This may pose a threat to the internal validity of the trial if large in 
magnitude. [279, 284] [67, 285] If reduced numbers of eligible patients are recruited 
or drop-out because of treatment preference this will delay recruitment or prevent 




a trial of treatments for acute anterior cruciate ligament injury, with many participants 
stating that they joined the trial to bypass surgical waiting lists. Participants 
consented to trial participation despite their lack of equipoise, and a high number 
who were randomised to the non-surgical training group crossed-over to receive 
surgery (22/34), but these participants did not necessarily report satisfaction with 
surgical outcomes in terms of recovery. [286] 
 
Preferences for treatment can also affect adherence to treatment groups in RCTs 
where blinding to trial interventions is not possible. [62, 287-289] If a patient is not in 
equipoise about treatments offered in a trial but still opts to participate because there 
is a chance, they may be assigned a preferred treatment, (e.g. in situations where 
treatment is not accessible outside the RCT) they may suffer ‘resentful 
demoralisation’. This is a state attributed to participants who have worse outcomes 
because they are randomised to their non-preferred treatment group. [62, 284, 290] 
Counter-intuitively, in some cases there is greater compliance to a study protocol by 
participants who did not get their preferred treatment. [289] This highlights that 
preference is not straight-forward or static and may change over time or differ 
between family members (e.g. parent and young person). A trial investigating type-
one diabetes in childhood found that although the majority of families expressed a 
preference for ‘home based’ (as opposed to hospital based) treatment before 
randomisation, most expressed a preference for the allocated treatment that they 
had experienced when asked about preference retrospectively (interviews were 




Two systematic reviews have examined treatment preference in RCTs, [279, 289] 
but findings relating to the effects of preference on recruitment and retention are not 
straightforward. The first, published in 2005, looked at the effects of participants’ and 
professionals’ preferences on recruitment and treatment outcomes.  [292] This 
systematic review extracted data from 34 RCTs, four of which were paediatric, 
(papers published from 1966 to 2003). It concluded that preferences did influence 
recruitment to trials, but there was little evidence to suggest that internal and external 
validity were compromised. Data suggested that refusal of randomisation was based 
on factors such as: unusual interventions (e.g. acupuncture), where differences in 
time committed to treatment were required (e.g. outpatient or inpatient treatment) or 
where treatments differed in terms of desirability (e.g. antidepressants or 
psychotherapy). [279] 
 
The second systematic review, [289] published in 2008, investigated the influence of 
preference on attrition and outcome (the RCTs included in final analysis were all in 
the area of musculoskeletal medicine). This review identified 17 patient preference 
RCTs and extracted data from 11, none of which were paediatric (papers published 
from 1999 to 2013). It found that participants who received their preferred trial group 
had better treatment outcomes. Treatment preferences were not detrimental to 
attrition rates, and participants randomised to their non-preferred treatment were 
more likely to return outcome measures. 
 
These systematic reviews did not report reasons for participant preferences 
qualitatively. Data relating to expressions of treatment preference as a reason for 




to date (see: Chapter 4). We do not therefore know whether preference is an 
important factor when parents and their children consider trial participation.  
 
Since paediatric trials involve the combined preferences of parent(s), patient and 
health professionals, in addition to a more complex consent process, the issues that 
pose as barriers or facilitators to recruitment in paediatric trials may differ from those 
cited in adult trials. [96, 107, 113] Preference for treatment may also influence 
retention differently in paediatric trials since there is the potential for parent and child 
to have different preferences or different ‘strength’ of preference in relation to 
allocated treatment. Identifying relevant paediatric RCT papers that have reported 
treatment preference as an issue in terms of recruitment or retention is challenging, 
(see: Chapter 4: Implications for future systematic reviews in this area). However, 
the recently developed ORRCA project (Online resource for Recruitment Research 
in Clinical triAls) has categorised papers into ‘recruitment research domains’, with 
the aim of helping those involved in trials research to identify and locate papers of 
interest and relevance to their area of research (e.g. Patient/Clinician preference). To 
date, ‘relatively few studies addressing recruitment of children under 16 years (12%) 
or aged between 16 and 18 years (7%)’ [293] [pg4] have been indexed via ORRCA, 
but going forward this is a valuable online resource with promising potential.  
 
Due to the complex nature of preference development and maintenance in RCT 
research, the 2005 systematic review of  empirical preference literature [279] was 
accompanied by a conceptual framework that focused on the nature of preference 




operation of preferences’. [294] [pg. 686] Bower et al proposed a four-stage model of 
preferences, which described preference development and operation, (see: Figure 
1:4). [294] In the model, preference is described as an ‘evaluation’ of the desirability 
(or utility) of two or more interventions. The first stage of the model focuses on 
information about interventions offered in the RCT. Information may be in the form of 
patient information leaflets, or wider sources such as the Internet or information 
conveyed by expert clinicians in the clinical field. The second stage focuses on the 
processes that underly the judgements made in relation to the desirability in the 
interventions. The third stage is a global preference for an intervention, and the 
fourth stage is patient decision-making about randomisation. [pg. 687] 
 
Figure 1:4 A model of patient preference and decision-making 





This is a useful model because it highlights the complexity of preference in the 
context of RCT research. Preference for treatment is not a simple judgement about 
an intervention, but incorporates patient characteristics, values and information 
about the intervention, which may come from a variety of sources. Preferences 
associated with certain values may be less amenable to change via information 
provision e.g. those associated with religious belief. Preference judgements also rely 
on expectancies about outcome that draw on a patient’s evaluation of their own self-
efficacy. [295] 
 
Self-efficacy is particularly important in the context of trial interventions investigating 
behavioural interventions, where participants may feel less able to carry out certain 
‘required’ activities, such as physical activity, because of their health condition. 
Judgements about the utility of taking part in an RCT will encompass not only the 
benefits of trial participation (such as positive feelings derived from altruistic 
behaviour), but also the potential benefit of improved health and quicker recovery 
(which may be enhanced when participants feel they are receiving a ‘new’ 
intervention) and opposing judgements about risk (such as intervention side effects). 
A patient’s attitudes toward risk can also play a part in their decision to participate. 
They may have different perceptions of the level of risk associated with interventions 
in the RCT. Bower et al summarise: 
the relationships between expectancies, values and preferences are 
complex, and there are a number of cases where simple distinctions 
between ‘informed’ and ‘uninformed’ preferences are unhelpful. It may 
make more sense to distinguish ‘informed expectancies’, where there is 




inaccuracies have been corrected, and patients have had time to consider 
this information in order to make a judgement based on their expectancies 
and the values they place on them. [294] 
 
Although preference for treatment can influence a patient’s decision to accept or 
reject randomisation as a means of deciding on a course of treatment, in many 
circumstances preference alone does not determine the acceptance of 
randomisation and trial participation. There are instances of patients entering a trial 
despite having preferences for only one of the interventions offered in the trial. [296] 
If an intervention is not available outside of an RCT problems may arise if patients 
enter the RCT to access a specific intervention, but then suffer ‘resentful 
demoralisation’ when randomised to their non-preferred intervention and either drop-
out post randomisation or do not engage with their allocated intervention. [62, 67, 
290, 297] 
 
Individual studies that have reported treatment preference in paediatric trials have 
raised issues relating to parental perceptions of ‘experimental’ or ‘new’ treatment as 
superior to a ‘control’ group acting as both a barrier and facilitator to paediatric trial 
recruitment, depending on the trial settings and paediatric condition under 
investigation. [94] [74] Experimental or new treatments have been reported as more 
acceptable in RCT setting where parents perceive trial participation as the best route 
for survival of their critically ill child. In RCT contexts where new and experimental 
treatments may be perceived by parents as ‘riskier’ preference for treatment may be 




Paediatric trials have the added complexity of multiple opinions about trial 
participation and preference for treatment, since parents’ preferences for a particular 
treatment may differ from those of their child, [66, 204] just as perception of 
symptoms has been shown to differ between parent and child in clinical practice. 
[298] A young person’s developmental stage, age and diagnosis will influence their 
interaction in the recruitment consultation, and a family’s decision to participate in a 
paediatric trial. [97, 299-301] A recent RCT recruiting adolescents to an obesity 
treatment trial found that a common reason for non-participation was adolescent 
refusal to participate, despite their parent giving consent for them to take part. [302] 
This highlights the fact that parent and child views on participation must be 
considered in parallel during paediatric recruitment consultations. 
 
Health professionals may have preferences for their own ‘specialty’ (e.g. surgery) 
whilst recruiting to a trial which involves surgery as only one trial option in addition to 
other specialties such as chemotherapy or active monitoring. [246] Evidence from 
comprehensive cohort studies with randomised and non-randomised treatment 
groups suggests that health professionals were ‘the dominant factor in choice of 
treatment among non-randomised patients’. [279] [pg45] In both adult and paediatric 
trials, the extent to which recruiting health professionals were in equipoise has been 
shown to influence recruitment. In some cases, eligible patients are not entered into 
the trial because recruiters have a ‘hunch’ about a specific treatment or feel that 
certain groups of patients are ‘better suited’ to particular treatments because of 
characteristics such as age or symptom severity. [303, 304] [305] Recruiters have 
indicated that they find approaching parents about paediatric trials problematic, 




who had been approached about trials reported that they did not find this 
burdensome, but felt it was a positive and exciting opportunity. [94, 96, 121, 306] 
 
 
1.8 What motivates young people and their parents to take 
part in RCTs?  
For some, treatment preference for an intervention might be a motivating factor for 
trial participation. [66] Two motivating factors reported by young people when 
considering trial participation include perceived personal health benefits [117, 172, 
307-310] and altruism. [172, 216, 307, 311]  Access to treatments or medical 
equipment which might otherwise be unavailable, [309, 312] a better understanding 
of their condition, closer monitoring and access to a specialist team [172] were all 
factors which young people considered motivational in terms of benefits to their 
health situation. Some younger children (aged 9-13 years) have been found to 
misunderstand RCT treatment to mean ‘individualised’ treatment which would 
directly benefit them, highlighting that extra care should be taken to avoid therapeutic 
misconception with younger patients when explaining RCT research. [216] Altruistic 
motivations for participation included elements of helping future patients and giving 
something back to the health-care teams caring for them. This has been described 
as a ‘network of exchange’ whereby trial participation was described by young 





Financial reward was cited by some young people as an incentive for taking part. 
[172, 311-313] Those who discussed financial incentives stated that this showed an 
appreciation for their participation, but some said they would still have taken part in 
the trial had this not been offered. [172] Some young people suggested that this type 
of incentive could encourage young people to take part for the wrong reasons. [172, 
312, 313] 
 
Barriers to research participation have included perceptions of research participation 
being inconvenient [311] and having competing activities which take priority. [308] 
Medical interventions such as blood or urine samples and medical examination have 
also been described as a reason for research dissent. [314] However, those who 
gave medical interventions as a barrier to participation were a sample of healthy 
young people. It is less clear how influential this would be for young people with 
specific health conditions who may have already been required to undergo medical 
procedures such as blood samples as part of their ongoing care. 
 
The two main motivating factors reported by parents considering trial participation for 
their child were the same as those reported by young people: hope that their child 
would benefit directly in terms of specific health outcomes [94, 270, 307, 308, 310, 
315-320] and altruistic reasons for participation, which in addition to helping children 
in future also included a sense of moral obligation and citizenship. [94, 96, 109, 113, 
228, 317, 319-330] Parents have reported that they would like to find out more about 
their child’s condition, [93, 319] and that having direct access to a specialist team 




Gaining access to treatment that might not be available (in some cases for free) 
outside of the RCT was also a factor for some parents. [93, 120] Free treatment is 
particularly important to those on low incomes in the USA and developing countries, 
[270, 316, 331] where parents consider research participation as a way to access 
new and potentially unaffordable health technology or treatments. Other more basic 
‘incentives’ only offered in the trial - including soap, transport and iron tablets - were 
also mentioned. [270, 316, 331] Parents of children with chronic health conditions 
such as diabetes reported being more willing for their child to participate if they 
‘didn’t have to change much of anything’ in relation to family life and their child’s daily 
routine. [270] [pg.147] 
 
Ultimately parents want to improve their child’s health outcomes, whilst protecting 
them from harm. For parents the benefits of RCT participation must outweigh any 
perceived risks posed by taking part. [97, 326, 332] Barriers to participation included 
inconvenience, [330] parental worries about risky or painful procedures, (such as 
extra intravenous lines or non-routine blood samples) [121, 321, 330] and, for 
parents of children with long-term health conditions, not wanting to disrupt the way in 






1.9 Ethical issues & randomised controlled trial 
participation 
1.9.1 Medical research and human participants 
The declaration of Helsinki is a statement of ethical principles which safeguards all 
human participants involved in medical research. This acts as a guiding document 
for those working in medical research. [333] The declaration has been amended 
since 1964 on a number of occasions, more recently the ‘dual role of the physician-
researcher’ is acknowledged, with the ‘role of healer taking precedence over that of 
scientist’. [334] Other authors go further, suggesting that the next revision of the 
declaration should include a statement about equipoise and uncertainty, which are 
key concepts at the heart of RCT research. [335, 336] The declaration of Helsinki 
states that any treatments offered to control participants should be ‘the current best 
standard treatment’, and that any new treatments under investigation should be 
‘similarly effective or better’. [333] In the research community there is widespread 
evidence that well-designed and conducted RCTs offer patients the best current 
treatment. [158, 337] The Convention on the Rights of the Child, in accordance with 
article 49, states:  
‘Parties recognize the right of the child to the enjoyment of the highest 
attainable standard of health and to facilities for the treatment of illness 
and rehabilitation of health. States Parties shall strive to ensure that no 
child is deprived of his or her right of access to such health care services’ 






Research with paediatric and adolescent populations has been recognised legally 
and socially as a necessary and positive way in which children and young people 
can participate in the production of progressive health treatment and policies. [44, 
168] Those under the age of 18 are typically identified as a ‘vulnerable’ group in 
society, who require protection by the law from potential exploitation. [338] However, 
applying a ‘blanket’ approach which presumes the vulnerability of young people in 
the context of health care research has also been challenged as simplistic and 
unethical. A blanket can promote complacency and a lack of progressive ethical 
research which seeks to improve the evidence-base and care of young people using 
the healthcare system.  [44] Young people who participated in a stakeholders 
meeting which discussed the concept of vulnerability stated that ‘being prepared’ or 
‘being empowered’ were important ways in which health professionals and 
researchers could address and challenge vulnerability in the context of research, in 
partnership with young people and their families. [339] 
 
Thinking about young people and their parents as active ‘users’ of the NHS also 
highlights the importance of ethical research carried out in ‘partnership’ with young 
people and their parents. With the support of their parents there is no reason to 
assume that young people are more vulnerable than an adult patient who is given 
the necessary support to consider participation in clinical research, providing that the 
research context enables health professionals and researchers to support young 
people and parents in their decision to participate. This might involve providing 
interactive, age-appropriate information material such as video or YouTube clips in 
addition to written patient information leaflets. Giving families the appropriate time 




also an important factor which should be considered. In some cases, treatment and 
the opportunity to participate in a research study may be time dependent, [340] and 
young people may be temporarily unable to make an informed decision about 
participation because they are severely unwell. [341] 
 
1.9.2 Informed assent and consent in RCT research: Children, 
young people and their parent(s)  
Consent for medical research is viewed as an informed decision made by an 
individual, and acts as a ‘voluntary agreement’ for their involvement in research. 
Only those aged 16 years or over are legally able to provide consent to be involved 
in RCT research. Young people under the age of 16 are encouraged, where 
possible, to provide their ‘assent’ for research participation while their parent or 
guardian would be required to provide legal consent for their involvement. Principles 
of Good Clinical Practice (GCP) [342] state that ‘informed’ consent involves an open 
two-way conversation with a potential participant. Assent refers to the agreement of 
children under the age of 16 years, who are viewed as ‘minors’ and are not able to 
legally consent to be involved in a research study themselves. However, if young 
people (and children) under the age of 16 years are considered to have the capacity 
to understand what is involved in taking part in a research study, The Nuffield 
Council on Bioethics suggest obtaining consent: 
‘We take the view that, where children and young people have this level of 
understanding, professionals have an ethical obligation actively to seek 
their consent, not their ‘assent’, regardless of any additional requirements 





In a paediatric research setting, young people are usually approached to gain 
consent or assent to participate in clinical research, alongside members of their 
immediate family. In most cases this would be the child’s mother, father or legal-
authorised proxy. [44] Guidelines suggest that young people value being involved in 
the decision making process about their participation in research. [1, 44] In an RCT 
context there are four components of informed consent: competence, information, 
understanding and voluntariness, all of which can also be applied to the process of 
gaining assent. [343] 
 
Competence 
Assent is taken as: ‘an expression of approval or agreement on their behalf’ and, 
rather than thinking about assent as a legal responsibility, it can be viewed instead 
as an ethical responsibility which might empower a child (aged 15 years or under) at 
a typically stressful and challenging time in terms of their health and wellbeing. [344-
347]  
 
Young people aged 16 and over are legally able to provide consent to participate in 
research, since they are considered to have the intellectual capacity and maturity to 
make decisions about research participation. Consent from 16 to 17-year olds would 
usually be supported by a family member. In most cases a parent will also be asked 
to provide consent for their child’s participation, if the young person feels that this is 
appropriate, and if their parent was present at the recruitment consultation. [347-350] 
Young people up to the age of 18-years have reported that they are influenced by 




decreased as their child’s age increased. [351] Young people also value being given 
the opportunity to make their own informed decision in collaboration with parents. 
[117] Young patients with a chronic or acute condition are typically supported by their 
parents. [233, 352] 
 
Parent(s) (or a legal guardian) not only support their child through the assent and 
consent process when they participate in research, but also provide emotional and 
practical support throughout the course of their child’s involvement with a research 
study. [353-356] In many cases, information is also sought directly from parent(s) 
when their child is involved in a research study. This might include impact on 
employment, health resource use, or the wider financial and emotional impact the 
condition has on parents. In these situations, it would also be necessary to gain 
parents’ independent consent, so that they are able to legally contribute information 
for use and storage by the research team. [357-360] 
 
Understanding 
Since young people develop and mature at different rates (both emotional and 
cognitive), age cannot be used in isolation to gauge their ability to make collaborative 
or independent decisions about their health choices and involvement in research. 
[117, 346, 361-365] For this reason, those recruiting into paediatric RCTs must make 
case-by-case decisions about the extent to which they involve children and young 
people in the decision-making process in collaborative discussions with parent(s). 
Assent has been described as ‘the emergent capacity to agree’ in a very young child, 




about participation but does not yet have the legal capacity to provide consent. [44] 
In some instances children and young people may not have the capacity to be 
involved in a discussion about research participation because their diagnosed 
condition or health related circumstances do not allow this (e.g. they are severely ill 
or unconscious). [366] In these circumstances, and where research involves very 
young children and babies, parents or the child’s legal-authorised proxy would be 
involved in discussions with health professionals, to establish whether or not 
research participation is the way in which the family wish to proceed. [367] 
 
Information 
Young people and their parents will be provided with specific, and usually separate 
patient information leaflets (PILs) informing them about a research study or RCT for 
which they are eligible to participate. [345] A PIL may be provided before or after a 
discussion with a health care professional. These discussions are often referred to 
as ‘recruitment consultations’, and the language used by health professionals should 
be pitched at an appropriate level depending on a young person’s developmental 
needs, without the use of unexplained medical jargon or research terminology. 
Situational factors should also be taken into account, such as the timing of the 
approach [119, 368] and if the child’s condition allows, actively engaging with both 
the young person and their parent(s). Parents may feel particularly vulnerable when 
approached about a research study due to the circumstances that surround their 
child’s illness, and this should be considered by those discussing research studies 
with families. Ensuring that all involved in the discussion feel comfortable about 
raising their own specific questions or concerns about a research study is an 




consultation and a ‘cooling off period’ for the family to consider the information they 
have discussed. [189, 369, 370] Further research is needed to investigate how best 
to communicate information about trials to families in varied and challenging 
paediatric trial environments [107, 113, 200, 306, 371-374] 
 
Voluntariness 
Voluntariness is a concept that may be challenging to understand when confronted 
with an RCT embedded in an ongoing or acute clinical care setting, [375-378] 
particularly in circumstances where parents and young people may be distressed 
and vulnerable. [379] However, in some studies children as young as six years of 
age have demonstrated a basic understanding of the purpose of research. [311, 376] 
Research involvement, unlike routine medical care cannot be framed as solely for 
the benefit or best interest of the child. In addition, there should be an understanding 
that the child’s involvement will contribute to something that will potentially benefit 
other families and wider society in the future. Research participation may indirectly 
benefit the child and should pose no additional risk or unacceptable burden to the 
child. [366] 
 
If a family is presented with trial information by their diagnosing clinician, the line 
between clinical care and voluntary research involvement may be more blurred than 
those introduced to a trial by a research nurse or researcher they have never met 
before. [109, 380-382] Parents may feel a sense of gratitude toward a clinical team 
providing ongoing and/or lifesaving care for their child, [96] and may not want to 




people have also reported feeling an obligation to take part in research because of 
perceived pressure from parents and/or those caring for them clinically. [307, 383] 
However, families (both young people and their parents) have also reported feeling 
empowered when approached to participate in research, when approached by a 
health professional they know and trust. [96] It is essential that young people and 
their parents are aware that they are able to decline or withdraw from a research 
study without it affecting their continued healthcare. [384] Difficulties may arise when 
parents and young people (who are the prospective participants) disagree about 
whether research participation is the best course of action. Although the autonomy of 
young people should be respected, [385] it is often the parents’ final decision that 
takes precedence and health professionals must be mindful to ensure that 
discussions lead to a joint decision that satisfies all involved. [375, 386] 
 
 
1.10 Communication and decision-making in paediatric 
recruitment consultations 
A young person’s age, developmental stage and diagnosis will have an influence on 
their participation in any joint discussions about consent/assent and their clinical 
condition (see: Section 1.9.2). [363] Young patients’ input in discussions in primary 
care settings is often limited, with estimates of patient quantifiable verbal 
involvement in discussions with a health professional in a clinical consultation being 
as low as 4-14%. [301, 387] Most communication between the clinician and young 
patient in these discussions was categorised as ‘social’ talk, or the clinician acting as 




discussions about planning and decision-making. [388-390] Most communication in 
routine clinical care and out-patient consultations takes place between the clinician 
and the parent(s). [391-393] 
 
Since consent and assent is sought from a parent and young person (where 
appropriate) for paediatric trial participation, the dynamic of the ‘clinician-patient’ 
relationship changes from a dyadic consultation to one that involves one or in some 
cases two parents, in addition to the clinician and patient. This brings with it added 
complexity in terms of whether it is the patient or parent(s) who contribute to 
discussions about diagnosis, planning treatment and research involvement. [394-
396] Parental verbal input in research consultations is on average 16%, ranging 
between 1-49%. [96] Estimates of young peoples’ involvement in research 
consultations is as low as 1-4.5%, with some young people saying nothing at all. [96] 
Parents reported that when their child raised questions in recruitment consultations, 
they were most often directed at the parent not the recruiting clinician. Although 
recruiting clinicians invited young people and parents to ask questions, they often did 
so via ‘closed’ questions which resulted in one-word responses. [96] However, 50% 
of parents approached about trial participation for their child in two trial contexts (HIV 
infection n=29, and malignant disease n=42) reported that their child contributed to 
the final decision about research participation. [349] 
 
Because young patients with a chronic or acute condition are typically supported by 
their parents, [233, 352] this changes the dynamic of the ‘physician-patient’ 




with it added complexity in terms of whether it is the patient or parent who 
contributes to treatment discussion and planning. [397] One characteristic of these 
triadic communicative interactions is that patients’ input can be limited: patient 
quantifiable verbal involvement is between 4 and 14%. Most utterances were found 
to be ‘social’ talk with the doctor, [301, 387] or the patient was an ‘information giver’ 
and had little or no involvement in planning and decision making. [388-390] The 
current study supports this observation since verbal input from young people was 
minimal in the vast majority of recruitment consultations. This may in part be due to 
the nature of the illness under investigation, but patients were affected to varying 
degrees on a mild to moderately severe continuum, so the illness cannot wholly 
account for this lack of verbal input from patients. 
 
Findings in relation to young people’s comprehension of research-related information 
- which influences their ability to make informed decisions with the support of 
parent(s) - is mixed. Some research suggests that children and young people are 
able to discern that there are risks associated with research participation. [312] Other 
studies have found that young people (aged between 7-18) had poor understanding 
of the additional risk associated with clinical research protocols, believing that 
medicines given as part of research protocols were ‘proven’ to be the best treatment 
for their illness. [383] 
 
Young people with cancer, who had been recently diagnosed, found it harder to 
distinguish between research protocols and routine clinical care in comparison to 




circumstances where young people may not fully comprehend the difference 
between research and routine clinical care, parents often play a vital supporting role 
and have reported being aware that certain tests and procedures were only carried 
out for research purposes.  [327] The concept of treatment alternatives can also be 
difficult for children and young people to understand. This could impact on the way in 
which young people understand RCT participation and clinical uncertainty 
(equipoise). [117, 383, 398] 
 
Young people making decisions in a healthcare setting have reported feeling most 
comfortable with a collaborative approach to decision-making, where they felt 
supported by parent(s) and health professionals, to make the decision to participate. 
[232, 395, 399] Young peoples’ views vary in relation to the extent they want their 
parents to take the lead and manage the decision-making process during 
discussions about their treatment. [232] Policy makers recognise the importance of 
shared decision-making, (e.g. NICE: The National Shared Decision-Making 
Collaborative). However, a recent systematic review that aimed to examine 
interventions promoting shared decision making for young people with a diagnosis of 
cancer found no eligible studies that met the inclusion criteria, despite searching 
databases from 1946 to 2012 inclusive. [400] The presence and seriousness of a 
child’s condition will influence how comfortable parents feel about making decisions 





1.11 Chapter summary 
In this chapter, I discussed the issues relating to some of the challenges associated 
with conducting RCTs. Recruitment and retention are of major importance in all trial 
contexts and can be affected by numerous barriers and facilitating factors, including: 
trial design, (e.g. blinded versus open) trial treatment interventions, (e.g. behavioural 
versus medical management), patient (and parent) characteristics, and contextual 
factors (such as health professional equipoise). Less is known about barriers to 
recruitment and retention in paediatric RCT settings. Some research investigating 
decision-making in this RCT setting are based on ‘hypothetical’ studies, or studies 
involving healthy participants. Findings may not be relevant to decision-making in 
RCT settings when young people are acutely or chronically ill. Contextual factors that 
appear to be of relevance to paediatric RCT context include the relationship that 
families establish with the recruiting medical team or the amount of time families are 
given to decide about trial participation. Ethical issues of voluntariness, patient 
autonomy and informed assent and consent are of paramount importance in the 
paediatric RCT setting, as they are in that of adults.  
A conceptual model that considers interlinking preference related factors that 
influence the decision-making process, including information, values, expectancies, 
utility and self-efficacy, highlight the complexity of investigating treatment 
preferences in an RCT context. Investigating preference in a paediatric trial setting 
comes with the added challenges of complexity in terms of communicating trial 
information to both patients, (at varied stages in their cognitive and social 
development) and parents often in stressful circumstances. Family members (those 




preferences for treatment. Preferences are not static, and the fact that young people 
and parents’ preferences for treatment may change over time has implications for 
behavioural interventions in particular that require ‘buy in’ from the patient, parent 
and treating health professional.  
 
Families motivations for participation in RCTs appear to be centred around perceived 
personal health benefits as well as altruistic motivations, or a ‘network of exchange’ 
as a way of giving back to society, future patients, friends and relatives. Health 
professionals are likely to have varied degrees of personal equipoise when recruiting 
participants to RCTs. This may affect their decision to approach families, and the 
language they use to convey information during recruitment consultations with 
families. In Chapter 2 the way in which qualitative research methods can be used in 
RCT settings will be explored in relation to the complexities described and outlined in 
this chapter. Chapter 2 will also provide details of four paediatric conditions and 





 Background - Qualitative research in 
randomised controlled trials 
 
2.1 Overview of Chapter 
Chapter 2 includes an overview of the way in which qualitative methods can be used 
effectively to investigate recruitment to RCTs, with a particular focus on exploring  
preferences for treatment. [401] It also details the key qualitative methods and 
approaches relevant to this thesis, including: qualitative interviewing (face-to-face, 
telephone and skype), the practice of audio-recording recruitment consultations, and 
communication training for those recruiting to RCTs (Section 2.3). Quality and rigour 
of data collected via qualitative research methods is also reviewed in Section 2.3, 
(trustworthiness, credibility and transferability). Background information relating to 
the conditions under investigation, (Section 2.4) and an overview of the four 
paediatric trials from which data were collected and analysed is included towards the 
end of this chapter, (Section 2.5) and finally the aims and objectives of this thesis are 
outlined (Section 2.6), along with Figure 2:3 providing a visual overview of the way in 






2.2 Qualitative research and adult randomised controlled 
trials 
The value of qualitative research in RCTs is increasingly recognised as beneficial to 
RCT design and conduct. [401] The ProtecT (Prostate testing for cancer and 
Treatment) study demonstrated that qualitative methodology was an effective way to 
identify and implement changes to RCT recruitment strategies. [98, 123, 207] The 
study used qualitative methodology to investigate barriers to recruitment and 
improve informed consent in a field which had previously failed to successfully recruit 
to RCTs. [402, 403] The authors even went as far as describing the trial as being 
embedded within the qualitative research: 
‘The ProtecT feasibility study embedded the randomised trial within the qualitative 
research and followed a sociological iterative approach. Thus, qualitative research 
methods applied in combination with open minded clinicians and flexible or 
innovative trial designs may enable even the most difficult evaluative questions to be 
tackled and have substantial impacts even on apparently routine and uncontroversial 






Differences between the complications of treatments offered in the ProtecT study 
(radiotherapy, surgery and monitoring) but not in survival rates, coupled with past 
difficulty to recruit had resulted in an environment where there was considerable 
mixed opinion in the clinical community with O’Reilly stating: ‘a study comparing 
surgery and radiotherapy is still possible, but it is unlikely ever to be a randomised 
study’. [pg. 1556] 
 
Recruiting health professionals in the ProtecT study were trained to use techniques 
which encouraged an open discussion about treatment options, randomisation and 
RCT involvement to address issues that emerged from earlier qualitative research 
within the RCT. Techniques included, re-wording misinterpreted terms such as 
‘watchful waiting' to ‘active monitoring’, changing the order that treatment options 
were presented, an emphasis on the equivalence of different treatments, actively 
exploring treatment preferences, providing evidence-based counter balancing 
information, and addressing specific patient concerns about treatment. These 
techniques improved recruitment from 40% to 70% during the first year of the study, 
[98] and immediate acceptance of treatment allocation rose from 65% to 81% in the 
following five years of recruitment. [404] 
 
Exploration of treatment preference proved crucial in allowing eligible patients to 
make a more informed decision about treatment options, many who presented 
initially with a treatment preference, found that their preference diminished after a 
more thorough explanation of all trial treatments and the lack of evidence-based 




trained to elicit and address patient concerns about treatment and preferences, in an 
open and non-coercive way that enabled those who may not have considered trial 
participation to do so. [124, 247, 407] 
 
Although the rise in those recruited to the trial could not be solely attributed to the 
changes initiated via the qualitative intervention during the ProtecT study, similar 
qualitative interventions that specifically target communication during RCT 
recruitment have now been used in a number of other RCT settings with similar 
improvements in the overall process of informed consent. [207, 408] Since many 
potential participants will present initially with a treatment preference, intuitively it is 
reasonable to assume that these preferences might diminish after in-depth 
discussion with a recruiter providing a thorough explanation of each trial intervention 
and targeted evidence-based information. [405, 409] To incorporate elements of 
measurable improvements in randomisation rates, authors have developed, refined 
and adapted this approach with varied degrees of success over the past 20 years, 
[180, 201, 202] and it is now presented as: The ‘QuinteT Recruitment Intervention’ 
(QRI). [408] 
 
The QRI is undertaken in two distinct phases which can be integrated at any trial 
phase, including feasibility, pilot, at the beginning of a main trial, or part way through 
if the trial is experiencing ongoing recruitment issues. Phase one consists of 
researchers developing an in-depth understanding of the trial recruitment process to 
identify and investigate sources of recruitment difficulties. This typically includes an 




study documentation (e.g. the patient information leaflet and consent forms), and 
analyses of audio-recorded recruitment consultations to understand what is said by 
recruiters and how participants respond to trial information. In-depth interviews can 
be carried out with members of the Trial Management Group, (TMG) clinical and 
recruitment staff, and participants eligible for recruitment, and there may also be 
observations of investigator meetings. 
 
Phase two of the QRI involves feedback of anonymised findings to the Chief 
Investigator and TMG, identifying factors that appear to be hindering recruitment and 
developing a plan of action to improve recruitment, such as how to explain 
randomisation and explore patient treatment preferences. There may be the need to 
redraft the patient information leaflet (PIL) or change aspects of organisation in 
clinical centres to stream the patient pathway. Phase two also involves an evaluation 
of the impact of the plan of action, e.g. recording the number of eligible patients 
consenting to the trial in comparison to the percentage approached about the RCT 
across recruiting sites to check if recruitment rates are improving. Interviews may be 
conducted with recruiters, asking about the acceptability of the QRI plan of action 
and the changes that have been made. The QRI approach is flexible and some or all 
elements of the model can be used depending on whether or not the trial is recruiting 
or retaining participants successfully. [408] QRI techniques have not been applied in 
paediatric RCTs, and further research is needed to explore treatment preference 





Another useful approach that incorporates qualitative and quantitative methods in 
trials research is the ‘Study Within A Trial’ initiative that aims to increase the 
evidence-base in relation to research into trial processes. (SWAT 
http://www.methodologyhubs.mrc.ac.uk/resources/swat ) [410, 411] SWATs have 
included investigations which measure the effect of PI site visits on recruitment, [412] 
alternative ways of providing PIL information [413] and assessing the effect of online 
versus classroom based training for those obtaining informed consent. [414] The 
SWAT website is a valuable information source for trialists who may be looking for 
information in relation to a specific area of trial conduct or design. The SWAT 
repository also allows for meta-analyses of SWATs as more data is deposited, 
forming a stronger evidence-base for trials methodological research. 
 
 
2.3 Using qualitative research methods to investigate 
treatment preference 
Integrated qualitative research methods are well placed to capture and report on the 
complexity of the trial context. Preference for treatment and recruiter equipoise are 
complex issues that have been explored in adult trials using qualitative methods. 
[125, 280, 407, 415, 416] Data collected during the early stages of a feasibility or 
internal pilot RCT, and the insights and theory developed from it are vital when 
developing future trial protocols, making decisions about stop-go criteria and 





2.3.1 Treatment preference: recruitment and continued 
participation 
Evidence for treatment preferences can be obtained via detailed tracking and 
analyses of RCT screening and recruitment logs. If qualitative methods are being 
used to investigate recruitment processes during an internal pilot or feasibility RCT, 
this might be carried out as soon as the trial starts screening and recruiting patients, 
to monitor recruitment numbers in or across sites. Feedback about any 
misunderstandings can be used early in the trial to instigate changes to recruitment 
processes or practice, should this be required. [408] There may be reasons why 
members of clinical team(s) do not screen eligible patients for inclusion in an RCT, 
e.g. time constraints or a lack of understanding of eligibility criteria. However, failure 
to screen eligible patients for inclusion could also indicate that those recruiting have 
an issue with equipoise and feel that one (or more), of the RCT treatments is not 
appropriate for some or all eligible patients. Further investigation via interview or 
informal discussion with staff responsible for screening eligible patients may be 
required to distinguish between the need to implement further training in relation to 
understanding the eligibility criteria or to address lack of equipoise in relation to trial 
interventions. [417] 
 
High numbers of participants dropping out immediately post-randomisation could 
indicate that families who were not allocated their ‘preferred’ treatment were 
withdrawing to receive this treatment outside the trial. This might highlight that 
preference for treatment is not being adequately discussed or understood in 




investigation of what is said during recruitment consultations could be obtained via 
the recording and analysis of recruitment consultations between patients and 
recruiters to determine whether preference is an issue. [123, 177] 
 
Views about continued trial participation (retention) can be analysed using qualitative 
methods such as interview and the recording of intervention sessions to determine 
levels of engagement with an allocated treatment regime. [418] Trialists may also 
want to determine levels of engagement with trial outcome follow-up, (trial 
questionnaires and outcome measures). [419] In some trials treatment is delivered 
over a number of weeks or months, and pre-randomisation treatment preferences 
may influence participant engagement with treatment if they were randomised to 
their preferred or non-preferred treatment group. Participants who discontinue trial 
treatments may do so because they feel they are not benefiting from their allocated 
treatment whether they initially preferred it at the time of randomisation or not. 
Participants may then wish to receive the opposite treatment offered in the trial 
(termed cross-over) or a treatment offered outside of the trial (discontinued trial 
intervention). In addition to discontinuing trial intervention, participants may also want 
to withdraw from trial follow-up. It is possible for a participant to discontinue trial 
intervention and withdraw from trial follow up or withdraw from treatment but not trial 
follow up and vice versa (although the later would result in missing data it might 






2.3.2 Qualitative interviewing 
The participant interview was the most frequently used qualitative method in the field 
of RCTs when a mapping review was carried out on journal articles published 
between 2008-2010. [209] Interviews are usually divided into three broad categories: 
structured, semi-structured and unstructured. Structured interviews are very similar 
to questionnaires, and widely used to quantify responses. Interviewees would be 
expected to provide a yes or no answer to set of pre-determined questions. 
Structured interviews can be used deductively to test existing theory. In contrast, 
semi-structured and unstructured interviews are more readily associated with 
inductive data collection, where data are collected with the aim of generating new 
interpretations and theories. [420-422]   
 
Interviews can be undertaken to explore the understanding and experiences of 
individuals who have a ‘personal stake’ in an event or process under discussion e.g. 
RCT participation. A researcher will typically use an interview topic guide, aiming to 
cover several different areas of interest, and providing a degree of structure and 
consistency across participant interviews. Participants will also be encouraged to 
raise issues they feel to be relevant and important. Using open questions during 
semi-structured interviews can facilitate a range of responses, and exploration of 
issues perceived to be important to the interviewee. [421] Open questions are 
particularly useful since they avoid a short ‘yes/no’ response to a question and 
encourage depth of discussion. [421] This type of inductive data gathering can be 
useful when researchers are seeking to generate insight or theory, when little is 




Meaning will be co-constructed by the interviewer and the interviewee during each 
interview, and the way in which the interviewee ‘makes sense’ of the questions will 
be influenced by the interviewer, who is an active part of the interview process. [423, 
424] Qualitative researchers routinely reflect on the interview process, recording 
contextual and reflexive notes after an interview, and discussing relevant issues with 
colleagues. These reflections on interview content and process can be drawn upon 
to inform analysis of the interview and improve the conduct of future interviews (see: 
Section 3.6.2 for further discussion of reflexivity and the interview process). 
 
The time point at which an interview is conducted can have a significant influence on 
the type of information that is collected. For example, retrospective interviews which 
occur sometime after a family has been randomised in an RCT may be problematic if 
researchers are seeking to gain an in-depth understanding of how young people and 
their parents’ feel about the prospect of randomisation, and their preferences for 
treatment before randomisation. However, retrospective interviews can be useful 
when seeking to gain insights relating to families’ reflections on the process of 
randomisation and continued participation after randomisation. Retrospective 
interviews can also provide insights into the way in which families report changes of 
preference for treatment as a trial progresses ensuring a discussion about 
participants’ experiences of their allocated intervention can take place. [424, 425] 
 
A series of interviews conducted before and after randomisation, and after delivery of 




over the course of the trial. [426] There may be some instances where the time-point 
of interview is restricted by the trial protocol, to post randomisation or post primary 
outcome measure (e.g. six-month time point). These restrictions may be imposed to 
avoid researcher interaction with participants, and their engagement in an interview 
that may influence the way participants think about or engage with randomisation or 
treatment interventions. 
 
Interviews are also useful when investigating what influences decision-making 
processes. In RCT research this might include the decisions made by recruiters 
about which patients were eligible and approached about a trial. [408] Interviewing 
families who do not provide consent to trials provides insight into their reasons for 
declining to participate, that may include preferences for treatment. Families who 
decline a trial may feel they need to provide ‘justification’ as to why they did not wish 
to take part. [427] Therefore, these families may be harder to engage in the research 
process, and care should be taken to introduce the ‘interview’ as a discussion that is 
inclusive of all families’ experiences irrespective of participation outcome. Joint 
interviews with a young person and their parent, or two parents might also include 
discussions or debates about what influenced the ‘joint’ decision to participate, or 
decline the RCT. 
 
Interviewing children, young people, parents and health professionals 
Ensuring that children and young people are able to provide feedback about the 
research projects they are asked to participate in is a vital part of the successful 




people highlights that they often enjoy taking part in research and feel that it is a way 
of helping others and learning more about their health condition. [172, 173] Ensuring 
the methods used to collect data are appropriately chosen to maximise the quality of 
data obtained is vital in any research setting, but when conducting research with 
young people additional consideration is needed to ensure they feel comfortable and 
confident in the research setting. Kvale 2007 described the interview process as ‘a 
professional conversation’ [429] [pg. 14] highlighting the asymmetry in terms of 
power between the interviewer and the interviewee. This power imbalance is 
exacerbated when interviewing a young person or child, who may feel a need to 
convey a ‘correct’ answer. [430-432] In some circumstances a young person may 
have been encouraged by their parent to participate in an interview (or a research 
trial) despite their apprehension about the situation. [433, 434] 
 
Encouraging young people (and children) to talk openly with an individual they have 
just met can be facilitated by building initial rapport with a parent and their child, and 
by asking age appropriate unrelated or ‘non-research’ questions at the beginning of 
the interview (e.g. favourite animal or holiday destination). [428] Methods of building 
rapport and ensuring children and young people are comfortable with the interview 
situation will vary depending on the age and preferences of the interviewee. [44, 435, 
436] Setting up basic ‘ground rules’, (prior to the more formal process of signing the 
assent/consent form) at the beginning of the interview process can give the young 
person an idea of what to expect, particularly if they have no experience of taking 
part in a research interview.[433, 437] By confirming how long the interview is 




‘topics’ the discussion will cover, and that they can stop at any time or not answer 
questions without giving a reason may help alleviate any apprehension about the 
‘formality’ of the interview setting. [438, 439] 
 
Activities such as colouring and drawing while answering questions may help some 
young people to engage and interact during an interview; these tasks eliminate the 
need to maintain eye contact between the interviewer and interviewee and change 
the ‘focus’ of the interaction. [435] Having an interactive interview schedule that 
children can annotate is also another way of engaging children as the interview 
proceeds, potentially enhancing their focus and understanding of the subject matter. 
[440] Sending a ‘topic guide’ or interview schedule in advance (to any research 
participant irrespective of age), or explaining what the discussion will involve by 
telephone prior to the interview are also ways in which researchers can ensure 
young people are more informed about what the interview will involve. [441] 
 
Young people may request that their parent be present during their interview; this 
can be helpful since it can be reassuring for them, and parents can provide important 
contextual information allowing the young person to recall more about a situation or 
procedure. [437] However, any co-constructed interview setting where more than 
one participant is contributing will potentially be more challenging for the interviewer. 
[428] Young people may defer to their parent if they are present, and the interviewer 
will be required to try and actively encourage the young person to answer questions 




disagreements between the young person and their parent should be dealt with 
sensitively. It is useful to note any observed dynamics which occur during an 
interview, such as mum or dad interrupting the young person (or vice versa) when 
they are trying to give an account of their experiences. [442] If a young person is 
present while their parent is being interviewed it is necessary to be mindful that the 
young person will be listening to the questions being asked, which in some cases 
may be directly about their condition and recovery. [443] 
 
Face-to-face, online (skype) and telephone interviews 
Face-to-face interviews are often classed as the ‘gold standard’ context in which to 
conduct qualitative research interviews. However, more recently online (skype) and 
telephone interviews have been used in more research settings. [444-447] Skype 
and telephone interviews can be useful when interviewing participants who live 
across a wide geographical area, [448] or where travel to participants’ homes may 
be time consuming and increase research costs. Individuals experiencing painful and 
chronic symptoms, (such as those associated with CFS/ME) can participate in an 
interview that they might not otherwise have felt well enough to engage in, without 
the disruption and formality of a researcher coming to their family home. Young 
people may feel comfortable being interviewed by someone remotely since they 
participate in many virtual activities and discussion with peers. [449] 
 
Skype and telephone interviews could be perceived as less asymmetrical in terms of 
the ‘power’ inequality between interviewer and interviewee, particularly for young 




not want to continue to answer questions they could simply switch off the Internet 
connection or call and terminate the interview more easily than if they were 
participating in a face-to-face setting. [451] One of the most notable issues with 
skype interviews can be problems with connectivity, sound quality, and difficulties 
with rapport if there is a time lag between the interviewee and interviewer. [449, 452] 
Installing the correct software is something highlighted by parents more so than 
young people as an additional time consuming ‘hassle’ associated with a skype 
discussion. [449] The influence of ‘researcher effects’ based on participants’ 
perceptions of researcher characteristics such as class, age, gender and ethnicity 
may also be less apparent during telephone interviews. [453] 
 
Interviews with colleagues 
Collecting interview data with colleagues who have previously worked alongside the 
interviewer can also be challenging, irrespective of mode of interview. This may raise 
ethical issues of disclosure and confidentiality. Although having existing rapport and 
familiarity may mean that the dynamic of the interview is one which is relaxed and 
allows for depth of discussion, neutrality will be required if a colleague participating in 
an interview has a different stance or perception of events. [454, 455] 
 
2.3.3 Audio-recorded recruitment consultations 
The audio recording of recruitment consultations as a method of data collection has 
been used by several qualitative studies investigating RCT recruitment processes. 




collecting data to obtain an in-depth understanding of the way in which recruiters 
describe RCT rationale, design and interventions. [408] It is also possible to gain a 
greater understanding of the questions that prospective participants have when they 
are provided with information about RCT participation and an understanding of 
reasons given for declining or participating in the RCT. [123, 125] If RCT information 
is not being provided from a position of equipoise further training can be provided for 
recruiting teams as a whole or tailored to suit the needs of individual recruiters and 
delivered on a one-to-one basis. 
 
Using a combination of data collection methods, particularly audio-recorded 
recruitment consultations and interviews with recruiters and families, is useful when 
the aim of data collection is to gain an in-depth understanding of what is said during 
the course of a recruitment consultation, as well as the way in which individuals 
reflect upon and make sense of what was said during the recruitment consultation. 
[96] Data collected via interviews with health professionals can be used to gain 
greater understanding of recruiters’ experiences and feelings about recruiting to trial 
but can also include an in-depth discussion of specific recruitment consultations, e.g. 
a consultation which highlighted best practice, or a discussion that felt problematic to 
the recruiter. [177] 
 
2.3.4 Providing training for recruiters and wider clinical teams 
Training can be a key part of improving trial conduct. [206, 207, 247, 408] Providing 
feedback in relation to recruitment consultations and gaining feedback from health 




equipoise. [246]Providing on-going support to deal with both the practical aspects of 
recruiting (e.g. making changes to the recruitment process so it runs more smoothly 
and targets are reached), and the ‘emotional’ aspects of recruiting to trials (e.g., 
dealing with patient disappointment), are also of paramount importance. [197, 457] 
 
2.3.5 Assessing the quality of qualitative research 
Trustworthiness, credibility and transferability 
Terms such as ‘trustworthiness’, ‘credibility’ and ‘transferability’ are often used when 
considering the quality and rigour of data collected via qualitative research methods. 
[420, 458, 459] Such terms are used in place of the established concepts of 
reliability, validity or generalisability, which are associated with the rigour of 
quantitative methods. [460] Triangulation is a concept that relates to the 
trustworthiness of qualitative research findings and is used to enhance the credibility 
of findings and theory generated by a study. Triangulation can involve multiple 
researchers, data or theoretical frameworks: two or more researchers analysing the 
same sample of data, two or more data sources or using more than one theory to 
explain a phenomenon. [461] Triangulation is largely associated with a realist 
paradigm since it strives to eliminate subjective bias and relies upon the concept of a 
‘superior explanation’. [462] [pg. 1117] A similar useful concept is ‘crystalization’: a 
practice that uses multiple researchers, varied methods and theoretical frameworks, 
but the aims for doing so lie in the development of a more in-depth and thorough 
understanding of the issues under investigation. [463] Transferability of qualitative 
research findings is ensured by reporting a detailed description of the context, 




used to collect and analyse data from an RCT. It is then possible for those working 
on future RCTs to decide if a piece of research is ‘similar’ to their own RCT context 
and participant population to decide if the findings are transferable. [464] 
 
 
2.4 Conditions under investigation in this thesis  
2.4.1 Chronic fatigue syndrome/myalgic encephalomyelitis 
(CFS/ME) 
Condition: CFS/ME is characterised by debilitating fatigue that is triggered by 
minimal activity, unlike everyday fatigue which often improves after sleep. CFS/ME 
patients typically report unrefreshing sleep, post-exertional malaise, cognitive 
difficulties, (e.g., problems with concentration and recall) and chronic pain. [465] 
Children and young people will be diagnosed with CFS/ME only if their symptoms 
have persisted for more than three months. [465] CFS/ME has a negative impact on 
quality of life and school attendance, affecting social and emotional development in 
adolescence. [466-470] On average, children aged 11-16yrs with a diagnosis of 
CFS/ME missed ≥20% of school, [471] and at some stage over half are bed bound. 
[472] Between 54–94% of young people and children diagnosed with CFS/ME 
recover with specialist treatment, unlike the recovery rate in adults who have 
treatment, which has been reported to be as low as 22%. [473-475] 
 
Treatment: NICE 2007 [465] guidance recommends referral to specialist services 




patients (who are not participating in an RCT) are offered a combination of Cognitive 
Behavioural Therapy (CBT), Graded Exercise Therapy (GET) or activity 
management (AM) to treat CFS/ME depending on their needs and goals. All young 
people are routinely offered advice about sleep, and medication use. [465, 476, 477] 
Treatment aims to convert the ‘boom and bust’ pattern of activity into a sustainable 
pattern of gradually increased activity leading to recovery. A typical boom and bust 
cycle of activity involves doing lots of on a good day (physical, cognitive or 
emotional) when the young person is feeling relatively ‘well’ and doing very little or 
nothing on subsequent bad days. On a bad day the young person may be confined 
to their bed or the sofa because they had ‘crashed’ and experienced increased 
symptoms of fatigue. 
 
Specialist Paediatric CFS/ME Service: Treatment in the SMILE, MAGENTA and 
FITNET-NHS trials was delivered by a paediatric CFS/ME specialist service. During 
the SMILE and MAGENTA trials, a diagnosis of CFS/ME was given or confirmed 
during a face-to-face initial assessment appointment. Follow-up appointments were 
family-based meetings (lasting one hour), with a health professional working on the 
team. During the SMILE RCT all follow-up appointments were completed on a face-
to-face basis, during the MAGENTA trial families were offered follow-up 
appointments via Skype if they did not wish to travel to a face-to-face appointment. 
During the FITNET-NHS trial the initial assessment was conducted via telephone, 
and a diagnosis was provided if this had not already been established prior to 
referral to the service (see: Appendix 5: FITNET-NHS: Eligibility assessment). The 
timing and number of follow-up sessions typically varied depending on individual 




to six months. Health professionals working on the specialist team included: clinical 
psychologists, physiotherapists, occupational therapists and paediatric consultants. 
The specialist team delivered follow-up treatment based on NICE guidelines. [465] 
Detailed information leaflets on all aspects of treatment (e.g. sleep hygiene, 
relaxation) were provided on a website maintained by the Paediatric Specialist 
CFS/ME Service. 
 
2.4.2 Acute uncomplicated appendicitis 
Condition: Acute uncomplicated appendicitis is the most common surgical 
emergency in children, [478] and commonly occurs in early adolescence. The 
lifetime incidence of appendicitis is 7-8%. [479] It is characterised by inflammation of 
the appendix which is a narrow tube which extends from the large intestine, see 
Figure 2:1. Inflammation and the subsequent infection is thought to be caused by 
obstruction of the lumen of the appendix, typically caused by faecal matter. [480] 
Appendicitis is experienced initially as intermittent pain in the lower abdomen, which 
then travels to the lower right-hand side of the abdomen and become more severe 
and constant. Pressure and movement can make the pain feel more severe and 






Figure 2:1 Information sheet for teenagers (12-15 yrs.) v2: Inside your tummy 
 
Treatment: In 2014 there were approximately 12,000 emergency appendicectomies 
performed on children in England. [479] Most surgeons in the UK still consider 
appendicectomy to be the gold standard treatment for acute uncomplicated 
appendicitis. [481] Intravenous antibiotics are administered to patients until they 
undergo an appendectomy either by laparoscopic or open surgery. Although 
appendectomy is a relatively routine procedure, there are associated risks, which 
include those associated with a general anaesthetic and the complications 
associated with surgery. The rate of complications associated with the surgical 
procedure may be as high as 25%. [482] The need for re-admission to hospital 
because of post-operative complications is 4-5%. [483, 484] Table 2:1 provides a 
breakdown of the type of complications which may arise from appendectomy. There 
is also the possibility of removing a histologically normal appendix. The rate of 
‘negative’ or unnecessary surgery was 10%, when measured in 242 cases of 
paediatric appendicectomy across 19 surgical units. [485] In the same paediatric 
population the need for re-admission, re-intervention and complication after surgery 




A benefit of the removal of the appendix is that there is no risk of a recurrent episode 
of appendicitis in the future. However, the prospect of undergoing a surgical 
procedure can cause a significant amount of stress, (both psychological and 
physiological) for a paediatric patient. Parents are likely to be apprehensive about 
their child undergoing a general anaesthetic and surgery, and some may question 
whether a surgical procedure is necessary, particularly if their child presented with 
few or minor symptoms and begins to recover when given initial non-operative 
treatment (fluids and antibiotics will be administered prior to surgery). Table 2:1 
shows a breakdown of the type of complications which may arise from non-operative 
treatment of appendicitis. Estimates of recurrence of appendicitis when treated non-
operatively in the paediatric population are between 5-25%. [486-488] A recent 
meta-analysis estimated that the risk of recurrence of appendicitis in 413 children 
treated non-operatively was approximately 14%. [489] There is a significant financial 
burden associated with carrying out appendectomy in the paediatric population, this 





Table 2:1 Associated risks: Appendectomy and non-operative treatment 
Risks associated with surgical (appendectomy) 
management of appendicitis  
Risks associated with non-
operative (conservative) 
management of appendicitis 
General anaesthetic side effects (common and include: 
sickness and vomiting, bladder problems, dizziness, 
bruising, sore throat, shivering or feeling cold and 
damage to the mouth or teeth) 
 
General anaesthetic complications (rare but include: 




Complications during surgery (damage to other organs 
and bleeding) 
 
Complications after surgery (wound infection, 
haematoma, intra-abdominal or pelvic abscess, 
adhesional small bowel obstruction, scarring and 
incisional hernia) 
https://www.nhs.uk/conditions/appendicitis/complications/  
Antibiotics fail to treat the 
infection and symptoms to do 
improve 
 
Recurrence of the condition 
and the need for hospital 
readmission and further 
treatment with antibiotics or 
surgery 
 




It has been known for many years that appendicitis can be treated non-operatively, 
usually in situations or locations where it is not possible to carry out a surgical 
procedure. [490] There has been a growing interest in investigating non-operative 
treatment of appendicitis and establishing an evidence base so that it can be 
incorporated into mainstream health care systems. [491-497] Antibiotics are routinely 
used to treat complex cases of appendix mass in children and adults. [498-500] In 
the paediatric population a scheduled or ‘interval’ appendectomy (delayed surgery) 





An appendix mass is the result of a more severely infected appendix, and surgeons 
will avoid operating immediately because of increased risks of complications and 
further localised infection. [501] The practice of routinely removing the appendix after 
successful non-operative treatment of an appendix mass has been questioned in 
recent years because recurrence of appendicitis is low, and there are additional 
complications and risks associated with potentially unnecessary surgery. [502] 
Although data from studies carried out with paediatric patients is scarce, a recent 
systematic review suggested that 80% of paediatric patients with an appendix mass 
did not require surgery. [486] A multi-centre RCT carried out with paediatric patients 
diagnosed with appendix mass also showed that three-quarters could be 
successfully treated without the need for surgery. [498] 
 
Research into the treatment of acute appendicitis, (which is clinically different to an 
appendix mass) with antibiotics in paediatric populations has shown that between 
62-93% of patients can be treated successfully non-operatively. [503-505] However, 
these were relatively small studies, and only one used randomisation to allocate 
participants. [503] Providing it is safe and effective, non-operative treatment for acute 
uncomplicated appendicitis is considerably more cost effective when compared to 
operative treatment, The National Appendicectomy Audit  showed that 45% of 
paediatric appendectomies were carried out between 18.00pm-8.00am, therefore 
non-operative treatment would reduce the demand for costly out-of-hours surgery. 
[506] Ultimately the safety and efficacy of treating appendicitis non-operatively in 





Paediatric care for acute uncomplicated appendicitis: Treatment in the 
CONTRACT RCT was delivered by paediatric surgeons working on three specialist 
NHS paediatric surgical units in England. This treatment typically consisted of an 
initial physical examination and diagnosis of acute uncomplicated appendicitis. 
Young people allocated to receive an appendicectomy underwent either open or 
laparoscopic appendicectomy at the surgeon’s discretion. Young people receiving 
non-operative antibiotic treatment were cared for by the same consultant surgeons 
and wider paediatric nursing staff caring for those on the appendectomy pathway 






2.5 Collaborating trials (qualitative data sources) 
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2.5.1 SMILE - Specialist Medical Intervention and Lightning 
Evaluation  
SMILE trial rationale  
Many young people accessing the Specialist Paediatric CFS/ME Service have 
experienced CFS/ME symptoms for a prolonged period of time, [471, 507] and 
families often enquire about or report using a number of different complementary 
treatments. These treatments include: homeopathy, acupuncture, dietary methods, 
herbal remedies and the Lightning Process®. [508] Families accessing paediatric 
specialist CFS/ME services wanted advice about whether the Lightning Process 
might be an appropriate treatment for their child, and some provided feedback about 
their child’s attendance on the course. It is estimated that over 250 young people a 
year used the Lightning Process intervention for CFS/ME in 2010, but no studies had 
investigated whether it was either effective or safe. [78] Integrated qualitative 
methodology was used to assess the feasibility and acceptability of conducting the 
SMILE RCT, specifically to understand issues that would relate to the successful 
design and implementation of a full-scale RCT (see: Appendix 3: SMILE: Integrated 
qualitative aims and objectives). [78] The SMILE trial flow diagram can also be found 
in Appendix 3. 
 
SMILE intervention groups 
Specialist Medical Care (SMC) consisted of a combined approach to energy 
management that included elements of activity management and Graded Exercise 
Therapy. Young people were routinely given advice in relation to improving their 





emotional and psychological support. 
 
The Lightning Process (LP) course is a training programme which uses the basic 
premise that the body and mind work together to affect your health. It trains 
participants to recognise when they are triggering unhelpful physiological responses, 
with the aim of developing more appropriate responses to challenging behaviours 
and situations (www.lightningprocess.com). It is run as a group course for 3 hours 45 
minutes a day on three consecutive days. Courses were run specifically for young 
people participating in the SMILE RCT (Appendix 3: Inclusion/exclusion criteria). A 
parent was able to accompany their child on the course as an observer, they did not 
participate in course activities. The course is facilitated by one LP Practitioner trained 
to use principles drawn from neurolinguistic programming (NLP), hypnotherapy and 
life coaching. Lightning Process practitioners are not medically trained. See 
Appendix 3: for further details of both SMILE intervention groups. 
 
2.5.2 MAGENTA - Managed Activity Graded Exercise in Teenagers 
and Pre-Adolescents 
MAGENTA trial rationale 
NICE guidance recommends that young people are referred to specialist services to 
receive specialist care which typically involves a combination of either CBT, Graded 
Exercise Therapy or activity management to treat CFS/ME depending on the 
patient’s individual needs and goals. [465] Since elements of activity management 
and Graded Exercise Therapy were being used in combination by most of the young 
people using the specialist service, it was impossible to understand which elements 





Treating young people with a combination of Graded Exercise Therapy and activity 
management also puts significant restrictions on all areas of young people’s day-to-
day lives (both cognitive and physical activities) and requires them to take in high 
volumes of information about more than one treatment approach. 
 
During the planning phase of MAGENTA there were several RCTs investigating the 
effectiveness of Graded Exercise Therapy with adult CFS/ME patients [509] but 
there was no evidence for its effectiveness or cost effectiveness for paediatric 
CFS/ME patients. It is not possible to extrapolate results from adult trials, and 
CFS/ME in young people has been shown to have different symptoms and a more 
optimistic recovery rate compared to adults. [475] A feasibility trial with young people 
(see: Appendix 4: Inclusion/exclusion criteria) was needed to assess the feasibility 
and acceptability of conducting a full-scale RCT investigating Graded Exercise 
Therapy compared with activity management in a paediatric population, (see: 
Appendix 4: MAGENTA: Integrated qualitative aims and objectives and trial flow 
diagram). 
 
MAGENTA intervention groups 
Graded Exercise Therapy (GET) is a NICE recommended intervention for young 
people with mild to moderate CFS/ME. [465] It is currently used by the Specialist 
Paediatric CFS/ME Service in addition to other CFS/ME treatments such as CBT 
and activity management. In the MAGENTA trial Graded Exercise Therapy offered 
advice that was focussed on exercise and a detailed assessment of daily physical 





overexertion.  The level of physical activity was gradually increased in intensity, 
using a programme tailored to the young person’s individual goals. For a detailed 
overview of the way in which Graded Exercise Therapy was monitored via 
‘mandatory’, ‘flexible’ and ‘prohibited’ activities see Appendix 4: MAGENTA 
Intervention groups. 
 
Activity management (AM) is also a NICE recommended intervention for young 
people with mild to moderate CFS/ME. [465] Activity management is also used 
alongside other CFS/ME treatments such as CBT and Graded Exercise Therapy. 
Activity management in the MAGENTA trial focused on the ‘cognitive’ component of 
activity management (as opposed to cognitive, physical and emotional components 
of a combined activity management programme outside the RCT). Cognitive 
activities that were monitored in the trial included: time at school or doing 
schoolwork, reading, some craft/hobbies, socialising and screen time (phone, laptop, 
TV, computer, other devices). For a detailed overview of the way in which activity 
management was monitored via ‘mandatory’, ‘flexible’ and ‘prohibited’ activities see 
Appendix 4: MAGENTA Intervention groups. 
 
2.5.3 FITNET-NHS - Fatigue In Teenagers on the interNET in the 
NHS 
FITNET-NHS trial rationale  
Most children in the UK are unable to access a local specialist paediatric CFS/ME 
service (see: Figure 2:2 below). NICE guidelines recommend that children and 
young people should be offered referral to a specialist service within six months if 





immediately if they are severely affected. [465] Because most young people live too 
far away from specialist services to access face-to-face appointments, having 
access to online and skype appointments with a specialist team is a potential 
alternative mode of treatment delivery for patients who often experience an increase 
in symptoms when they travel a significant distance from their home. Although 
FITNET was found to be effective in the Netherlands, [510] it has not been used 
within the NHS in the UK therefore, it was necessary to investigate whether the 
implementation of FITNET in the NHS is cost-effective, feasible and acceptable (see: 
Appendix 5: FITNET-NHS: Integrated qualitative aims and objectives and trial flow 





Coloured areas represent specialist 
paediatric CFS/ME services in UK.  
 
Included in this thesis courtesy of 
Professor E Crawley. 
Figure 2:2 Specialist paediatric CFS/ME services in UK 
 
FITNET-NHS intervention groups 
FITNET Online CBT is a treatment package specifically for paediatric CFS/ME 
patients, it was created in the Netherlands. [510] The programme has psycho-
educational and CBT sections for young people and a separate parallel programme 





of CFS/ME: the relationship between CFS/ME, anxiety, depression and other 
illnesses. How the diagnosis is confirmed. Treatment for CFS/ME. How to explain 
CFS/ME to friends and what the future (without CFS/ME) is likely to look like. The 
CBT section is activated by a clinical psychologist once the child/parent has 
completed the psycho-educational sections (Appendix 5: FITNET-NHS Intervention 
groups). 
 
Activity management via Skype incorporated cognitive, physical and emotional 
components of a combined activity management programme (unlike the MAGENTA 
trial which focused only on the cognitive component). During the FITNET-NHS trial 
treatment all appointments were delivered via skype. For a detailed overview of the 
way in which activity management was monitored via ‘mandatory’, ‘flexible’ and 
‘prohibited’ activities see Appendix 5: FITNET-NHS Intervention groups. 
 
2.5.4 CONTRACT - CONservative TReatment of Appendicitis in 
Children – randomised controlled Trial (Feasibility study) 
CONTRACT trial rationale  
The aim of the CONTRACT study was to assess the feasibility and acceptability of 
recruiting children and young people (see: Appendix 6: Inclusion/exclusion criteria) to 
a multi-centre RCT with two intervention groups, non-operative (antibiotic) or 
operative treatment (appendectomy) for acute uncomplicated appendicitis. 
Antibiotics are routinely used to treat complex cases of appendix mass in children 
and adults. [498-500] Cases of appendix mass are initially treated with antibiotics to 
reduce infection, which can include peritonitis and infection of the abdominal cavity 





appendectomy (delayed surgery). However, if patients are recovered the question as 
to the necessity of surgery is raised. Many parents find the proposal that their child 
needs emergency surgery frightening and one they are keen to avoid if a safe 
alternative is available. [358, 504] Antibiotic treatment for acute appendicitis was 
(and is currently) not routinely offered by the NHS when children, young people or 
adults are given this diagnosis. Findings from the CONTRACT feasibility trial will be 
used to determine whether families are willing to participate in a trial comparing 
surgical and antibiotic treatment for acute uncomplicated appendicitis in young 
people, and whether surgical teams are able and willing to recruit. (see: Appendix 6: 
CONTRACT: Integrated qualitative aims and objectives and trial flow diagram). This 
will inform the planning and implementation of a larger full-scale multi-centre cost 
effectiveness, pragmatic RCT. 
 
CONTRACT intervention groups 
Non-operative intervention (antibiotics): Young people randomised to receive 
antibiotic treatment received fluids and a minimum of 24-hours broad spectrum 
intravenous antibiotics, (cefotaxime and metronidazole) as per local policies. 
Reviewing surgeons actively monitored participants for any changes in symptoms, 
such as (but not limited to) increased fever, tenderness and tachycardia. Formal 
reviews were performed 24 and 48 hours post-randomisation, and any participant 
deemed to have significantly deteriorated underwent an appendicectomy. If 
consultant surgeons observed deterioration at any stage prior to the 24 and 48 hour 
reviews the possibility of an appendectomy was discussed with parents and the 





treating consultant since predefined criteria for the management of non-operative 
appendicitis did not exist. Participants who were stable or improved clinically 
continued with antibiotic treatment and active monitoring. Participants who required 
an appendicectomy for failure of non-operative treatment underwent an operation 
and were treated post-operatively according to standardised appendectomy 
treatment pathways at each participating institution (described below). 
 
Operative intervention (appendectomy): Participants randomised to receive an 
appendectomy received fluids and broad-spectrum intravenous antibiotics from the 
time of randomisation (identical to those used in the non-operative intervention 
group). Participants then underwent either open or laparoscopic appendicectomy at 
the discretion of the supervising surgeon. See Appendix 6: CONTRACT: Intervention 






2.6 Thesis aim and objectives  
Aim: 
 
To explore how treatment preferences influence recruitment and participation in 




1. Undertake a systematic literature search and qualitative synthesis of studies 
that have reported treatment preference in paediatric RCTs, (children and 
young people aged 0-17 years and parents). 
 
2. To develop an understanding of the way in which treatment preferences are 
expressed by young people and their parents during recruitment to paediatric 
RCTs. 
 
3. Understand how health professionals respond to treatment preferences 
expressed by young people and their parents.  
 
4. Investigate the effectiveness of recruiter training in responding to  expressed 
treatment preferences and explore whether this had an impact on recruitment. 
 
Figure 2:3 (see next page), visually displays the way in which the aim and objectives 










2.7 Chapter Summary 
This chapter included a detailed overview of the way in which qualitative methods 
can be used effectively to investigate recruitment processes, specifically preferences 
for treatment in RCTs. Three paediatric feasibility trials investigating complex 
behavioural interventions for young people with CFS/ME were introduced (SMILE, 
MAGENTA, and FITNET-NHS), along with a surgical feasibility RCT recruiting young 
people with acute uncomplicated appendicitis (CONTRACT). The aim and objectives 
of this thesis were outlined, along with a figure, (Figure 2:3) providing a visual 
overview of the way in which preferences for treatment were explored. Qualitative 
researchers working in any setting are required to think about the concepts of 
trustworthiness, credibility and transferability when collecting and analysing 
qualitative data. Key methods of collecting data (such as in-depth interview and 
audio-recording recruitment consultations), and methods to improve trial conduct 
(such as communication training for those recruiting to RCTs) were highlighted as 
useful approaches when exploring recruitment processes in an adult trial context. 
However, these methods have not been used in a paediatric trial setting; I believe 
there is scope to do so, therefore Chapter 3 will detail the way in which these 








3.1 Overview of Chapter 
This chapter details the qualitative research methods drawn upon for data collection 
and analyses for the doctoral research. This includes an initial rationale for the use of 
qualitative methods in this research area. Section 3.3 describes the methods used 
for the systematic search of literature and synthesis of qualitative data. Section 3.4 
details the way in which elements of the QuinteT Recruitment Intervention (QRI) 
were used to inform data collection in each qualitative sub-study, this included: 
screening, recruitment and retention figures, audio-recorded recruitment 
consultations and interviews with families and members of clinical teams. Data 
analyses methods are described in Section 3.5, including methods relevant to each 
of the four paediatric trials, and the way in which this data were drawn together and 
analysed collectively. Finally, the ways in which ethical implications were considered 
are presented in Section 3.6, these included burden and disclosure, researcher 
reflexivity, safety, lone-working and data related considerations such as anonymity, 





3.2 Rationale for qualitative methodology 
Barbour 2000 highlights the role of qualitative research in relation to its potential 
contribution to evidence based medicine, defining qualitative research as 
‘exploratory’ and used to address questions of: ‘what, why or how’, as opposed to 
questions which seek to quantify evidence or estimate a ‘significant difference’ 
between groups. [511] Qualitative research seeks to describe, understand and 
explain phenomena with an emphasis on context, using methods of data collection 
(such as interviews or focus groups) which place at the forefront the perspectives of 
the individuals participating in the research. Barbour also states that ‘qualitative 
research is well placed to provide an enhanced understanding of communication’ 
[pg. 156] by documenting difficulties or obstacles in the communication process, as 
well as focusing on language used to convey and provide explanations of events 
such as diagnosis, treatment and the opportunity to participate in research activities.  
 
O’Cathain recently outlined ‘10 rationales’ for using qualitative research methods in 
RCTs, [401] [pg5-10] one of which is ‘to understand complexity’. Qualitative methods 
are well placed to explore the complexity of preferences for treatment in paediatric 
RCTs, since preferences could be expressed by young people, parents or health 
professionals. Using different qualitative data sources enables exploration of the 
complexity of recruitment practice, for example, analysis of participant flow, 
(recruitment figures) in combination with the way in which preferences are 
communicated, (audio-recorded recruitment consultations) viewed, and experienced 





RCTs operate within the ‘positivistic’ (realist) tradition which assumes there is a 
‘truth’ out there to be discovered via the application of rigorous objective and 
unbiased scientific methods of data collection and analyses. [512, 513] RCTs 
develop meaning via quantification and establishing a causal relationship between 
variables under investigation. [464, 514] In contrast, qualitative research methods 
can be located on a continuum from critical realist (contextualism) [515] to relativism 
(constructionism). [516] This does not assume that there is a discoverable truth; 
instead meaning is constructed via discourses which are often based on well-
established cultural and political ideologies, e.g. discourses around mental health. 
[517] 
 
Since I found myself working between the potentially opposing worlds of RCT and 
qualitative research epistemology (and associated methods), I adopted the ‘middle 
ground’ of contextualism which does not assume a single reality, but neither does it 
reject the idea that knowledge can be considered valid in certain contexts. [518, 519] 
Contextualism also sits with the ‘critical realist’ position which underpins the 
grounded theory approach was used for data analyses in each of the four RCTs, 
(see: Section 3.5: Data analyses: Qualitative methods embedded in four paediatric 
trials). [422] There are multiple possible ‘readings’ or ways of making sense of 
qualitative data. Researchers play a part in shaping the data collection and analytical 
processes, (see: Section 3.6.2: Reflexivity). Some methods are linked to an 
approach or epistemology (such as constant comparison methods and Grounded 
Theory), while others such as thematic analysis can be applied independently of an 




3.3 Systematic literature review and qualitative synthesis 
3.3.1 Protocol and formulating the research questions 
I developed and registered the review protocol with PROSPERO: 
https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015015942. 
[520] Scoping exercises were used to define and refine relevant search terms initially 
the PICOC model was used: Population, Intervention, Comparison, Outcomes and 
Context. [521] 
 
3.3.2 Eligibility and inclusion criteria 
Qualitative or quantitative papers were eligible for review if they reported: i) young 
people aged 0–17yrs recruited to an RCT: ii) reported either primary RCT 
outcome(s) and/or secondary findings including embedded/related qualitative studies 
iii) reported treatment preference for all or some of the participants/parents and iv) 
any clinical area. Database searches were limited to 1950-2014 inclusive (Appendix 
2: Eligibility and inclusion criteria). 
 
3.3.3 Search strategy 
A search strategy was developed with guidance from University of Bristol data 
specialists (NIHR CLAHRC West and Cochrane Group), the search strategy can be 
found in Appendix 2 (MEDLINE Search strategy). Database searches of MEDLINE, 
CINAHL, EMBASE, and COCHRANE were carried out. Relevant reference lists and 
work not published in peer-reviewed journals such as dissertations (‘grey literature’) 




containing registered clinical trials. (http://proquest.umi.com/login, 
http://www.open.ac.uk/library/library-resources/theses-dissertations, 
https://www.ukctg.nihr.ac.uk/, https://clinicaltrials.gov/ct2/home  
http://www.anzctr.org.au/TrialSearch.aspx)  
Authors were contacted by email to establish whether full RCT results had been 
published. Two provided copies of their papers, [325, 522] and three confirmed that 
they had not yet published findings. [523-526] 
 
3.3.4 Screening and data extraction 
Duplicate papers retrieved from database searches were removed using Cochrane 
Register of Studies (CRS), (desktop version 2015). Each title and abstract was 
screened for inclusion by two reviewers using the data platform Covidence, 
(Appendix 2, Title and abstract screening: Inclusion criteria). [527] Discrepancies 
were documented, discussed and resolved in regular meetings attended by 
reviewers and the wider systematic review study management team (EC and NM). 
Questions about the eligibility criteria were addressed in these meetings to ensure 
that the eligibility criteria were understood and any screening queries were resolved 
consistently. At the full text review stage papers were read in chronological order by 
two researchers (LB and AB, HK, RL or RP). Author(s) extracted relevant numeric 
data and/or descriptive reports of treatment preference into an Excel template (see: 
Appendix 2: Data extraction fields). These data were summarised (see: Table 4.1) 
and aggregated (Table 4.2). [528, 529] Qualitative data (participant quotations and 
first authors discussion points relating to treatment preference) were imported into 




3.3.5 Critical appraisal of synthesised papers 
Qualitative papers [66, 74, 96, 97, 107-109, 115, 120, 325, 326, 531] with relevant 
participant/parent quotations for inclusion in the qualitative synthesis were critically 
appraised using the Critical Appraisal Skills Programme (CASP) qualitative research 
check-list (Appendix 2: CASP). [532] Each paper was appraised by two members of 
the systematic review team (LB and either, AB or RP). Disagreements were 
discussed by the team members who had appraised the paper and resolved by a 
senior member of the supervision team (EC). [533, 534] The appraisal tool was used 
to explore the qualitative papers in more depth, and a sensitivity analysis was carried 
out to investigate whether leaving lower quality papers out of synthesis altered the 
qualitative findings. Because this review did not seek to statistically measure 
treatment preference between trial groups, and due to time restraints and the high 
number of papers retrieved with relevant descriptive preference data, the remaining 
40 papers were not assessed for risk of bias. [8] 
 
3.3.6 Synthesis of qualitative data 
Meta-ethnography 
The synthesis of qualitative data drew on techniques of meta-ethnography, initially 
outlined by Noblit and Hare in a seven step process: 1. Getting started, 2. Deciding 
what is relevant to the initial interest, 3. Reading the studies, 4. Determining how the 
studies are related, 5. Translating the studies into one another, 6. Synthesising 
translations and 7. Expressing the synthesis. [535] Qualitative data were extracted 
from 12 papers (see: section 4.3.2).Qualitative data were imported into the 




primarily by the first author (LB) with supervision, (EC, NM, BY). The scope of the 
synthesis concentrated on relevant treatment preference data, in the context of the 
wider aims and findings from the original papers, e.g. the Caldwell paper highlighted 
a range of parental attitudes to their child’s participation in an RCT; only a subset of 
themes/concepts in the original paper indirectly related to expressions of preferences 
for a treatment group. 
 
Data were structured using Schutz’s concepts of first (participant quotations) and 
second (authors’ analyses) order constructs. [536] Authors’ original themes and 
interpretations were organised in NVivo ‘node’ and ‘mapping’ structures, with 
relevant quotations (Appendix 2, Example: meta-ethnography – second order 
constructs). Concepts from individual papers were translated into one another (a 
reciprocal translation) to develop evolved interpretations (see: Meta-ethnography: 
Translation of first, second, and third order constructs). Third order constructs were 
taken forward as a line of argument in a new interpretive context: expressions of 
treatment preference. [537-539] Synthesised data were reviewed by the wider 
supervision team (EC, NM & BY) one of whom was an author on two of the original 





3.4 Data collection: Qualitative methods embedded in four 
paediatric trials 
The qualitative work presented in this thesis was carried out in collaboration with four 
paediatric RCTs, three focusing on treatment for CFS/ME, and one surgical trial 
focusing on treatment for appendicitis (see: Section 2.4). Each trial received ethical 
approval from relevant research ethics committees, (Appendix 1: Ethical approvals) 
and all were registered on the ISRCTN registry. An overview of each collaborating 
RCT can be found in Table 2.2. 
 
3.4.1 Recruitment and retention figures 
Recruitment and retention figures were evaluated as each trial progressed; figures 
relating to number of eligible patients assessed, recruited, declined, withdrawn and 
discontinued treatment were reviewed on a month-by-month basis. These figures 
were reported at relevant TMG and TSC meetings and were used to inform 
purposive sampling (see: Section 3.4.6) for family and health professional interviews 
in each of the four trials. 
 
3.4.2 Audio-recorded recruitment consultations 
Recruitment consultations were audio-recorded with written assent/consent for the 
recording from parents and young people in all four trials. This is a novel method 
used initially by colleagues working on the ProtecT study and is now used routinely 
as an ongoing part of the QRI approach. [408, 540] Those recruiting to each 




had with all eligible families who were given information about each RCT. 
Recordings were deleted if families decided they did not want the recording to be 
used for research purposes. See Appendices 3, 4, 5, and 6 for further details of data 
collection and randomisation in each trial setting. 
 
During the SMILE and MAGENTA trials recruitment consultations were conducted 
within one month of the young person’s first clinical appointment with the specialist 
CFS/ME service.  In the SMILE RCT consultations were conducted face-to-face with 
the recruiter in the family home. In the MAGENTA RCT most consultations were 
conducted via telephone, some were conducted at the local hospital if the family 
preferred. If families declined participation in the MAGENTA trial the recruiter 
recorded whether this occurred before or after verbal discussion of the trial had 
taken place, and reasons for decline were discussed when these were offered by 
young people and parents. In the FITNET-NHS RCT all consultations were 
conducted via telephone and were preceded by an eligibility assessment since 
young people lived out of area and had not had a face-to-face consultation with the 
specialist service diagnosing CFS/ME. Recordings of the eligibility assessment with 
families could not be made during the FITNET-NHS trial, because research consent 
had not yet been obtained from families, therefore recordings were only made when 
families declined the trial at the recruitment consultation stage. See Appendices 3, 4, 





3.4.3 Interviews with young people and their parents 
Each trial PIL (Appendices 3, 4, 5, and 6) stated that a subset of families would be 
contacted by a researcher to discuss the trial in greater detail. This was described as 
an optional interview(s) that families could participate in, in addition to participation in 
the main trial. Young people were eligible to take part in an interview as part of each 
embedded qualitative study dependent on the following age criteria: SMILE: 12-
18yrs, MAGENTA: 8-17yrs, FITNET-NHS: 11-17yrs and CONTRACT: 7-15yrs). 
Parents of all young people eligible for each trial could participate in an interview. 
 
Families who declined RCT participation in the SMILE, MAGENTA and CONTRACT 
trial were invited to take part in an interview. Consent for interview (contact from the 
research team) was not obtained from families who declined the FITNET-NHS trial, 
therefore only those who consented to the trial were able to participate in a 
qualitative interview. Table 5:5 provides a breakdown of the number of families who 
participated in interviews. 
 
During the SMILE RCT (prior to this PhD) I interviewed parents at three time points: 
1. After initial assessment and before randomisation, 2. After randomisation and 
before the intervention, and 3. After the intervention. This provided a clearer 
understanding of how families experienced the prospect of RCT participation prior to 
randomisation and how they experienced the process of randomisation and their 





During the MAGENTA, FITNET-NHS and CONTRACT trials families participated in 
one interview at various time points post randomisation. During the MAGENTA trial 
this was either after randomisation or after having received 6-months of their 
allocated intervention. FITNET-NHS families were interviewed at the early, mid or 
late stage of their allocated intervention so that the acceptability of the interventions 
could be explored. CONTRACT families were interviewed 1-4 weeks after discharge 
from hospital where possible. The Contribution Statement provides details of all 
those involved in data collection for each individual trial. 
 
Interviews with young people participating in the CONTRACT trial were up to 30 
minutes in duration. Parent interviews were up to an hour long, and Interviews were 
audio-recorded with written consent, transcribed verbatim, and anonymised. 
Interviews followed a checklist of topics to ensure consistency, (see: Section 3.4.5: 
Interview topic guides). 
 
3.4.4 Interviews with clinical teams 
Recruiters and members of each clinical team were invited to be interviewed, to gain 
insight into their perceptions of trial processes and progress. Health professionals 
were purposively sampled (see: Section 3.4.6), to take part in an interview if they 
recruited participants or delivered RCT interventions in three of the collaborating 
RCTs (MAGENTA, FITNET-NHS and CONTRACT). Most health professionals were 
interviewed only once, but there was scope to interview at more than one time point. 




interest arose during recruitment consultations, or when health professional practice 
changed. Table 5.8 provides details of the number of health professionals who 
participated in interviews. 
 
3.4.5 Interview topic guides 
Semi-structured interviews were conducted in each of the nested qualitative studies 
reported in this thesis. Each topic guide followed a checklist of topics to ensure 
consistency and can be found in Appendices 3, 4, 5, and 6. Each topic guide 
covered questions relating to prior knowledge of the interventions, beliefs, 
expectations and preferences about both interventions, the recruitment process, 
acceptability of written and verbal information provided, and experiences of the 
interventions. During interviews, parents and young people were encouraged to raise 
issues they felt to be relevant and important. Initially the topic guide was developed 
by NM for the SMILE RCT (Appendix 3). I developed and updated the topic guide for 
use in the MAGENTA trial, comments were provided by NM in relation to changes to 
questions, specifically making questions about preference less direct (Appendix 4) 
The MAGENTA topic guide was used as a template for FITNET-NHS and 
CONTRACT trials, with additional comments from NM and BY prior to participant 
recruitment, and in collaboration with RP and FS as recruitment progressed 





3.4.6 Sampling and sample size for interviews 
Sampling was initially guided by each trial protocol and included a range of 
participant characteristics in terms of age, sex, and where possible socioeconomic 
circumstance, as well as participants from both intervention groups (maximum 
variation sampling). As recruitment progressed, and by drawing on recruitment 
consultation data I was able to target participants with characteristics of interest (e.g. 
preferences for treatment or discontinued treatment) to follow-up and develop 
findings. I purposively sampled families to take part in qualitative interviews during 
the SMILE and MAGENTA RCTs. [541] Purposive sampling specifically targeted 
families who declined to participate, those who expressed a preference for treatment 
during recruitment consultations but went on to participate in the RCT and those who 
discontinued treatments. [542] 
 
I also actively approached fathers for their views in relation to their child’s 
participation, because no fathers were available to provide feedback during the 
SMILE RCT. I worked collaboratively with other qualitative researchers responsible 
for conducting interviews during the FITNET-NHS and CONTRACT trials (RP and 
FS) to ensure that families were not only purposively sampled to include a range of 
‘participant’ characteristics, (such as age, sex and trial group) but also those who 
discussed preferences for treatment during recruitment consultations. All 






Due to the nature of CFS/ME (the potential for fluctuation in symptoms), some 
participants who were purposively sampled for interview postponed or declined the 
interview request. Some parents declined the opportunity for their child to take part in 
an interview during the CONTRACT trial, or young people themselves declined 
because they had a poor recollection of the recruitment process due to pain from 
their appendicitis (Table 5:5: Families approached and interviewed). 
 
Health professionals were purposively sampled to take part in an interview when 
they had either discussed the trial with two or more prospective families (those 
recruiting participants during CONTRACT) or had been delivering trial interventions 
for approximately five months (MAGENTA and FITNET-NHS). Recruiters who had 
discussed the trial with families who had declined were initially contacted for 
interview. Where possible, members of the wider clinical team who were not involved 
in recording recruitment consultations (e.g. ward nurses and senior surgeons), were 
also contacted to gain information in relation to wider team equipoise. Health 
professionals working with young people who had discontinued CFS/ME treatment 
during the MAGENTA trial were also approached for interview. Due to high 
workloads and difficulties scheduling interviews with busy clinical teams, the majority 
of those who provided recruitment consultations (CONTRACT) and all members of 
the CFS/ME specialist service team were contacted to take part in an interview 
(Table 5.8 Health Professional Interviews). 
 
The interview sample sizes in each trial were determined by data saturation, i.e. when 




30 interviews with families, and 10-25 interviews with health professionals would be 
conducted in each trial. However, more health professional interviews were carried out 
than initially anticipated, to gain additional feedback into recruiter and wider team 
equipoise (see: Section 5.3.4: Health professional and recruiter equipoise). Family 
interviews could include separate interviews with a young person and then their 
parent, (individually), or a joint interview where a young person and their parent(s) 
were interviewed together if preferred by the family. 
 
3.4.7 Patient and Public Involvement (PPI) 
Patient and public (PPI) involvement and feedback were sought during the 
development phases of each of the four RCTs in which qualitative methods were 
embedded. Patient information sheets, consent forms and each interview topic guide 
were reviewed by PPI members before and during each of the four RCTs. Detailed 
information relating to the way that PPI was developed and informed trial 
documentation can be found in Appendix 12. 
 
3.4.8 Training: communicating equipoise in paediatric trials 
Training for recruiters in the four paediatric trials developed and changed in structure 
from basic one-to-one feedback discussions in 2010, (SMILE RCT) to structured 
group feedback sessions in 2015-2017 (MAGENTA, FITNET-NHS and CONTRACT 
RCTs). Early training in the SMILE RCT was developed with specific reference to 
work carried out by Professor Jenny Donovan and colleagues in the ProtecT study. 




also drew on findings from the Quintet Recruitment Intervention (QRI) (see: Section 
2.2: Qualitative research and adult randomised controlled trials). [127, 177, 246, 408, 
540] Those recruiting to each collaborating RCT were asked to routinely record 
every recruitment consultation, (section 3.4.2) and these recordings formed the basis 
of ongoing training as each trial progressed, see Appendices 3, 4, 5 and 6. 
 
 
3.5 Data analyses: Qualitative methods embedded in four 
paediatric trials 
Thematic analysis techniques which drew on constant comparison and grounded 
theory were used during the course of each trial. Subsequently themes and findings 
from each of the four trials were compared, contrasted and integrated using 
framework analysis. [544] Each analysis method is discussed in turn in the following 
sections. 
 
3.5.1 Thematic analysis 
Data from four trials were included in this thesis, SMILE data which I had already 
collected and analysed (Secondary analysis: SMILE RCT 2010-2013), and data 
collected during three prospective trials (MAGENTA, FITNET-NHS and 
CONTRACT). Methods of constant comparison derived from grounded theory were 
used to analyse recruitment consultation and interview data in each of the four trials 
as each trial progressed. [545-547] Analysis was an iterative process and informed 




identify common or divergent themes using thematic analysis. [458, 548] 
Recruitment consultation and interview transcripts were coded using NVivo. [530] I 
regularly fed back qualitative findings from each trial to relevant TMG and qualitative 
sub-study meetings so that findings were reviewed by the wider team members, and 
changes to study processes could be made as each trial progressed. 
 
Secondary analysis: SMILE RCT 2010-2013 
Prior to starting this PhD, I conducted the qualitative interviews for the SMILE RCT, 
these data were included in this thesis. I conducted interviews with parents at three 
time points (before recruitment consultations, post randomisation and post 
intervention). Young people were only interviewed at one time point to avoid burden, 
either post randomisation or post intervention. Family interviews and recruitment 
consultation data were collected and analysed drawing on techniques of constant 
comparison, grounded theory and thematic analysis. 
 
PhD data analysis 
SMILE: Secondary analysis 
I retrospectively listened to all SMILE recruitment consultations. All relevant 
preference related data were extracted from earlier NVivo coding structures 
(recruitment consultations and family interviews). I re-familiarised myself with earlier 
thematic analysis carried out with SMILE data, by reviewing coding structures. I re-
read recruitment consultation and interview transcripts, reflexive notes, analytic 




consultations that had not already been transcribed and analysed (those conducted 
towards the end of the trial in 2013). [547]  
 
MAGENTA, FITNET-NHS, CONTRACT: Prospective data collection and analysis 
During the MAGENTA, FITNET-NHS and CONTRACT trials analyses was carried 
out as each trial progressed. Separate NVivo projects were created for each trial, 
and separate coding structures were created for each data type (recruitment 
consultation, family and health professional interviews). I initially listened to each 
recruitment consultation and took notes, each consultation was then transcribed 
(see: Section 3.6.4: Anonymisation, transcription). Interview and recruitment 
consultation transcripts were imported into NVivo and coded using an inductive open 
coding approach. [549] Data-derived codes (from recruiters’ and participants’ own 
words, or in-vivo coding) were created. As more transcripts were coded categories 
and concepts were developed via an iterative process of constantly going back and 
forth between data sources (recruitment consultations and interviews), analytic 
memos and discussions with colleagues (EC, NM, BY, FS, RP). [458] Descriptive 
accounts and reports of findings were developed and revised as each trial 
progressed. I cross-referenced data from recruitment consultations with matching 
interview data where possible. This cycle continued iteratively as more data were 
collected and analysed during the course of recruitment to each trial. I kept reflexive 
notes recording contextual information; this included information about the young 
person’s condition, (mild or moderately affected) family circumstances and parents’ 





I paid particular attention to: possible justifications for expressions of preference, 
misunderstandings related to communication in recruitment consultations, language 
used by those recruiting that may have influenced families’ preferences for trial 
interventions and the way in which recruiters responded to families’ preferences for 
trial interventions. I also focused on the way in which recruiters accepted or explored 
treatment preferences expressed by young people or their parents (recruitment 
consultation data), and the justifications provided by young people and parents for 
declining or participation (interview data). Families who expressed views that were 
unexpected or whose recruitment practices were ‘different’ were studied in detail as 
‘negative cases’. [550] This included instances where treatment preferences differed 
between parent and child, and families who expressed preference for treatment but 
consented to the trial. 
 
Care was taken to distinguish between themes and findings that were specific only to 
young people, parents or health professionals. Ten percent of the qualitative data 
were independently coded by another team member (DJ, NM, RP, FS) to enhance 
coding reliability. [359, 360] These data were discussed collectively by each 
qualitative sub-study group, which included senior members of each research team 
(EC, NM & BY). Discrepancies were resolved via modification of coding categories 
where necessary. To compare and contrast common and divergent findings across 
the four trials, the final analytic stage involved combining data from multiple trials and 
sources. Framework analysis was used to compare codes and themes across data 
sets (see: Table 5:9 Thematic framework) encompassing similar (and contrasting) 




context of each individual trial, [458] and the way in which previous data analyses 
affected later data collection and analyses. 
 
3.5.2 Content analysis 
Content analytic methods are not always associated with qualitative approaches to 
data analyses since they generally involve the ‘counting’ of words or content. [551] 
However, qualitative content analysis also seeks to understand the context in which 
words and conversation are used, [552] and involves a basic ‘interpretation’ of the 
data under analysis. [553] A deductive and directed content analysis was used to 
retrospectively analyse recruitment consultation data from the SMILE RCT. [554-
556] The approach was deductive because it used coding categories that were 
predefined and derived from analysis of data from a previous adult RCT. [123, 405] 
This analysis aimed to understand how and when young people and their parents 
expressed preference for treatment. 
 
An existing checklist which categorised preference as: definite, probable, or not 
stated was used (developed by NM, Appendix 3: Content analysis checklist). This 
content analysis was directed because it was based on prior knowledge of the 
research area under investigation, given that a thematic analysis of SMILE trial 
consultation and interview data had already taken place. The checklist was used to 
record whether treatment preferences were expressed by young people and their 
parents. The number of young people and/or parent(s) who expressed the following 
were counted: 1. A preference or non-preference (dislike) for treatment ‘at outset’ 




and whether or not the preference was ‘definite’ (repeated at various points in the 
discussion) or ‘probable’ (the individual expressing the preference seemed unsure, 
changed their mind or didn't give reasons for their preference). 3. As the consultation 
progressed, a judgement was made in relation to whether the preference or non-
preference appeared to be entrenched or dispensed with at the end of the 
consultation. The outcome of the recruitment consultation, e.g., randomised or 
declined participation was also recorded. Instances where the young person and/or 
parent expressed a preference or non-preference after the young person had agreed 
to randomisation and had been given their intervention allocation were recorded. The 
category ‘can't tell / preference not stated’ was used if the young person or parent(s) 
verbal response to questions relating to preference were not expressed or explored 
by the recruiter during recruitment consultations. 
 
The aim of this analysis was to understand the frequency and perceived ‘strength’ of 
expressed preference (definite or probable) for treatment in paediatric recruitment 
consultations. This also provided important contextual information in relation to 
whether it was the patient or parent (or both) expressing preference, and the timing 
of expressions of preference, whether they were made before or after randomisation 
and treatment allocation. These findings are explored in detail in Chapter 5, Section 





3.6 Ethical Considerations  
3.6.1 Burden and disclosure 
An ethical issue relating to this research was the potential for additional burden on 
young people and their wider family. Interviews with young people who were 
currently unwell (with CFS/ME), or those who were being asked to recall a stressful 
acute episode of ill health (appendicitis) could be a burden, distressing or upsetting. I 
ensured that all interviews with young people diagnosed with CFSME were no longer 
than 20-30 minutes, with rests during the interview if appropriate. Interviews with 
young people participating in the CONTRACT trial were also monitored so that they 
were appropriate for the age of the young person taking part. 
 
I worked closely with recruiting health professionals, study primary investigators and 
health professionals delivering clinical care so that all relevant information about 
participants’ health conditions (e.g. recent increase in CFS/ME symptoms or a 
particularly unpleasant infection after appendicitis surgery) were taken into 
consideration when arranging interviews. Young people were given the option of 
interview with, or without their parent(s) being present. I ensured that young people 
were well enough to take part in interviews by checking with them (or their parents if 
they were 15 years old or under) the day before or the morning of the interview, to 
ensure that any vulnerable young people, (e.g., those experiencing more moderate 
symptoms of CFS/ME) were not overburdened. Interviews were cancelled if the 
young person was unwell, and rescheduled where possible. 
 
Another potential issue was that of disclosure during the qualitative interview. At the 




professionals), were informed of their right to confidentiality, and it was stressed that 
information discussed during interviews would not be passed on to the health 
professionals delivering clinical care, or in the case of health professionals, other 
members of the clinical team. I also highlighted that information would only be 
shared with a third party in instances where I believed that a participant was at risk of 
harm. I also informed participants if elements of the interview were to be disclosed 
because of concerns about welfare, this would always be discussed with them at the 
end of the interview. 
 
3.6.2 Reflexivity  
A qualitative researcher is an ‘active’ part of the research process. [557] A 
researcher’s age, sex, perceived social class and professional role are all likely to 
have an impact upon interaction during data collection, influencing the way in which 
participants disclose information and the way in which researchers ask questions. I 
told families that I was not a ‘medically trained’ person, neither was I a member of 
the clinical team they had seen ‘at the hospital’. [558] However, my status as 
someone who worked ‘for a university’ was disclosed, [559] and was likely to have 
affected the way in which families perceived me. I always highlighted that 
participants were the ‘experts’ and I was interested in what they had to say, both 
positive and negative. I made an effort to develop a ‘friendly but professional’ rapport 
with parents and young people, and reflected on occasions when young people or 
parents may have wanted me to overstep these professional boundaries. [560] 
 
I also reflected on the way in which my professional role as a researcher might 




some knowledge of the research area when I started this PhD, therefore my ‘pre-
conceptions’ about the research area may have influenced the probing questions I 
asked during interviews. I may have focused upon preference more than my 
colleagues without an interest in this research area. I kept reflective notes as each 
trial progressed and strove to remain open minded during data collection and 
analyses, and frequently discussed findings with members of the wider trial teams. 
[562, 563] I also reflected on the way in which my clinical colleagues (particularly 
those working on the wider CFS/ME specialist team) may have felt about discussing 
their views and opinions with me during interviews, as someone they knew and had 
worked with for a number of years. [454, 455] 
 
3.6.3 Researcher safety and lone working 
It is necessary to ensure that suitable systems are in place for contacting research 
staff when they are working alone and away from their usual place of work. FITNET-
NHS protocol stated that all interviews would be conducted via skype or telephone.  
During SMILE, MAGENTA and CONTRACT trials researcher protocols stated that 
participants would be given the option of being interviewed in their own home. The 
risks of lone working can include increased vulnerability to verbal and physical 
aggression and isolation from timely help and support in situations of equipment 
failure, accident and illness. 
 
Researcher safety was considered carefully in each paediatric trial prior to, during, 
and following participant interviews, some of which were scheduled outside of 
normal working hours. Travel to interviews required that I drive long distances, 




during hours of darkness at certain times of the year. Local NHS lone working 
procedures from each sponsor/trust were reviewed by researchers working on each 
of the three RCT. However, unlike NHS staff who undertake external home visits, 
research staff did not have access to records where issues of potential risk within 
households or neighbourhoods might be documented.  I developed procedures for 
SMILE, MAGENTA and CONTRACT lone working, (Appendix 10) with reference to 
University of Bristol School of Social and Community Medicine Fieldwork Safety 
Policy. 
 
3.6.4 Anonymisation, transcription 
Anonymisation requires the removal of name, address, full post code and any other 
detail or combination of details that might support identification. Anonymised 
information does not identify an individual directly, and cannot reasonably be used to 
determine identity. [564] A participant ‘qualitative’ identifier code (e.g. Young person 
20) was linked to each participant’s trial research code and used as a ‘pseudonym’ 
for all families who consented to a recording of their recruitment consultation, or who 
participated in interviews. All participant identifiers were pre-fixed with a letter 
corresponding to the trial (e.g. ‘C’ – CONTRACT Young person C20). Upon 
transcription, all identifiable information was removed so that it was not be possible 
to identify any individuals. A sub-set of recruitment consultations from the SMILE 
RCT were transcribed professionally, and I transcribed relevant sections of all 
remaining recruitment consultations retrospectively. I also transcribed relevant 
sections of recruitment consultations as soon as they became available during the 




NHS and CONTRACT) were securely transferred to two external, approved 
transcription companies who held confidentiality agreements with either the 
University of Bristol or University of Liverpool. Both companies transferred all files via 
secure sockets layer (SSL) or transport layer security (TLS) protocols, with advanced 
encryption standard (AES) 256-bit while in transit and at rest on their server. 
 
3.6.5 Storage and transfer of data 
All qualitative data were stored securely during the course of each RCT in 
accordance with University of Bristol and local NHS Data Protection Policies. [565] 
This included precautions to avoid physical loss or damage of electronically stored 
data. Access to electronic records containing identifiable participant information was 
restricted to members of the relevant research teams via University of Bristol 
servers, with access assigned and maintained by University of Bristol IT services. All 
electronic records containing identifiable participant information were also password 
protected, this included electronic copies of signed consent and assent forms. All 
paper records (with details pertaining to families and health professionals who 
participated in the trials) were kept in locked cabinets within areas of the Universities 
of Bristol and Liverpool with restricted university secure card access. All other data 
(such as recruitment consultation and interview transcripts), were stored securely in 
another secure, locked cabinet. 
 
Care was taken when paper or electronic records were taken away from the 
University of Bristol (e.g. en route to family interviews). Digital recorders used to 




university sites (and to transfer recruitment consultation data during the SMILE trial) 
were encrypted to ensure secure transportation. I developed procedures for 
transferring audios from the encrypted digital recorders to secure university servers 
(Appendix 11) and all files were then deleted from devices. 
 
Recruitment consultation data were transferred electronically via secure data transfer 
systems, (Research Data Storage Facility and DatAnywhere) approved by either the 
University of Bristol or University of Liverpool during the MAGENTA, FITNET-NHS & 
CONTRACT trials. Nominated members of each clinical team at each trial site were 
responsible for uploading all recruitment consultations from digital recorders to 
transfer systems. It was not necessary for audio files to be re-accessed by any NHS 
personnel at collaborating NHS sites after the initial data transfer process, so all data 
were stored securely on University servers and deleted from devices held in NHS 
sites. 
 
Consent and assent were managed via the Research Electronic Data Capture 
(REDCap) system during the MAGENTA and FITNET-NHS trials since the majority 
of recruitment consultations were conducted by telephone. [566] I developed two 
REDCap projects with support from the University of Bristol REDCap technical 
support team (prior to this PhD). Projects were stored on secure University of Bristol 
servers, and an electronic consent URL (secure webpage) was sent by the recruiter 
to an email address specified by parents or directly to young people aged 16-17 
years. Young people and parents were able to use this URL to access age 




accessed and submitted either in real time, or at an agreed point in the future if 
families wanted more time to consider trial participation. Interviews completed via 
skype or telephone also used the same REDCap system to gain consent and assent 
from participants and health professionals. 
 
3.7 Chapter Summary 
This chapter detailed the research methods used during this PhD thesis in two key 
areas: 1. The systematic review of paediatric preference literature and synthesis 
(meta-ethnography) of qualitative data retrieved via the systematic review. 2. The 
collection and analyses of data from four paediatric RCTs. Elements of the QuinteT 
Recruitment Intervention (QRI) approach were used to inform data collection and 
analyses methods during the latter. [408] Data from all four trials were drawn 
together and analysed collectively using framework analysis. Finally, relevant ethical 
considerations: burden, disclosure, researcher safety and lone-working were 
discussed, along with data management considerations (anonymity, transcription, 
storage and transfer). The next two chapters describe findings from the systematic 
review and qualitative synthesis (Chapter 4) and findings from the four paediatric 




 Findings – Systematic literature review and 
qualitative synthesis 
 
4.1 Overview of chapter 
This chapter reports the results and discussion points raised from the systematic 
review of literature relating to treatment preference in paediatric RCTs, and the 
synthesis of qualitative data. Section 4.2 details analysis of ‘descriptive’ preference 
related data extracted from 40 papers, and Section 4.3 synthesis of ‘qualitative’ data 
(relevant quotations and first authors’ analyses) extracted from 12 papers. This 
chapter also includes a discussion (Section 4.4) of the strengths, limitations and links 
to previous literature. The implications for future practice and implications for future 
systematic reviews in this area are also considered. 
 
 
4.2 Summary of included studies (descriptive data) 
Database searches retrieved 23,449 papers, and additional searches yielded 101 
papers. After deduplication, title and abstract screening was carried out on 17,036 
papers, and 676 were read in full, with 52 papers eventually included in analyses 
(see: Figure 4:1). Table 4:1 describes all the papers included in the systematic 
review, 27 reported data from RCTs conducted in the UK and Europe and 23 
elsewhere, (USA, Canada, Australia and Brazil). Most papers were published from 
the year 2000 onwards (n = 42). Searches were carried out to locate primary trial 




583] It was not possible to find all the primary trial papers because some secondary 
papers did not explicitly use identifiable trial names or registration numbers. 
 
Of the 52 papers, seven reported findings from multiple trials, [96, 97, 107, 325, 326, 
584, 585] and two were abstracts from poster presentations. [523, 524]  Forty-two of 
the papers reported ‘conventional’ RCTs, [74, 94, 96, 97, 107-109, 120, 220, 319, 
323, 325, 326, 381, 522-526, 531, 585-606] two of which were in the feasibility or 
pilot stages. [586, 587] Eight papers described RCTs with parallel ‘preference’ 
groups at trial outset, [66, 607-613] and two introduced preference groups due to 
slow recruitment. [584, 614] Seven papers reported trials using participant blinding or 
double blinded, [319, 381, 526, 594, 599, 605, 606] and all remaining papers 
reported unblinded non-inferiority/equivalence RCTs. Ten papers reported use of a 





































 Additional records identified 
through other sources 
(n = 101) 
Records after duplicates removed 
(n = 17,036) 
Records screened 
(n = 17,036) 
Records excluded 
(n = 16,360) 
Full-text articles assessed 
for eligibility 
(n = 676) 
Full-text articles excluded  
(n = 624) 
Reports patient OR parent 
satisfaction with treatment 
outcome 272 
No discussion of preference 
between study arms 141 
Adult Population 88 
Wrong study design 58 
Abstract, economic evaluation, 
report, poster or protocol & hand 
search of author(s) found no 
related/relevant main trial paper 21 
Data analysis not separated by 
age for those under/over 18yrs 13 
Not published between 1958-2014 
10 
Data reported in another 
report/paper by the same author 7 
Full text not available 7 
 
Assumption(s) of patient/parent 
preference made by author or trial 
staff 4 
Wrong patient population 3 
 
Studies included in data 
extraction 
(n = 52) 
a. descriptive analyses 
aggregative  
(n = 40) 
b. Qualitative synthesis 
Meta-ethnography 
(n = 12) 
 
Records identified through 
database searching 




Table 4:1 Systematic review of literature: Included papers 
Conventional RCTs (n=42) 
Author 
Paper type 
(primary or secondary paper*) 






Assessed feasibility of recruiting young women into an 





Primary paper Azzopardi 2009 [569] 
>36wks 
Compared intensive care plus total-body cooling for 72 
hours with intensive care without cooling among term 
infants with asphyxial encephalopathy. 
Banks  
2012 [587] 
Primary   
(Pilot) 
5-16yrs 
Assessed feasibility of carrying out a fully powered RCT 
comparing care of childhood obesity intervention 




Primary paper Wake 2009 [581] 
5-10yrs 
In-depth understanding of why families chose not to 





Do parents prefer antibiotic administration for treatment 
of acute otitis media by a single intramuscular (IM) 







Assessed the impact of a Certified Child Life Specialist 
(CCLS) on parent satisfaction, staff satisfaction, child 
satisfaction, and parent and staff perceptions of child 




Primary paper Vora 2013 [580]   
2-11yrs 
Examined how recruitment looked to an observer and 
how it felt to parents, (of children with low-risk acute 
lymphoblastic leukaemia) to identify how doctors’ 






Not stated  
Explored parents’ attitudes to children’s participation in 
trials, identifying factors that influenced decision-making 
and perceived risks and benefits. RCTs included 




Primary paper Moreira 2013 [577] 
<3yrs 
The understanding and perceptions of mothers 
regarding the informed consent and randomisation 
processes linked to an RCT that compared behaviour 




Children - age 
not stated 
Parental and child understanding of RCT participation 
(Acute lymphoblastic leukaemia FRALLE 2000A 
protocol) and evaluations of the readability of written 
documents provided.  
Duncan  
2004 [590] 
Primary 11mths-12yrs  
Effectiveness of osteopathic manipulation, acupuncture 
or wait list control as a 6-month therapeutic adjunct for 







Primary paper Mitchell 2005 [576] 
4-16yrs 
Mothers' (of children newly diagnosed with Acute 
Lymphoblastic Leukaemia: ALL) views regarding 
consent to randomised controlled trials.  
Forsander  
1995 [591] 
Primary  12-15yrs 
Evaluation of family attitudes in relation to the two 3wk 
care systems for diabetes management: early discharge 
from ward to training apartment and treatment on a ward 




Primary paper Glogowska 2000 [115] 
3-4yrs 
Reported attitudes of parents whose child took part in a 
speech and language therapy RCT comparing 




Primary paper Van Asperen 1992 [578] 
6mths-3yrs 
Double-blind, placebo-controlled trial of ketotifen, a new 




Secondary (poster presentation) Primary 
paper Hissink Muller 2017 [574] 
Children - age 
not stated 
Comparison of three treatment strategies, and feedback 
relating to treatment preferences among parents of 




Secondary (poster presentation) Primary 
paper Hissink Muller 2017 [574] 
12-18yrs  
Comparison of three treatment strategies, and feedback 
relating to equipoise among parents and patients with 






Assessed participant and parent experiences in the 










Assessed the experiences of participants and parents of 
children in the oral insulin study of the Diabetes 






Explored the thoughts and feelings of parents in their 
decision-making process, in either choosing or declining 






Retrospective parent perceptions of communication of 





To determine if nebulised fentanyl is a feasible 
alternative to IV fentanyl for the treatment of acute pain 
in children presenting to the emergency department 




Views and preferences for anaesthetic related issues 











Children - age 
not stated 
Described parents' experience of their child being 
enrolled in a HIV infection RCT, including the degree to 
which it interfered with life, and their feelings about use 







Primary  16-24mths 
The effectiveness of ventilation tubes on the language 
development in infants with persistent otitis media with 




Primary paper Atkinson 2007 [568] 
6mth-16yrs 
Parental views on the informed consent process, 
information provided, reasons for taking part and 
willingness to participate in future research.  Compared 




Effectiveness of 3 methods of orthodontic anchorage 





Assessed the clinical effectiveness of a paediatric 





Compared the level of care from nurse practitioners with 






Primary paper Balle 1998 [570] 
1-10yrs 
Evaluated the efficacy of amoxicillin-clavulanate and 




Secondary (Multiple RCTs) 
MASCOT: funding extension application 
rejected & trial closed prematurely [575] 
MASCOT: 6-
15yrs  
Identify strategies to improve recruitment and trial 










TIPIT: < 28wks 





Primary paper UK Collaborative ECMO 
Trial Group [573] 
Neonates 
Exploration of parental reactions to random allocation of 
treatment in a neonatal RCT comparing two methods of 
life support, conventional management (CM) and 
extracorporeal membrane oxygenation (ECMO). 
Recruitment was stopped early, because data showed a 




Loss of clinical equipoise and declining 
accrual rates led to trial termination. 
8wk-3yrs 
Compare oral rehydration therapy (ORT) and 





Primary paper Craig 2009 [571] 
<18yrs 
To identify modifiable and unmodifiable factors 
associated with parental consent to a trial investigating 
long-term, low-dose antibiotics in preventing recurrent 




Primary paper Diabetes Control 
Complications Trial Research Group 
[572] 
11-18yrs 
Identify reasons/characteristics of adolescents who 
refuse or consent to participate in an RCT of intensive 












Compared cast versus splint for distal radial buckle 
fractures in children in terms of parental and patient 
satisfaction, convenience and preference. 
Woodgate  
2010 [325] 
Secondary (Multiple RCTs) 6mth-15yrs 
In-depth understanding of Canadian parents’ 




Secondary (Multiple RCTs)  
MASCOT [575] funding extension 
application rejected & trial closed 
prematurely. 
MENDS [567] 







TIPIT: < 28wks 
Explored how a parent’s understanding of a trial might 
be associated with the way that the trial was explained 




Recruitment was expected to take 3yrs 
but took 6yrs. 
4-10yrs 
Investigated early application hip spica compared with 
external fixation in paediatric femoral fractures. 




Primary paper Wang 2011 [582] 
<18mths 
In response to slow recruitment study coordinators 
evaluated factors that affected enrolment and accrual in 






Secondary  7-17yrs 
Reported results of two studies of social phobia, 
assessing the extent to which parental reluctance 
toward medication resulted in pre-treatment attrition in: 
behavioural, fluoxetine and placebo groups. 
 




Trial 1: preference group added  
and trial terminated early due to 
inadequate sample size. 
Adolescents 
(age not stated) 
Reported two RCTs, both terminated early due to 
inadequate sample size. Trial 1: Multi-centre Orthodontic 
RCT which compared two different methods of treating a 
specific type of malocclusion in adolescents. (Trial 2: 




Compared the clinical effectiveness of inpatient against 
outpatient treatment and of generalist against specialist 




Trial extended from 5 to 7yrs to increase 
patient recruitment. 
4-15yrs 
An embedded qualitative study informed the 
development of the RCT, it explored patient/parent(s) 
preferences for different treatment options in patients 
with recurrent sore throats who had recently been 
referred to ENT clinic. Extended from 5 to 7yrs to 








Assessed adenoidectomy in connection with 
tympanostomy compared with tympanostomy only in 









Assessed the efficacy of adenoidectomy, comparing 
surgical and non-surgical management, with equivalent 




Compared conductive education (CE) programme with 
equivalent intensity traditional neurodevelopmental 
programmes of rehabilitation for young children with 




Compared ventilation tubes (VT) and watchful waiting 
(WW) in the management of patients with otitis media 
with effusion. The generalisability of randomised 
patients with eligible non-randomised patients was 








The effectiveness of bracing, compared with observation 
in preventing progression of the curve to 50 degrees or 
more in idiopathic scoliosis patients, with equivalent 




Van Wijk  
2014 [612] 
Secondary  
Primary paper Van Wijk 2014 [579] 
4.5-6.5mths 
Primary: Effectiveness of helmet therapy for positional 
skull deformation compared with the natural course of 
the condition Secondary: Assess parents’ decision for 
helmet therapy in infants with skull deformation. 
*Primary papers were defined as those reporting primary RCT outcome(s). Secondary papers were those reporting embedded/related studies (e.g. 





4.2.1 Impact of treatment preference on recruitment  
Conventional RCTs with randomised treatment groups 
Table 4:3 aggregates all descriptive preference data from the included papers. 
Seventeen papers reported the number of eligible families declining participation 
because of a preference for treatment, this ranged from 2-50% in conventional trials, 
[94, 108, 319, 381, 589, 590, 593, 594, 596-601, 604-606] and 4-70% in the two 
pilot/feasibility phase trials. [586, 587] Eleven RCTs reported the preferences of 
families who opted for trial participation, [74, 108, 522-526, 588, 591, 602, 603] these 
treatment preferences were either expressed at enrolment or after randomisation. 
Five trials reported withdrawal after randomisation. [120, 592, 595, 597, 600] 
Families either withdrew consent or refused their allocated intervention, but only one 
of these trials specifically attributed this to a preference for the alternate treatment 
group. [592] 
 
Patient Preference Trial or Comprehensive Cohort Design 
Eight papers (see: Table 4:3) reported RCTs that used non-randomised ‘preference 
groups’ in addition to randomised treatment groups from the outset. [66, 579, 607-
610, 613, 616] All of these trials reported the number of eligible families declining 
randomisation groups because of a preference for treatment, this ranged from 11-
55%. One of these trials was extended by two years to increase recruitment to 
randomised trial groups. [66] Two additional trials introduced preference groups 






Treatment preference: Trial design and intervention type 
Thirty papers provided figures in relation to the number or percentage of families 
declining the trial specifically because of preference for treatment (Table 4:3). [66, 
94, 108, 319, 381, 585-587, 589, 590, 592-594, 596-601, 604-610, 612-614, 616] 
RCTs were grouped by trial type, (feasibility/pilot, conventional or patient preference 
RCT) and graphed in terms of the percentage of participants declining the trial due to 
preference (see: Figure 4:2). Trials with preference arms were more impacted by 
preference, with families declining and opting for preference arms. The median 
number of participants declining RCTs with preference arms was consistently higher 
(46%) when compared to conventional RCTs without preference arms, (10%) see 
Table 4:2. 
Table 4:2 Median number of families declining randomisation due to 





Total number of 
participants 








declining due to 
preference
(%) Median, IQR 





Pilot/feasibility phase trials 2 13 7 7 (37%) 20-53% 4-70% 
Conventional trials 18 875 49 17 (10%) 4-16% 2-50% 
Patient preference and 
comprehensive cohort trials
9 1447 161 133 (46%) 34-51% 11-55% 
*29 papers provided data on the number of participants declining due to preference, 1 further paper reported the % declining due to preference. Papers 




Figure 4:2 Percentage of families declining randomisation due to preference 
for treatment: Trial design 
 
 
Intervention arms perceived to be active or more intense were more consistently 
preferred in comparison to standard care, usual care, placebo and watchful waiting 
intervention arms. [74, 96, 97, 107, 109, 323, 526, 531, 586, 588-591, 594, 597, 599, 
605, 612-614] However, in some RCTs placebo arms were preferred if parents 
wanted to avoid antibiotics and medication, particularly when parents were 
concerned about the side effects of a new drug. [319, 381, 606] Parents considering 
neonatal RCTs often preferred active treatment arms. [74, 96, 107, 531] There were 
no consistent findings in relation to preference for more intense treatments in 
oncology RCTs, [97, 108, 109, 325, 522, 585] those investigating chronic illness, 
(diabetes and asthma) [319, 525, 526, 591, 601] or RCTs where families considered 




Table 4:3 Included papers: Aggregated descriptive data relating to treatment preference 
Conventional RCTs (n=42) 
Author 




Number of eligible patients not randomised 
because of treatment preference n (%) 
Is preference expressed by 
patients  












Unclear, preference reported qualitatively. [531] 












9 (26%) of non-responders reported concern with 
being in either the intervention or control group, but 








(total eligible not 
reported). 
Not reported. 
Parents were asked their preference at enrolment and 
551 (85%) of those randomised preferred single-dose 
therapy over standard therapy. 
n/a children under 6yrs. 
Blickman  
2013 
142 (88%) 4 (2%) 
Unclear (patients aged 4yrs+ were 






Not reported, preference reported qualitatively. [109]  
215 (29%) not randomly assigned: 97 refused, 7 had 
Down’s syndrome, 4 because of toxic effects, 28 other 





multiple trials.  




48 'recruited' [120] 
44 (100%) 
'randomised'. [577] 
Not reported, preference reported qualitatively. [120] 
3 (7%) parents refused allocated interventions post-





Not reported.  
Some Parents felt that standard treatment was the best 
group for their child because it was less risky. 









eligible not reported. 
8 (between 12-16%) No. 
Eiser  
2005 
1621 (90%) [576] 
181 (10%) declined randomisation 
(opted for PRED =165, DEXA =16) [576] 
Preference reported qualitatively,16 (32%) ‘agreed 







Immediately after randomisation 3 families in the 
control group reported that they would have preferred 




159 (69 %) [115] 
Not reported, preference reported qualitatively. [323]  
Declined trial in total 70 (31%). [115] 







40 (30%) of families declined because of ‘concern 
about side effects of the new drug’ (ketotifen) 60 
declined in total. 




Not reported.  
41% participating parents reported a preference for 
therapy with methotrexate and etanercept and 6% had 
hoped against assignment to this group. Primary 
aversion was highest (25%) in the prednisone group. 





Not reported.    
65% participating parents reported a preference for 
therapy with etanercept. 5 parents and 2 patients 
participated in the study to access treatment with 
etanercept, as initial treatment was not possible nor 









Participating families stated: Close monitoring group - 
27% parents and 70% participants were glad to be in 
that group. 74% parents and 35% participants 
sometimes wished they had been assigned the 
intervention group. Intervention group - 53% parents 
and 21% participants were glad to be in that group. 
25% parents and 47% participants sometimes wished 





Not reported.  
Participating families were blinded to treatment but 
were asked which treatment group they would have 
preferred. 60% parents and 53% participants chose the 
capsule condition.  8% parents and 21% participants 
chose the no intervention condition. Very few 
















3 (14%) stated they declined participation because 







Declined randomised 9 (18%) reasons not reported.  
After allocation 4 (10%) parents requested that their 
child receive nebulized fentanyl rather than the 





Calculated as 322 
(69%) of eligible 
patients. Paper 
reports recruitment 
rate of 75%. 
59 (50%) ‘Around half of the eligible participants who 
refused to participate did so because there was a 50% 
chance of the child being randomised to the 












4 (3%) parents stated explicitly that they were 








Not reported.    
19 (10%) parents withdrew consent straight after 
randomisation (15 in ventilation tubes group and 4 in 
watchful waiting group). 10 (5%) children in the 
watchful waiting group were treated with ventilation 
tubes.  








25 (9%) declining families stated they wanted a 
specific treatment (IV =20 or oral =5). [94]  
43 (15%) declined to take part n=6 (2%) excluded post 
randomisation reasons: 4 withdrawn by parents / 2 by 





7 (8%) Three did not want to wear headgear for 
anchorage, three did not want the Nance button palatal 
arches, but only one patient did not want to take part 
because he or she was unhappy at “the thought of 





10 (2%) 7 families withdrew from ‘hospital care’ group 





4 (2%) Preferred only dermatologist (n = 2), preferred 









120 (10%) parents insisted that the child had grommet 












153 (57%) [583] 
Unclear, preference reported qualitatively. 
MASCOT Assessed for eligibility (n = 898), Not 
registered (n = 732), Excluded (n = 103). [575] 
MENDS 27 (16%) assessed for eligibility but not 
randomised: ‘declined 11’ ‘other 16’. [567] 
TIPIT 57 (21%) assessed for eligibility but not 




185 (79%) [573]  
 
Unclear.  
 ‘majority of parents had a keen preference for  
ECMO treatment group’. Preference reported 
qualitatively.[74]  
48 (21%) were registered but not randomised: 14 died, 









24 (7%)  
A further 3 parents refused participation after 
randomisation to oral rehydration therapy before 
starting treatment.  
n/a children under 3yrs. 
Sureshkumar 
2012 
412 (37%) [381]  
 
214 (19%) Prefer antibiotics 71/ Prefer no antibiotics 
143. [381]  
Primary paper reports patients excluded because 




56 2 (5%) 






19/31 patients completed a preference questionnaire / 
10 (43%) preference for oral, 2 (9%) for suppositories, 
7 (30%) no preference / preference for oral more 









A significantly larger percentage of parents and 
patients in the cast group reported that they would not 
choose the same method of immobilisation again at all 










63 [575]    
MENDS: 




153 (57%) [583] 
Unclear, preference reported qualitatively. 
MASCOT Assessed for eligibility (n = 898), Not 
registered (n = 732), Excluded (n = 103). [575] 
MENDS 27 (16%) assessed for eligibility but not 
randomised: ‘declined 11’ ‘other 16’. [567]  
TIPIT 57 (21%) assessed for eligibility but not 








108 (46%) 41 (33%) No. 
Wynn  
2010 





‘Reluctance toward medication treatment accounted for 
44.7% of study refusals and was disproportionately 
common among ethnic minority families. 
No. 
 






A small number of patients who were eligible declined 
the trial as they had a treatment preference. These 
were patients allocated to both intervention groups, so 
one treatment option was not preferred to the other. 











286 (28%) declined any follow up, authors assumed 
that all had a patient preference. 
461 (45%) opted for preference groups in cohort. 
Only in qualitative sample.  
Authors did not attempt to 
differentiate between parent/child 




137 (45%) 169 (55%) opted for preference groups. n/a children under 2yrs. 
Paradise  
1984 
91 (49%) 96 (51%) opted for preference groups. No. 
Paradise 
1990 
99 (46%) 114 (54%) opted for preference groups. No. 
Reddihough 
1998 




133 (34%) opted for non-randomised cohort groups. 
66 (17%) refused randomisation/follow up via cohort. 
n/a children under 1yrs. 
Van Wijk 
2014 







228 (21%) opted for preference groups. 
297 (27%) declined all follow-up due to preference. 






4.2.2 Patient or parent preference? 
Nine papers explicitly reported the treatment preferences of young people, as well as 
their parents. [66, 96, 524-526, 586, 597, 601, 602] Child/parental views on preferred 
treatment groups differed on three occasions. [66, 96, 525] Twelve papers reported 
findings from trials involving children under the age of six years, so did not include 
information on the preferences of young people or children. [74, 319, 325, 531, 588, 
589, 595, 600, 605, 610, 613, 616] Finally, one trial reported that parents who 
refused randomisation did so because of “a desire to have decisional control, and 
they trusted their physician’s choice of treatment more than a computer’s choice”. 
[111] 
 
4.2.3 Health professional preferences for trial treatments   
Most studies did not comment on families’ reasons for treatment preference, but six 
papers reported different forms of health professionals’ preference for treatment 
which may have influenced family’s preferences. [96, 381, 524, 603, 610, 616] Two 
trials stated that staff experienced discomfort with children’s medication/intervention 
being selected by a process of randomisation, [96, 610] one highlighted that 
“consent was more likely when the recruiting physician was a member of the 
research team” [381] and in another, a parent whose child was randomised to a 
splint treatment group was told the day after randomisation by a clinician outside the 
RCT that, “all buckle fractures need to be casted”. [603] These findings suggest that 
recruiters and treating health professionals may be an important influence on parent 





4.3 Summary of included studies (qualitative data) 
Forty papers contained only descriptive data relating to preference, e.g., CONSORT 
diagram figures for the number of families declining the trial because of a preference 
for treatment. These papers did not contain qualitative data in the form of parent or 
participant quotations so were not included in these analyses. Twelve papers 
contained parent/participant quotations relating to expressions of preference, and 
data from these papers were synthesised. [66, 74, 96, 97, 107-109, 115, 120, 325, 
326, 531] Two of these papers also contained participant quotations, in addition to 
those of parents. [66, 96]  Four papers also investigated the communication 
practices of families and health professionals at the point of recruitment. [74, 96, 97, 
108] Table 4:4 summarises all 12 papers with qualitative data; nine were published 
in the UK, and one in Canada, Australia and Brazil respectively. Eleven of the 





Table 4:4 Summary: Papers with qualitative data 
Publication 
year / Author Country 
Age range 
months/years 
(Participant) Description of RCT and interventions 
1997  
Snowdon [74]  
UK Neonates 
The ECMO Trial (UK Collaborative trial of extra corporeal membrane oxygenation) compared two 





UK 3-4yrs Speech and Language Therapy: i) immediate treatment: ii) watchful waiting. 
2003 
Caldwell [97]  
Australia Not stated  Multiple RCTs / research groups involved, including oncology and renal: interventions not defined.  
2005 
Eiser [108]  
UK 4-6yrs 
Acute Lymphoblastic Leukaemia (ALL): Drug intervention: dexamethasone and 6-thioguanine compared 
with agents used in previous trials (prednisolone and 6-mercaptopurine respectively). 
2006 
Allmark [531]  
UK >36wks 
Total Body Hypothermia (TOBY) trial investigated the use of whole-body cooling for term infants with 
evidence of perinatal asphyxia and compared intensive care plus total-body cooling for 72 hours with 
intensive care without cooling.  
2009 
Jollye [326]  
UK Neonates 
Multiple RCTs, non-urgent neonatal: i) Ventilation trial comparing two modes of CPAP ventilation, ii) 
blood transfusion trial comparing a single infusion to a divided dose 24 h apart, iii) immunoglobulin trial 





Acute Lymphoblastic Leukaemia (ALL). The trial randomised at 1 of 2 points: Point 1 approximately four 
weeks after treatment had begun: If child in remission at 28 days but MRD high levels of residual 
disease i) standard treatment ii) a more intensive treatment. Point 2 approximately 12/13 weeks after 
treatment had begun: If child in remission at 28 days but MRD low levels of residual disease i) standard 
treatment (ii) reduced intensity treatment. 
2010 
Lock [66]  
UK 4-15yrs 
RCT with preference groups: Recurrent sore throat: i) tonsillectomy and adeno-tonsillectomy, ii) non-





year / Author Country 
Age range 
months/years 
(Participant) Description of RCT and interventions 
2010 
Woodgate [325]  
Canada 6mth-5yrs 
Various trials - individual trial aims not reported.  Children were diagnosed with either leukaemia or 
lymphoma, and 8 had a solid tumour.  
2011 
Shilling [96]  
UK 
MASCOT:  
6-15yrs                     
MENDS:  
3-15yrs            
POP:4-18yrs  
TIPIT: Pre-
term infants  
<28wks 
gestation 
MASCOT Management of asthma in school age children on therapy: i) Inhaled fluticasone + placebo 
tablet, ii) inhaled fluticasone and salmeterol (combined inhaler) + placebo tablet, iii) inhaled fluticasone + 
montelukast tablet. Funding extension application rejected & trial closed prematurely.                                                                                                                                           
MENDS – The use of melatonin in children with neurodevelopmental disorders and impaired sleep: i) 
Melatonin, ii) placebo.  
POP – Prevention and treatment of steroid-induced osteopaenia in children and adolescents with 
rheumatic diseases: i) Risedronate, ii) vitamin D 
analogue 1-alphahydroxycholecalciferol, iii) placebo.                                                                                                          
TIPIT - A randomised controlled trial of thyroxine in pre-term infants under 28 weeks’ gestation: i) 




An RCT that compared advanced behaviour management techniques for pediatric dental rehabilitation. 
Dental Sedation: i) physical restraint, ii) moderate conscious sedation, iii) general anesthesia. 
2013 
Woolfall [107]  
UK 
MASCOT:  
6-15yrs                     
MENDS:  
3-15yrs             
POP: 4-18yrs 
TIPIT: Pre-
term infants  
<28wks 
gestation 





All 12 papers with qualitative components collected interview data, three collected 
data via recorded recruitment consultations in addition to interviews, [96, 107, 109] 
and one study used focus groups in addition to interviews. [97]  Four studies 
collected data during or after the initial recruitment consultation, therefore obtaining 
parent and patient feedback directly at the point the trial was initially discussed, [96, 
107, 109, 120] while the remaining studies asked parents or young people to 
retrospectively reflect and provide feedback on the recruitment process, or their 
experience and feelings about the offer of trial participation. Five studies 
incorporated a constant comparative approach. [96, 97, 107, 109, 325] Three studies 
drew on thematic analysis, [66, 107, 108] three framework analysis [96, 323, 531] 
and one paper stated that ‘content analysis’ was used to develop themes. [120] Two 
studies did not clearly state which analytic approach was employed. [74, 326] and 
four did not describe an underpinning approach or epistemological stance. [108, 115, 
120, 531] 
 
Six papers presented data collected retrospectively at interviews conducted in the 
months following randomisation. [66, 74, 97, 108, 323, 326] Three papers presented 
data from audio-recorded recruitment consultations that happened prior to 
randomisation, as well as interviews conducted after randomisation. [96, 107, 109] 
One paper presented preference data collected immediately after informed consent 
and straight after the randomisation process. [120] Qualitative sample sizes ranged 
from 7 (families) to 84 participants (mother, father and their participating child). 
Ninety-two quotations relevant to preference were extracted in total, with a median of 

















participants) Study theme(s) 
Is preference expressed 
by patient/parent prior 







Snowdon   
37 parents:  
21 mothers  
& 16 fathers 
Parents' responses to the process of 
randomisation. Detailed exploration of 
parental reactions to random allocation of 
treatment in a neonatal RCT.  
No - retrospective report 
of preference from RCT 
parents  
In-depth interviews: 
in 16 interviews both 
parents were 










Glogowska   
20 parents 
Reported attitudes of parents whose child 
was invited to take part in an RCT.  
No - retrospective report 
of preference from RCT 







Caldwell   
33 parents:  
29 mothers  
& 4 fathers 
Explored parents’ attitudes to children’s 
participation in trials, identifying factors that 
influenced decision-making and perceived 
risks and benefits. Multiple trials, oncology 
and renal & parents of healthy children.   
No - retrospective report 
of preference from RCT 
parents and non-trial 
parents 








Eiser   
50 mothers 
Mothers' (of children newly diagnosed with 
Acute Lymphoblastic Leukaemia) views 
regarding consent to randomised controlled 
trials.  
No - retrospective report 
of preference from RCT 






Allmark   
30 sets of 
parents 
To assess whether continuous consent, a 
process in which information is given to 
research participants at different stages in 
a trial, and clinician training in that process 
were effective when used by clinicians 
while gaining consent to the TOBY trial. 
No - retrospective report 
of preference from RCT 









Jollye   
7 families 
Explored the thoughts and feelings of 
parents in their decision-making process, 
either choosing or declining to participate in 
neonatal clinical trials.  
No - retrospective report 
of preference from RCT 
parents and non-trial 
parents 
Semi-structured 
interviews - 2 















30 parents: 17 
mothers  
& 13 fathers 
Examined how recruitment looked to an 
observer and how it felt to parents, (of 
children with low-risk acute lymphoblastic 
leukaemia) to identify how doctors’ 
communication could promote or inhibit 
optimal recruitment. 













Lock   
12 families:  
mothers & 
young people 
An embedded qualitative study which 
informed the development of the RCT. 
Investigated families’ experiences of 
recurrent sore throat and their preferences 
for different treatment options. 
No – families participating 
in a nested qualitative 
study reported preference 
when interviews were 
undertaken to inform the 











Woodgate   
31 parents:  
20 mothers & 
11 fathers 
In-depth understanding of parents’ 
participation in decisions about childhood 
cancer clinical trials. 
No - retrospective report 
of preference from RCT 
parents  
In-depth interviews: 
Twenty parents from 
10 of the families 
interviewed as 
couples, parents 
from the remaining 
20 families (mothers 
n = 20, father n = 1) 





Shilling   
Interviews:  
84 members 
of 60 families.   
58 mothers, 
4 fathers and 
22 young 
people. 
Communication about trials as observed 
and experienced & factors that influence 
decision-making. Aimed to identify 
strategies to improve recruitment and trial 
conduct, by comparing practitioners’ and 
parents’ accounts of the invitation to enter a 
child into clinical trial.  
  















Carvalho   
15 mothers 
The understanding and perceptions of 
mothers regarding the informed consent 
and randomisation processes. It was 
assumed that mothers would have 
difficulties understanding the consent form 
and that most would accept randomisation 
because their children needed dental 
treatment. 
Yes - after the informed 
consent process 
Interviews in two 
phases: 1. After a 
parent had signed 
the consent form: 
















Explored how a parent’s understanding of a 
trial might be associated with the way that 
the trial was explained during the 
discussion with a practitioner. 





















4.3.1 Critical appraisal 
CASP scores are shown in Table 4:6. Five papers which each scored six points were 
included in a sensitivity analysis to assess whether synthesised data changed 
significantly if they were removed. [74, 108, 323, 326, 531] This was not the case, 
and since none of the papers were deemed to be ‘fatally flawed’ [617] and unsuitable 
for inclusion, all assessed papers were included in the final synthesis. The most 
frequent areas of weakness included lack of transparency in reporting of: data 
analysis methodology, ethical issues, and reflexivity. However, there is a lack of 
consensus around quality assessment criteria and the way in which this is applied to 













































3.2             
Vulnerability     
and 
responsibility






3.5             
Anger and 
happiness
Carvalho 2013 9 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Woolfall 2013 9 ✓ ✓ ✓ ✓ ✓
Shilling 2011 9 ✓ ✓ ✓ ✓ ✓ ✓
Lock 2010 9 ✓ ✓ ✓ ✓
Byrne-Davis 2010 8 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Caldwell 2003 8 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Woodgate 2010 7 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Jollye 2009 6 ✓ ✓ ✓ ✓ ✓ ✓
Allmark 2006 6 ✓ ✓ ✓ ✓
Eiser 2005 6 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Glogowska 2001 6 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓







score      






Third order construct one                      
Making sense and asking questions 
about the RCT 
Third order construct two                                                                        
Motivations  and reservations about taking part in an RCT  
Third order construct three                                                                  




4.3.2 Synthesis of Qualitative data: Meta-ethnography 
Data from the 12 original papers were translated into each other to form a 
synthesised translation made up of three overarching (third order) constructs, 
consisting of eleven inter-linked sub-themes from parent data, and eight interlinked 
sub-themes from patient data (see: Section 4.3.6 The preferences of children and 
young people). Appendix 2 provides the translation of all first, (quotations) second, 
(authors’ themes) to third order (synthesised) constructs. 
 
Synthesis of treatment preference data 
Only one of the original papers included in this meta-ethnography explicitly referred 
to preference as a named theme in the primary data analysis: ‘Preference for 
different arms of the trial’.[108] However, treatment preferences were expressed in 
several data extracts, and five further papers discussed preference for treatment 
within other themes of their analyses or discussion sections. [66, 74, 97, 109, 325] 
Six authors discussed equipoise, [66, 74, 96, 97, 109, 323] but only one explicitly 
used the term ‘equipoise’ in a heading outlining a key finding: ‘Parents appeared to 
understand equipoise, voluntariness and randomisation’. [109] 
 
Parents’ preferences for treatment were identified in all 12 papers, but only two 
papers included in this synthesis reported the views of young people in relation to 
preference for treatment and trial participation, [66, 96] (see: section 4.3.6 The 
preferences of children and young people). One paper demonstrated that parents 




in this case parents overwhelmingly preferred surgery and young people a non-
surgical intervention. [66] 
 
Line of argument parent data: Doing the best for my child 
Table 4:7 displays the third-order constructs, inter-linked sub-themes and line of 
argument developed from parental data. There was considerable overlap between 
each overarching third order construct, and the sub-themes within them. Parents’ 
understanding of trial processes (e.g., randomisation and equipoise) influenced their 
motivations and reservations about their child’s participation (e.g., perceived benefits 
and risks). Some parents were emotional in the run up to randomisation, when 
provided with information of their child’s allocated treatment group, or when recalling 
aspects of the recruitment consultation (e.g. the responsibility they felt when making 
the decision to participate). Parental emotion ranged from happiness to 
disappointment, and parents demonstrated a vulnerability to the randomisation 
process that includes hopes, fears, anger and relief. A new interpretation of the data, 
an expression of the synthesis, was taken forward as the line of argument: ‘Doing 
the best for my child’.  Parents not only engaged in ‘sense making’ work in relation to 
trial processes, they also engaged in ‘moral identity’ work as they juggled ‘sense 
making’ and the principle of ‘altruistically’ helping to progress medical research for 
future young patients, with the competing demands of being a good parent and 





Table 4:7 Parents’ data: Third-order constructs, inter-linked sub-themes and 
line of argument 
Third-order constructs and inter-linked sub-themes Line of argument 
1. Parents’ preferences for treatment: expressed while 
making sense and asking questions about the RCT  
1.1 Understanding of trial processes (nature of RCT, 
randomisation, equipoise) 
1.2 Understanding of treatment groups and unanswered 


















2. Parents’ preferences for treatment: expressed 
motivations and reservations about taking part in an RCT   
2.1 Perceived benefits and risks (facilitators and barriers 
to trial participation) 
2.2 Access to treatment (medication or therapy) 
2.3 Management of condition and practical implications 
2.4 A difficult decision 
3. An emotional response to randomisation and 
expressions of preference for treatment 
3.1 Hopes and fears 
3.2 Vulnerability and responsibility 
3.3 Fate and luck 
3.4 Disappointment and relief 




4.3.3 Parents’ preferences for treatment: expressed while making 
sense and asking questions about the RCT  
A minority of parents understood trial aims and rationale for randomisation. These 
families also appeared to be in a place of equipoise about trial treatments and 
preferences were not expressed: 
“that’s the thing with the randomisations they don’t have the figures at the 
moment to say well yes this regime does work better than this regime” 
[Byrne-Davis] 
 
“treatment is excellent anyway and anything they offer [in the trial] can 
only be better” [Eiser] 
 
One parent highlighted the importance of being treated as capable of understanding 
trial processes, (such as placebo) and having information provided in a way that was 
accessible. This was developed in the line of argument as the way in which parents 
assimilated new information with their pre-existing knowledge of RCT research: 
“if it is explained to people...you are more likely to get a positive sort of 
response […] if...I didn’t know anything at all about trials, I’d be thinking 
trials to me sound experimental, placebo to me sounds like it’s not a real 
drug. ...it all depends on how it’s been worded and how it’s been 
explained...” [Caldwell] 
 
Some parents questioned equipoise when trial groups delivered either ‘standard’ or 
‘high intensity’ treatment. These families expressed preference because their “gut 




assimilating new information into their pre-existing cultural or personal knowledge of 
treating a known condition e.g. cancer. Another family also found it difficult to let go 
of their initial preference for ‘high intensity’ treatment, and struggled with the concept 
of equipoise: 
“very difficult for me to say, yes, he could just have one [intensive block]” 
[Byrne-Davis] 
 
“in the back of my mind I can’t let go of the thought that two intensive 
periods is better than one” [Byrne-Davis] 
 
Some families confused eligibility for the RCT with eligibility for their preferred trial 
treatment: 
"anybody eligible for it should use it [ECMO]" [Snowdon] 
 
Expressions of preferences were sometime subtle before randomisation and group 
allocation: 
“Oh, fear of what I want not happening” 
[said by a mother while waiting for randomisation: Carvalho]  
 
The majority of parents described misunderstandings about trial processes, 
particularly the ‘reasons’ for using a process of randomisation to determine 
treatment. Parents correctly understood the ‘end result’ of randomisation, that their 




there was often a lack of understanding ‘why’ this process was used. Parents lacked 
equipoise and felt there was a ‘right’ treatment group, which would be more effective. 
Parents involved with trials that had a watchful-waiting group, or placebo found it 
particularly difficult to understand the rationale and legitimacy for use of a placebo 
group: 
“[placebo group] that’s just like going to the doctor and them saying well 
we are just not going to treat this child” [Caldwell] 
 
“I was told yes, he had a problem and he needed help and I think now, 
well, I’ve got to wait ... to get any help” [Glogowska] 
 
“What my question is, if they say he’s gonna take the placebo… the 
dummy one what is he going to benefit from the study?” [Shilling] 
 
Parents also assigned their own ‘rationale’ for randomisation, because of ‘cutbacks’ 
not because of uncertainty about treatment effectiveness: 
“It was a case of if his name came out of the box ... then he was lucky 
enough to go on it [active therapy as opposed to watchful waiting] which I 
think is wrong ... but then I suppose it’s all the cutbacks” [Glogowska] 
 
Expressions of preference were frequent during interviews with families who had 
consented to trial participation, suggesting that these families decided to participant 
despite preference for treatment. This was often the case where trial treatment was 




“I remember saying to him… ‘Oh great, great, like some effing placebo’ is 
what I said to him… so, no, I totally understood that idea, [randomisation] 
so I was kind of glad” [because baby received preferred ‘active’ treatment] 
[Allmark] 
 
“We were disappointed. You go through all that talking and decision-
making and then you get the old treatment anyway” [Eiser] 
 
Some parents believed that the only way to access a preferred treatment for their 
child was via trial participation: 
“in order to get that tablet he has to participate in the trial” [Shilling] 
 
“I was just thinking I hope he gets the [trial drug] one’’ [Woolfall] 
 
In one study [120] it was unclear whether all the interventions offered via the RCT 
were available to families outside the trial. In this study most parents (all but two) 
accepted the randomised allocation despite nine having expressed that they would 
have chosen one of the other trial interventions for their child when they were asked 
before randomisation: 
“We would like to have gotten the general anesthesia . . . now we have to 
do it with the sheet” [Mother’s expectation before randomisation, general 





 “Oh, no!” [Mother’s expectation before randomisation, physical restraint. 
Group assigned, general anesthesia] [Carvalho] 
“Oh, I would not want [to do it]. I came here with my heart in my hand 
thinking about it. I thought I could choose to come here and say ‘I do not 
want general anesthesia.’ The doctor at the health center had already said 
that a sedative might be necessary, so I was already thinking ‘I will not 
allow it.’” [Mother’s expectation before randomisation, physical restraint. 
Group assigned, general anesthesia] [Carvalho] 
 
Although some parents had preferences for a specific trial group, upon 
randomisation to their non-preferred group they made altruistic comments about 
‘helping others’: 
“We would have wanted the old one [drug] but if it helps others it’s Okay. 
They pick you at random and we got picked [for the new drug]” [Eiser] 
 
“Maybe he might get [the trial drug], maybe he mightn’t. Maybe, if he does 
get it, it might help him in some way and if he doesn’t get it then, you 
know, at least I tried to help [you] with the study” [Shilling] 
 
Some parents incorrectly believed that their child was randomised to a treatment 
because the process of randomisation considered ‘factors’ about their child’s 
condition and/or circumstances, which resulted in randomisation to a specific 
treatment, (therapeutic misconception). When a minimal residual disease test result 
came back as ‘higher risk’ a parent believed this was the reason why her child was 
randomised to regimen C rather than staying on regimen A. This mother expressed a 




bit hopefully to [...] get the leukaemia under control” [Byrne-Davis]. Parents felt their 
child was receiving the ‘right’ treatment for their specific needs via RCT participation: 
“If she’d [the therapist] seen something ... and thought ... this is something 
really serious well then he wouldn’t have been put on that sort of waiting 
group” [Glogowska] 
 
“I thought that the doctor had entered Timothy for the trial as he was 
perfect for the ECMO treatment” [Snowdon] 
 
A lack of understanding about RCT eligibility criteria also resulted in the perception 
that treatment had been chosen completely ‘randomly’ with no specified criteria: 
“the computer makes the decision [...] and I just think, they give you all 
this information and then, you know, randomisation is just purely you’re 
picked at random, it’s a lottery. […] I think they should have certain 
criteria, that maybe if you fit these specific criteria’s, or if you have a 
daughter that’s fifteen years of age, or twelve years or whatever, a reason 
for not going on it would probably be better rather than just saying ‘oh 
well, the computer picks and that’s it.’” [Byrne-Davis] 
 
Parents’ potential misperceptions of trial processes appeared very logical when 
analysed with data from recorded conversations of recruitment consultations. [96] In 
the extract below a recruiter is trying to explain that specific trial drugs would be 
assigned by a process of randomisation. During a later interview this parent 





Doctor: And by randomised, what we mean is that we just randomly pick 
one. So it’s almost like a sort of, it’s usually a computer program that just 
sort of. 
Parent: A lucky dip? 
Doctor: Yeah it is exactly like that. Like a lucky dip […] so it’s almost like 
just, you know, saying well we just picked this out of a hat and [your son] 
got this treatment”  
Recruitment consultation [Shilling] 
“A bit wary, […] because I thought, ‘Oh what’s, just going to give him 
some random tablets or anything’” 
Interview [Shilling] 
 
Another mother declined participation because she simply "switched off” after the 
doctor first mentioned the way that drugs would be administered to her baby in the 
RCT: 
Doctor: The hormone is given through err … an infusion. It’s called err a 
syringe pump basically, which is, you know, puts medicine to the veins. 
Um and we will give it once a day 
Mother: Okay 
Doctor: All these procedures won’t cause distress to your baby […] if your 
baby is not getting fully milk feeds, then we will use the lines. Once a baby 
is going on to full or milk feeds, then we will give drops and things […] so 
it won’t cause any distress 





"[Doctor] told me, I think, they’re going to put like kind of a small tube 
inside him, so […] I remember after that, I just hated this idea of the tubes 
were going to go in! So I don’t remember why they was putting the tube. I 
think they were studying something, but I just, I just didn’t like the idea 




Where available, recruitment consultations also highlighted the way in which parents’ 
lack of equipoise about treatment groups might be subtly reinforced via the language 
used by clinicians during recruitment consultations: 
“So we are running this study for the last year now, where I’m afraid half 
the [babies] get the supplement and half the [babies] doesn’t get it” 
[Shilling] 
 
Some parents still had ‘unanswered’ questions after their child had been 
randomised, questions focused on treatment and associated risks: 
“is there a risk of death?” [Mother’s expectation before randomisation, 
general anesthesia. Group assigned, general anesthesia] [Carvalho] 
 
“he [the doctor] was saying, you know “you’ve got to balance out the low 
risk here to the high intensity here”. Does that balance out? And with her 
having the [name of serious infection], um, do we really want to put her at 
risk from being susceptible to those sort of things again when, maybe, she 
doesn’t really - in the bracket that she’s in, where it is a 85%, 95% cure 




4.3.4 Parents’ preferences for treatment: expressed motivations 
and reservations about taking part in an RCT   
Parents participating in 10 studies discussed the ways in which their children might 
benefit from participation in the RCT. Benefit was sometimes linked to gaining 
access to a preferred treatment, with parents feeling that one treatment group was 
better than the other: 
 “They might get the new drugs that work..” [Caldwell] 
 
"I just felt there could have been ten other babies with exactly the same 
problems as him and now there is nine sets of parents who are now being 
told that their baby's not being accepted onto the trial [conventional 
management]. And I did feel a bout of guilt for that but I could have gone 
out and...danced on water...when I got told that he'd been accepted 
[ECMO]" [Snowdon] 
 
Some parents were aware that they could access RCT interventions outside the trial 
and decided before randomisation, if their child was not randomised to the ‘right’ 
group they would request the treatment they perceived as ‘right’ for their child. The 
‘right’ treatment group was often perceived as ‘active’, ‘new’ or ‘more aggressive’, as 
opposed to ‘inactive’ ‘old’ or ‘standard’: 
“I couldn’t justify saying O.K. we'll go along with this research group 
[watchful waiting] and wait for a year because he needed help then” 





“I’d heard about [trial drug] and I’d read a few things on the internet, 
because of [child’s name’s] sleeping, and I just thought, right I’m going to 
ask if he can have it’’ [Woolfall] 
 
“He would be peeved off if he got the jelly beans...[placebo] he would 
want the real thing...” [Caldwell] 
 
Families accepted allocation to a ‘placebo’ or ‘old’ treatment in the short term, 
because their child would then be able to access the ‘real’ or ‘new’ treatment at the 
end of the trial: 
“I was at the end of my rope...if it was the placebo, well that means that 
we can try the real thing anyway [at the end of the trial]” [Caldwell] 
 
“We were glad to get the old treatment. It means if she relapses we can 
still have the new treatment [at the end of the trial]” [Eiser] 
 
Parents also believed that access to any treatment, or their preferred treatment was 
only possible via the RCT, even when medication was available outside the trial: 
“It cannot continue the way it is. I am like really afraid of general 
anesthesia, but, as others say, if it is necessary, what can I do? . . . As I 






“I didn’t see why I […] could say ‘no’ to it. Because I thought, well it’s, you 
know, a 50/50 chance of her getting […] this additional help which she 
might need” [Shilling] 
 
‘‘I’ve got sort of a 50/50 chance of either she gets the drug or she gets the 
placebo. But she wouldn’t be getting it [drug] otherwise’’ [Woolfall] 
 
Access to treatment and potential benefit were closely balanced with consideration 
of risk and possible deterioration. Some families also mentioned ‘risk’ in their 
discussion of preference for treatment. Although more aggressive treatments were 
more often preferred, less aggressive treatments were accepted as an alternative 
because of the benefit of lower risk: 
 “we were slightly disappointed that [...] he got regimen A but of course the 
flip side of the coin is if he gets away with it… and he avoids a much more 
toxic regimen… then fantastic” [Byrne-Davis] 
 
Some parents worried about making a decision that might result in their child being 
allocated to a treatment group that proves to be less effective in the long term: 
“it’s a worry thinking you’re doing the wrong thing...people don’t want 
to...(be) the one being responsible once again” [Caldwell] 
 
‘‘what if Anna is put on (one group of trial) and things didn’t work out as 






In two papers parents discussed preference in the context of decision-making and 
the ongoing day-by-day or long-term management of their child’s condition, in very 
contrasting medical conditions, childhood cancer and re-current sore throat. [66, 325] 
In the context of cancer treatment, preference was only hinted, parents reported 
having to live with the decision they had made (to opt for trial participation), with the 
anticipation of managing the condition via an assigned treatment regime perceived 
as ‘difficult’. These views were taken forward in the line of argument as ‘a difficult 
decision’: 
"I’m sure if he had been chosen for any other arm except for the difficult 
one, I would not have given it another great thought. But it all came down 
to the fact that he got chosen for the one with so much more intravenous 
and lumbar puncture medication, then it threw me for a loop and I went 
through a very tough period. Not the initial period because you have 56 
days before you get randomized. So you have a long time before you get 
randomized” [Woodgate] 
 
Parents expressed preferences for surgical treatment for recurrent sore throat, 
because of prior positive experience of this approach, and to minimise the long-term 
impact the illness was having in terms of pain, discomfort and school attendance: 
"Yeah his brother had his took out and he’s been brilliant since he got his 
done … it was the best thing I could have done for him … that’s why we 
are trying to push to get his done because it’s just recurring all the time, 
every couple of months or so and it’s not fair on the bairn and it’s not fair 
on his education either because he’s having to have the time off school 





"If it come to the 10 month up and he didn’t need it done, my wife says, 
‘Oh I might get it done anyway, just in case" (Father of 07, male, age 7) 
[Lock] 
 
4.3.5 An emotional response to randomisation and expressions of 
preference for treatment 
Some parents experienced the offer of treatment for their child, via a process of 
randomisation as an emotional decision. This was apparent in the language used by 
parents when describing the time leading up to randomisation, or the retrospective 
accounts of their response to being informed of the group their child had been 
allocated via randomisation: 
 “I came here [day of randomisation] with my heart in my hand thinking 
about it…” [Carvalho] 
 
“But the minute that it hit me full in the face was when we got chosen for 
the tough arm that hit me like a lead brick" [Woodgate] 
 
“unfair” "hard" "tough" [Snowdon] 
 
Emotional responses to randomisation included disappointment, fear or anger when 
a child was randomised to what was perceived as ‘the wrong’ or an ineffective 
‘placebo’ group. Expressions of relief, and in some cases, exhilaration were apparent 




“we were slightly disappointed that [...] he got regimen A” [Byrne-Davis] 
 
“We were disappointed. You go through all that talking and decision-
making and then you get the old treatment anyway” [Eiser] 
 
"We went back to the ward. The nurses said "Oh, he hasn't got the 
ECMO, he's staying here" and them saying that we thought, oh dear, you 
know, we've had the wrong one or something. We felt disappointed" 
[Snowdon] 
 
“then he was lucky enough to go on it” [immediate treatment group] 
[Glogowska] 
 
“Relieved. I feel like jumping for joy. That is great” [kisses child] [laughs] 
[Carvalho] 
 
In the context of a highly stressful situation, when parents had been told their new-
born child’s life was in danger, one parent could not recall being told about the use of 
randomisation in the trial. This parent had a clear ‘preference’, or perception that one 
treatment in the trial (ECMO) was more effective than the alternative trial treatment, 
which their child had already received and showed no improvement. In retrospect, 
this parent stated that having an understanding that treatment would be decided via 




"It probably would have killed me if l had known that it was a randomized 
test and if they had turned around and said she couldn't go on, [ECMO] 
...because I knew the ventilator wasn't helping her which meant...as good 
as ‘I am sorry there is nothing else we can do but wait for her to die’” 
[Snowdon] 
 
Some parents felt that they had nothing to lose by entering the trial because it gave a 
50% opportunity of getting ‘additional help’. Others felt they could not decline the trial 
and opt for their preferred treatment because it was not available ‘for free’ outside 
the trial: 
"I didn’t see why I […] could say ‘no’ to it. Because I thought, well it’s, you 
know, a 50/50 chance of her getting […] this additional help which she 
might need" [Shilling] 
 
“As I am receiving the treatment for free I accept what we get. And I have 
no choice” [Carvalho] 
 
Some parents questioned the ethical basis of randomisation when one treatment 
group was perceived as more effective than another. For example, ECMO treatment 
[74] was already used in the USA despite not having been compared with standard 
care via a trial. This was particularly apparent where trials were recruiting children 
who were already in pain, or facing a life-threatening condition: 





“why the hell have we got it on trial when it's been in the States and it's 
got an 89% success rate or whatever?” [Snowdon] 
 
Placebo treatment was perceived as ‘no treatment’ with a lack of apparent 
understanding about why a placebo was being used as a comparator:  
“[placebo] that’s just like going to the doctor and them saying well we are 
just not going to treat this child” [Caldwell] 
 
Preferences were described in terms of hopes and fears, hope for the treatment 
perceived to be ‘better’ and fear of getting a treatment that the parent was ‘afraid’ of 
in terms of the consequences of procedures (such as anaesthetic) involved in the 
process of getting the necessary treatment that their child required: 
“if there was a hope that he would get better treatment then at least we 
felt like we’d done everything that we could” [Byrne Davis] 
 
“It cannot continue the way it is. I am like really afraid of general 
anaesthesia, but, as others say, if it is necessary, what can I do?” 
[Carvalho] 
 
Parents understandably experienced a strong sense of responsibility about making 
the ‘right’ decision for their child. This highlights parents’ vulnerability to the 
randomisation process because of the preferences which they held: 
"She [the doctor) said had it been her child and this was chosen (standard 




was enough to make me calm...She too agreed with what I’m saying and 
feels that it’s a wise decision. That was enough to make me at peace 
again. And now whatever happens with [name of child’s] treatment… 
relapse or whatever, I will never look back and say I’ve made a poor 
decision. I will not do that" [Woodgate] 
 
“it’s a worry thinking you’re doing the wrong thing...people don’t want 
to...(be) the one being responsible once again.” [Caldwell] 
 
This emotional response related not only to parents’ preferences for a specific trial 
group and the fact that they were focused upon ‘doing the best’ for their child, but 
also in relation to parents’ vulnerability, since feelings of nervousness, regret and 
guilt were often discussed in relation to the decision to proceed with randomisation. 
Some parents responded to this vulnerability by discussing ‘fate’ and ‘luck’ in relation 
to the outcome of randomisation, despite having preferences for treatment: 
“I tell you it's kind of going through [your] whole life without following 
religion or anything like that but at that time you cling on to anything really 
and I thought there is only one decision here and it has to be Fate... He 
stayed and had traditional treatment and the fact that he didn't go to the 
ECMO as far as I'm concerned the decision was right. Fate played its 
hand” [Snowdon] 
 






“it was a case of if his name came out of the box ... then he was lucky 
enough to go on it ...” [Glogowska] 
 
4.3.6 The preferences of children and young people 
Line of argument patient data: Wanting to get better and help others 
Fewer data were available to provide a comprehensive translation of young peoples’ 
expressions of preference for treatment, but young people also engaged in their own 
‘sense making’ work in relation to trial processes, (such as randomisation) and 
access to treatment. Young people expressed overt preferences for treatment on two 
occasions, in two of the twelve papers. [66, 96] Both participants expressed a 
preference for ‘active’ treatment:  
“I was thinking, this could be really good for me but what if it’s the placebo 
then, um, it’s like I’m doing it for nothing basically” [11–14 years] [shilling] 
 
“I was a bit disappointed actually because I just wanted to get rid of it 
[sore throat] straight away” [randomised to non-surgical conventional 
medical management, 15-year-old-female] [Lock] 
 
One of these studies reported ‘substantial differences between children and their 
parents’ [66] [pg.34] in relation to preferences for non-operative or a surgical 
intervention for the management of recurrent sore throat: 
Lock: However, it must be made clear here that there were substantial differences 
between children and their parent(s) regarding their views on surgery. On only three 
occasions were parent(s) and child in agreement regarding their desire, or lack of 




for surgery while their parent(s) was less sure; these were the two oldest children in 
the sample. In all other cases it was the parent(s) who desired surgery while the 
child was either ‘worried’, ‘scared’, ‘panicked’ or adamant that they did not want 
surgery. [66] [pg.34] 
 
Four further quotations from young people related to other concepts discussed by 
parents, such as perceived personal benefit, but also the potential to help others 
presented with a similar situation in the future. Although these are not direct 
expressions of treatment preference, they did demonstrate that young people 
understood that different treatment options were available in the trial, and that there 
was unpredictability in terms of treatment and the long-term management of their 
condition: 
“They basically said that some people would get the real thing and others 
needed to get the placebo” [11–14 years] [Shilling] 
 
“You just think like ‘oh […] what are we gonna have to do’ like, ‘what 
medicines are we gonna take’ and then obviously […] ‘what will happen 
as a consequence of the medicine’” [11–14 years] [Shilling] 
 
“Even though one of them might not work for the bones [?placebo?] and 
things will it do some good for me?” [11–14 years] [Shilling] 
 
“It would benefit me and other children in the future for like if they have the 
same thing they can get medicine and not have to do the study but like 




Young people wanted to help other young patients in the future, but also wanted to 
facilitate their own recovery via RCT participation. One young person understood 
that there was unpredictability in terms of treatments available in the RCT, and two 
contemplated how their assigned treatment might impact the long-term management 
of their condition. A new interpretation of young peoples’ preference data was taken 
forward as the line of argument: Wanting to get better and help others. Table 4:8 
displays the third-order constructs, inter-linked sub-themes and line of argument 





Table 4:8 Young peoples’ data: Third-order constructs, inter-linked sub-
themes and line of argument 
Third-order constructs and inter-linked sub-themes Line of argument 
1. Participants’ preferences for treatment: expressed while 
making sense and asking questions about the RCT  
1.1 Understanding of trial processes (nature of RCT, 
randomisation, equipoise) 
1.2  Understanding of treatment groups and unanswered 
























2. Participants’ preferences for treatment: expressed 
motivations and reservations about taking part in an RCT 
2.1 Perceived benefits and risks (facilitators and barriers 
to trial participation) 
2.2 Access to treatment (medication or therapy) 
2.3 Management of condition and practical implications 
3. An emotional response to randomisation and 
expressions of preference for treatment 
3.1 Hopes and fears 
3.2 Disappointment 





4.4 Discussion: Systematic literature review and 
qualitative synthesis 
This is the first systematic review specifically investigating whether treatment 
preference influences recruitment into paediatric trials. This systematic review 
identifies that families often have preferences for treatment at recruitment, and some 
families consent to trial involvement despite having preferences for a specific 
treatment. Reports of preferences for treatment ranged widely in feasibility RCTs, (4-
70%) conventional RCTs, (2-50%) and in trials with preference groups (11-55%). 
Declining accrual rates and a loss of clinical equipoise led to the closure of two trials 
[584, 600] and two required extensions because of slow recruitment. [66, 604] Whilst 
several trials introduced preference groups to improve recruitment, this design can 
have disadvantages such as extended trial duration to meet recruitment targets and 
reducing external validity and generalisability of results. [288, 619] 
 
Synthesis of data from 12 papers drew on meta-ethnographic techniques, and three 
overarching third-order constructs were developed from these data which were taken 
forward as the line of argument: ‘Doing the best for my child’ and ‘Wanting to get 
better and help others’. Parents’ preferences for treatment were expressed while: 
making sense and asking questions about the RCTs, as motivations and 
reservations about taking part in the RCTs, and at times parents expressed an 
emotional response to randomisation, which was linked to preference for treatment. 
[66, 74, 96, 97, 107-109, 120, 323, 325, 326, 531] Only two papers included data 
relating to young people’s preference for treatment. [66, 96] Young people were 




understanding of the principle of ‘altruistically’ helping other young patients in the 
future. 
 
Strengths and limitations 
A key strength of this review is its breadth, a comprehensive number of paediatric 
RCT papers were screened for inclusion by two reviewers at all stages in the review 
process. The review was enriched via the inclusion of a wide range of paediatric 
conditions, trial contexts, recruiting paediatric participants of all ages. This review 
also included data from secondary papers reporting recruitment issues, and primary 
main trial papers were scrutinised, incorporating data that was reported using 
CONSORT guidelines. [620, 621] Synthesis of qualitative data drew on meta-
ethnographic techniques and provided an in-depth understanding of the way in which 
preferences for treatment are discussed by parents (and young people) in a wide 
range of trial contexts. It also identified preference related issues that were important 
to parents’ decision-making, e.g. perceived benefits and risks, access to treatment, 
and highlighted the vulnerability and responsibility that parents often feel when 
considering trial participation for their child. 
 
Seven papers in this review reported findings from multiple trials in one paper, [96, 
97, 107, 325, 326, 584, 585] and many of the secondary papers did not report full 
CONSORT flow diagrams, therefore those who were lost to follow-up or withdrew 
due to preference could not be reported. This systematic review was unable to 
describe or analyse the effects of preference for treatment on retention or the 
outcomes under investigation in paediatric trials, (due to time limitations) and these 




provided in secondary papers a search was carried out for each related primary 
paper, but only 18/28 additional papers were located. Data relating to ‘participant 
flow and recruitment’ was not always reported consistently in ‘primary’ RCT papers. 
The 40 papers reporting descriptive preference data were not appraised using The 
Cochrane Collaboration’s tool for assessing risk of bias. [8] Although this might be 
considered a limitation of this systematic review, the review did not analyse or 
compare data statistically across studies – this would have been impossible due to 
the heterogeneity of included papers. 
 
The 12 papers that provided data for the qualitative synthesis (meta-ethnography) 
reported findings from a wider range of trial contexts and paediatric conditions. [66, 
74, 96, 97, 107-109, 120, 323, 325, 326, 531] However, the included papers had 
very different research aims and objectives, none of which specifically focused on 
identifying preferences for treatment. Although the qualitative synthesis developed a 
line of argument, accounting for ‘preference’ related issues across the 12 papers, 
inevitably some of the complexity and wider analyses carried out by the first authors 
was not reflected in the synthesised data. For example, Shilling et al reported that 
‘Some parents viewed the trial approach as a positive or exciting opportunity’ [96] 
[pg. 69] and this finding was not reflected in the synthesised ‘preference’ data (e.g. 
An emotional response to randomisation: A difficult decision). However, every effort 
was made to carefully consider all themes, and the complexity of data reported and 





Links to previous literature 
Hope that their child would benefit from trial interventions, [94, 270, 307, 308, 310, 
315-320] and gaining access to interventions that might not otherwise be available 
[93, 120] were motivating factors for parents discussing trial participation, and these 
factors influences parents’ preferences for interventions offered in RCTs. This has 
also been reported in past literature. Parental reasons for strongly held treatment 
preferences included concerns about side effects and attitudes towards new 
‘experimental’ or ‘placebo’ interventions, these issues have also been reported in the 
wider literature. [92-95] Although altruism was often cited as a reason for RCT 
participation, some papers reported poor parental understanding of the process of 
randomisation, and perceived ‘personal’ benefit for their child. [105, 622] 
 
Findings from the systematic review suggest that young people from the age of 11 
upwards were willing to voice their views when given the opportunity. However, few 
papers in this systematic review reported the preferences of young people 
participating, parents’ preferences were reported more frequently. Only nine papers 
explicitly reported the treatment preferences of young people, as well as their 
parents. [66, 96, 524-526, 586, 597, 601, 602] In those papers that did report young 
person preference, their views differed from parental views on three occasions. [66, 
96, 525] In paediatric trials, parents and young people are often both involved in 
receiving information about the trial and making a decision about whether to take 
part, with support from a recruiting health professional. [383, 623] My findings are not 
consistent with guidance which suggests that children and young people’s voices 
need to be more widely heard, [44, 624] or approaches to communication which aim 




decision-making. [379, 625] My findings highlight the importance of planning and 
considering the impact that differing treatment preferences may have when 
discussing trial processes, specifically rationale for randomisation, equipoise and 
informed consent/assent. [246] Trialists should consider ways in which they might 
obtain young people’s views on treatment preference. 
 
Practice implications 
Findings from the meta-ethnography demonstrate the way in which preference for 
treatment could potentially be raised by parents, or explored by recruiters at many 
different points in the recruitment consultation, both while understanding trials 
processes (the nature of the RCT, randomisation and equipoise) and in the context 
of understanding the treatment options open to their child (benefits, risks, access to 
treatment, and ongoing management of the condition). This has important 
implications for practice and further research investigating preference for treatment 
in the context of RCT discussions. It reinforces the dynamic nature of preference 
discussions, and the fact that preferences for treatment are not static, they may 
change during the course of discussions. 
 
Findings from the meta-ethnography also demonstrate the emotional response to 
discussions of randomisation and treatment preference, highlighting that care should 
be taken to ensure parents, young people and recruiters are adequately supported at 
all points in the recruitment process. Parents may need to have open conversations 




of an RCT, and how this fits with young peoples’ understanding and expectations of 
RCT participation; as a means of ‘getting better’ and ‘helping others’. 
 
This in turn highlights the dynamic and important role the recruiter plays in relaying 
understandable and accurate information about the RCT and treatments offered, in 
collaboration with parents and young people. Providing balancing information about 
treatment options from a position of equipoise and exploring preferences may 
contribute to a better understanding of the trial as a whole for families but may be 
challenging for health professionals if they are not in a place of personal equipoise. 
 
Although this systematic review was not seeking to report health professional 
preferences for treatment in paediatric RCTs, six papers did report that members of 
the recruiting/treating teams had preferences. [96, 381, 524, 603, 610, 616] Health 
professional’s preferences for treatment has been reported as a factor that should be 
considered when investigating treatment preference in adult and paediatric RCTs. 
[188, 292]  It has also been shown to influence recruitment to adult trials. [90, 177, 
179, 626] In one paediatric trial 63% of parents said that doctors recruiting them had 
influenced their decision to participate. [94] Health professionals conducting and 
recruiting to paediatric RCTs are also weighing up the competing goals of doing the 
best for their patients, and striving to work towards the RCTs goals of optimising 
recruitment and ensuring families are able to provide informed consent. More 
research should be carried out to investigate the overall equipoise of local and 




preferences for treatment on the decision-making processes of families considering 
paediatric trial participation. 
 
Implications for future systematic reviews in this area 
The search strategy used in this systematic review identified a large number of 
papers, (16,936) many of which were screened as not relevant (16,360). The 
title/abstract screen, full text review and data extraction phases took a considerable 
amount of time and resource, (nine individuals over the course of two years). The 
search strategy included the term ‘satisfaction’ (Appendix 2: MEDLINE Search 
Strategy), this was unhelpful because it returned a high number of irrelevant papers 
reporting patient or parent satisfaction with treatment outcomes, not preference 
between treatment groups (n=272). These papers were not excluded until the full 
text review stage. To reduce the amount of time and resources required to complete 
a similar review in future, authors may choose to specifically focus on a specific 
condition or area of interest (e.g. CFS/ME, diabetes, surgical, or neonatal RCTs). 
 
The current review lacked clusters of search terms to retrieve ‘qualitative’ papers. 
However, the way in which qualitative papers are indexed has been described as 
‘less accurate than the indexing of quantitative studies’. [627] [pg. 223] The ORRCA 
project (Online resource for Recruitment Research in Clinical triAls) has developed a 
database of categorised research papers investigating recruitment related issues in 
RCTs (see: Chapter 1, Section 1.7: Treatment preference and randomised controlled 
trial research). The ORRCA team also identified a lack of indexed studies addressing 




628] Since the current systematic review was conducted, two authors have 
developed PUBMED search strategies, specifically designed to identify papers 
reporting ‘patient preference’. [629, 630] Patient preference search strategies could 
be tested and adapted with paediatric and RCT search terms, to develop a more 
focused search strategy. Therefore, a future systematic review of literature in this 
area should include an initial review of papers indexed via the ORRCA database, 
and scoping reviews using a combination of: qualitative, paediatric, patient 
preference, RCT and (possibly) ‘condition’ search term clusters. 
 
4.5 Chapter summary 
This systematic review has demonstrated that treatment preference can be a barrier 
to recruitment to paediatric RCTs. In some cases, this can result in the need to 
change the design of the trial (introduction of preference groups), extend recruitment 
or can result in trial closure. Further investigation is needed to understand the impact 
treatment preference has on retention, and the outcomes under investigation in 
paediatric trials. Only two papers included qualitative data relating to young people’s 
preference for treatment, synthesised data from these papers were expressed as the 
line of argument: ‘Wanting to get better and help others’. Parents’ understanding of 
trial processes (e.g., randomisation and equipoise) and motivations for consent to 
their child’s participation (perceptions of the benefits and risks associated with 
treatment groups, access to treatment, and long-term management of their child’s 
condition) were factors that promoted discussion of preference for treatment. Some 
parents were emotional when provided with information of their child’s allocated 
treatment group, or when recalling aspects of the recruitment consultation. This 




group, not their more general views about being offered an opportunity for their child 
to participate, which in many cases were more positive. Synthesised data relating to 
parent preferences were expressed as the line of argument: ‘Doing the best for my 
child’. Findings from the meta-ethnography demonstrate that preferences for 
treatment can be raised by parents, or explored by recruiters at many different points 
in the recruitment consultation which has important practical implications for training 
health professionals who recruit to paediatric RCTs. The views of health 
professionals recruiting to trials were also identified as important in terms of guiding 
and influencing parents at all stages of the recruitment process, particularly in 
relation to preference for treatment, (this will be discussed in more detail in Chapter 
6, Section 6.2.5: Equipoise, uncertainty and competing moral demands). This 






 Findings: Qualitative methods embedded in 
four paediatric randomised controlled trials 
 
5.1 Overview of chapter 
This chapter explores expressions of preference in four RCTs, (SMILE, MAGENTA, 
FITNET-NHS and CONTRACT). A breakdown of each data sample by data type 
(e.g. audio-recordings and interviews) can be found in Section 5.2. Exploration of 
how and when preferences were expressed, reasons for preference, and the way in 
which recruiters responded to preference are reported thematically in Section 5.3. I 
delivered training to recruiters that focused on communicating equipoise and 
exploring preferences for treatment. Qualitative examples of the way in which 
training influenced and changed communication practices in each RCT are 
discussed at the end of Section 5.3.2 ‘Equipoise, language and misperceptions 
about treatment’, and in Section 5.3.3 ‘Understanding how recruiters’ respond to 
treatment preference’ (see text boxes). Data relating to preference for treatment and 
its impact on participant flow, recruitment, and retention are reported in Section 5.4, 





5.2 Data samples 
5.2.1 Audio-recorded recruitment consultations 
Recruitment consultations were routinely recorded in each of the four trials, to 
understand the way in which recruiters responded to preference during recruitment 
consultations before randomisation to each RCT. Analysis of recruitment 
consultations before and after training allowed for exploration of any changes in 
recruitment consultations e.g. more thorough exploration of treatment preferences or 
changes in the language used to describe treatments after training, and whether 
training was associated with noticeable changes in recruitment rates. Table 5:1 
provides a breakdown of recruitment consultations by trial, showing the number of 
consultations conducted (by family) and those subsequently recorded. The number 
of families who consented to and declined each RCT is also shown. Missing 
consultation data varied between trials with the largest number of unrecorded 
consultations in the CONTRACT RCT (n = 57, 50%) and the lowest number in 
FITNET-NHS (n = 6, 6%). Table 5:2 provides a breakdown of the number of audio-
recordings analysed from each RCT, including whether analysed consultations 
corresponded with families who had consented to or declined the trials. Table 5:3 
provides an overview of the duration of recruitment consultations recorded during the 
four RCTs. 
 
Ten young people were not present when their parent conveyed their decision to 
decline the MAGENTA trial. In the CONTRACT trial many young people were not 
involved in the recruitment consultations, ten made no verbal input to the 




young people were present during every recruitment consultation recorded from 
SMILE and FITNET-NHS, their level of involvement in the conversations about the 
trial varied depending on current CFS/ME symptoms and age, but all made some 
contribution to recruitment conversations and either assented or consented to the 
trials. Table 5:4 provides details of baseline data for all trial participants (participant 





Table 5:1 The number of recruitment consultations recorded in each RCT 




















SMILE 49 133 100    33 3 90 43 (32%) 
MAGENTA 23 130 80 50 8 107 23 (18%) 
FITNET-NHS 35 96 83 13 0 90 6 (6%) 
CONTRACT n/a 115 57 58 n/a 58 57* (50%) 
*Fifty-eight recruitment consultations were available for analysis (20 with families who did not consent to the RCT, and 38 with families who did go on to 
consent). A further 19 families provided consent to the trial, and 38 families were approached but did not provide consent (see: CONTRACT CONSORT 








Table 5:3 Descriptive data: Recruitment consultations 
  
Trial 
Recruitment consultation data analysed 





SMILE 90 (68%) 89 1
MAGENTA 88 (68%) 58 30
FITNET 70 (73%) 66 4
CONTRACT 58 (50%) 38 20












SMILE 1 3 7- 87 45
MAGENTA 2 4 2- 54 30
FITNET 1 4 15- 91 50




Table 5:4 Baseline participant data: Participant age, onset of illness and school attendance by trial 
Trial Age 
(median) 
(25 percentile, 75 percentile) 
N Onset of illness (baseline) 
CFS/ME RCTs (Months) 
Acute appendicitis (24hr clock, 
to the nearest hour)  




SMILE 15 (14, 16) 98 12 (8, 20) 98 3.0 (0.5, 4.0) 99 
MAGENTA 14 (13, 16) 80 15 (10, 30) 79 3.0 (1.0, 4.0) 77 
FITNET-NHS 15 (13, 16) 83 Not collected 83 2.0 (0.5, 4.0) 83 
CONTRACT 10 (8, 11) 57 13 (11, 19) 39* n/a n/a 





5.2.2 Interviews with young people and their parents 
Young people eligible for each trial were also eligible to take part in an interview and 
families were purposively selected to participate in interviews during all four 
paediatric trials (See: Section 3.4.6: Sampling and sample size for interviews). 
Ninety-three families participated in interviews, and the Contribution Statement 
shows a breakdown of the number of interviews I conducted, and the number 
conducted by other researchers working on each trial. Collectively I interviewed half 
of the families who participated in qualitative interviews across three of the four trials 
(n= 50, 54%). Table 5:5 provides an overview of the interviews conducted in each 
trial. Tables showing interview participants’ age, gender, socio-economic status, 
status in trial (recruited, declined, discontinued treatment) treatment group by trial 
and site ID are located in Appendix 9. 
 
Five mothers were interviewed at all three time points during the SMILE RCT, with all 
remaining parents in the MAGENTA, FITNET-NHS and CONTRACT trials taking part 
in one-off interviews. All young people were interviewed at one time point across the 
four trials. Parent interviews lasted from 20 to 90 minutes and patient interviews 
were between 15 and 60 minutes. Eighty-three interviews were matched with 
corresponding recruitment consultation data. 
 
Views of families have been prefixed with a trial ID: ‘C’ CONTRACT (including the 
corresponding site D, E and F), ‘F’ FITNET-NHS or ‘M’ MAGENTA and a participant 
number (e.g. SMILE: Young Person S70, CONTRACT: Young Person CF20) to 




Table 5:5 The number of families approached and interviewed in each RCT 














in interviews  
SMILE 15 Young people         






MAGENTA 41 Young people      








28 Young people         






CONTRACT 28 Young people          






Totals 99 71 93 
 
Fathers’ participation in qualitative interviews increased over time in each trial 
because fathers were purposively sampled. Due to the high prevalence of CFS/ME 
in young female adolescents, more female patients were interviewed than males in 
the three CFS/ME trials. Conversely, more male participants were interviewed during 
the surgical trial because of the higher prevalence of appendicitis in adolescent 




crossed from one intervention group to the other when they were interviewed. 
Fourteen families (15%) were interviewed because they declined a trial (see: Table 
5:6). Twenty-two young people (31%), were interviewed without their parent present 
(see: Table 5:7). 










SMILE 13 13 0 
MAGENTA 32 27 5 
FITNET-NHS 20 20 0 
CONTRACT 28 19 9 
Totals 93 79 14 
 
Table 5:7 The number of young people interviewed with their parent present 
 
5.2.3 Interviews with clinical teams 
Interviews were conducted with members of the two clinical teams involved in 
recruitment and delivering treatment during three of the paediatric RCTs: 
MAGENTA, FITNET-NHS & CONTRACT. Health professionals either worked in the 
field of specialist paediatric CFS/ME or paediatric surgery. Health professionals were 
purposively selected for interview and 58 participated in interviews. The Contribution 
Statement shows a breakdown of the number of health professional interviews I 





Parent present during 
conversation
SMILE 12 6 6 0
MAGENTA 27 9 12 6
FITNET-NHS 18 4 14 0
CONTRACT 14 3 11 0




Table 5:8 provides an overview of the interviews carried out with members of the 
clinical teams. The remaining health professionals did not respond to email requests 
or stated they were too busy to participate. 
 
Table 5:8 Health Professional interviews 
RCT CFS/ME Specialists Surgeons Research nurses 
and nursing staff 
MAGENTA 12 n/a 0 
FITNET-NHS 8 n/a 2 
CONTRACT n/a 25 10 
Total 20 25 12 
 
During the MAGENTA RCT the majority of the CFS/ME specialists interviewed (n = 
11) were responsible for consenting families to further contact from the research 
team and delivering follow-up AM or GET interventions to participants recruited to 
the trial. One member of the team was responsible for conducting recruitment 
consultations in addition to delivering treatment to those participating. Interviews 
were carried out with nine health professionals who delivered specialist CFS/ME 
treatment in the FITNET-NHS internal pilot. Three of these health professionals were 
also responsible for conducting recruitment consultations. One interviewee was a 
research nurse who recruited to several different paediatric research studies across 
the hospital site. 
 
Thirty-five members of three paediatric surgical teams were interviewed during the 
CONTRACT RCT (Site D: n = 11, Site E: n = 15 and Site F: n = 9). Twenty-five 




actively recruited at the time of their interview. Seven research nurses who were 
supporting recruitment and three ward nurses were interviewed. Five members of 
the three teams were interviewed on two occasions (Site D: n = 1, Site E: n = 1 and 
Site F: n = 3) this included two research nurses and three surgeons. Eleven of the 
surgeons who were interviewed also conducted recruitment consultations which 
were recorded and had corresponding family interview data (Site D: n = 4, Site E: n = 
4 and Site F: n = 3). 
 
Views of recruiters have been prefixed with a trial ID: ‘C’ CONTRACT, ‘F’ FITNET-
NHS or ‘M’ MAGENTA and a recruiter number (e.g. MAGENTA: Recruiter M1) to 
denote the trial from which the data were collected. CONTRACT Recruiters IDs also 
include the corresponding site ID (Site D, E and F). Views of health professionals 
(who were not recruiting participants but were delivering RCT treatments) have also 
been prefixed with the trial ID: ‘C’ CONTRACT, ‘F’ FITNET-NHS or ‘M’ MAGENTA 
(e.g. FITNET-NHS, Health professional A: ‘FA’) to denote the trial from which the 
data were collected. Some health professionals referred to the MAGENTA trial 
during interviews about the FITNET-NHS trial, because FITNET-NHS interviews 




5.3 Expressions of treatment preference in four paediatric 
trials 
5.3.1 How and when preferences are expressed 
Content analysis (see: Section 3.5.2) was used to determine the frequency and 
strength of expressed preferences during SMILE recruitment consultations. During 
the SMILE RCT most young people did not give any indication of treatment 
preference, see Figure 5:1.  
 
Figure 5:1 SMILE: Number of young people expressing a preference for 
treatment 
 
Sixty-four consultations (71%) were coded as ‘no evidence/preference not stated’. 
Although young people were asked direct questions about how they felt about joining 
the RCT, and whether they preferred one treatment in the trial over the other, in 
many cases young people appeared uncertain about how they felt. Fourteen were 




these were coded as ‘probable’. Young people who expressed a probable 
preference didn't follow this up with reasons for their preference. This was usually 
because the recruiter did not try to elicit this information from the young person, or 
the young person’s parent interjected in the conversation. Three young people were 
coded as having a ‘definite’ preference for specialist medical care with the Lightning 
Process, they repeated their preference at various points throughout the consultation 
and/or they gave definite reasons for preferring this treatment. Seven were coded as 
preferring the specialist medical care group, (four probable and three definite). Five 
were coded as being in ‘equipoise’ prior to randomisation. 
 
Preference unclear 
Recruiter S4: Yeah… how would you feel if you were allocated either 
[treatment]? 
Young person S85: I don’t mind either way 
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process 17yrs Male 
 
Definite preference for Specialist Medical Care plus Lightning Process 
Young person S25: My only concern with it would be, in however many 
months if I’m still feeling awful and wasn’t in the group that had the 
Lightning Process, and wanted to try that as another option of something 
to try, would I then just pull out of the study?...My only worry is, it 
[Lightning Process] is the thing that makes me feel better, I don’t want to 
sign myself off from not doing it for a year 
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 





Probable preference for Specialist Medical Care plus Lightning Process 
Young person S96: it’s worth a shot, yeah, I mean I’ve heard, one of my 
friends said she knows someone who had tried it [Lightning Process] and 
it worked for them, so yeah, I mean it would be a bit annoying, obviously if 
you didn’t, but I’m not like strongly opposed to one or the other 
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process 16yrs Female 
 
Definite preference for specialist medical care 
Young person S31: no there’s nothing really, I just don’t wanna be sat 
round a table talking for half a day…it’s just I don’t want to do it [Lightning 
Process]. 
Recruitment consultation:SMILE Specialist Medical Care 12yrs Female 
 
Probable preference for specialist medical care 
Young person S99: Yeah, I think I can do the questionnaires… 
Mum S99: Its whether you want to do that [Lightning Process] course? I 
can tell from your… 
[young person laughs] 
Recruiter S2: would you like me to go away, so you can have a little think? 
Young person S99: Yeah. 






Young person S23: I can’t really lose cos I’ll be getting the treatment I 
would have got anyway, even if I’m not in the Lightning group, and it’ll 
help people after, it’s more if it doesn’t help me then it will help people 
understand different things… 
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process 15yrs Female 
 
At times it was unclear whether young people were in equipoise, indifferent, or 
simply agreeing to trial participation to please their parent (or potentially the 
recruiter). If recruiters paused and ceded the floor when discussing the study with 
young people, parents often cut in and either changed the course of the conversation 
or expressed their feelings about treatment or their child’s participation in the RCT 
(see: Complexity of triadic consultations): 
Recruiter S2: what do you think up til now, how do you feel about it [the 
study]? 
Young Person S42: umm, yeah, I’m not sure really, yeah, I’d like to 
probably discuss it, a bit more before I make any, like, firm decision, but, 
yeah, it seems like a good thing, yeah, worth trying, just to see… 
Recruiter S2: as far as being involved with the study is concerned, the 
only things we’re doing is asking you to fill in these questionnaires for us 
[continues to explain questionnaire]  
Mum S42: If we ended up on the 50% that wasn’t on the Lightning project 
would we just continue as we are, or would we have to start again? 





Young Person S65:…and that’s clarified the rest of it. I don’t see any 
problem with it personally I ...  
Mum S65:…Neither do I but I wouldn’t have to be doing it so you know the 
thing is, I mean there’s nothing unusual about it, they’re all, I mean it 
sounded like the cognitive behaviour bit of it, I know it’s not, but the 
equivalent of…. 
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process 15yrs Female 
 
In contrast a larger number of parents expressed treatment preferences for trial 
interventions, see Figure 5:2.  
 
Figure 5:2 SMILE: Number of parents expressing a preference for treatment 
 
Forty parents (45%) were coded as preferring specialist medical care with the 
Lightning Process (32 probable, eight definite preference) and one had a ‘definite’ 
preference for the specialist medical care group. Forty-one did not express treatment 




of these were parents of the young people who expressed equipoise. One young 
person discussed the trial without their parents present. Three parent/child pairs 
expressed conflicting preferences, (see: Conflicting parent-child preference). 
 
Preference unclear 
Mum S101: I’ve only heard about it [Lightning Process] through a friend, 
who knew somebody that had done this, and… raved about the results. 
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process 16yrs Female 
 
Definite preference for specialist medical care and the Lightning Process 
Mum S52: I think we’re quite keen to do it, [Lightning Process course] I 
think it would benefit [patient name] to get to talk to other people in her 
age group that have the symptoms, I don’t know, she must feel quite 
isolated, and we do as parents almost as well because, I can’t experience 
what she’s going through. 
Recruitment consultation:SMILE Specialist Medical Care 16yrs Female 
 
Mum S84: We’re very much of the mind, I mean we don’t like, you don’t 
like taking tablets, if body and mind can work together and it’s as natural 
as possible I think that’s more beneficial for the individual, mentally, 
physically, emotionally from all aspects really, so for us it’s [Lightning 
Process course] a really positive, it’s a holistic thing, it encapsulates 
everything. 
Recruitment consultation:SMILE Specialist Medical Care 16yrs Female 




Mum S37: We’ve done some clinical hypnotherapy… we quite like the 
hypnotherapy but it didn’t work out time wise… cos it [Lightning Process] 
might help might it, there’s no guarantee is there, but it might help. Or 
[?you?] might get better just as we’re going now, doing our gradual 
increase, [specialist medical care] might be the same…. 
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process 12yrs Female 
 
Definite preference for specialist medical care 
Mum S70: Because I don’t agree with it [Lightning Process] and you’re not 
18 and I wouldn’t agree to you being hypnotised. 
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process17yrs Female  
[After establishing that hypnotism was not part of the Lightning Process 
course, parent accepted randomisation for their child.] 
 




Mum S13:…we're happy whichever group we end up in, because, you 
know if we're in the control group then we’ll feel we'll be helping the study 
without actually having to put ourselves out, other than to fill in a few 
questionnaires, umm, and if we end up in the group that has the Lightning 
Process then that's going to be interesting and possibly very helpful. 
Recruitment consultation:SMILE Specialist Medical Care 13yrs Female 
Parents were more likely to express ‘probable’ preferences before randomisation 




preferences after the recruiter told them their intervention allocation (see: Elation or 
relief post allocation). Young people generally expressed preferences for one of the 
trial interventions after their intervention allocation had been given to them. 
 
The themes presented below relate to families’ reactions to randomisation across all 
four RCTs. During the SMILE, MAGENTA and FITNET-NHS trial consultations, 
families’ responses to their random allocation were audio-recorded as part of the 
recruitment consultation. Recordings of families’ responses to randomisation were 
not routinely made during the CONTRACT RCT, therefore, only interview data were 
available in relation to families’ responses to randomisation. Participants and parents 
often discussed preferences for treatment when making decisions about stopping 
treatment or trial participation. Table 5.9 provides details of the thematic framework 





Table 5:9 Thematic framework. Expressions of treatment preference in four paediatric RCTs 
 
Expressions of treatment preference in four paediatric trials SMILE MAGENTA FITNET-NHS CONTRACT
	 How and when preferences are expressed
Elation or relief post allocation ✓ ✓ ✓ ✓
Disappointment post allocation ✓ ✓ ✓ ✓
Conflicting parent-child preference ✓ ✓ ✓ ✓
Conflicting parent-parent preference ✓
Complexity of triadic consultations ✓ ✓ ✓ ✓
Young people struggled to recall information ✓ ✓ ✓ ✓
Missing conversations from the consultation process ✓ ✓ ✓ ✓
Absent family members, decision making and preference for treatment ✓
Preference discussions can happen at any time during the consultation ✓ ✓ ✓ ✓
Reasons for preferences
Recovery: Wanting help to get better ✓ ✓ ✓
Recovery: Wanting to get better as quickly as possible ✓
Recovery: Practicalities and family circumstances ✓
Access to treatment: A new angle, something different ✓ ✓ ✓ ✓
Access to treatment: Affordability ✓
Access to treatment: Positive results or recommendations ✓ ✓
Being better suited to a specific treatment ✓ ✓ ✓ ✓
Active (positive) versus Control treatment ✓ ✓
Experimental versus Standard (positive) treatment ✓ ✓
Risk of harm ✓ ✓ ✓ ✓
More is better ‘pick and mix’ approach’ ✓ ✓ ✓
Past experience of intervention ✓ ✓
Anxieties about treatment and treatment delivery ✓ ✓ ✓ ✓
Misunderstandings: Evidence-based treatment ✓ ✓
Misunderstandings: Therapeutic misconception ✓
Altruism ✓ ✓ ✓ ✓




Table 5:9 continued  
Thematic framework: Expressions of treatment preference in four paediatric RCTs 
 
 
Expressions of treatment preference in four paediatric trials SMILE MAGENTA FITNET-NHS CONTRACT
Understanding how recruiters’ respond to treatment preferences in paediatric trials
Acceptance of preference and missed opportunities to explore preference ✓ ✓ ✓ ✓
Exploring preference ✓ ✓ ✓ ✓
Health professional and recruiter equipoise
Individual versus collective equipoise n/a ✓ ✓ ✓
Discussing uncertainty and equipoise: what would you do? n/a ✓ ✓ ✓
Questioning the eligibility criteria n/a ✓ ✓ ✓
Discontinued treatment, treatment failure and recurrence n/a ✓ ✓
The impact of treatment preference on recruitment and retention in four paediatric RCTs  




Elation or relief post allocation 
Parents in the three CFS/ME trials who received their preferred treatment were often 
elated when they were given their child’s random allocation: 
Parent S8:…you’re having the lightning treatment, oh that’s brilliant 
Young Person S8: Oh, I’m pleased with that. 
Parent S8: [laughs]…oh [patient name] I am pleased!... I’m feeling all 
emotional a minute, oh it’s fantastic [mum tearful]. 
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process 16yrs Female 
 
Young peoples’ responses to randomisation in the three CFS/ME trials were more 
reserved. One young person suggested her approach to trial participation was 
“cautious”, she had not expressed her preference for CBT treatment (this was brought 
up by her dad during interview), because her past experience of treatment for CFS/ME 
had been disappointing and she didn’t want to get her hopes up: 
Young person F12:…When we went through [discussed] both sides I said 
I didn’t mind which one I would be put into… 
Dad F12:… honestly I think [patient name] was a little bit reserved at that 
point, [before randomisation]…obviously her hope was that she’d go onto 
the CBT side of the study, but there was no expectation at that point… 
Young person F12:…Yep. I was definitely cautious. I didn’t want to get my 
hopes up because of being let down and disappointed by my experience 
at [other hospital].  




Disappointment post allocation 
Parents in each of the four trials reported disappointment when their child was 
randomised to their non-preferred treatment group. Some families reported 
disappointment but continued with their allocated intervention. This was most 
apparent during the SMILE trial. Parents were often more openly disappointed than 
young people immediately after being informed of their child’s allocation of Specialist 
Medical Care: 
Young Person S42:…I don’t mind, I’m happy to try it yeah, nothing else 
has worked, [mum and young person laugh] I think it would be worth 
giving it a go. 
Recruiter S2:…you’ve been allocated to the Specialist Medical Care 
group. 
Young Person S42:…Yep, good. 
Parent S42:…I’m a bit disappointed. 
Recruitment consultation:SMILE Specialist Medical Care 18yrs Female 
 
Health professionals recruiting to CONTRACT reported that families expressed 
disappointment when they were not allocated to their ‘preferred’ treatment group 
(antibiotics). One CONTRACT mum described disappointment when her child was 
not allocated to her preferred treatment and also described the manner in which she 
was informed of the allocation as insensitive: 
Mum CD19:…I was talking to a nurse… the consultant came ‘round and 
said ‘no, sorry, she’s not got it’, I was like, ‘what?  Not got what? What?’ 




about that… that felt like it was thrown at me... that seemed to happen 
quite quickly. 
Interview:CONTRACT Appendectomy 6yrs Female 
 
Although parents often reported disappointment after allocation to their non-preferred 
treatment group, sometimes after experiencing their non-preferred treatment, the 
preference dissipated: 
Mum F20:…so when I thought, “Ooh, we can do it online,” I thought, “Yes, 
that would be great. We’ll see if that could benefit her.” So, I was 
disappointed when we got the activity management, but you know, fine, 
we’ll go for it, and actually, I’m so glad, because I think it’s been quite 
important, what we’ve learnt with this. Without the activity management 
advice, I don’t know if any CBT would have helped her, because she’d still 
be doing all that high-energy activity, so it’s worked out beautifully. I’m 
really pleased. 
Interview:FITNET-NHS Skype activity management 13yrs Female 
 
Conflicting parent-child preference 
Some young people in all four trials had a different preference from their parents. In 
most cases, when conflicting preferences for treatment were apparent, they were 
discussed between families and recruiters. Families opted for trial participation when 
parents felt their child was keen to participate, and if parents felt sufficiently 
reassured about their non-preferred treatment to consent to their child’s participation: 
Young Person S70:…Can’t I do it [trial] 




Young Person S70: Why? 
Mum S70: Because I don’t agree with it and you’re not 18 and I wouldn’t 
agree to you being hypnotised.  
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process 17yrs Female  
[After establishing that hypnotism was not part of the Lightning Process 
course, parent accepted randomisation for their child.] 
 
Young Person F18:…I was just excited to know that I was going to do one 
of them. 
Mum F18:…I think I was a bit different. I was really keen that [participant] 
did the FITNET side of the study, partly because we’d been trying to 
manage with activity anyway, and it was just, sort of doing less and less 
and less … 
Interview:FITNET-NHS Online CBT 13yrs Male 
 
Mum CD18:…[Patient] broke down [when he heard which treatment he 
was allocated]… and I had a secret high five… he was really adamant he 
wanted the antibiotics and I think he was really gutted that it came up he 
needed surgery.  
Interview:CONTRACT Appendicectomy 9yrs Male 
 
Some parents felt that their child might not ‘engage’ with one of the trial treatments, 





Mum S34:…Yeah see, I mean he’s very erm (..) analytical and very erm, 
scientifically minded …and he’s not really into alternative therapies at all. 
So that’s why I didn’t initially tell him about it …was only after we’d been to 
the clinic I wasn’t going to [tell him] until I knew he’d be receptive…he was 
a reluctant candidate even though I was thrilled that he’d been selected… 
Interview:SMILE Specialist Medical Care plus Lightning Process 15yrs 
Male 
 
Young Person S34:… I’ve always sort of turned my nose up at all of the 
sort of homeopathy and all of these kinds of … so I mean I’ve got to be 
honest, especially after the first day, I was really not happy about coming 
back… it was just completely out of my comfort zone in terms of what I 
think… also what I’d have thought worked. 
Interview:SMILE Specialist Medical Care plus Lightning Process 15yrs 
Male 
[Mum and young person interviewed separately.] 
 
At other times a parent and child did not have a conflicting preference, but they did 
have a conflicting opinion about whether they should join the trial. Only one instance 
of this occurred during the MAGENTA RCT, and it was the young person who made 
the final decision about trial participation. This participant’s parents would have 
declined the trial, but since their daughter was 17 years old, she decided she wanted 
to take part, but crossed-over to her preferred treatment at the six-month point: 
Young person M35:…Just because I’d already tried this side [activity 
management] and it hadn’t worked before, so I was sort of wondering if 
maybe like the other side would work. But, I’m happy to try this side and 




Interview:MAGENTA activity management 17yrs Female 
[Discontinued treatment at 6 months to do Graded Exercise Therapy.] 
Mum M35:…we would have joined without hesitation if we were getting 
the new treatment, [Graded Exercise Therapy] different one from what we 
tried before. [participant’s name] took the decision herself, said she was 
going to go for it, and then of course, she got the wrong one… 
Interview: MAGENTA activity management 17yrs Female  
[Discontinued treatment at 6 months to do Graded Exercise Therapy.] 
 
Similarly, the preferences of young people were at times unclear (see also 
Complexity of triadic consultations), especially when families were interviewed 
retrospectively about the preferences they had when they were considering trial 
participation. The participant below “agreed” with her mum’s preference for FITNET 
online CBT during the recruitment consultation, “have you got any thoughts about 
either of the two sides of it [treatments]”: 
Mum F23:…I think the cognitive behaviour [FITNET-NHS Online CBT] 
one would be better for her. I think with the activity management one, I 
think it’s similar to some of the things that were suggested by the chronic 
fatigue service. I think she’s got to get to a stage where she can accept 
her condition before she moves on. She’s got all the information about the 
activity management and about pacing herself, she is still refusing to do 
that. 
Young person F23:…Yeah I agree with that, I don’t know like, it is hard for 
me to like accept my condition, that sort of side will be more useful for me 
I think. 





However, retrospectively at interview this young person discussed her preference for 
a “face-to-face” mode of treatment where “you’ve got a physical person”, also 
highlighting that preferences for treatment during the FITNET-NHS trial could be 
based on mode of treatment (face-to-face skype versus Online email) and/or content 
of the treatment pathway (Activity Management or CBT): 
Young person F23:…The FITNET, she did explain it was a lot of content 
to cover.  So she did warn me about that and then she said the other one, 
it was something about Skype calls, more face-to-face thing. 
Mum F23:…I think, had you have been able to choose, you would have 
chosen the other one. 
Young person F23:…Yeah. Face-to-face… for me it would be more 
effective …you’ve got a physical person who’s telling you specific coping 
strategies to do and I think it’s more effective than completing tasks. 
Interview:FITNET-NHS Online CBT 16yrs Female 
 
Conflicting parent-parent preference 
At times during CONTRACT recruitment consultations it became apparent that 
parents had different preferences, although it was not always apparent how these 
differences were resolved. In many cases it seemed the resolution might have 
occurred during unrecorded family discussions: 
Mum CD6:…I think we should try the antibiotics, yeah.  
Dad CD6:…Are you sure? 
Mum CD6:…I am sure.   





Mum CD6:…But she said..... a 10% chance.  
Dad CD6:…Will he pull that [canula] out or... 
Mum CD6:…He’s been gentle with it. He’d rather have that than go and 
have an operation.  
Recruitment consultation:CONTRACT Antibiotics 8yrs Male 
 
One recruiter reflected upon one occasion where parents differed in relation to their 
preference for treatment, “it’s fair to say that kind of one parent feels one way about 
what they want, and another parent feels another way” with the recruiter suggesting 
that randomisation offered a solution to this difference of opinion: 
Recruiter CD9:…So they’ve decided that because, you know, we haven’t 
got a definite plan of what we want to do, you’re happy to go into the 
research study where the computer chooses, and then we go with that 
option until, you know, unless you change your mind or if, you know, as I 
said he has the antibiotics and then he doesn’t respond. 
Dad CD5:…Yeah.  
Recruitment consultation:CONTRACT Appendectomy 9yrs Male 
 
Complexity of triadic consultations  
Instances where parent and young peoples’ preferences for treatment differed added 
an element of complexity to communication and decision-making. During recruitment 
to CFS/ME trials often only one parent (usually the mother of the child) was present 
during the consultation, and it was sometimes difficult to ascertain the extent of 
young peoples’ preferences during these conversations. During CONTRACT 




present to discuss the trial with the recruiter. This adding a level of complexity, and 
multiple occasions where mothers and fathers differed in their preferences for 
treatment (see: Conflicting parent-parent preferences). 
 
Young peoples’ engagement in recruitment conversations varied widely, with some 
taking the lead during consultations, specifically when their parent left the room for 
any period of time. Other young people said very little unless specifically prompted 
by their parent or the recruiter. At times it was difficult to gauge their feelings about 
interventions, specifically when young people appeared to ‘agree’ with statements 
made by their parent: 
Mum F17:…I think I would have preferred the Skype one. The activity 
management, just because of the contact. 
Young Person F17:…Yeah. 
Mum F17:…I feel it would have been a lot better for us. Do you [name]? 
Young Person F17:…Yeah. 
Recruitment consultation:FITNET-NHS Online CBT 15yrs Male 
 
Young peoples’ preferences were not always expressed as strongly as parents’ 
preferences for treatment during recruitment consultations or interviews in all four 
trials. During recruitment to the CFS/ME trials, young people appeared more 
accepting of either trial group: 
Young Person F14:…I suppose I would like the exercise one to see, to go 




open for either because I know that either would benefit me, so I am not 
particularly fussed to be fair. 
Recruitment consultation:FITNET-NHS Online CBT 17yrs Female 
 
Young person M109:…[what did you think about having treatments 
allocated by randomisation?] Erm, I don’t really mind to be honest. I was 
happy with either one.  
Interview:MAGENTA Graded Exercise Therapy 17yrs Male 
 
There were also instances where parents interrupted or answered question on their 
child’s behalf. On some occasion’s parents appeared to want to help their child if 
they were struggling to find an answer: 
Recruiter F1:…Right. Have you thought about the difference between the 
two groups? 
Young Person F10:…Um, um, [pause]… 
Mum F10:…I don’t know whether [child] has or not. I certainly have.  
Recruiter F1:…Right. 
Recruitment consultation:FITNET-NHS Online CBT 16yrs Female 
 
Some young people felt confident enough to correct their parents when they felt they 
were presenting their symptoms or views differently from how they perceived the 
situation, as demonstrated below. Although this extract is not directly related to 
preference it highlights the way in which young people and their parents may 




Mum F13:…with a bit of help from the school counsellor and a bit of time it 
[anxiety] sort of sorted itself out didn’t it… is that fair [name] 
Young person F13:…I’d say it was a lot of help from the school 
counsellor, it didn’t exactly sort itself out, it was more…. 
Mum F13:…What I mean then is the symptoms you were having then 
have, you don’t get panic attacks any more do you? 
Young person F13:…No I don’t. 
Recruiter F1:…Okay that’s great. 
Recruitment consultation:FITNET-NHS Skype activity management 15yrs 
Female 
 
Due to age (median age 10yrs) and severity of illness, fewer young people who were 
eligible for CONTRACT actively participated in recruitment consultations. There was 
no verbal dialogue from young people during 25 consultations. It was not always 
clear if a young person was present but not talking, or if parents were in another 
room away from their child’s bedside discussing the trial. Some consultations were 
conducted late in the evening or during the night when young people were asleep. 
Some parents reported that they wanted, (or would have liked) to have the 
recruitment consultation away from their child’s bedside to reduce their child’s 
anxieties and allow them to concentrate on the study information: 
Recruiter CE10:...Now I understand that she [participant] wasn’t involved 
in a conversation… 
Mum CE20:…No, I will explain it to her.  I just, I wanted to talk to you 




have concentrated on what you were saying to me. So I will explain it all 
to her.  
Recruitment consultation:CONTRACT Antibiotics 11yrs Female 
 
Many young people participating in CFS/ME trials had spent significant time off 
school and had been unable to socialise with friends. Parents often reported a 
deterioration in their ability to engage in conversation, particularly with people they 
did not know. This may have been due to young people’s CFS/ME symptoms, ‘brain 
fog’ (a symptom associated with confusion, difficulty concentrating and memory loss) 
and loss of confidence in social situations. Parents made attempts to engage their 
child and provide feedback to the recruiter about ‘non-verbal cues’, “she’s nodding” 
[Dad F11]. However, during analyses it was difficult to distinguish the extent to which 
non-engagement was due to young peoples’ symptoms, negative perceptions of one 
or more trial interventions, or a more general lack of engagement in the research 
process: 
Mum F11:…Okay, don't shrug your shoulders. Classic 13 years old. She's 
very quiet and this is the trouble. She's quiet naturally and since she's had 
this illness she's got even quieter. She's a little bit too passive about the 
whole thing. 
Mum F11:…Which do you think you'd rather do? 
Young Person F11:…I don't know. 





Young people in all four trials struggled to recall information given to them about the 
studies during the recruitment consultation. This was particularly apparent during 
interviews with young people who had participated in CONTRACT, since many of the 
young people had been in considerable pain, and highly anxious about being 
admitted to hospital: 
Researcher 2:…Did they go into much detail about the two… treatments? 
Young person CE7:…Yeah.  Um, they did.  I can't remember a lot about 
that actually. 
Interview:CONTRACT Antibiotics 14yrs Male  
[Recurrence also treated with antibiotics.] 
 
Researcher 2:…Do you remember them telling you about the CONTRACT 
study?   
Young person CE4:…I wasn’t really listening. 
Interview:CONTRACT Antibiotics 10yrs Male 
[Recurrence also treated with antibiotics.] 
 
Researcher 2:…Do you remember something on a DVD, like an iPad or a 
laptop?  Do you remember watching something? 
Young person CF9:…I remember mummy and daddy watching it… I might 
have done but I can't really remember. 





Researcher 1:…So did she [surgeon] come in and speak to you about it? 
Yeah? And do you remember what she said? 
Mum CD18:…So, you’re on about when the doctor come in with the 
results, aren’t you? But why, why did you want to do the study? 
Young person CD18:…I don’t know. 
Interview:CONTRACT Appendectomy 9yrs Male 
 
Their recollection of the two treatment groups and information leaflets was 
sometimes limited, particularly during interviews which occurred sometime after 
randomisation: 
Young Person S38:…I can’t remember the past four weeks, you know I 
can remember when I was like five, but I can’t remember the past four 
weeks, my memory’s really bad. 
Interview:SMILE Specialist Medical Care 16yrs Female 
 
Young Person M49:…I can’t remember [what the other one was]. 
Interview:MAGENTA Graded Exercise Therapy 15yrs Male 
 
Young person F20:…I remember getting it. [PIL] I don’t remember …I did 
read it, yes… 





Missing conversations from the consultation process 
It became apparent that the recruitment process was split into four separate stages, 
only one of which was recorded, the ‘main discussion’, See Figure 5:3: 
 
Figure 5:3 Stages of the recruitment process 
 
1. Initial mention  
All families had spoken to at least one other health professional before a recording 
was made of their ‘main’ discussion with a recruiter about the RCT: 
SMILE and MAGENTA: Assessing CFS/ME specialist at the first clinical assessment 
appointment. 
FITNET-NHS: Referring local GP or paediatrician primary care setting, and wider 
CFS/ME Administration team. 





2-3 . Main discussion, Obtaining consent and randomisation 
SMILE: Member of the research team travelled to the family home and discussed the 
trial, gained assent/consent and used a telephone-based randomisation system. 
MAGENTA and FITNET-NHS: A health professional from the specialist CFS/ME 
team discussed the trial with the family over the phone, gained assent/consent and 
used an online randomisation system. 
CONTRACT: A member of the surgical team discussed the trial with the family in an 
acute care or observation ward setting, gained assent/consent and used an online 
randomisation system. 
 
The SMILE trial highlighted the importance of recording the families’ responses to 
randomisation. After intervention allocation many families had expressed more 
definite, or a first expression of preference for treatment: 
Recruiter S4:...[name] has been allocated to the arm to receive the 
continuing care she would, specialist medical care… and to go on the 
lightning process course 
Dad S73:…Oh great [dad clapping]. 
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process 14yrs Female  
[Participant did not attend Lightning Process course.] 
 





Mum S27:…I’m really disappointed are you? 
Young person S27:…?Inaudible? 
Recruitment consultation:SMILE Specialist Medical Care 15yrs Female 
 
There were instances when it was clear that an extensive conversation had already 
taken place between the recruiter and the family, which may (or may not) have 
provided information about the family’s preferences for treatment. At the first phone 
call made by the recruiting researcher 9 families (27%) declined to hear more about 
the SMILE trial, because they had a preference for treatment. It was unclear how 
many other families had in-depth conversations with recruiters or members of the 
wider clinical team prior to the main recruitment consultation: 
Recruiter S3:…I know we talked quite a bit on the phone, didn’t we, about 
the study… 
Mum S44:…Yes, yes, yes.  
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process 15yrs Female 
 
During the MAGENTA and FITNET-NHS trials recruiting health professional’s audio-
recorded the main trial discussion, consent/assent process and randomisation 
outcome, and a high number of main recruitment consultations (82% and 94% 
respectively). Only 14 (13%) and 10 (14%) randomisation outcome conversations 
were not recorded during the MAGENTA feasibility and FITNET-NHS internal pilot. 
In contrast, during the CONTRACT feasibility trial, most data were obtained from 




recruitment consultations were recorded and available for analyses. Multiple 
recruitment conversations were made with 20 CONTRACT families, (nine SMILE, 36 
MAGENTA and 31 FITNET-NHS) and CONTRACT recruiters fed back via interview 
and training sessions that in theory it was feasible to make audio-recordings of 
consent and randomisation discussions. However, in practice only three ‘extra’ 
recordings were made. Whether or not it is feasible or useful to make additional 
records of these conversations in an acute care setting will be discussed further in 
Chapter 6: Discussion. 
 
Absent family members, decision making and preference for treatment 
During the CONTRACT trial it also became apparent that the recorded recruitment 
consultation often only involved one parent (usually the mother), who would state 
that she needed to contact the child’s father or another family member before a 
decision about participation could be made. In these situations, if families declined 
the trial, it was difficult to understand whether preference for treatment was an issue 
for the absent parent: 
Mum CE12:… Obviously it’s something I’ll discuss with her dad and we’ll 
make a joint decision. But thank you for giving me the opportunity. Okay, 
right, I’m gonna see if I can get hold of her dad. 
Recruitment consultation:CONTRACT Declined trial 9yrs Female 
 
Preference discussions can happen at any time during the consultation 
Preferences discussions were not specific to one ‘area’ of the consultation (e.g. 




be discussed early in the consultation when recruiters asked families, “What do you 
think about the study?”. A direct question about preference, such as, “Do you have a 
preference for treatment?” was unnecessary and discouraged during communication 
training sessions. Neutral questions about treatment were encouraged “Have you got 
any questions to start us off about the treatments?” (Appendix 4: MAGENTA: Tips for 
recruitment and informed consent). Direct preference questions might incorrectly 
lead to families believing they ‘should’ have a preference for treatment, and result in 
parents or young people forming a "preference”. A lack of exploration of preference 
may therefore be attributable to the fact that recruiters were responding to other 
concepts which they felt were the main topic of discussion at that particular point in 
the recruitment discussion, e.g. randomisation or what the trial interventions involve. 
 
5.3.2 Reasons for preferences 
Participants and parents often discussed preferences for treatment when recruiters 
asked for their views on the trial, randomisation or trial treatments and these views 
centred around motivations or benefits (hopes) and reservations or risks (fears) 
about taking part in each of the three CFS/ME RCTs (see: Section 4.3.2). Some 
families declined because of preference for treatment whereas others were willing to 
consent to the trial despite having some reservations (see: Section 5.4.1). 
 
Recovery: Wanting help to get better 
Young peoples’ motivation for accessing a ‘preferred’ treatment in the three CFS/ME 
RCTs centred around getting better and gaining help and support with their recovery 




physical fitness, better management of cognitive ‘thinking’ activities, (SMILE, 
MAGENTA and FITNET-NHS) or developing coping strategies to deal with unwanted 
or unhelpful patterns of thinking which contributed to an improvement in CFS/ME 
fatigue symptoms (SMILE - Lightning Process and FITNET-NHS - CBT). Some 
young people talked about potential for a ‘quicker’ recovery and there were 
perceptions that specific treatment approaches in each RCT might mean a quicker 
recovery. Those who had been ill for long periods of time stated they were just happy 
that someone was investigating CFS/ME treatments for young people; they saw 
participation as an opportunity to improve their current health, and return to school 
and social activities more quickly: 
Young person S12:…I am really, really happy I got picked [Specialist 
Medical Care plus Lightning Process group] because otherwise I could 
have been ill for so many more years… 
Interview:SMILE Specialist Medical Care plus Lightning Process 15yrs 
Female 
 
Young person M20:…I prefer the sound of the physical one….my exams 
are really important, so if I start now, I might even be able to be, getting 
better for my exams… 






Mum F15:…I think at the time, [patient name] would have preferred to 
have gone on the CBT side of the study… she said it was more a matter 
of well it doesn’t matter that I got the other side at least it’s some form of 
treatment and something to work with.  
Young person F15:…Well obviously I would have preferred the CBT side 
but I, just like mum said, I don’t really mind… I was just willing to give it a 
try really... I just wanted to get better really… It’s just something really. 
Just a chance to get better to be honest.  
Interview:FITNET-NHS Skype activity management 12yrs Female 
[No recruitment consultation available.] 
 
Recovery: Wanting to get better as quickly as possible 
Young people considering recruitment to the CONTRACT RCT discussed their wish 
for a quick recovery. Some discussed wanting to recover for a school trip, holiday 
abroad or so they could start doing physical activities they had been told to stop 
during recovery: 
Young person CE1:…I want the easier one…medication [antibiotics]. 
Mum CE1:…You what? You’d rather try the medication?   
Young person CE1:…Yeah. ‘Cause [it’s] like easier, ‘cause like, I’ve got 
six weeks and I’ll just be indoors recovering from being cut open and that.  





Young person CE4:…I did prefer the sound of having medicine instead of 
the operation. Because you get to go back to things quicker…I wanted to 
get straight back to diving. 
Interview:CONTRACT Antibiotics 10yrs Male 
[Recurrence also treated with antibiotics.] 
 
Young people with CFS/ME had typically been ill for prolonged periods of time (see: 
Table 5:4, Baseline participant data). If parents expressed preferences for treatment, 
they generally followed this with a statement that made it clear to the recruiter, they 
would accept either intervention: 
Mum F16:…I think it would be the Skype. I think it might work better but I 
don’t know. I think that’s the way I’m leading towards, where you actually 
have that face-to-face contact and you can talk it through…we’re 
desperate for anything really, so we will go with whatever is offered. 
Recruitment consultation:FITNET-NHS Online CBT 16yrs Male 
 
An urgent need for ‘any’ kind of treatment delivered by a specialist team to aid 
recovery was a more prominent theme in the FITNET-NHS RCT, because this RCT 
was designed for families with no access to local treatment. This was often 
discussed in the context of a lack of service provision in their local area. FITNET-
NHS families didn’t want to travel long distances to access CFS/ME services and 




Mum F24:…Yeah, I don’t think we have anybody local to us. I know that 
the paediatrician was trying to find out. I think the nearest is about an hour 
and a half, two hours away from us. 
Recruitment consultation:FITNET-NHS Online CBT 17yrs Female 
 
Recovery: Practicalities and family circumstances 
In the CONTRACT RCT, acute illness resulted in the need to make unscheduled 
arrangements for cover of their paid employment and/or childcare for siblings at 
short notice. For some families, preferences for treatment were linked to making the 
best decision not only for their sick child, but one that would have least impact upon 
the wider family given current family circumstances: 
Mum CE10: …my husband's going away for a month and I'm gonna be 
here on my own and so if we have the antibiotics and they don't work, it's 
bound to fall right in the middle of that, when he's [away] and I'm here on 
my own…Yeah, there's a five-year-old [sibling] as well.  
Interview:CONTRACT Declined trial 8yrs Male 
 
Access to treatment 
Young people and their parents discussed their reasons for a preferred treatment 
during recruitment consultations and interviews. Some families considering 
participation in the CFS/ME trials had already tried a ‘form’ of treatment they 
considered similar to, or the same as one of the study groups (predominantly activity 
management, (see: Past experience of intervention). In the past, use of what was 




people and parents expressed a preference for accessing a ‘new’ and different 
treatment approach via the SMILE, MAGENTA and FITNET-NHS trials (the Lightning 
Process, Graded Exercise Therapy or FITNET Online CBT respectively): 
Mum F18:…I think I was a bit different. I was really keen that [patient 
name] did the FITNET side of the study. Partly because we’d been trying 
to manage with activity anyway, and it was just, sort of doing less and less 
and less and I, I felt that um, a new angle on helping [patient name] 
recover would be helpful but yeah, having a fresh angle on the um, you 
know the mental strategies, as well as the physical strategies  
Interview:FITNET-NHS Online CBT 12yrs Male 
 
Young person M108:…Activity management sounded a bit like what I’d 
already been doing in a way and graded exercise sounded like a new 
thing I think because it does... it sounds like exercise; “Oh good, I’m 
actually going to be doing some exercise and stuff”  
Interview:MAGENTA activity management 14yrs Female 
[Withdrew from trial.] 
 
If young people or their parents had a preference for one of the treatments offered in 
the SMILE, FITNET-NHS or CONTRACT trials (because some or all treatments were 
not routinely accessible outside the trial), some families felt they had nothing to lose 
by consenting to participate: 
Mum S9:…We were in that position that she was so unwell that actually if 
somebody was saying, “you can do this [Lightning Process] as part of this 




Interview:SMILE Specialist Medical Care plus Lightning Process 12yrs 
Female 
 
Young person F20:…I was kind of like, “It might help; it might not help, so 
it’s not really kind of a bad – can’t really lose, so I’ll just see if it helps.” 
Interview:FITNET-NHS Skype activity management 13yrs Female 
 
Antibiotic treatment for acute appendicitis was not a routine treatment pathway 
outside the CONTRACT RCT, (see: Section 5.4.2: Retention: Preference and 
ongoing participation - CONTRACT): 
Mum CF21:…You might decide to be in the study group because you 
might be really interested in an alternative option than surgery.  But then, 
because you’re randomly allocated to one branch or the other, you could 
be then in a situation of actually not getting what you really were quite 
interested in having. Do you see what I mean? Even though you decided 
to be in the study. 
Interview:CONTRACT Declined trial 15yrs Male 
 
Many parents could not afford to access the Lightning Process (while the trial was 
recruiting the course cost £620), outside the SMILE trial: 
Mum S35:…Why I wanted to be involved… because I've had 
recommendations that there might be a programme or treatment or 
whatever it's called [Lightning Process]. So when I heard that there was a 
possibility that it might be available through this, [trial] then I thought, 
“Fantastic cos I haven’t got the money for it” 




For some there was also a perception that the preferred treatment had already been 
shown to be effective in another research setting (FITNET in the Netherlands), or 
because of figures relating to the Lightning Process from surveys conducted with 
adults that were provided in the SMILE PIL (Appendix 3): 
Young person F19:…Just the statistics of how it worked in the previous 
trials, in Holland was it? And just because it was something new. I think if I 
was on the other one, it might have been more repetition of what I’ve 
already done.   
Interview:FITNET-NHS Online CBT 14yrs Male  
 
Mum F15:…I think it was probably driven by the headlines that had come 
out …in terms of the success rates, the CBT side of things… and kind of 
jumping onto that hope really...  
Interview:FITNET-NHS Skype activity management 12yrs Female 
[No recruitment consultation available.] 
 
Mum S61:…The Lightning Process you wanna try don’t you? 
Young person S61:…Yeah. 
Mum S61:…I mean the figures do look very promising, I know they are 
only figures on a bit of paper… 





Some parents had also heard about the Lightning Process anecdotally, and knew 
someone else who had personally had positive results and benefited from the 
treatment: 
Mum S7:…It’s a long story but [name] her sister, a friend of hers, her 
daughter had, had ME for quite a few years and her mum had just paid for 
the Lightning Process and said it was fantastic, and other people had said 
you know, heard really good things about it. 
Interview:SMILE before randomisation. Specialist Medical Care plus 
Lightning Process 13yrs Male 
 
Being better suited to a specific treatment 
Young people and parents in the CFS/ME RCTs perceived certain treatments 
offered in the trials as being ‘better suited’ to their personality, treatment needs or 
current lifestyle: 
Mum S35:…It's neuro lingual programming [Lightning Process] and as far 
as I understand, that’s… the basis of it which is a well-tested system of 
working, which actually I think would sadly suit [patient name] and her 
personality hugely well.  
Interview:SMILE Specialist Medical Care 12yrs Female 
 
Young person F21:…[discussing a preference for the activity 
management group] …I think it was because like I’m more of like a ‘get up 
and go’ and like kind of ‘achieve’ person so I was kind of aiming more 
towards that…. 





In the MAGENTA RCT Graded Exercise Therapy was viewed as more appropriate if 
they were ‘sporty’. Activity management was perceived to be more appropriate if 
they didn’t like or didn’t currently do a lot of exercise. Activity management was also 
perceived to be better suited to those who had a heavy workload at school, and 
wanted advice about managing their workload, or cutting down: 
Young person M25:…I liked the idea of the graded physiotherapy [Graded 
Exercise Therapy] because I play a lot of sport so getting fit… 
Interview:MAGENTA Graded Exercise Therapy 16yrs Female 
 
Some families with a preference for treatment declined the trials, if they knew they 
could access their preferred treatment, one they felt was ‘better suited’ to their child 
outside the trial: 
Mum CE12:…In my circumstance my daughter really does not like taking 
antibiotics. She has been sick on them, she has refused, she has cried, 
she has stamped her feet, I can’t get her to take them. So I think in this 
instance, I think I’ve made my decision.  
Recruitment consultation:CONTRACT Declined trial 9yrs Female 
 
Families who were unsure about which treatment might suit them saw trial 
participation as an opportunity to take the decision about treatment out of their 
hands: 
Mum F22:…I wasn't quite sure which one would be better suited for her 
really so, that's why I'm going to leave it in your capable hands now. 





However, several families who expressed preference for treatment still consented to 
the MAGENTA trial despite the fact they could access their preferred treatment 
outside of the trial (see: Consent to trial despite preference for treatment). 
 
Perceptions of young people’s current physical and emotional condition were 
considered and discussed alongside preferences for treatment during recruitment 
consultations and were also discussed in the decision-making process when families 
withdrew or discontinued interventions post-randomisation (see: Discontinued 
treatment, treatment failure and recurrence). Overt signs of young patient distress 
(such as audible crying) were more apparent during CONTRACT recruitment 
consultations. In these circumstances some parents opted for surgical treatment 
outside the trial, particularly if it was framed by recruiters as ‘quicker’ and more 
definitive. Post randomisation drop-out in the CONTRACT RCT was discussed in 
relation to ‘treatment failure’ and perceived ‘deterioration’ in the young person’s 
physical state when treated with antibiotics. 
 
Active versus Control and Experimental versus Standard treatment 
Preference for the ‘active’ as opposed to the ‘control’ treatment was discussed as 
positive and more beneficial in the SMILE and FITNET-NHS trials.  The Specialist 
Medical Care plus the Lightning Process group and FITNET online CBT group were 
referred to as ‘active’ trial groups by families. Recruiters had not used these terms 
during recruitment consultations but families either had some understanding of RCT 
research or this information had been passed on by a friend. However, interventions 




trial context. One father referred to FITNET Online CBT as the “experimental one”, 
but this was a positive for him as it was his preferred treatment group, because he 
felt: “this experiment in Holland had quite a lot of success for teenagers” [Participant 
F2, 13yrs, female, Online CBT group]: 
Mum F19:…We were obviously hoping for the active arm, but it didn’t 
really matter because whatever you got was going to be extra, but helping 
him in some way that he didn’t already have access to.   
Researcher F8:…And by the ‘active arm’, do you mean activity 
management? 
Mum F19:…Oh, sorry no I mean the FITNET arm. Sorry, I have a friend 
from a medicine profession and she describes the active arm, as in this is 
the active arm of the trial, and the other one is the control arm, i.e. what 
we already know works. 
Interview:FITNET-NHS Online CBT 14yrs Male 
[No audio of recruitment consultation.] 
 
Mum S35:…If we end up as the control group, it's a shame but you have 
to have a control group, and if it means that eventually the NHS go, ‘Yes 
this is great’, then, you know, someone benefits, and if people don’t take 
part then it doesn’t happen… [laughs] I’m quite gutted that we’re in the 
control group… if it gives you your control group, it gives you your control 
group, then you’ve got your data. 
Interview:SMILE Specialist Medical Care 12yrs Female 
 
In contrast, during the MAGENTA and CONTRACT trials, ‘standard’ treatments 




and perceived as potentially more beneficial for their child, as opposed to 
‘experimental’ treatments (Graded Exercise Therapy and antibiotics) which were 
perceived as more risky or harmful: 
Dad M42:…Isn’t there usually an incentive to go for just the standard 
treatment [activity management] that’s been tried on young people? 
Recruitment consultation:MAGENTA Declined trial 14yrs Male 
 
MUM CE9:…My child not gonna be like a mouse in a laboratory 
because… I never heard that, [antibiotic treatment for appendicitis] my 
child not gonna be experimental toy. 
Recruitment consultation:CONTRACT Declined trial 13yrs Male 
 
However, it should be noted that many young people responded positively to the 
prospect of doing more managed exercise in the MAGENTA trial, and were 
enthusiastic about increasing, or starting to do some exercise: 
Young person M20:…And I like doing exercise…I wasn’t doing any 
exercise because I was just so tired … so like we were saying it would be 
good if I start exercising. 
Interview:MAGENTA Graded Exercise Therapy 17yrs Female 
 
Risk of harm 
Parents’ perceptions of risk differed between the CFS/ME trials (SMILE, MAGENTA 
and FITNET-NHS) and the surgical trial CONTRACT due to the contrasting long 




activity management group or treatment outside of the MAGENTA trial because of 
online information suggesting that Graded Exercise Therapy may be harmful to 
someone with CFS/ME: 
Mum M110:…The research that I’ve done has indicated that there may be 
some complications to some patients through Graded Exercise, 
especially, and I just don’t feel that I can take the risk with my own child, I 
think if it was me I might give it a go, and also it is [patient name] decision 
obviously… I wanted her to make a decision as well and she’s read 
through the information as well, she’d like to go down the other route. 
Recruitment consultation:MAGENTA Declined trial 12yrs Female 
[Only mum present during recruitment consultation.] 
 
In the FITNET-NHS trial a minority of parents were concerned that FITNET Online 
CBT might reinforce the condition as being psychological and not physical, but more 
often parents felt that psychological support in either study group would be beneficial 
to their child: 
Mum F11:…It worries me that it makes it out that it’s more of a 
psychological condition when you know, obviously if you’re seeing it first 
hand and I know how physically it affects the body so yeah, I’ll be honest 
that side of it [FITNET] I am probably more a little bit more concerned 
about.  
Recruitment consultation:FITNET-NHS Skype activity management 13yrs 
Female  
 
Preference for treatment was not raised by parents or young people during the 




the trial (some patient groups were against the Lightning Process being researched 
in relation to CFS/ME, particularly in a paediatric setting): 
Mum S38:…I mean looking at the information that you gave us it 
[Lightning Process] does seem to be more successful than other things 
and seems to do less harm than other things… So made worse GET… 
mind you CBT is quite high as well… 
Recruitment consultation:SMILE Specialist Medical Care 16yrs Female 
 
In the context of acute appendicitis (CONTRACT) a ‘new’ or ‘non-standard’ 
treatment, such as antibiotics, was seen by some parents as posing unnecessary or 
unacceptable risk. This contrasts the positive perceptions of ‘new’ treatment in the 
SMILE and FITNET-NHS trial (see: ‘Access to treatment: A new angle, something 
different’ and ‘Active versus Control and Experimental versus Standard treatment’): 
Mum CE7:…I think from my side of things, it's working out what the risk is 
to [Patient name] without the standard approach. 
Recruitment consultation:CONTRACT Antibiotics 14yr Male 
[Recurrence also treated with antibiotics.] 
 
DAD CE19:…Surgery is, you know, it is kind of the standard… 
intervention at the moment… when it’s your child that’s lying there, you 
want something that you know is gonna work. 





During the CONTRACT RCT the antibiotic group was also seen as potentially 
dangerous because the appendix was being “left” which was perceived as “delaying” 
treatment. Parents also felt there was potential to cause more harm later because 
antibiotic treatment could potentially be ineffective, causing recurrence and a more 
advanced infection and complications: 
Dad CE14: … I'm more inclined probably to pass at the moment and that's 
only because mine was left when I was young and mine actually ruptured, 
so I was an emergency, rushed in.  And my only concern is if we leave his 
and it doesn't work, I don't want him to be in that same boat where it's 
left… and, you know, because that can become life threatening, can't it? 
Recruitment consultation:CONTRACT Declined trial 5yrs Male 
 
Young person CF21:…[?I want?] Surgery. 
Mum CF21:…You think you’d rather just have it done? …then you just 
know what you’re dealing with don’t you, whereas if you have, if you’ve 
got allocated to antibiotics then you’d have to wait to see if that worked 
first, and then you might still end up having it anyway. 
Recruitment consultation:CONTRACT Declined trial 15yrs Male 
 
More is better ‘pick and mix’ approach 
Risk for those considering participation for their child in a CFS/ME trial was more 
focused on trial entry limiting access to treatment which might have potential to 
improve their child’s condition and quality of life. In the context of the MAGENTA trial 
combining elements of graded exercise and activity management at the same time 




possible and was more achievable outside of the RCT. Families sometimes 
discussed the perception that more or using both treatments outside the trial at the 
same time was a better option. In MAGENTA this ‘pick and mix’ approach was also 
described by health professionals treating MAGENTA participants (see: Individual 
versus collective equipoise).  The ‘risk’ of not having access to potentially beneficial 
treatment was therefore greater for those considering participation in the MAGENTA 
trial: 
Mum M52:…We felt both approaches need to be put into place, it was too 
focused down one line, too limiting. Treatment offered in the trial wasn’t 
enough, it’s parts of the pieces of a jigsaw, but it’s not seeing the whole 
picture. 
Young person M52:…I thought I needed to look at a whole range of things 
Interview:MAGENTA Declined trial 15yrs Female 
 
In SMILE and FITNET-NHS more was equated with ‘one’ of the trial groups, 
Specialist Medical Care plus the Lightning Process or the FITNET Online CBT group 
which had ‘more’ chapters as opposed to three skype sessions, (after feedback from 
interviews the number of skype sessions was increased to six when the internal pilot 
was converted to a main trial). The mode of treatment delivery, e.g. group, skype or 
email were frequently discussed in relation to preference for treatment during 
FITNET-NHS and SMILE consultations and interviews, as opposed to the 
underpinning treatment approaches, e.g. neuro-linguistic programming, activity 
management, or CBT. Many young people eligible for SMILE were apprehensive 




Young person F13:…I think the idea of having a set number of calls 
means that if it doesn’t work out… I still need some more treatment. It kind 
of just feels a bit like ‘so where do I go now?’ 
Recruitment consultation:FITNET-NHS Skype activity management 15yrs 
Female 
 
Past experience of intervention 
If a parent had experienced appendicitis themselves in the past, or had experience 
of a close family member being particularly ill after a perforated appendix, they often 
stated this as their reason for declining the trial and opting for surgery outside of the 
RCT: 
Mum CF6:…I think the worry is, is that he’s [dad] really adamant he wants 
the surgery. I think it’s just his old-school, gut feel thing… his brother had 
a really bad, his brother’s appendix, so I think he’s just got this, like 
emotional. 
Recruitment consultation:CONTRACT Declined trial 5yrs Female 
 
Mum CD3:…Um, I don't think... no, I'd just rather get ?him?... Yeah, the 
normal way. 
Recruiter CE5:…Okay, that's absolutely fine.  Um, so in that case, what 
we'll try to do is take his appendix out, okay… We tend to do it as a key- 
hole procedure. 
Mum CD3:…Yeah, that's how mine was, yeah. 





Because activity management involved restricting activities that young people 
enjoyed, and manually recording them (on paper sheets or an App 
https://itunes.apple.com/gb/app/activeme/id458308805?mt=8)) some young people 
reported that they had already tried this and had not enjoyed doing it: 
Young person M25:…I’ve done the sheets before… [name] gave us the 
sheets from the [local hospital] so I had to colour those in, and that was 
just a bit time consuming, to be honest [laugh]. 
Interview:MAGENTA Graded Exercise Therapy 16yrs Female 
 
Anxieties about treatment and treatment delivery  
Anxiety about treatment mode (e.g. group work, lack of face-to-face contact) or the 
treatment itself (e.g. Graded Exercise Therapy or a surgical procedure), were factors 
which young people (and some parents) considered important in relation to their 
preferences for trial treatments. Parents of children considering CFS/ME trials 
reported searching for evaluations of CFS/ME treatments online from non-NHS 
sources. For young people eligible for the SMILE and MAGENTA RCTs it was fear 
or apprehension about the prospect of having to do something they didn’t want to do, 
either group work in the Lightning Process (SMILE trial) or ‘exercise’ in MAGENTA 
trial. 
The Lightning Process was delivered in a group setting, and this was the main 
apprehension young people had about participating in the RCT. One of the two 
SMILE patients who declined the trial after the recruitment consultation expressed a 
preference for specialist medical care because she had considerable anxieties about 




Patient S18:…Do I have to do the course, like where you like go and meet 
people, or can you just do the questionnaires?  
Recruitment consultation:SMILE Declined Trial 16yrs Female 
 
Some young people and parents considering the MAGENTA trial felt that they, or 
their child would simply be unable to follow the Graded Exercise Therapy treatment 
pathway because the level of ‘exercise’ required would be too much for them: 
Young Person M57:…I wanna do the research but I don’t really want to do 
the graded exercise, because of the 50:50 chance of doing that, so I think 
I’d rather just not be in the study. 
Dad M57:… Because we know it’s a 50:50 chance, he’s not prepared to 
take that risk. 
Recruitment consultation:MAGENTA Declined trial 16yrs Male 
 
Mum M140:…[Graded Exercise Therapy] wasn’t a route he wanted to go 
down… I think he’s researched this quite a lot.  
Recruitment consultation:MAGENTA Declined trial 16yrs Male 
[Only mum present.]  
 
Some families declined the FITNET-NHS trial during the internal pilot phase of 
recruitment because they preferred face-to-face treatment outside the trial (24/48 
50%). During the recruitment consultation, recruiters either offered face-to-face 
treatment or discussed waiting times and families stated, “I think we probably need 




Mum F8:…Could I just ask if she decides not to go ahead with the study 
and we come for face-to-face appointments at [location] how regular 
would they be? 
Recruitment consultation:FITNET-NHS 
[Declined trial and opted for face-to-face appointment.] 
 
Other families mentioned a preference for face-to-face treatment but still opted to 
participate in the trial, it was unclear whether this was due to difficulties with 
accessing treatment locally or differences between parent and young person 
preference: 
Mum F22:…Me personally, I don't like it [skype] because I'm highly old 
fashioned. I like to go into a room and I like to talk to somebody … and 
that's it.  But that's just me… 
Researcher 8:…What about you [patient name]?  Did you think it could 
work being treated over Skype? 
Young Person F22:…Yeah. [inaudible comment]. 
Interview:FITNET-NHS Skype activity management 11yrs Female 
 
Many of the young people eligible for the CONTRACT trial were apprehensive about 
surgery. Parents often expressed preference for antibiotics on their child’s behalf, 
because of anxiety and fear of the prospect of an operation: 
Young person CD14:…[Speaking very quietly] I don’t want an operation. 




[Withdrew from trial.] 
 
Dad CE25:…I mean…he’s saying he’s not too bothered but… he would 
rather...you know, not have the operation.  
Recruitment consultation:CONTRACT Antibiotics 9yrs Male 
[Treatment failure - revert to surgery.] 
 
Misunderstandings: Evidence-based treatment and therapeutic misconception 
A minority of parents in the MAGENTA and FITNET-NHS trials had misperceptions 
about one of the treatment groups in the study, believing that activity management 
was evidence-based: 
Dad M42:…Just for clarification, I think [health professional] talked a bit 
about this, the graded exercise therapy, is the treatment that isn’t 
standard treatment for young people at the moment… the dis-incentive of 
that isn’t there, with the little evidence that graded exercise therapy works 
well with young people at the moment, cos the study hasn’t been done… 
Recruitment consultation: MAGENTA Declined trial 14yrs Male 
 
There was no audio-recording of the conversation between ‘Dad M42’ and the health 
professional he spoke to at his child’s initial assessment (see: Missing conversations 
from the consultation process). A FITNET-NHS mum discussed her preference for 
the activity management group, not because of an existing evidence-base but 
because it involved face-to-face interaction, despite there being no evidence that 




Mum F13:…One of the things I thought was an advantage of this arm 
[activity management] …you have the sort of face-to-face interaction over 
Skype...I suppose I always tend to think that face-to-face interaction is 
nicer and more helpful.  
Recruitment consultation:FITNET-NHS Skype activity management 15yrs 
Female 
 
One CONTRACT parent expressed a belief that her son had been randomised to the 
antibiotic treatment group because that was the most appropriate treatment for him 
personally given his clinical diagnosis. In contrast her son appeared to understand 
randomisation as a chance of receiving antibiotic treatment via the trial, “without 
doing the trial I would definitely had to have had the operation” [Participant CE7]. 
Mum CE7:…No, that's interesting 'cause obviously that's maybe a lack of 
understanding on [patient name] side because I think the, [surgeon 1 
name] and [surgeon 2 name] had been saying look we're going to try this 
antibiotic approach because we think that's the right thing to do, but you 
do have a choice if you want to have an operation and not to do that.  So 
that was a care thing, wasn't it, rather than the actual trial itself?  
Interview:CONTRACT Antibiotics 14yrs Male 
[Recurrence also treated with antibiotics] 
 
Altruism 
All participating families (young people and parents) discussed altruistic reasons for 
trial participation: 
Mum S35:… I do actually really believe in research, and I understand the 




them that it's worth it… even if we don’t get to do it, if we end up as the 
control group, it's a shame but you have to have a control group, and if it 
means that eventually the NHS go, “Yes this is great”, then, you know, 
someone benefits, and if people don’t take part then it doesn’t happen. 
Interview:SMILE Specialist Medical Care 12yrs Female 
 
Mum F19:…[Participant] felt quite excited when he realised he could get 
on with the trial, and I guess help others in the future as much as he’d like 
to make sure he gets better as well.   
Interview:FITNET-NHS Online CBT 14yrs Male 
[No audio of recruitment consultation.] 
 
Young Person CD9…'cause like I think the next person [in the future] who 
got this might be able to go on to antibiotics and it would help them even 
more if there was a better method of getting rid of it. 
Interview:CONTRACT Antibiotic 12yrs Male 
 
Some young people discussed altruism and their interest in science as overriding 
reasons for taking part: 
Young person M43:…I didn’t really mind really whichever way it went…the 
research would sort of help people in the future...any of the outcomes 
were positive…. I mean doing the science subjects that I did, biology and 
psychology and doing studies about, research studies… I was quite sort 
of eager to take part in one. 





Equipoise, language and misperceptions about treatment 
Analyses of recruitment consultations showed that some of the language used by 
health professionals when discussing the SMILE, MAGENTA, FITNET-NHS and 
CONTRACT did not convey equipoise between treatment groups. In the SMILE RCT 
there were frequent examples where the Lightning Process was described 
favourably e.g. “we're getting good anecdotal evidence that it's helpful” [Family 7], 
“it’s called the Lightning Process… is because some people have rapid results” 
[Family 37]. In contrast, Specialist Medical Care was described as “normal medical 
care” [Family 8] and families were told their child would “just carry on as you are” 
[Family 11]. When reassurance was offered families were told that if randomised to 
this trial group they would still be receiving “some treatment” [Family 37], or “you 
would continue to get the care you would receive anyway” [Family 72]. On occasions 
the Lightning Process was framed as a “new process” [Family 73]. 
Recruiter S2:…One group which will have the umm, normal medical care 
with the chronic fatigue service. 
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process 16yrs Female 
 
Similar language was also apparent in early consultations in the CONTRACT RCT, 
where surgery was framed as a known entity, “what we usually do” [Family CF16] 
“the…previous normal treatment” and antibiotic treatment was framed as something 
which was being tried or tested “the experimental side” [Family CE16]. Language 
used framed the trial as investigating whether antibiotics “on their own” are “as good” 




Recruiter CE10… If you decide oh no, I don't want to have all of this done, 
I don't want to go to all this trouble, I would like to go the old…I would like 
to do it the standard way, at the moment our appropriate, our standard 
way would be at the moment, is to go for an operation. 
Recruitment consultation:CONTRACT Declined trial 8yrs Male 
 
Training points CONTRACT: 
Alternative and neutral language to explain surgical and antibiotic treatment 
groups were discussed in the second training sessions: 
 
After training there were more instances of recruiters using these alternative 
‘neutral’ terms to present trial groups. This was accompanied by a statement about 
both approaches having pros and cons and a link to the study rationale:  
Recruiter CE3:…What we know is there are two ways of treating 
children like this with appendicitis. The first is with antibiotics, okay, 
given through the drip for a day or two, followed by a longer course of 
antibiotics that can be taken at home. Once we’re sure that he’s 
responded to the antibiotics and is getting better… and the second 




have risks and they both have benefits, and because of that we’re 
doing a research project to compare the two… 
 
 Recruiter CF11:…One is with an operation and that’s something that 
we’ve usually done, and the other way is with antibiotic treatment.  
Okay?  And that’s with antibiotics through a vein, and these two 
treatments both work well and we want to know which of them works 
best in simple appendicitis treatment… 
 
Training re-iterated the emphasis on uncertainty about the most effective 
treatment. That despite appendectomy being used widely in practice, antibiotics 
were now more effective and reliable which highlights rationale for the trial:  
Recruiter CE4: …Maybe like 50 years ago, everybody was getting an 
operation, but now we know there are more options and… we want to 
see which one’s best… 
 
Some of the language used in early recruitment consultations during the MAGENTA 
and CONTRACT trials also suggested that involvement would be burdensome: 
Recruiter M1:…Have you had the information sheet you were given at 
your appointment…it’s quite a lot… 
Recruitment consultation:MAGENTA Declined trial 14yrs Female 
 
Recruiter CE9:…So the way it works is if you agree to go ahead with the 
study, um, we have lots of paperwork… 





Interviewed families reported that they valued the opportunity to take part in research 
and appreciated being followed-up in CONTRACT, so these findings were fed back 
to those recruiting: 
Young Person CE7:…I'm very pleased I've done that, yeah, just to help 
out and not have to have an operation was also quite a good bonus.  
Interview:CONTRACT Antibiotics 14yrs Male 
[Recurrence also treated with antibiotics.] 
 
Mum CF9:…It was a sort of selling point, wasn't it… for the study… that 
you get this extra follow-up. 
Interview:CONTRACT Appendectomy 8yrs Female 
 
In early consultations recruiters in the MAGENTA and FITNET-NHS RCTs recruiters 
consistently framed the RCTs as restricting choice, not providing a way in which to 
make a decision about treatments in an area where there was uncertainty about the 
effectiveness of treatment, and reinforcing trial rationale: 
Recruiter M1:…So if you decide to be in the study, we will randomly 
allocate you to one of the groups so that means you can’t choose which 
group you’re in… 
Young person M109:…Alright 
Recruiter M1:…Okay, so There’s a 50% chance you’ll be in the graded 
exercise therapy group and a 50% chance being the activity management 
group okay? 




Recruiter M1:…So you can’t choose which group…. 
Recruitment consultation:MAGENTA Graded Exercise Therapy 17yrs 
Male 
 
This also occurred in the CONTRACT trial, but it was not the recruiter, but the 
research nurse who highlighted lack of choice: 
Research Nurse CE1:…Just to say obviously you won't be able to choose 
your treatment option [laughs].  
Mum CE10:…No. 
Recruitment consultation:CONTRACT Declined trial 8yr old male 
 
Training points Randomisation: 
Information relating to how randomisation would be carried out had been provided 
in early recruitment consultations but why randomisation was used was not 
discussed as frequently with families. After training there were more examples of 
recruiters explaining why randomisation was used: 
Recruiter CE14:...Obviously we don’t choose who gets which treatment, 
because in order to have two groups of children that are the same, they 
have to be randomised. So they have to have a fair chance of getting 
either treatment.  Otherwise if we pick what treatment they get, it might 






There were instances in the MAGENTA and FITNET-NHS trials when recruiters 
stated how pleased they were when families were randomised to their ‘preferred’ 
treatment: 
Recruiter M1:…Okay, now you have been allocated to the graded 
exercise therapy group… 
Young person M109:…Okay. 
Mum M109:…That’s what he wanted. 
Young person M109:…Yeah. 
Recruiter M1:…That’s good news. 
Recruitment consultation:MAGENTA Graded Exercise Therapy 17yrs 
Male 
 
Recruiter F10:…So you have been allocated to the online CBT arm, the 
FITNET. 
Mum F16:…Okay. 
Recruiter F10:…How do you feel about that? 
Mum F16:…Fine, no fine, he will be absolutely fine. 
Recruiter F10:…Great…I think it will be a good fit for you as well. I think 
either arm you would have done fab in, but I personally, I think that this 
can be quite helpful because some of the bits that you have both been 
saying over this phone call. 





During the MAGENTA and FITNET-NHS trial some consultations reinforced certain 
misperceptions that parents had about trial involvement. In the MAGENTA trial this 
included a perception that outside of the trial more treatment was available to young 
people with CFS/ME, who would be offered “a bit of everything”. The recruiter did not 
highlight the rationale for the study or current lack of evidence base for treatment 
delivered outside the trial: 
Dad M32:…It’s just purely that we didn’t want to exclude any element of 
the package that [health professional] had spoken about…. 
Recruiter M1:…If you decide not to go into the trial we will arrange an 
appointment as soon as we can…which will set up a programme, it will 
involve some activity management, possibly some Graded Exercise 
Therapy, as you said, the whole package if you like, absolutely every 
programme we set up is individualised. If you decide to go in the study, 
50% of the children will be allocated to activity management and 50% to 
Graded Exercise Therapy. 
Recruitment consultation:MAGENTA Declined trial 13yrs Male 
 
Recruiter M1:…We’d be asking you to do that amount of activity, if you’re 
in the study that would be either activity management or Graded Exercise 
Therapy, if you decide not to be in the study it will be a mix of everything 
kind of thing. 







Training points MAGENTA: 
During MAGENTA families had concerns that doing one or the other 
treatment might not be as effective as doing a combination of the two. There 
was little change in the presentation of information when parents raised this 
concern during recruitment consultations, although after training the recruiter 
sometimes highlighted trial rationale: 
Recruiter M1:…If you’re in the study you’ll be randomly allocated to 
either be in the Graded Exercise Therapy group or the activity 
management group… the reason we’re comparing these two groups is 
because we’re already using these treatments and we want to know if 
by concentrating on one of these treatments children will do even better 
 
The recruiter also highlighted that families were “free to look up other information” 
themselves, e.g. if randomised to activity management they could manage 
physical activity themselves without guidance: 
[2 minutes into conversation] 
Recruiter M1:…We want to know if concentrating on one treatment is 
better than doing a bit of everything…. 
[15 minutes into conversation] 
Mum M69:…What I’m meaning is you know if she’s in one group as 
opposed to the other group will there be things that she won’t have 
access to in terms of what you think….. 
Recruiter M1:…If you don’t do the study you’ll get a little bit of 
everything, but the difference with being in the study is that you know, 
whichever group you’re in, the emphasis will be on one or the other, but 




who’s seeing you’s point of view, their treatment and advice will be 
focusing on one or the other, the general information about managing 
chronic fatigue syndrome is the same in both groups but the actual 
specific treatment will focus on either the activity management or the 
graded exercise therapy…  
Recruitment consultation:MAGENTA Declined trial 17yrs Female 
 
Suggestions put forward during training which were not put into practice included: 
• Consistently discussing equipoise and the current lack of evidence-base for 
treatment interventions. 
• Discussing the potential burden of using activity management and Graded 
Exercise Therapy techniques. Using ‘both’ approaches would involve the 
patient ‘monitoring’ and ‘restricting’ physical and cognitive activities, when it 
may only be necessary to monitor/restrict either cognitive or physical 
activities to see improvement in symptoms of fatigue. 
 
In a minority of FITNET-NHS consultations there were connotations that face-to-face 
treatment outside of the trial was the ‘gold standard’, implying any treatment offered 
in the trial via Skype or Online CBT would be less beneficial: 
Recruiter F1:…Well, I mean, the best thing you can have is a face-to-face 
appointment… is being near enough to a local specialist service that can 
give you the support and help and advice you need to get better in our 
opinion. 





In the extract below the recruiter has just explained each treatment option available 
in the RCT, (activity management via Skype and Online CBT) the family have not 
asked about face-to-face treatment but this is still discussed as the benchmark for 
treatment which is used in the gold standard delivery mode: 
Recruiter F10:…Like I said, they’re both the approaches we use face-to-
face, so we know they’re good.  
Recruitment consultation:FITNET-NHS Online CBT 16yrs Female 
[Randomisation outcome discussion not audio-recorded.] 
 
At times recruiters appeared to struggle with the concept of conveying equipoise 
throughout the recruitment consultation, stating after the families group allocation 
had been given, that they were ‘secretly hoping’ they would be randomised to the 
treatment they had stated they preferred earlier in the recruitment consultation: 
Recruiter F12:…So you have been randomised into the FITNET NHS, 
online CBT arm. 
Mum F7:…Oh yes, ideal. 
Recruiter F12:…Yes, I was secretly hoping you would be because I know 
you guys have a preference… 
Recruitment consultation:FITNET-NHS Online CBT 14yrs Male 
 
Equipoise between treatment groups within the FITNET-NHS trial was not always 
communicated effectively during recruitment consultations. The name of this trial 
may have made this particularly difficult for recruiters because it appeared to 




represented the activity management (Skype) group. In the extract below the 
participant’s father perceived FITNET Online CBT to be the active group, “the 
effective route for helping people suffering from CFS”, that was being compared with, 
“an alternative” treatment used to “verify whether the CBT is more effective”. The 
recruiter does not address this perception of lack of equipoise between treatment 
groups, and tells the dad, “that’s it, in a nutshell” positively affirming this rationale for 
the RCT as correct. The recruiter does go on to state, “they’re both good standard 
approaches that we currently use in our specialist service” and also highlighted: “we 
don’t know which of those treatments is best” but closed this section of the 
conversation by again confirming dad’s perception of the RCT. This recruiter did not 
acknowledge that the meaning the dad has assigned the ‘Skype’ activity 
management group was one of ‘control’ comparator: “as you said, it’s which one of 
these works better”: 
Dad F12:…The study’s going to look at the effect of whether CBT, online 
delivered CBT, is the effective route for helping people suffering from CFS 
and if that will improve their condition. That has to be done against two 
sets of criteria. One where there’s CBT and one where there’s an 
alternative put forward to verify whether the CBT is more effective than 
the alternative. 
Recruiter F10:…Lovely, yeah, that’s fab. So that’s in a nutshell, that’s it 
really. So there’s the two arms to the study. The FITNET NHS study is 
comparing the two treatments for children and young people with CFSME 
who don’t have access to a local specialist service...  We use both of 
those with our face-to-face patients to treat CFS/ME, but we don’t know 
which of those treatments is best, is more helpful for young people to help 
them recover, and that’s why we’re doing the study. As you said, it’s which 
one of these works better and also can we adapt them to do them over 




Recruitment consultation:FITNET Online CBT 16yrs Female 
 
CFS/ME health professionals delivering treatment had a preference for face-to-face 
appointments which they felt were superior, since “maybe they’re [families] not 
getting as much of a package as they perhaps would [Health Professional FR]” if 
they were seen face-to-face as opposed to in the trial via Skype or Online delivery: 
Health Professional FR:…Yes so naturally I probably would have a 
preference to see them face-to-face ‘cause I kind of get how they walk, 
how they come in, how they just hold themselves and their posture… 
[Interview] 
 
Because of the nature of the condition, and an existing evidence base in adult trials, 
the CONTRACT trial was the only trial in which recruiters used figures in discussions 
of risk. Although most CONTRACT recruiters reported feeling confident about using 
communication techniques to balance families’ treatment preferences before any 
training had taken place, analysis of early recruitment consultations identified that 
although both treatments were discussed, the risks of surgery were minimised. 
Recruiters discussed the risks of surgery less often and in a more general way than 
antibiotic treatment, and omitting numeric figures that represented the risk of 
complications: 
Dad CF21:…Is there a high risk of getting an infection from the surgery? 
Recruiter CF15:…Is there a high risk, no. 





Figures in relation to the risk of complications related to having surgery were only 
presented in seven consultations during the whole 12 months of recruitment. Surgery 
was often communicated as “an operation that we do routinely and is very safe” 
[Family F18]: 
Recruiter CD19:…So they would be, erm, damaging something inside the 
tummy, erm, is very rare.  We think it’s less than 1 in 1,000… 
Recruitment consultation:CONTRACT Appendectomy 11yrs Female 
 
During the CONTRACT recruitment consultations, figures relating to the risk of 
antibiotic treatment failure and recurrence when treated with antibiotics were 
communicated in 51 consultations, and the use of figures to represent the risk of 
future appendicitis recurrence varied: 
Recruiter CE2:…There are risks during those operations that we can 
cause damage doing that… you can get infections…so we know that most 
patients with sort of an appendix mass or complex appendicitis… I think 
about 85% will be successfully treated in their first… presentation of that.  
And of the ones that are successfully treated, about a quarter of them will 
need to have…appendicectomy in the future 
Recruitment consultation:CONTRACT Antibiotics 14yrs Male 
 
Training points CONTRACT: 
After discussion (during the third training session) about the way in which figures 
were being presented to families about the risk associated with antibiotics but not 




with supporting percentages or figures: 
Dad CF11:...Why are you trialling this system?  What do you think are 
the possible benefits of going that route rather than the traditional route 
of just getting the appendix out?   
Recruiter CF11:…Well some, some parents, erm, would rather not have 
surgery...because surgery isn’t without fail. Surgery does have 
complications, and you’re looking at around 25% of, erm, patients who 
have an appendicectomy have complications related to that. 
Recruitment consultation:CONTRACT Appendectomy 13yrs Male 
 
Examples of good practice from phase two recruitment also highlighted the way in 
which antibiotic treatment could be discussed in terms of the ‘success’ instead of 
‘failure’ rate: 
Dad CF20:…Well I think my first concern obviously is if you do with the 
antibiotics, does that mean that it can come back again?   
Recruiter CFS11:…I described it being at one in seven children who are 
treated that way [with antibiotics] would have that recurrence…but that’s 
a six in seven chance of success which is pretty good. 
Recruitment consultation:CONTRACT Antibiotics 7yrs Male 
 
Although the risk of recurrence and treatment failure were discussed more 
frequently throughout trial recruitment, there were slight changes in the way that 




later stages of recruitment, with examples where surgical risk was presented with 
figures to clarify risk: 
Recruiter CF14:…20% of the people having an operation may have 
complications, not all of them are major 
Recruitment consultation:CONTRACT Appendectomy 7yrs Male 
 
There were times during the CFS/ME trials when recruiters didn’t give young people 
and parents time to respond to points they had made or questions that recruiters had 
asked which might have resulted in a discussion about preference for treatment:  
Recruiter M1:…Okay…you don’t mind which group you go in to? Cos 
that’s the way it is, it’s just a chance [recruiter doesn’t cede the floor] I put 
your age and umm, whether you’re a girl or a boy into the computer and 
then I press the recruit button and the computer decides which group 
you’re in, okay, so that’s how we randomly allocate you to one of the 
groups. 
Recruitment consultation:MAGENTA activity management 13yrs Female 
 
When this family were given their allocation, it was apparent they had a preference 
which had not been discussed: 
Young person M88:…That’s the one I wanted anyway… 
Mum M88:…Yay… [both laugh]. 
Recruiter M1:…Oh I’m so pleased.  





Recruiter S4:…There’d be a little presentation, a bit of group work, how 
does that sound [patient name]? [recruiter does not cede the floor]… 
Would you be alright with that? [recruiter does not cede the floor] … 
Sitting in a group, they might ask you a few questions, in a little group. 
Anything you don’t wanna do you just say you don’t wanna, you know. 
They give you up to half an hour of homework a day, but that is to help 
you take in what you’ve learnt…. 
Mum S73:…Yeah. 
Recruitment consultation:SMILE Specialist Medical Care plus Lightning 
Process 14yrs Female  
[Participant did not attend Lightning Process course.] 
 
Recruiter F10:…Thinking about the two different arms, do you have any 
kind of preference? [recruiter does not cede the floor] Though, as I said, I 
don’t choose and you don’t choose, but if you could choose would you 
have a preference for which one of the arms you’d go into? 
Young person F12:…Hmm... I... No, not particularly. I don’t mind. 
Recruitment consultation:FITNET-NHS Online CBT 16yrs Female 
 
In other consultations, the recruiter did not respond to misconceptions about 
treatment: 
Young person F13:…I suppose at first I was a bit suspicious of the fact it’s 
all over the Internet [Online CBT]. That is a strange idea, to me 
Recruiter F1:…Right okay. 





In the following example, the recruiter did not balance this information by providing 
similar information about the Online CBT group, which is also a treatment delivered 
‘face-to-face’ by the specialist CFS/ME service. Later in the consultation the recruiter 
did go on to explain that, “FITNET one is over the internet, and although you may not 
see the person you do develop a personal relationship with that person because 
you’re sent, they will be sending you personal emails”. Although the young person 
acknowledges this with a “yes” she re-iterates during a later interview discussion that 
she was still unclear as to whether she would have been speaking to a “real” person 
if she had been randomised to the FITNET Online CBT, or was it just “an online 
computer system” without input from a health professional: 
Young person F13:…I was quite glad that I’d actually be speaking to 
someone [via Skype]. In the sense that I was never sure with the other 
one whether I would be speaking to someone or if it would all just be an 
online computer system.  
Interview:FITNET-NHS activity management via Skype 15yrs Female 
 
Training points FITNET-NHS: 
In the FITNET-NHS trial language was changed to reflect fact that both 
approaches were ‘standard’: 
Recruiter F1:…Both activity management and cognitive behavioural 
therapy are both currently used in our service. Up to now they are 
mostly delivered face to face in a clinic here in [city]. They are both 
good and standard treatment approaches for the treatment of chronic 





Recruiter F12:…We don’t know which is better, otherwise if we knew 
which is better that’s the one we would be offering everyone. 
 
5.3.3 Understanding how recruiters respond to treatment 
preferences in paediatric trials 
This section reports themes which were developed from analysis of the ways in 
which recruiters communicated to elicit preference, explored and responded to 
treatment preferences during consultations. This involved the analysis of recruitment 
consultations before and after training had taken place in each of the recruiting trials.  
Of interest was the way in which recruiters identified and responded to families’ 
preferences. Two commonalities were identified across the four trials: 
1. Recruiters accepting preferences raised by parents and patients at face value.  
 
2. Recruiters used language that may have created or reinforced existing 
preferences and did not convey equipoise. 
 
Acceptance of preference and missed opportunities to explore preference 
During the early months of recruitment to the MAGENTA and CONTRACT trials, 
recordings of recruitment consultations highlighted that when parents expressed 
preferences for treatment, these views were often accepted at face value. 
Expressions of parental preference in the MAGENTA trial focused on preferences for 
activity management due to negative perceptions of Graded Exercise Therapy: 
Recruiter M1:…In which case it [Graded Exercise Therapy] probably isn’t, 




Recruitment consultation:MAGENTA Declined trial 14yrs Male 
 
Recruiter M1:…I think if you do have a strong preference it’s probably not 
the best thing to do at the moment… 
Recruitment consultation:MAGENTA Declined trial 15yrs Female 
 
Training points MAGENTA 
Some parents had concerns about their child using Graded Exercise Therapy (see 
also: Risk of harm). Using anonymised extracts from the MAGENTA trial, training 
highlighted: open questioning, equipoise, discussing what GET/AM interventions 
involve, lack of evidence-base. After training sessions there were observed 
changes in recruiters’ communication practice in response to parents’ negative 
perceptions of Graded Exercise Therapy, with more examples of open questions 
and attempts to correct misperceptions that Graded Exercise Therapy would 
require the participant to do high levels of exercise: 
Young person M3:…It’s the exercise one I don’t really like the sound of 
 Recruiter M1:…Graded Exercise Therapy doesn’t mean that you’ve got 
to go and do, sort of a jog round the block, it doesn’t mean that you 
have to start working out at the gym more, doing loads of umm, high 
level activity…we’re not talking about [laughs] you know getting to 
Olympic athlete standard, you know a programme to build you up like 
that, we’re talking about just, you know just focussing on you, what is 
appropriate exercise for you and to build that up for you as an 
individual, little by little…  






Mum M49:…I think he was worried about being picked for the exercise 
one. 
Recruiter M1:…Don’t be frightened by that, you know, we’re all different 
and, think of it as physical activity rather than exercise…  we take the 
amount of physical activity that you’re able to do on good days now and 
use that as a baseline on which to build… 
Recruitment consultation: MAGENTA Graded Exercise Therapy 15yrs 
Male 
 
Recruiter M1:…So it doesn’t mean that you are gonna be asked to do 
circuit training or jogging or anything like that [both recruiter and 
participant laugh] umm, okay, it’s just the name of the treatment… 
Recruitment consultation:MAGENTA Graded Exercise Therapy 17yrs 
Female 
 
Surgery was often the preferred treatment for parents in CONTRACT, because of 
the perceived urgency of “getting on” with treatment, and the risks of further 
deterioration, a “burst” appendix or recurrence in future. Some parents also raised 
their own experiences of appendicitis in the past (see also: Past experience of 
treatment), or wanting their child to be treated “the normal way” and these were 
important factors which resulted in many parents declining the trial for their child: 
Mum CE16:...I just wanna get him sorted.  
Recruiter CE5:…Yep, fair enough.  So you just want to go and have 
surgery you think?... Fair enough. 





Mum CF16: …I spoke to my family and that’s the...main 
Recruiter CF11: okay…that’s fine…okay, in that case that’s okay, we will 
use... the usual treatment that we would do, okay. 
Recruitment consultation:CONTRACT Declined trial 13yrs Female 
 
Recruiter CD5:…Do you want to know a bit more about it? 
Mum CD3:…Um, I don't think... no, I'd just rather get ?him?... 
Recruiter CD5:…You'd just rather get on? 
Mum CD3:…Yeah, the normal way. 
Recruiter CD5:…Okay, that's absolutely fine.   
Recruitment consultation:CONTRACT Declined trial 13yrs Male 
 
At times during the CONTRACT trial recruiters explored preference but then 
appeared to ‘accept’ that families had a preference and often left them ‘to think about 
it’ on their own, without input from the recruiter. Since audio-recorders were usually 
turned off at this point in the conversation it is not known whether recruiters offered 
any further information to balance treatment groups or challenge preference: 
Dad CD11:…He said he wants the op though, he doesn’t want to go for 
the antibiotics. 
Recruiter CD3:…You don’t want to go for the antibiotics?  
Young Person CD11:…Yeah, that’s what me mum said ‘cause we’re flying 
in 12 days. 




Dad CD11:…It’s up to you how you wanna do it?  
Recruiter CD3:…And you don’t have to make a decision immediately.  We 
kinda give you all this...information and then, we can give, half an hour, an 
hour or so. You’re not, you’re not gonna go to theatre in that time... 
Recruitment consultation:CONTRACT Declined trial 13yrs Male 
 
Training points CONTRACT: 
Equipoise and exploring preference for surgical treatment. 
Using anonymised data extracts during the CONTRACT trial training: Encouraged 
recruiters to explore families’ reasons and beliefs in relation to preference for 
treatment and trial participation, instead of accepting preferences for surgery at 
face value. There were examples of recruiters reassuring parents that their child 
was eligible for the trial because they had ‘simple’ appendicitis and they would be 
closely monitored and cared for: 
Recruiter CE14...We now know that for people who’ve got a simple 
appendicitis, so you’ve probably heard burst appendixes and those 
sorts of things, it’s not how [patient name] appears at the moment.  
There’s no evidence to support that… so if someone like him, an option 
to avoid a general anaesthetic and an operation would be to give him 
antibiotics only… and that is… we know as a safe alternative to just 
putting you to sleep and offering you an operation, basically.  
Recruitment consultation:CONTRACT Antibiotics 9yrs Male 
 
The majority of parents had some concerns about their child’s appendicitis being 




member had, had a bad experience of appendicitis in the past. Training 
encouraged recruiters to emphasise that both treatments were good options, both 
had pros and cons, hence the reason for the trial: 
Dad CF20:…I’ve had it myself, I know how...painful… I don’t want him 
to go through that again, you know what I mean? Now with the 
surgery... it ain’t coming back.   
Recruiter CF11:…Yeah, that’s certainly a valid view and a valid 
apprehension… certainly a fear that parents have but it’s still a good 
chance of it being managed effectively... in the recent past there have 
been lots of studies because parents have wanted an option to 
surgery…  
Recruitment consultation:CONTRACT Antibiotics 7yrs Male 
 
Recruiter CE5:…Um, I think I can assure you that whatever we do, 
you'll be very closely looked after, um, and [patient name] will be very 
well cared for. 
Recruitment consultation:CONTRACT Declined trial 10yrs Male 
 
These conversations did not always result in consent to the trial (particularly where 
one parent was not present for the recruitment consultation) but more recruiters 
were introducing the concept of uncertainty about which treatment was most 
effective: 
Mum CF18:…So even if he takes antibiotics and it comes back you 
have to operate… Whichever is best for him, I’d like you to tell me 




Recruiter CF17:…I can understand what you’re saying...you’re saying, 
look there’s that element of uncertainty and you want to ask me what do 
I think’s... best.   
Recruitment consultation:CONTRACT Declined trial 13yrs Male 
 
Recruiter CE14:…So and the reason we’re talking about it is because 
we don’t actually know which is the better thing to do… we routinely 
would, in the past, do an operation, take it out but in adults and children 
we know that there is an alternative that is safe and avoids an operation 
and avoids an anaesthetic… 
Mum CE1:…He needs antibiotics anyway.  Like you say, you won’t be 
able to operate on him today anyway, so it would be tomorrow and 
that’s a good 24 hours away…   
Recruitment consultation:CONTRACT Appendectomy 13yrs Male 
 
Recruiters’ responses to expressed preference was slightly different during early 
FITNET-NHS consultations, mainly because families did not always express 
preferences as directly or clearly before randomisation in this trial. FITNET-NHS 
recruiters also used closed questions when asking about preference, therefore 
missing opportunities to explore and discuss preferences. Young people generally 
stated they were willing to accept “whichever one” [young person F13]. With parents 
stating they felt treatments would “help either way” [mum F6]. Recruiters accepted 
neutrality at face value and responded to it positively, “Great”, “Lovely”, “brilliant”, 
“that’s really good to hear” discouraging families from expressing or discussing 
preference further. Recruiters sometimes highlighted that having a preference for 




discussion in relation to the trial, without ceding the floor to explore preference 
further: 
Recruiter F10:…Thinking about the two different arms, do you have any 
kind of preference? Though, as I said, I don’t choose and you don’t 
choose, but if you could choose would you have a preference for which 
one of the arms you’d go into? 
Young person F12:…Hm... I... No, not particularly. I don’t mind. 
Recruiter F10:…Great. How about you, [dad’s name]? Do you feel the 
same? 
Dad F12… I’m easy. Really, anything that... Everything has a value. The 
support, whatever shape or form, whatever it comes in is going to be 
helpful. 
Recruiter F10:…Lovely. That’s really good to hear. Obviously if you did 
have a preference for one or the other that wouldn’t be a problem, it would 
just be something to bear in mind that you may not get the one you were 
after, but it sounds like, actually, you’d both be happy with either.  
Recruitment consultation:FITNET-NHS 16yrs Female 
 
Families F12 and F6 who did not express preferences for treatment during 
recruitment consultations appeared to have been in equipoise, but interviews 
confirmed that both parents had not discussed their preferred treatment during the 
recruitment consultation: 
Dad F12:…The element that was missing in [patient name] treatment was 
the [FITNET Online] CBT side… and you know it seemed to me that was 
something that [patient name] didn’t have and that could have a very 
positive impact.  




Mum F6:…I was hoping we were going to get the FITNET [Online CBT]  
Young person F6:…I didn’t really mind because I didn’t mind which one it 
was… I was fine with it. 
Interview:FITNET-NHS Online CBT 13yrs Female 
[Mum and young person interviewed separately.] 
 
Training points FITNET-NHS 
Equipoise and missed opportunities to offer balanced information. 
Training session one used the ‘Recruitment Tips’ document and highlighted ways 
in which recruiters could encourage parents and young people to discuss their 
preferences e.g. ‘What were your thoughts when you first heard about the 
study/treatments?’ (Appendix 5: FITNET-NHS: Tips for Recruitment and informed 
consent). Training session two provided examples of good practice, particularly in 
relation to using open questions to explore potential for preferences (e.g. What do 
you think about treatment?) without suggesting families should have a preference 
(e.g. Do you have a preference for treatment?): 
Recruiter F1:…How do you feel about those two treatments? 
Young Person F5:…Yeah, okay. 
Recruiter F1:…You feel okay? 
Young Person F5:…I quite like the Skype one. 
Recruiter F1:…You like the sound of the skype one, is there any reason 
for that? 




Recruiter F1:…It sounds better, why do you think that sounds better 
than the other treatment? 
Young Person F5:…Umm, because it’s more individually face-to-face, 
well as face-to-face as it can be over the Internet, that’s sort of good. 
Recruiter F1:…Yes, as face-to-face as it can be over the Internet, yes I 
understand that. With the other group, with the CBT, you will have an 
individual clinician delivering your treatment, delivering your care and 
you will have a lot of communication with that individual so you will have 
an individual relationship with the clinician giving the FITNET treatment 
[online CBT) as well. 
Recruitment consultation:FITNET-NHS Skype activity management 
15yrs Female 
 
When families expressed preferences there were examples of recruiters providing 
information about the opposite treatment group, to balance perceptions of 
treatment: 
Mum F4:…But if there was a choice I’d prefer the CBT approach… 
Recruiter F11:…Yeah I appreciate that the CBT has sort of different 
strengths to the activity management in terms of looking at how your 
coping with the chronic fatigue, but that’s also something which… when 
you have the face-to-face contact with the therapist they will problem 
solve… how you’re dealing with the activity management plan and 
what’s getting in the way… so there will be that side of things. 






Recruiters also emphasised the need to be accepting of both treatment groups:  
Mum F3:…I don’t know if it’s right or not, but the other one, [Online 
CBT] I don’t know that more… geared towards someone who is a bit 
more down in themselves and all that kind of thing… 
Recruiter F11:…Well I mean both of the treatments will focus on what 
your goals are [child], if your goals are to get back to swimming and 
stuff like that, then both of them will focus on that. 
Recruitment consultation:FITNET-NHS Skype activity management 
14yrs Male 
 
SMILE was the only trial which used researchers to recruit, not health professionals 
who were part of the clinical teams also delivering treatment to participating young 
people. For this reason, SMILE consultations were slightly different from the other 
three trials from the outset. Recruiters had an in-depth understanding of trial 
concepts and appeared more comfortable discussing uncertainty with families: 
Recruiter S2:…The main thing to go on to is the concept of the design of 
the study, in health research we do randomised controlled trials… usually 
there’s two different treatments being looked at…you need to feel happy 
about being in either group, [brief explanation of both treatment groups] 
and the reason we’re doing this whole study is because we don’t know 
which treatment works and whether one treatment might be better than 
another. We didn’t want to leave the people in the Lightning Process 
group without any medical backup, so we didn’t feel it would be ethical to 
do that, so that’s why the medical care is still in there… 





In early SMILE consultations many families explicitly expressed a preference for the 
specialist medical care plus Lightning Process trial group (see: Section 5.3.1 How 
and when preferences are expressed). Recruiter ‘acceptance’ of preference often 
involved missed opportunities to explore and challenge preferences. Instead 
recruiters responded by consistently stressing the need for “two groups” and 
sometimes highlighted trial rationale. The recruiter reassured the mother, “that’s fine 
if you feel that way” but in early consultations recruiters did not provide balancing 
information about the specialist medical care group of the trial or discuss preference 
any further, instead it was accepted that the family would “take pot luck”: 
Mum S4:…I’m happy to go ahead, I must admit I would prefer, I think, to 
be in the trial group for the Lightning Process but equally I’m just happy 
that now we’ve seen the service and we are getting some positive 
treatment and we’ve had a lot of feedback from them already and a lot of 
steps forward already so I’m feeling very positive about that, if nothing 
was happening there I’d be feeling a bit desperate, so no, I’m fine with 
that and whichever way we go… 
Recruiter S2:…Okay, yeah, I mean, I do labour the point about the two 
groups being very important to us… Because if you felt at this point that 
you couldn’t, you wouldn’t be bothered to carry on with the study if you 
weren’t in the Lightning group, then umm 
Mum S4:…I can see that being an issue 
Recruiter S2:…But that’s fine if you feel that way, but I’d say, then let’s not 
go any further, if you feel, in the way that you’ve just described, that you’re 
willing to take the, pot luck, and you’ll carry on… 





After feedback was provided by qualitative researchers (NM and LB) the recruiter also 
more consistently discussed the possibility that the Lightning Process “may not add 
anything” and that those having Specialist Medical Care may get better “just as 
quickly”:  
Recruiter S2:…We don’t know, the state of knowledge we’re at is that we 
don’t know whether it [Lightning Process] does add anything or not, and 
this is why, when they’ve started doing the clinical management, 
[Specialist Medical Care] with the clinical team, we could find that people 
get better just as quickly on that rather than having them both together. 
Recruitment consultation:SMILE Specialist Medical Care 17yrs Female 
 
When recruiters didn’t explore preferences for treatment during the course of the 
recruitment consultation, they were often expressed for the first time immediately 
after randomisation. Although recruiters tried to explore preference, some families 
appeared reluctant to disclose their views. Families either underestimated or 
concealed the extent of their preference for treatment. If families were randomised to 
their non-preferred group there was disappointment or elation depending on whether 
or not they were allocated their preferred treatment. The trial context is perhaps 
important when considering non-disclosed preference, because similar treatment 
was not easily available for these families outside the trials (SMILE and FITNET-
NHS). The examples below are taken from two families, showing their feelings and 
preferences before and after randomisation: 
Mum S33:…If [patient name] gets it, [Lightning Process] it’s a bonus, she 
may not get it anyway, in which case she’ll just have what’s available 




Recruitment consultation:SMILE Specialist Medical Care 15yrs Female 
 
Mum S33:…[patient name] put on a face…‘yes I’m fine, yes I don’t mind’ 
and I remember thinking at the time, you know, it’s all very well to put an 
adult through the disappointment of not getting that, there’s another thing 
to put a teenager through that, I do remember feeling very uncomfortable 
with that whole, the way that it happened, there and then… I don’t think 
it’s very fair on them, certainly as a mum I can’t even begin to tell you the 
disappointment that you feel, that you think I’m just going to be the 
comparison group and that’s it, and to me there’s no benefit in that… 
Interview:SMILE Specialist Medical Care 15yrs Female  
[Participant not interviewed; family paid for their child to complete the 
Lightning Process.] 
 
Recruiter F1:…Dad, have you got any thoughts about either of the 
treatments? 
Dad F2:…We’ll spin the wheel and see what happens. 
Recruitment consultation:FITNET-NHS Online CBT 13yrs Female 
[Discussion before randomisation.] 
 
Recruiter F1:…and you’ve been allocated to the FITNET study, the 
FITNET treatment 
Dad F2:… heeeey! [cheers, laughs] I had a slight preference for that one. 
Recruitment consultation:FITNET-NHS Online CBT 13yrs Female 






The SMILE trial was similar to FITNET-NHS in that many families could not access 
the Lightning Process (one treatment group) outside of the RCT. Although recruiters 
explored preferences from the beginning of the RCT, there were still instances when 
recruiters missed opportunities to promote a position of equipoise. Recruiters did not 
always highlight that the Lightning Process may not be necessary to facilitate 
recovery when parents and young people expressed a preference for the specialist 
medical care plus Lightning Process group of the trial.  
 
Early consultations in both FITNET-NHS and SMILE trials generally involved gaining 
confirmation from the family that they understood and were willing to accept 
randomisation to select treatment. In addition, the recruiter in SMILE also explored 
whether the family “wouldn’t be bothered to carry on” if they were randomised to their 
non-preferred treatment. This was not apparent in FITNET-NHS, and recruiters lack 
of preference exploration may have been related to an underlying assumption that 
families were happy to take part in the trial because they did not have local service 
provision. Examples of acceptance of preference and missed opportunities were 
used for training and feedback during each of the four trials (see: Acceptance of 
preference and missed opportunities to explore preference). 
 
Recruitment training had been carried out prior to opening both the MAGENTA and 
CONTRACT trials to recruitment (see: Figures 5:4 and 5:6: The impact of 
communication training on recruitment figures). Recruiters were aware that 




explore these preferences by offering balanced information about both treatment 
groups, and at times this was apparent in early consultations. But instead of 
challenging preference, recruiters more often gently explored families’ reasons for 
preference, and then accepted them without providing balancing information about 
the potential ‘risks’ of surgery and information relating to the rationale of the trial: 
Mum CF1:…Alright, I understand it and when my husband comes...I’ll just 
discuss with him... 
Recruiter CF14:...Fine...I, I’ll leave you to convince him. 
Recruitment consultation:CONTRACT Antibiotics 4yrs Female 
 
It should also be noted that CONTRACT recruiters did not try to balance preference 
for treatment when families expressed preference for antibiotic treatment, this was 
generally accepted as a willingness to enter the study since antibiotic treatment was 
not routinely available outside the trial. There was one instance of balancing 
preference in the opposite direction, by pointing out the benefit of surgery when a 
family showed a very strong preference for antibiotic treatment. This family withdrew 
from the trial when they were randomised to the appendectomy group: 
Recruiter CD9:…He’s quite unusual because he’s got very, potentially 
very early appendicitis, the scan only showed some mild inflammation. 
So, um, you know, we’ve talked about the fact that we would potentially, 
um, just give him antibiotics for now and see how things go… So, are you 
saying that if you went into the study and the computer said, 
appendicectomy, you would immediately drop out? Is that right? 
Mum CD14:…Yes. 
Recruiter CD9:…If we treat him with antibiotics now there is still the 




operation definitively treats it. So, yeah, it does have to be either or... But 
you can change your mind. 
Recruitment consultation:CONTRACT Appendectomy 8yrs Male 
[Withdrew from trial.] 
 
Some of those recruiting to the CONTRACT RCT felt at times that preference 
exploration might feel coercive for families: 
Recruiter CD21:…What I didn’t want to do was to be the person who 
pushes it too much and they, and they complain. So, I try to be as, as 
objective as possible. Some said yes, some said no, and that was it. 
 
Recruiter CE14:…Dad’s body language, just the whole sort of thing was, 
you know, I mean I didn’t feel I was gonna push it necessarily, which I 
guess I could have done even more but it was sort of clear to me that they 
weren’t gonna agree.  
 
In contrast, several families from all recruiting sites discussed during interview that 
they did not feel pressurised to participate in the trial: 
Mum CF15:…We were told it was completely our choice, there was no 
pressure. 
Interview:CONTRACT Declined trial 5yrs Male 
 
Mum CE7:…There was no pressure was there? 
Young Person CE7:…Yeah, there wasn't a lot of pressure and, um, yeah, 




Mum ME7:…Quite inclusive but it wasn't, instructive and you weren’t 
made to feel guilty. 
Young Person CE7:…Actually, I think the most important thing which, was 
the amount of information that they could give you and tell you all about 
the trial, um, which gives you kind of the knowledge to then make your 
decision. 
Interview:CONTRACT Antibiotics 14yrs Male 
 
Mum CD8:…Yeah, I didn’t feel rushed or pressured to make a decision or, 
pressure to take part. I thought that all the information was given in quite 
an unbiased manner...and it was all very clear. 
Interview:CONTRACT Declined trial 13yrs Male 
 
During CFS/ME trials recruiters and health professionals did not discuss coercion as 
an issue when exploring preference, but they did emphasise the importance of 
‘patient choice’ and the way in which trial participation might limit patient and family 
choice, because families had preferences for a particular intervention: 
Health Professional ME:…Some of them sense that it’s a bit more 
restrictive, [trial involvement] i.e. you know you have no choice. They 
might say oh well I want to do Graded Exercise Therapy but most of them 
understand the randomisation 
 
Health Professional MB:…I think it’s also about choice and I think that 
when you are asking people to go on a journey, which you know, without 
sounding a bit glib calling it a journey, but when you ask people to go on a 




engage in that journey if they feel they have some element of control and 
choice. 
 
Health Professional MS:…I really emphasise the consent issues that it is 
their choice to engage with this or not and they can change their mind at 
any time so that they should not feel under any obligation.  I really heavily 
stress that because I don’t want people to feel at all pressured that they 
are not going to get a service unless they enter the trial and I say to them 
“It is absolutely your choice” and that’s part of my preamble you know just 
in terms of speaking to people about research. 
 
5.3.4 Health professional and recruiter equipoise 
This section reports themes and findings relating to the way in which recruiter and 
health professional equipoise influenced discussions of trial treatments with families. 
Interviews were not conducted with members of the Specialist CFS/ME team during 
the SMILE RCT, therefore these themes were developed from interviews with health 
professionals who were recruiting to or caring for patients following treatment 
pathways in the MAGENTA, FITNET-NHS and CONTRACT trials. 
 
Individual versus collective equipoise 
During interviews several health professionals reported a lack of individual equipoise 
in relation to their own personal views about the treatment pathways offered in the 
each of the trials. Other interviewees stated that they knew colleagues who did not 




Recruiter CF2:…Because we… all agreed and the team [agreed] to be in 
it, to be all in it. There are people who don’t necessarily agree with is it 
worth it, and is it okay to do it, and all those questions. 
 
During the MAGENTA trial lack of equipoise centred around not being able to 
introduce ‘prohibited’ elements of activity management. There was an assumption 
that outside the trial most patients would be treated using activity management 
techniques, which was a ‘standard’ less restrictive and more familiar approach: 
Health Professional FU:…If people don’t agree to MAGENTA then we do 
activity management... 
 
Health Professional MP:…I think it feels like the activity management has 
more content but only because that’s what I’m used to doing. It feels like 
maybe I’m a bit too restrictive when I’m doing Graded Exercise Therapy 
because I’m so aware of not saying anything cognitively-based. 
 
Health Professional MA:…Sometimes after my assessment I can tell 
which would be better for them so I have to keep ‘stuhm’ about that…it's 
very difficult if they're given Graded Exercise Therapy knowing that activity 
management will help them, that's very, very difficult. 
 
There were also suggestions that outside the ‘trial’ setting, (MAGENTA and FITNET-
NHS) health professionals used a mix of activity management and Graded Exercise 




Health professional MQ:…Our general treatment there is a sort of a 
smorgasbord approach where you can have a bit of exercise through it. 
You can have a bit of that and throw in a bit of CBT and whatever. And 
some of them [families] quite like that. I suspect many of the therapy team 
quite like the smorgasbord approach as well…because you obviously 
don’t know how people are going to respond to particular treatment until 
they’ve tried it.  
 
Rationale for the MAGENTA trial (focussing on a one treatment approach, see: 
Section 2.5.2) was discussed by only one member of the specialist CFS/ME team, in 
contrast to the more widely held team opinion that a mixture of the two treatment 
approaches was more beneficial for young people: 
Health Professional FK:…It is an awful lot of information to have 
altogether, [activity management and Graded Exercise Therapy] because 
it is every part of your life really. 
 
Graded Exercise Therapy was never discussed as a stand-alone treatment for 
CFS/ME outside the MAGENTA trial, and was always viewed as an additional ‘tool’: 
Health Professional FK:…So that’s the reason, sort of trying to split those 
two [activity management and Graded Exercise Therapy] was quite an 
issue to begin with because it was so different to what you’ve been 
doing… So there was a lot of concerns about ‘oh well am I giving the 
person the best’. You know shouldn’t they have activity management as 





There was also an awareness of online ‘activists’ influencing families’ decisions to 
participate in the MAGENTA trial, because of a negative campaign suggesting 
Graded Exercise Therapy was dangerous for those with CFS/ME: 
Health Professional FO:…My last few where they have turned down 
MAGENTA is because they wanted activity management, but that may be 
biased by the fact that the activists have been adversely affecting the 
impression of Graded Exercise Therapy. 
 
Team views in relation to the two treatments used in the FITNET-NHS trial became 
less polarised as the trial progressed: 
Recruiter F1:…Initially we thought that the two groups were quite different. 
But I think they're more even than I realised in their treatment of CFS. 
 
Health Professional FR:…But I might be biased ‘cause I’m doing the 
activity [management] [laughs]… I’ve definitely had preferences in 
MAGENTA but not really in FITNET. 
 
Many surgeons recruiting to the CONTRACT trial minimised the risk of surgery and 
anaesthesia. However, only a minority of surgeons reported a strong preference or 
‘bias’ for surgical treatment for appendicitis: 
Surgeon CE12:…Very rarely have I regretted operating… There have 
been several times in my career where I think, do you know, I should have 
done that earlier… I’m honestly not trying to make a case against the 





Most surgeons recognised that culturally, in the UK appendectomy is viewed as the 
standard and traditional approach to treat appendicitis which posed a challenge 
when introducing the trial to families:  
Recruiter CD20:…They [families] see surgery as the answer and not 
antibiotics, they don't see [antibiotics] as the answer because culturally 
[surgery] that's what was always done… So they're quite frightened to 
think that you're not… they think they've got some sort of ticking time 
bomb inside them, and it might burst and then terrible things are gonna 
happen… and I think sort of explaining that stuff to them is quite 
complicated and new. 
 
Some surgeons were surprised that families wanted ‘an alternative’ treatment for 
appendicitis: 
Surgeon CF5:…The most surprising thing was that there are families who 
are looking for an alternative treatment other than surgery. 
 
At the same time recruiters reported that there was ‘collective’ equipoise for the 
CONTRACT trial. Collectively each of the three recruiting teams felt that there was a 
question to be asked about the acceptability of antibiotic treatment for appendicitis, 
and the need for well conducted RCT research with a paediatric population. Some 
health professionals delivering RCT treatment on the wider CFS/ME team also 
reported commitment to the FITNET-NHS trial: 
Recruiter CF10:…I do really like it [the trial] and I really hope that it does 





Health Professional FT:…No, as I said, I’m really excited. I’m really 
committed to it as a trial and I just think it’s gonna be interesting to see 
what the results are. 
 
One surgeon presented antibiotic treatment as a “natural progression” in medicine, 
just as techniques change and improve, so do treatment methods: 
Surgeon CE18:…I found that it’s quite useful to say that we have changed 
the way we operate on appendicitis, or we’ve gone from an open 
appendicectomy to a laparoscopic appendicectomy and we now have an 
extra level of that, but we are comparing the two different treatments… I 
don’t call it conservative, I don’t call it anything. I call it antibiotic process, 
antibiotic treatment versus surgical treatment. 
 
Discussing uncertainty and equipoise: what would you do? 
In clinical practice health professionals may be used to reassuring families with their 
medical knowledge, thus reducing uncertainty in relation to treatment efficacy and 
outcome “you’re the expert”. In contrast, in a trial environment there is more emphasis 
on uncertainty, explaining why ‘randomisation’ is used, because of a lack of evidence-
base can be problematic for health professionals: 
Health Professional ME:…I think it’s interesting that when you talk about 
research… in effect you’re admitting to patients and families at the very 
outset that there are still things that we don’t have answers to and we 
don’t know what the effective treatments are. 
 
Health Professional MB:…Patients are coming to us for specialist advice. 




do? Well what do you think [own name]? You’re the expert’ you know, or 
‘You’re the one who supposed to know the answer to that question. We 
don’t know, you know, we don’t know what we’re doing, whether we’re 
going left or right. You must know what comes if you turn left, if you go left 
or right or whatever’… 
 
Some recruiters highlighted that despite uncertainty, a lack of evidence-base and the 
collective equipoise of the wider team, during the early stages of recruitment they 
found conveying equipoise problematic, potentially because they did not have 
personal equipoise at that point in time: 
Recruiter CE18… I was a little bit sceptical about it [the trial] because, you 
know, you always come in and think, okay, what would I say, you know, if 
someone came to me and said, okay, well, let’s give your kid antibiotics, I 
would say, well I don’t think so, I want the appendix out… So the first 
patient I contacted, it didn’t work out, and I didn’t even record the 
conversation which was a bit bad really, but it was quite clear that I didn’t 
go in full-heartedly and I didn’t convince the parents because I wasn’t 
convinced myself. 
 
At times parents asked recruiters, (and health professionals on wider clinical teams) 
what they would do, as a parent, if they were in their situation, or in terms of their 
professional experience. Some recruiters appeared to struggle with the uncertainty 
of using randomisation to allocate treatment and did not draw on trial rationale or 
state a position of personal or collective equipoise in response parents’ questions: 
Mum M103:..What would you advise her to do, not even thinking about all 




Recruiter 1:…I have literally only got the little pink piece of paper, with 
your address and your phone number, [laughs] I think if you feel, you 
obviously know yourself very well [patient name]… and you know [patient 
name] better… [mum’s name] if you feel, that she would particularly 
benefit from one or the other, and feel very strongly… then it’s probably 
better not to be in the study 
Recruitment consultation:MAGENTA activity management 15yrs Female 
 
Dad CE13:…What would you do? 
Recruiter CE8: …What would I do, really difficult question. Me personally, I 
mean, it’s really awkward, isn’t it? I can’t really answer that question. I 
mean I, I would always, the thing I would say about participating in a 
research study regardless of which arm you go into is that you’re 
monitored really closely. 
Recruitment consultation:CONTRACT Antibiotics 5yrs Male 
[Treatment failure - revert to surgery.] 
 
Health Professional MA:…They quite often say to me, what would be best 
for me, umm, and I say well I can't answer that, because that will mess up 
the results and make you bias. But that has come up quite a bit. ‘What if I 
get the activity management and I want Graded Exercise Therapy?’  
 
Five recruiters and one research nurse discussed whether they would consent to 
their child’s involvement in the CONTRACT trial, (during recruitment consultations 
and/or at interview) all but one recruiter stated they would. Only one recruiter 




consultation, highlighting that there was uncertainty “we don’t know what’s the right 
thing to do”: 
Dad CD21:…So being a surgeon and mother, what would you do then? 
Recruiter CD9: …Good question.  Erm, I think it’s really important that we 
answer these questions, you know, because we don’t know what’s the 
right thing to do…I’m a believer in research and I think that, you know, the 
more people we have in the study, the better it is.  
Recruitment consultation:CONTRACT Antibiotics 5yrs Male 
[Withdrew from antibiotics as felt child was getting worse.] 
 
Research nurse CE1:…Having two young kids myself I did wonder would 
I take part in the study, it’s always one of the first things that, would I do 
that with my children?  Erm, and yes, I probably would. 
 
Recruiter CE7:…So I think it’s always a very good test for a trial if you, if 
you’re on the battle line thinking, if it was my child I’m not sure I’d be up 
for this but, you know, I genuinely think I would be. 
 
Questioning the eligibility criteria 
Those perceived to be at the extreme end of the trial eligibility criteria (severely 
affected) were problematic for those recruiting to the CONTRACT trial. In these 
cases perforation was ‘suspected’ but not clearly confirmed, “the only way to know 
for sure was to operate” [Recruiter CE7]. Some families were considered eligible for 




Recruiter CD5:…Cause, here’s a one of the other challenges… one of the 
other things I find difficult for some patients is picking the ones who are 
simple and not perforated, and there are at least one or two where we’ve 
not judged it quite right. In retrospect, at the time it felt like the right 
decision, but in retrospect we haven’t… 
 
Recruiter CE7:…So that’s something I think we would try and redefine or 
define better. [eligibility criteria] I think there was always a tendency to 
slightly – especially early on, I want to say well I think they might 
perforated, we won’t bother, rather than...I think the default early on was 
more, it’s extra work so let’s be cautious and let’s not put them in… 
 
One patient was discussed as ‘mildly affected’ and this was challenging because 
these patients would ‘routinely’ undergo surgery outside the trial, and in this instance 
the family had a preference for antibiotic treatment (Consent to trial despite 
preference for treatment): 
Recruiter CD9:…Yeah. Well I was, he’s, like I said to you, he, he does 
show signs of appendicitis. He’s not completely fine… I think this is a 
difficult situation, because it’s not straightforward. [Child was not severely 
affected]. 
 
Those introducing the MAGENTA RCT sometimes decided not to introduce the RCT 
because of ‘softer’ eligibility issues, or less severe co-morbid conditions that didn’t 
meet the exclusion criteria: 
Health Professional MO:…If you looked at it on paper you’d probably say 
she is eligible but actually taking all those sort of softer things into 




over into saying “Let’s do the – let’s do the…” you know, it was hard 
enough doing the consultation without adding that on to the mix really… 
 
Health Professional ME:…My only real issue in some of it, is that the 
research criteria is quite restrictive…a lot of them do have a lot of high 
anxiety, and you can’t… I can’t often at an initial consultation know how 
much is Chronic Fatigue….and people who have multiple other stuff, um I 
know we probably should be recruiting them but you know someone has 
Asperger's chaotic lifestyle all over the place, whatever and I think “Oh.” 
 
In one case, the eligibility of a young person who had already been recruited was 
questioned by a treating colleague going forward: 
Recruiter F10:…She got the activity management arm and then the 
clinician who picked her up after the first Skype session… stated I don’t 
think she is appropriate for research because she’s so severe this isn’t 
right. Ah like should I not have recruited her but then there’s no... The 
exclusion criteria don’t mention severity in any way. 
 
Discontinued treatment, treatment failure and recurrence 
Cases of ‘treatment failure’ in the CONTRACT trial, when antibiotics either failed to 
improve symptoms during the inpatient stay, or when young people were discharged 
because they had shown improvement but experienced a ‘recurrence’ of symptoms 
and were re-admitted to hospital, were discussed as problematic by health 
professionals at interview: 
Recruiter CF8:…I felt really upset. Um, I felt, I felt a little guilty that I’d 




they actually ended up having a whole second hospital admission with 
prolonged antibiotics. And then having to come back again for the 
operation that he didn’t want in the first place. 
 
Some treatment failure was not perceived to be ‘true’ failure but more patient or 
parent choice to opt for surgery: 
Recruiter CD5: …I think if you get the right patient, if you get the nice and 
simple ones.  The ones that we’ve had fail, I’ve looked into those quite 
closely, because we had five fail and it felt like a lot… the first one was the 
boy that I mentioned earlier, who probably just was getting bored of sitting 
there on antibiotics and was wanting something exciting like an operation. 
Did it really fail in him?  No, I don’t think it did... 
 
There was also a perception that cases of treatment failure had a negative effect on 
the motivation and confidence of the wider team: 
Recruiter CF11:…I had one of my consultant colleagues who was initially 
happy to, um, recruit his patients into the study, he was the one who saw 
this patient after, [treatment failure] so he’s not wanting to be involved 
now…So that certainly has affected his equipoise.   And I think, you know, 
some of the registrars I imagine might feel the same way. 
 
Research nurse CF10:…They [ward nurses] hate it. [the CONTRACT trial] 
she’s like, ‘oh, God’, sort of, you know, that sort of reaction… it doesn’t 
work, it doesn’t work, you know. That’s what she said. … really surprised 
me because that was the first reaction I received like that and, to be fair, 
not many of our patients had to change treatment… Perhaps they 
remembered, the last boy that…he had to go into theatre because he got 




An early case of treatment failure at one site was highlighted as affecting team 
equipoise. This site did not record any recruitment consultations or recruit any 
eligible participants for three months after this case, despite five patients being 
screened as eligible for the trial: 
Recruiter CF8:...Failing it that has put people [on the team] off actually….It 
was a bit of a disaster…It’s affecting people’s, what is it, equity. 
Researcher 2: …Equipoise. 
Recruiter CF8:…Equipoise…definitely. 
 
One family in the MAGENTA trial felt their treating health professional had facilitated 
the decision to cross-over to the opposite treatment group: 
Young person M29:…Well I suppose I was very eager to sort of start 
doing a bit more exercise ‘cause we completely cut out [exercise] on the 
activity management…they [health professional] advised that we go on to 
the other one because that actually enabled me to do some. So that’s how 
we got on to it [Graded Exercise Therapy]. 
Interview:MAGENTA activity management 15yrs Male 
 
Health Professional MQ:…I think I had one young person who started to 
indicate quite strongly that… after a few months that they were wanting 
some guidance around the physical exercise and some GET guidance… I 
did talk to them, about the choice… went through the options with them 
and they chose to withdraw and to have the GET guidance. So black mark 




5.4 The impact of treatment preference on recruitment and 
retention in four paediatric RCTs   
5.4.1 Recruitment: Preference and reasons for trial decline 
A full breakdown of all recruitment figures and CONSORT diagrams for each trial 
can be found in the Appendix 7. Preference for treatment was the main reason 
provided when families declined participation in three of the four paediatric RCTs 
(MAGENTA, FITNET-NHS and CONTRACT). 
 
Eligible young people (families) declining the four trials because of preferences for 
treatment ranged from 4-27%. Those declining due to preference, as a percentage of 
the overall number declining ranged from 15-60%, with the greatest number 
declining because of preference for surgical treatment in the CONTRACT feasibility 
RCT. The number of eligible families declining each RCT because of preference are 
displayed in Table 5:10, along with the time point at which families declined (e.g. 
initial eligibility assessment, or after the recruitment consultation). Reasons for 
decline were recorded by the health professionals on the wider clinical teams, or 
recruiters who assessed patients for eligibility. Fourteen families who declined 
participation went on to take part in interviews during the MAGENTA and 











Total eligible young 
people declined:                 
All reasons                          
N (%)
Total eligible young 
people declined: 
Preference                                      
N (%)
Total declined by 
time point: 
Preference                   
N
Time point of decline
Reason for decline                                   
(preference)
Breakdown 
declined                   
by reason 
No to group work 2
Child wants to do Lightning Process 1
No to group work 4
Mum interested in Lightning Process but child 
did not want to do the course 2
Child wants specialist medical care 1
Lightning Process would impact Specialist 
Medical Care 1
Child wants to do Lightning Process 1
23 (14%) 6 First clinical assessment
Preference for treatment / didn't like the idea of 
randomisation
6
Would like Graded Exercise Therapy 3
Unwilling to use Graded Exercise Therapy 9
Would like Activity Management 5
Unwilling to use Activity Management 2
Would like both: Graded Exercise Therapy & 
Activity Management
2
11 (7%) 7 Referral Preference for face-to-face appointment 7
Preference for face-to-face appointment 10
Unwilling to use Skype 2
Unwilling to use online treatment 1
Preference for face-to-face appointment 7
Unwilling to use Skype 1
CONTRACT 131 58 (44%)
35 (27%)                                         
(60% of those who declined)       
35 When recruiter made contact Preference for surgery	 35
FITNET-NHS 148
28 (19%)                                           
(58% of those who declined)
             First phone call              13







21 When recruiter made contact
161
When recruiter made contact
SMILE
58 (36%)
12 (4%)                                           
(15% of those who declined)       
First clinical assessment49 (16%)
33 (11%)
27  (17%)                                           





Twelve eligible young people declining the trial because of a stated preference for 
treatment (4%). The main reason for refusal during the SMILE trial was ‘not 
interested’ at the end of the initial assessment appointment, (n = 35, 71% of those 
who declined at the end of the initial assessment). ‘Too much at the moment’ was 
provided as a reason by eight families (16%), who had provided consent to contact 
details but declined when recruiters made contact. It was not possible to establish 
whether these young people (or their parents) were ‘not interested’ because they 
had a preference for treatment outside of the trial i.e., for Specialist Medical Care, or 
they did not wish to participate in the Lightning Process course because they felt that 
was ‘too much’. Alternatively, they may not have been interested in participating in 
research more generally. These reasons were provided by families but there may 
also have been some degree of ‘interpretation’ by health professionals or recruiters 
on the SMILE research team. 
 
One-hundred and twenty-five (48%) of the consent to contact forms given out to 
young people at the initial clinical appointment were not returned, (via post or at the 
next follow-up appointment) so the research team could not make contact with these 
families. It was not possible to establish why these young people (or their parents) 
did not wish to engage with the RCT, and potentially some of them may have had 
preferences for treatment. The number of young people who returned consent to 
contact forms but declined due to preference when the research team contacted 
them was nine (27%). When contact was made by the research team more varied 
and detailed reasons for trial decline were recorded than those detailed by the 




treatment’. Data obtained from recordings of first clinical assessment as part of the 
SMILE RCT (not presented in this thesis) suggested that some health professionals 
felt it was too burdensome for young people to complete the consent to contact 




Twenty-seven eligible young people declining the MAGENTA trial because of a 
stated preference for treatment (17%). To ensure as many families as possible 
received information about MAGENTA, the health professional who conducted the 
initial clinical appointment gave the family a brief verbal introduction to the trial and 
sought consent for further contact, (a recruitment consultation). Only 23 families 
declined further contact (14%). Nearly half of families who declined the MAGENTA 
trial at the end of the initial assessment appointment were recorded as ‘reason 
unknown’, (n = 11, 48%). In contrast, only three families who declined when the 
research team made contact (5%) were recorded as ‘reason unknown’. 
 
FITNET-NHS 
Twenty-eight eligible young people declining the trial because of a stated preference 
for treatment (19%). Preference for a face-to-face appointment with the specialist 
CFS/ME service outside the RCT was the most common reason for families 
declining to participate in the FITNET-NHS trial at all time points (referral, first phone 
call and eligibility assessment). Families could ‘request’ a face-to-face appointment, 




funding from the families local NHS trust, and their ability/willingness to travel long 
distances to an appointment. Three did not want skype appointments and one parent 
was not comfortable using online treatment. Neither of these treatment approaches 
(skype appointments with the specialist service or online FITNET-NHS modules) 
were available to patients outside of the trial.  
 
CONTRACT 
Thirty-five eligible young people/parents declined the CONTRACT trial because of a 
stated preference for treatment (27%). Only three reason codes were used to 
categorise all 58 declining families (see: CONSORT diagram Appendix 7) and 
preference was the main reason reported for trial refusal (by 60% of those who 
declined). After nine months of recruitment I analysed whether the rate of families 
declining participation was similar across CONTRACT sites, or whether families in 
one site were consistently declining more, and/or for a specific reason e.g., ‘surgical 
treatment preference’. The rates of decline were similar across sites when analysed 
against the percentage of families approached. However, site D consistently used 
the reason, ‘preference for surgery’ more than sites E & F, where conversely the 
reason ‘did not want to take part in research’ was more frequently used (see: 
Appendix 8, CONTRACT: Reasons for decline by site at nine months) All families 
were approached shortly after a diagnosis of acute appendicitis had been made by a 
treating surgeon. Informed consent and randomisation happened within four hours of 
the recruitment consultation. A reason was provided/assigned for all families who did 




Consent to trial despite preference for treatment 
There were instances where families consented to trial involvement, despite 
discussing preference during the recruitment consultation. This was apparent in the 
SMILE and MAGENTA trials, although during the SMILE trial many families 
expressed these preferences more overtly after randomisation, when they were 
given the allocated trial group (see: Section 5.3.1: How and when preferences are 
expressed). Analysis of recruitment consultations from the MAGENTA trial 
suggested parents or young people felt ‘reassured’ about their non-preferred 
treatment before randomisation, when recruiters explored preference (e.g. “Do you 
understand the difference between the two groups?”). Recruiters reassured families 
that the graded exercise pathway did not demand high levels of exercise, “with 
Graded Exercise Therapy people have been a bit concerned with the word 
exercise… it’s the name of the treatment rather than a description of what it actually 
is” (see: Section 5.3.3: Understanding how recruiters’ responded to preference). 
However, interview data suggested some families still had some reservations about 
their non-preferred treatment group despite having consented to the trial: 
Mum M72:…Okay, that’s the thing that worries me, because at the 
moment he doesn’t get any exercise…I was scared it was going to get 
him moving too much… Worth going for it, we’ve got nothing to lose, and 
it’s helping others. 
Recruitment consultation:MAGENTA activity management 10yrs Male 
 
Mum M72:…I would have been a bit scared about what he would’ve been 
made to do [in GET group] because I don’t know what he would’ve been 
made to do… I’m sure it would have been tailored more specifically so in 




I was asked I thought ‘Oh god I hope we get the you know the activity 
management one rather than the exercise one’ because I was a bit 
‘aaahhhh’. 
Interview: MAGENTA activity management 10yrs Male 
 
During recruitment to MAGENTA it was apparent that families valued the opportunity 
to help others in the future (see: 5.3.2 Reasons for preference – Altruism). Both 
treatments were available outside the RCT but families still wanted to participate in 
the trial despite their preferences for treatment: 
Mum M23:…I knew which one I wanted him to go on, if that makes sense.  
And we were just lucky and he was randomised on that one anyway… 
With leukaemia treatment everybody’s on a trial… and those trials benefit 
people who are getting treatment years and years down the road.... I think 
research studies are worth their weight in gold.   
Interview: MAGENTA activity management 12yrs Male 
[Only mum interviewed.] 
 
In contrast, families eligible for FITNET-NHS could not access either treatment 
outside the trial without travelling long distances for face-to-face appointments. 
Fewer FITNET-NHS families expressed strong preferences for treatment before 
randomisation, and when preferences were discussed the family usually followed 
with a discussion about the fact that they would be happy to accept either treatment 
group because they wanted specialist advice. Families were more open about their 




Mum F1:…Well I’m very pro CBT because, I mean I’m a counsellor 
anyway….obviously we are open to trying both, because, both could 
help…I mean when I first heard of it, in fairness my thoughts were, 
hopefully we will get into the CBT part because I think that could be really 
helpful… but if we don’t, we don’t. We will, [patient name] will give it a go. 
Recruitment consultation:FITNET-NHS Skype activity management 14yrs 
Male 
 
It seems possible that preference for a particular intervention arm might affect 
participant (and parent) engagement with a trial as well as the intervention itself 
(particularly when it is a behavioural intervention). For example, a family randomised 
to the Specialist Medical Care plus Lightning Process group who decided not to 
attend the Lightning Process course, (and later withdrew from the trial) did not 
express preferences during the recruitment consultation but did so at interview post 
randomisation. This family did not return any outcome measures during the RCT. 
Also, the family raised some concerns about the group work involved in the Lightning 
Process course during the recruitment consultation: 
Recruitment consultation SMILE: 
Mum S5:…[Patient name] did have one concern, group work and whether 
I could go, but [you] answered that, I’d be able to go with her and she’s a 
lot more happy about that aren’t you [all laugh] 
Recruiter S2:…I guess from the lack of questions you’re happy to go onto 
the next stage? 
Mum S5:…Definitely, yeah. 





Interview after randomisation SMILE: 
Mum S5:…We were tending to think…perhaps just the consultant care 
[Specialist Medical Care] Cos umm, going through the pack [PIL] it is quite 
overwhelming, quite intense… but obviously having someone talk through 
it… she was a bit worried about going into groups and things at the course 
but when [recruiter] said I could come [patient name] was quite happy. 
Specialist Medical Care plus Lightning Process 13yrs Female 
[Participant did not attend Lightning Process course and withdrew from 
trial.] 
 
One family from the CONTRACT trial withdrew consent immediately after 
randomisation because they wanted antibiotic treatment and their child was 
randomised to the surgical group. These parents had expressed a strong preference 
for antibiotic treatment before randomisation because they were told their son had 
“potentially very early appendicitis” but they were informed they could, “change their 
mind at any point” [Recruiter CD9] presumably because antibiotics were not routinely 
available outside the RCT. The point at which this family made their decision to 
participate was not audio-recorded (see: Sections 5.3.1 Missing conversations from 
the consultation process, and 5.3.4 Questioning the eligibility criteria): 
Mum CD14:…The only question that I’ve got is, if he does get chosen, [for 
surgical group] can we decline the operation at this point? 
Recruiter CD9: …So what happens when you go into the study is you kind 
of have to be happy to go with either option. You have to be happy to go 
with the surgery or antibiotics. Um, but if you… you can change your 




Mum CD14:...Right, okay. So if I say yeah now, and then I could change 
my mind. I’m just worried, like I said before, of putting him through an 
operation that he doesn’t really need. 
Recruitment consultation: CONTRACT Appendectomy 8yrs Male 




The impact of communication training on recruitment figures 
Training sessions that focused on best practice and included strategies to 
communicate equipoise and explore treatment preferences, were routinely 
conducted in the MAGENTA, FITNET-NHS and CONTRACT RCTs. Training and 
recruitment figures were not formally conducted or monitored during the SMILE trial. 
(see: Section 3.4.7). During the MAGENTA RCT, four training sessions were 
provided in months -1, 2, 6 and 12. Each session was associated with an increase in 
the percentage of eligible young people recruited the RCT. During month 11 of the 
MAGENTA trial the specialist paediatric CFS/ME service moved to a new site and 
recruitment decreased significantly during month 12. 
     = Communication training 
 
 
Figure 5:4 Training MAGENTA feasibility: Percentage recruited of those 





Figures 5:5 and 5:6 show overall increases in recruitment as the FITNET-NHS and 
CONTRACT trials progressed: 
 
Figure 5:5 Training FITNET-NHS Internal pilot: Percentage recruited of those 
eligible for the trial by month 
     = Communication training 
 
 
Figure 5:6 Training CONTRACT feasibility: Percentage recruited of those eligible 




Preference for treatment had a negative impact on recruitment, it was the main 
reason provided when families declined participation in three of the four paediatric 
RCTs (MAGENTA, FITNET-NHS and CONTRACT). When a trial was introduced, 
and participation declined, health professionals treating CFS/ME were reluctant to 
ask families if they were willing to provide a reason for their decline. This reluctance 
may have been compounded by the condition under investigation (CFS/ME), or the 
time at which information was provided (at the end of the first clinical appointment) 
and associated worries about burden. Those recruiting to the FITNET-NHS trial were 
more willing to explore reasons for trial decline with families via telephone during 
discussions about patient eligibility. 
 
The way in which ‘reasons codes’ for declining patients were used and recorded did 
not appear to be consistent across recruiting sites (CONTRACT RCT) or at different 
time points in the recruitment process e.g. consent to contact and consent to trial 
(SMILE and MAGENTA RCTs). More general reason codes such as ‘not interested’ 
and ‘too much’ did not provide enough information to establish whether preference 
for treatment or trial participation were an issue for families. 
 
Qualitative findings suggested that targeted training that focused on equipoise and 
exploring families’ treatment preferences, had beneficial effects on recruitment to the 
MAGENTA, FITNET-NHS and CONTRACT trials. There was no evidence of high 
numbers of participants withdrawing immediately post randomisation during each of 
the four trials. Feedback from families (via interview) suggested that they were happy 




rises in recruitment in each of the four trials cannot be solely attributed to the training 
programmes, patterns of improvement and increases in recruitment post training 
could be accounted for via alternative explanations. Regression to the mean [631] is 
a statistical phenomenon whereby a variable (e.g. recruitment to trial) may be 
extreme in one instance, (month) but is likely to be closer to the average on second 
measurement, or vice versa: ‘Any intervention aimed at a group or characteristic that 
is very different from the average will appear to be successful because of regression 
to the mean’. [632] [pg. 1083] Since regression to the mean is likely to occur in small, 
non-random samples, it must be considered that some of the more ‘extreme’ 
differences or improvements in recruitment post training could be accounted for by 
regression to the mean. 
 
Recruiters may have gained confidence and become more skilled at discussing the 
RCT as each of the trials progressed. As an RCT progresses recruiters are likely to 
become more familiar with the inclusion and eligibility criteria, trial materials, and 
other related trial information that they routinely verbally discuss with participants 
and family members. This might result in more succinct and successful 
communication strategies, resulting in more families consenting to RCT involvement. 
It could also be argued that ‘tips for recruitment’ documents kept locally accounted 
for patterns of improvement in recruiters’ ability to successfully recruit, not the 
structured training delivered by researchers at regular intervals throughout each 
RCT. However, the pattern of change (increasing after training and then reducing as 
the time since training increased) and consistency across trials, combined with the 





5.4.2 Retention: Preference and ongoing participation 
SMILE 
Fifteen participants (15%) in the SMILE RCT did not receive their allocated 
intervention as per protocol (n=12, 24% in the Specialist Medical Care plus Lightning 
Process group, and n=3, 6% in the Specialist Medical Care group). Three 
participants received specialist medical care and one day of the Lightning Process 
course (6%), and nine only received specialist medical care (18%). Two participants 
in the specialist medical care group paid to complete the Lightning Process course 
(4%). One participant (2%) did not receive any specialist medical care and paid to 
complete the Lightning Process course. 
 
Feedback from the mother of one young person who did not want to attend the 
Lightning Process course despite being randomised to that treatment group 
suggested their reason for non-attendance was partly related to the treatment 
approach: 
Mum S76:…he read the book and didn't like the approach, he felt it was 
brain washing 
Email feedback SMILE Specialist Medical Care plus Lightning Process 
15yrs Male 
 
This does not provide evidence for a preference between treatment groups. Neither 
parent or young person expressed a preference for treatment during their 
recruitment consultation, but the family did express some worries about the amount 




Although response to outcome measures has not been analysed in relation to 
retention in this thesis, it is worth noting that 81 participants (81%) completed the 
primary SMILE outcome (SF-36 Physical Function) at the six-month point in the trial.  
Fewer participants in the Specialist Medical Care group returned primary outcome 
measures at six months, which could indicate dissatisfaction with treatment. This 
should not be confused with having a specific ‘preference’ for one treatment group in 
comparison to another. Non-return of outcome measures could also be related to 
questionnaire burden or a variety of other factors. 
 
MAGENTA 
Six participants (43% of those who discontinued a trial intervention within six-months 
of randomisation, 8% of those randomised), gave preference as a reason for 
discontinuing their trial intervention (Table 5:11). Although the number of participants 
discontinuing treatment (for all reported reasons) was equal between intervention 
groups, the number discontinuing because of a reported preference for the opposite 
intervention was higher in the activity management group. Five participants (13%) in 
the activity management group discontinued treatment because they had a 
preference for Graded exercise Therapy. Only one participant in the Graded 
Exercise Therapy group discontinued their allocated intervention because they had a 
preference for activity management (3%). 
 
Although discontinued treatment does not provide evidence for a preference 
between intervention groups at trial outset, some families who had expressed a 




allocated (non-preferred) intervention. However, parent (and participant) preferences 
for treatment at the point they discontinued treatment, did not always appear to 
correspond with the preference they expressed during their recruitment consultation. 
Although family M70 stated ‘preference for other group’ as a reason for discontinued 
treatment, when given the participant’s allocation mum stated: “I actually feel better 
about that one, [15yr old female, randomised to activity management] than the other 
one [Graded Exercise Therapy]” This participant went on to discontinue treatment 
their parent appeared to prefer, or was at least satisfied with at trial outset. 
 
One family reported past experience of the intervention (in addition to preference) as 
a reason for discontinuing their allocated trial intervention: 
[Participant 28] started on the activity diary choice in the MAGENTA trial, 
but felt after a time that a year already of doing this had got her nowhere. 
[health professional] was supportive of her trying Graded Exercise 
Therapy, so [participant 28] left the trial. 
Email from mother 28: MAGENTA activity management 14yrs Female 
 
After six months of treatment (and the six-month primary outcome point) only one 
family in the activity management group (20% of those who discontinued a trial 
intervention) reported preference as their reason for discontinuation, (Table 5:12). 
However, It was explicitly stated in the parent and patient information leaflets that 
young people could “change treatment” at the six-month point if they chose to, (see: 
Appendix 4 Information leaflet for young people (12-17yrs) and Information leaflet for 
parents - ‘Are there any disadvantages to taking part in this study?’). Feedback after 




participants wishing to ‘swap’ treatments or continue with their allocated treatment ‘in 
the background’ whilst using elements of the ‘opposite’ trial treatment at the same 
time: 
[Participant 62] was not able to sustain Graded Exercise Therapy on a 
daily basis. She was therefore not making progress. As it has been 6 
months she wanted to swap [Email from health professional] 
 
Thirty-five participants were due to complete their six-month follow-up questionnaires 
during the first 12 months of the trial and 32 participants (91%) completed the six-




Table 5:11 MAGENTA feasibility trial: Participants who discontinued treatment within six months of randomisation 
 






























outside of the 
trial














AM 15 Female 0  ✓  ✓ Y Y
AM 16 Male 1  ✓  ✓ Y
AM 12 Female 1  ✓  ✓ Y Y
AM 14 Female 2  ✓  ✓ Y
AM 17 Female 2  ✓ Y Y
AM 16 Female 2  ✓  ✓ Y Y
AM 14 Male 3  ✓ Y
GET 16 Female 1  ✓ Y
GET 12 Female 1  ✓ Y
GET 12 Male 1  ✓ Y
GET 14 Female 1  ✓  ✓ Y Y
GET 16 Female 2  ✓ Y
GET 15 Female 3  ✓ Y Y





























outside of the 
trial














AM 17 Female 6  ✓ Y
AM 15 Male 7  ✓ N Y
AM 15 Male 9  ✓  ✓ Y Y
GET 10 Female 6  ✓ Y





Retention and follow-up rates were high during the internal pilot phase of the 
FITNET-NHS trial. Seven participants (8% of those randomised) discontinued their 
trial intervention: one at three-months, four at the six-month point and two after the 
six-month point. Six participants in the online CBT intervention group discontinued 
treatment (15%) and one discontinued skype activity management (2%). One (2%) 
of the participants in the online CBT group also withdrew from trial/research follow-
up. None of the participants who discontinued treatment gave preference as a 
reason, however two reported that they were unsatisfied with their treatment 
program and both were categorised as ‘deteriorating in allocated group’. Further 
notes on these family’s reasons for withdrawal stated that one family were, “not at all 
confident in the online CBT approach… she [participant] was quite sarcastic about 
the approach”. The other had found that, “symptoms worsening rather than 
improving, going to be offered face to face assessment”. Neither family continued to 
receive treatment from the Specialist Paediatric CFS/ME Service. There was no 
further qualitative interview data available from families who discontinued treatment. 
























































AM 15 Female 8  ✓
FITNET 16 Female 3 Y
FITNET 13 Male 6  ✓
FITNET 16 Female 6  ✓  ✓
FITNET 15 Female 6  ✓  ✓  ✓
FITNET 16 Female 6  ✓
FITNET 12 Female 9  ✓  ✓  ✓





One family declined treatment immediately after randomisation to the surgical 
intervention because they wanted antibiotic treatment (2% of those randomised). 
Eight participants in the non-operative arm received an appendicectomy due to 
treatment failure (14% of those randomised). It is not known to what extent decisions 
to discontinue non-operative treatment were initiated or facilitated by young people, 
parents, nurses or surgeons when participants switched to appendectomy. Neither is 
it clear whether family members or health professionals made the decision to treat 
those with recurrent appendicitis with an operation when they returned to the hospital 
post discharge (seven, 24% of participants randomised to the non-operative arm). 
Two young people who participated in interviews reported that they were 
successfully treated with further antibiotics when they returned to hospital with 
recurrent symptoms post discharge. Treatment of recurrence with antibiotics was 
only apparent at one of the three participating sites. 
 
The impact of treatment preference on retention in paediatric RCTs 
It is not possible to be certain that preferences formed prior to, or during recruitment 
consultations had an impact on retention. There are several reasons that make these 
analyses difficult, including the length of time from randomisation to discontinuation 
of treatment in the behavioural trials (SMILE, MAGENTA and FITNET-NHS). There 
are multiple additional factors that might influence retention (e.g. disease activity, 
interaction with health professionals, school or family issues, ongoing satisfaction 
with trial intervention and trial burden). In addition, the overall number of participants 





Discontinuation (of trial interventions and/or trial withdrawal) because of a reported 
preference for the opposite trial intervention was most apparent in the MAGENTA 
RCT, seven families (37% of those who discontinued a trial intervention) reporting 
this as a reason. However, families could provide multiple reasons, and trial burden 
was also reported by the same number of families (n=7, 37%). Only two families 
provided both preference for treatment and burden as reasons for discontinuation. 
The stated option of, ‘having the other treatment after six months’ in MAGENTA PILs 
may have influenced families’ decision-making and engagement in relation to 
continuing with their allocated intervention. 
 
No families reported preference for treatment when discontinuing interventions or 
withdrawing from the FITNET-NHS RCT. Trial context (e.g. the lack of an easily 
accessible local paediatric CFS/ME service for FITNET-NHS participants), may have 
increased families’ willingness to participate and engage with trial interventions. 
Although there was some qualitative evidence to suggest that preference for 
treatment resulted in families withdrawing post-randomisation (CONTRACT) and 
discontinuing treatment after reading about or receiving some of the allocated 
intervention (SMILE), these preferences at the time of discontinuation cannot be 
linked directly to preferences expressed during recruitment consultations. The extent 
to which preferences for treatment interact with and influence young people and their 





5.5 Chapter summary of findings 
This chapter explored the ways in which young people and parents’ preferences for 
treatment affected recruitment rates and trial participation in four paediatric RCTs: 
SMILE, MAGENTA, FITNET-NHS and CONTRACT. Exploration of how and when 
preferences were expressed found that expressions of preference occurred while 
families made decisions about taking part in research, when they reacted to the 
outcome of randomisation, and when they decided to discontinue treatment or 
withdraw from one of the RCTs. 
 
Parent preference often became more apparent immediately post-randomisation, 
when preferences were more overtly expressed by parents in response to 
information about their child’s intervention group allocation. This was more apparent 
during the SMILE and FITNET-NHS trials. Strength or conviction with which 
preference for treatment was expressed (before or after randomisation) changed 
depending on whether similar treatment was accessible outside the trial - preference 
discussions were more apparent before randomisation during the MAGENTA RCT 
where similar interventions were also accessible outside the trial. 
 
Young people were less likely than their parents to express preferences for 
treatment during recruitment consultations, with parents also expressing stronger 
preferences than young people for specific interventions. At times, the preferences of 
young people and their parents differed, as did preferences between parents when 




Recruitment conversations were split roughly into four separate stages: an initial 
mention, main consultation, obtaining consent and randomisation. Rarely were all 
conversations recorded and available for analyses. However, the importance of 
recording as many interactions with families as possible (particularly families’ 
responses to randomisation) became apparent when seeking to understand 
preferences for treatment, and which family member(s), (young person, mum or dad) 
had preferences. 
 
During the ‘main’ recruitment consultation, young people and parents often 
discussed preferences for treatment in relation to motivations or reservations about 
taking part in the trial. However, discussions about preference were not specific to 
one ‘area’ of the consultation (e.g. when discussing treatment) and were also 
apparent during discussions about randomisation or recovery. Recovery was the 
main priority for families (young people and parents) but they also frequently 
discussed altruism as a motivation for taking part in the trials. 
 
Many families consented to involvement in paediatric RCTs despite having 
preferences for a specific intervention group, post-randomisation interviews 
confirmed that some families were not in equipoise, but still decided to participate. 
Preferences for the ‘active’ or ‘control’ treatment groups were apparent depending on 
trial context, with ‘new’ or ‘experimental’ treatments more likely to be perceived as 
potentially harmful by CONTRACT and MAGENTA trial parents, as opposed to more 





Data relating to preference for treatment and its impact on participant flow, 
recruitment rates, and retention were reported in Section 5.4. The number of eligible 
families declining participation in these four paediatric trials because of preferences 
(at recruitment) ranged from 4-27% (see: Table 5.10). Although preference for 
treatment was a consistent reason for trial decline, all four trials were able to 
successfully recruit participants. The three paediatric CFS/ME trials successfully 
converted to full trial status, and the CONTRACT feasibility RCT met the HTA target 
of recruiting between 52-65 patients over a 12-month period, (57 participants were 
randomised). Preference was reported when families declined treatment immediately 
after randomisation, (CONTRACT) and discontinued and crossed between 
intervention groups (SMILE and MAGENTA). However, figures relating to preference 
and discontinued trial interventions / trial withdrawal were problematic and will be 
discussed further in Chapter 6. 
 
Health professionals initially responded to preferences by accepting them at face 
value, some of the language they used to communicate trial rationale and treatments 
did not convey equipoise between treatment groups, and potentially reinforced 
families’ preferences. Training for health professionals included tips on how to 
explore preferences for treatment, offer balanced information about intervention 
groups, and how to communicate and discuss trial rationale, uncertainty and 
randomisation. This training contributed to an improvement in observed recruitment 





Some recruiters and health professionals providing ongoing care may have found it 
difficult to explore families’ preferences and highlight the equivalence of trial 
interventions because they reported a lack of personal equipoise about one 
intervention offered in the trial. Periodic training for recruiters that focused on 
communicating equipoise and exploring preference provided examples of the way in 
which training influenced and changed communication practices in each RCT and 
appeared to have a positive effect on recruitment figures. There were more 
examples of recruiters’ using open questions and exploring families’ preferences for 
treatment after training. This included exploration of reasons for preference, offering 
balanced information about treatment groups and changing language which might 
convey recruiter biases for treatment or reinforce existing family preferences. Health 







6.1 Overview of Chapter 
This final chapter includes a comprehensive review of the findings reported in 
Chapter 5 and acts as a starting point for further exploration of treatment preference 
and equipoise in paediatric RCTs. I will reflect on the qualitative methods used and 
discuss findings in the context of existing literature. A discussion of findings from the 
systematic literature review and qualitative synthesis can be found in Chapter 4, 
Section 4.4. Finally, this chapter highlights the strengths, and limitations of my 
research, and implications for future research in this area.  
 
 
6.2 Context of findings 
6.2.1 Using qualitative research methods in RCTs 
Only 12% of trials reported the use of embedded qualitative methods to improve 
recruitment between 2008 and 2010. [633] This figure is likely to be smaller in 
paediatric trials. It is important to improve the design and conduct of trials which 
recruit young people and children by ensuring that recruitment processes are 
transparent. [175] As discussed in Chapter One, recruitment problems can delay or 
prevent trial completion with adult [124, 179-187, 634-637] and paediatric trial 
populations. [188, 217, 219, 220, 587, 638] The use of qualitative research methods 
in RCTs - particularly in relation to improving rates of recruitment and retention - 




Elements of the ‘QRI approach’ (see: Section 2.2) [408] were applied in the four 
paediatric trials described in this thesis, to explore and understand treatment 
preferences and promote good communication practices. I have demonstrated that 
these embedded qualitative methods (e.g. tracking participant flow, analyses of 
audio-recorded recruitment consultations and interview data to understand 
preference, and individualised trial training to improve communication about 
preference related issues), can be used effectively in varied paediatric RCT settings 
(with acute and long-term paediatric health conditions). Qualitative findings reported 
in the current thesis were observed alongside increases in recruitment after training 
sessions that incorporated suggestions on how to explore expressed preferences 
and convey equipoise. (see: Chapter 5, Figures 5:4-5:6). [641, 642] 
 
6.2.2 The impact of preference on trial recruitment 
The data I collected for this thesis has identified that recruitment to paediatric RCTs 
is impacted by parents’ and young peoples’ preferences for treatment (see: Sections 
4.2-4.3 and 5.3-5.4). This is consistent with findings from adult trials, whereby 
preference for treatment had been shown to influence recruitment. [62, 279, 287-
289, 292, 540] The ProtecT study [98, 123, 404, 405, 643] found that patients’ 
preferences for treatment diminished after targeted discussion and exploration of 
preference with a recruiter. [247, 405, 407, 409] The composition of paediatric trial 
samples could be affected if families decline trials because of preference for 
treatment, particularly if families of young people with strong preferences differ from 




may have been ill for longer). [67, 644, 645] Slow recruitment can also result in the 
need for trial extension [66, 604] or closure. [584, 600] 
 
It was previously not clear whether preference was consistently cited as a reason for 
trial decline with a paediatric population, and in what way preference impacted 
recruitment. Past research has reported a number of factors which might act as 
facilitators or barriers to paediatric RCT participation. [93, 94, 205, 317, 319, 328, 
365, 622] The way in which preference for treatment impacts paediatric RCTs is 
complex, i.e. those with preferences do not simply decline trial participation. These 
findings are consistent with systematic reviews investigating the effects of preference 
on retention in RCTs. [213, 279, 289] 
 
Findings from this thesis indicated that treatment preference was discussed in the 
context of perceived risks and benefit, (see: Sections 4.2-4.3 and 5.3-5.4) therefore 
highlighting the importance of preference consideration in recruitment consultations 
at all points in the conversation. An honest discussion of RCT risks and benefits has 
been cited in previous research as important to parents considering RCT 
participation for their child. [214, 224, 229-232] Mis-perceptions of risk also highlight 
the way in which perception of trial interventions and preference issues relate to 
research integrity, parents might incorrectly assume being involved in a trial poses 





My findings also support existing literature which has linked preferences for 
treatment to perceptions of trial intervention groups being ‘control’ or ‘experimental’ 
(see: Active versus Control and Experimental versus Standard treatment). The 
potential for perceptions of treatment to act as barriers or facilitators to trial 
participation has been highlighted in past literature as important when discussing trial 
participation. [74, 646, 647] Parents have raised concern around the type of 
interventions offered in RCTs, e.g. an intervention which is a change from ‘current’ or 
‘standard’ recommended practice, [225] and factors associated with perceived 
disparity between intervention groups linked to a lack of equipoise. [227] Preferences 
for the ‘active’ or ‘control’ intervention differed depending on trial context. Trials with 
a ‘normal’ or ‘control’ intervention (surgery) were preferred in the acute care context. 
Trying something ‘new’ (Graded Exercise Therapy) was viewed negatively by some 
parents concerned about potential harm during the MAGENTA RCT. Impact on wider 
family circumstances, (e.g. siblings, planned activities and holidays) and close family 
members past experience of treatment (e.g. negative experiences of appendicitis) 
were important factors discussed by families who declined the CONTRACT RCT. 
However, the extent to which wider family members facilitate or inhibit RCT 
participation remains unclear. [234-236] 
 
6.2.3 The impact of preferences on trial retention 
I have identified that parents and young people entered trials despite their 
preference for treatment. If families enter a trial despite having preferences for 
treatment, those randomised to a non-preferred intervention group may be less 




to bias. [644] Data collected for this thesis also identified that continued participation 
in paediatric RCTs was impacted by parents’ and young peoples’ preferences for 
treatment (see: Retention: Preference and ongoing participation). However, not all of 
those who expressed preferences before randomisation went on to discontinue trial 
interventions or withdraw from trial outcomes, particularly in the FITNET-NHS trial. 
 
While it may seem obvious that treatment preference may influence retention 
(particularly with those receiving a long-term intervention), the evidence relating to 
the way in which preferences affect continued trial participation and satisfaction with 
treatment is not clear. [279, 289, 292, 648-653] Collaboration between parent and 
child has been recognised as a crucial facilitating factor in terms of retention in trials 
which investigate long-term conditions, [270, 353-356] therefore the influence of 
parents in terms of their preferences for trial interventions should also be considered 
as a trial proceeds, particularly when parents are also responsible for completing 
outcome measures (e.g. measures of health economic impact). 
 
The role of health professionals’ ongoing equipoise during the delivery of long-term 
interventions, and the extent to which this impacted families’ decisions to discontinue 
RCT interventions, was also unclear (particularly during the MAGNETA RCT). Long-
term health conditions such as CFS/ME and diabetes involve RCT interventions 
which require buy-in, motivation and effort, or a change in behaviour from those 
participating. [78, 359, 360] Not only does this require commitment from participants, 
it also requires commitment from the parents of participants, as well as the health 




A recent article found that few PILs (n = 6, 12%) informed participants that they 
would be asked (if willing) to provide a reason if they decided to withdraw from the 
trial. RCT documents (consent forms) rarely included information about the 
importance of equipoise (n = 3, 6%) or the difference between ‘discontinuing trial 
interventions’ and ‘withdrawing’ from the trial (completion of outcome measures). 
[654] If this information was presented in an accessible format in written PILs, health 
professionals approaching participants and families might be more willing to verbally 
explore reasons for decline, discontinued treatment and/or withdrawal with potential 
participants and their families (see: Section: 5.4.1: SMILE and Section 5.4.2 
MAGENTA). 
 
6.2.4 The impact of preference on trial design and interventions 
Trial dimensions which may impact treatment preference in paediatric RCTs include: 
a) trials requiring commitment to an on-going intervention or behavioural programme, 
versus those that have an immediate or short-term intervention, such as non-
behavioural trials, b) trials that can be blinded (versus those that are open) and c) 
trials offering treatment that can be obtained outside the trial compared to those 
where a new treatment can only be obtained within the trial. 
 
Trials requiring commitment to an on-going intervention or behavioural 
programme  
RCTs requiring commitment to an on-going intervention or behavioural programme 




have an ongoing effect on the retention of participants. In circumstances where 
families (young people and/or parents) do not receive a preferred treatment, 
motivation, adherence and commitment to the allocated non-preferred intervention, 
and completion of trial questionnaires may be more challenging for them to engage 
with over the extended period needed for such an intervention to demonstrate 
effective changes in behaviour (e.g. when the primary outcome point is six months). 
Thus, preference effects were more pertinent to the CFS/ME trials included in this 
thesis. The SMILE, MAGENTA and FITNET-NHS RCTs all required behaviour 
change and a significant level of physical and/or mental commitment and input from 
young people (and their parents) post-randomisation, for an extended period of time 
(12 months). This issue can be generalised to other paediatric (and adult) trials 
exploring interventions for other long-term conditions, (such as asthma, diabetes and 
obesity) where motivation and commitment from young people and their parent(s) is 
of paramount importance to intervention adherence and completion of RCT outcome 
measures. [237, 526, 655] 
 
Blinded versus open RCTs 
Although open (unblinded) trials are considered ‘at risk’ of bias, [79] and the 
possibility of receiving a non-preferred treatment can result in some eligible patients 
refusing these RCTs, [292] open RCTs typically have higher consent rates as 
patients like to know which treatment they will receive. [80-82, 213] Past research 
into paediatric RCTs has shown that when study groups are perceived as very 
different in terms of effectiveness (e.g. placebo versus active treatment) decision-




when a child is seriously ill. [97, 218, 227, 233] Open RCTs investigating markedly 
different treatments taking place soon after randomisation, (e.g. surgical versus non-
surgical interventions are also susceptible to preference effects at the point of 
recruitment. [84] 
 
Preferences for treatment can affect adherence to treatment groups post-
randomisation in open RCTs. [62, 287-289] If a patient is not in equipoise about 
treatments offered in a trial but still opts to participate, they will be assigned their 
preferred or non-preferred treatment. This is an issue because the direction in which 
preference effects influence commitment and adherence to treatment interventions in 
RCTs is not straight forward. As might be expected, allocation of a non-preferred 
treatment can result in disappointment and resentful demoralisation in some 
instances. [62, 292] However, participants who receive their non-preferred trial group 
have been found to be more likely to return outcome measures in adult trials. [289] 
Varied post-randomisation preference effects should not be overlooked in open 
paediatric RCTs, where findings have shown non-preferred trial arms have either; 
been accepted without having a negative effect on retention, [656] or become the 
preferred treatment after experience of the intervention, despite a preference for the 
opposing treatment approach prior to randomisation. [291] 
 
All of the trials analysed in this thesis were open because blinding was not feasible. 
Blinding is particularly difficult for any RCT which compares and evaluates 
behavioural interventions where participants are asked to follow a specific 




under investigation had significant problems recruiting the specified number of 
participants during feasibility and internal pilot phases. [204, 657-659] However, 27% 
of eligible families declined the CONTRACT RCT because of preference for a 
surgical intervention, which lends weight to finding that markedly different surgical 
versus non-surgical intervention RCTs can be susceptible to preference effects at 
the point of recruitment. [84] 
 
Availability of treatment outside an RCT 
The availability of treatment outside an RCT can also have an impact upon the 
effects of preference (see: Ethical issues and participation in paediatric RCTs). 
Concerns around the type of treatment offered in RCTs, e.g. a treatment that is not 
familiar or is a change from ‘current’ recommended or accepted treatment, have 
been observed as a barrier to recruitment in previous research. [225] However, 
young people and their parents have reported new or free access to treatment as a 
positive reason for participating in RCTs, particularly for those on low incomes or in 
countries where healthcare is not free at the point of need. [93, 120] When an 
attractive, costly or new intervention is not yet available outside an RCT, (e.g. the 
Lightning Process, or online treatment for CFS/ME, antibiotic treatment for 
appendicitis) families reported that they had ‘nothing to lose’ by participating in the 
RCT if they wanted the routinely ‘unavailable’ treatment. However, many then felt 
disappointed when their child was not allocated the preferred unavailable treatment. 
A high proportion of families eligible for the MAGENTA RCT declined because they 
perceived ‘more as better’ i.e. their child could receive ‘a bit of both’, (activity 




At times during interviews health professionals also expressed the view that ‘more’ 
or ‘both’ activity management and GET was preferred. Issues relating to the rationale 
for including specified treatment pathways in an RCT should be discussed openly 
with clinical teams prior to commencing a trial in order to reinforce team equipoise 
going forward, especially if treatments continue for a long period of time post-
randomisation. [197, 457] Little is known about the way in which preference impacts 
intervention adherence and the completion of outcome measures in regard to 
whether or not treatment is available outside an RCT. [93, 120, 270, 309, 312] 
 
6.2.5 Equipoise, uncertainty and competing moral demands 
Findings reported in this thesis (Chapter 5 - Understanding how recruiters’ respond 
to treatment preferences in paediatric trials) indicate that prior to training descriptions 
of trial interventions were unbalanced. Recruiters referred to one intervention as the 
‘gold standard’ (surgery) or ‘the best’ (face-to-face treatment for CFS/ME, FITNET-
NHS). Since RCT recruitment is mainly carried out by those who also have day-to-
day clinical responsibilities, this has important implications - health professionals 
taking on the additional role of ‘recruiter’ may not consciously view themselves as 
‘researchers’ when they participate in trial related activities. [260-262] Interview 
feedback highlighted that health professionals often accept the concept of ‘collective’ 
equipoise, that there is a lack of current evidence-base, and that there is a need for 
randomisation to ensure methodological rigour. However, after randomisation in the 
MAGENTA and FITNET-NHS trials some recruiters also disclosed ‘personal 
opinions’ based on intuition relating to allocated intervention (e.g. I think you’ll be 
well suited to that one). During CFS/ME trials some health professionals expressed 




more regular basis (e.g. surgery or activity management). This is consistent with 
descriptions of equipoise in the adult literature, where a lack of personal equipoise at 
recruitment (expressed inadvertently via personal or expert opinion) can undermine 
discussions of collective equipoise. [177, 262, 660, 661] 
 
Fluctuation in personal and collective (clinical) equipoise poses a challenge in trials 
research. Levels of equipoise will change over time at an individual and group level 
as trials progress. [255] Health professionals recruiting to CFS/ME trials reported 
occasions where they felt that they knew patients ‘needed’ a certain approach (e.g. 
Graded Exercise Therapy or activity management) at a specific point in time, 
drawing on knowledge from past experience and specialist expertise. During the 
CONTRACT trial an incident of antibiotic ‘treatment failure’ early during recruitment 
resulted in the loss of equipoise for some members at one recruiting site. This 
highlights the relevance of Gifford’s ‘sliding scale’ approach to equipoise, [255] 
where young people, parents and health professionals may be ‘in equipoise’ to 
differing degrees and at different points in time. Lack of personal equipoise, and the 
effect of ‘disclosure’ by recruiters or members of the wider clinical team may have an 
effect on the treatment perceptions of parents and young people at any point in the 
trial process, therefore the effects on retention are less clear. 
 
Findings from the line of argument developed via the meta-ethnographic parent data, 
(Chapter 4) and parent/recruiter data from the four collaborating RCTs (Chapter 5) 
highlighted the emotional nature of discussions during paediatric RCT recruitment 




social discourses, and accounts of parents’ experiences of decision-making about 
their child’s trial participation can be linked to the ‘rhetoric of morality’. [662] Trial 
participation takes place against the backdrop of competing moral demands, since 
paediatric RCTs have the added dimension of parents consenting for an intervention 
on behalf of, or in collaboration with their child. This results in ‘clashing ethical 
norms’ when parents struggle with an overwhelming wish to do the best for their 
child, whilst also drawing upon wider cultural discourses (e.g. altruism) when 
discussing participation in research. [663] 
 
Data from the four collaborating trials (Chapter 5) also supported the line of 
argument. Parents’ language conveys their vulnerability, and the accountability they 
feel in relation to making a ‘wise’ or a ‘poor’ decision. [325, 664] Parents also convey 
‘worry’ and the potential for judgement, ‘thinking you’re doing the wrong thing’. [97] 
These findings are supported by wider research into parent decision-making for 
elective surgery in the field of cleft lip and/or palate. [665] In the context of elective 
surgery, parent decision-making was framed in terms of emotional, social and 
cultural expectations, all of which had a key influence on parental motivation: 
“parents appeal to ‘doing the right thing’ as part of a perceived ‘moral’ obligation of 
being a ‘good’ parent”. [665] [pg. 802] Establishing the legitimacy of actions and 
beliefs is also a key aspect of the decision-making process for parents who decide to 
participate: ‘I do actually really believe in research… even if we end up as the control 
group’ (SMILE RCT), and particularly for those who decline participation: “I just don’t 





Those recruiting to CONTRACT reported feeling ‘really upset’ and ‘guilty’ when those 
randomised to the antibiotic group did not respond to treatment. It was suggested 
during interview feedback from those recruiting to the CONTRACT trial that some 
members of the wider teams ‘didn’t like’ or believed that antibiotic treatment was 
‘ineffective’. It was unclear who had initiated discontinuation of antibiotic treatment 
during the CONTRACT trial - whether it was instigated as ‘necessary’ by surgeons, 
‘requested’ by parents, or by the young people themselves. Health professionals 
also used language highlighting their struggle with the competing demands of the 
expert clinician providing the best care for their patient, coupled with the uncertainty 
required in both the discussion of RCT participation and the allocation of treatment 
via randomisation: “you’re admitting to patients and families… we don’t know what 
the effective treatments are” [Health Professional ME]. Findings outlined in this 
thesis demonstrate that the attitudes and personal opinions of health professionals 
affect the way in which interventions are discussed with families at recruitment, and 
during intervention delivery. This is likely to influence families’ preferences for 
treatment and continued participation as a trial progresses - however the 
mechanisms of this interaction are not yet clearly defined. 
 
Past literature has reported the ‘emotional’ response of recruiters and parents when 
dealing with disappointment with an allocated intervention group after randomisation. 
[109, 457] Recruiters (surgeons and research nurses) particularly valued training that 
focussed on conveying equipoise, rationale for randomisation, and exploring 
preferences for treatment. Ongoing training and support appears beneficial to 




competing demands of RCT recruitment, further developing training courses offered 
to those recruiting to RCTs. [246, 641] 
 
My findings also suggested that many families were not in equipoise when they 
consented to trial participation - this has also been reported in the adult literature. 
[286] If families consent to randomisation despite reporting preference for treatment 
(before or after randomisation) they may be more susceptible to the comments and 
views of health professionals who lack personal equipoise later in the trial process. 
At times it was difficult for health professionals in the MAGENTA trial to provide 
treatment ‘as per protocol’, particularly when they perceived that young peoples’ 
treatment needs had changed e.g. “they now need to do exercise”. This was 
reported as a particular issue for health professionals with substantial experience of 
treating young people, using a specific approach/technique over a number of years. 
If a procedure has been routine for many years, it may be more challenging to train 
health professionals to discuss alternatives to that treatment from a place of 
equipoise. [666] Although there may be collective uncertainty among health 
professionals about the effectiveness of interventions in a specific clinical area, both 
health professionals and trialists may ‘suspect’ or have anecdotal evidence that 
preferences exist in the wider patient community. [667] [668] [669] 
 
Trials that have surgical and non-surgical intervention groups may be particularly 
susceptible to preferences for treatment where, prospective participants and society 
at large have apprehensions about not ‘removing’ tumours or infected tissue (such 




where the public have widely accepted views about what is the best course of action 
in the case of cancer (tumour removal to provide a cure) or appendicitis (removal of 
the infected organ to avoid rupture and more serious prolonged illness). This may 
also be relevant to other diagnosed conditions, such as CFS/ME, where patient and 
support groups campaign against certain treatment approaches (e.g. Graded 
Exercise Therapy and the Lightning Process). The effect of these ‘discourses’ on the 
way in which equipoise is communicated to families has not been widely explored, 
but is likely to be a two-way process, resulting in changes in health professionals’ 
views and equipoise as they encounter families with entrenched views. In such 
circumstances, health professionals might draw on discourses of autonomy and 
patient choice to legitimise their lack of equipoise, highlighting a family’s preference 
for treatment as the reason why trial participation is not appropriate. [112, 670] 
Uncertainty which arose from the use of randomisation to determine a treatment 
pathway offered in the RCTs was problematic for some health professionals (see: 
Discussing uncertainty and equipoise: what would you do?). 
 
Uncertainty about the most effective available treatment led parents to draw upon 
other sources of knowledge, such as past experience of treatment (particularly in the 
context of appendicitis), and some asked recruiters what they would do if it were 
their child in this situation. This has been reported in the wider paediatric trials 
literature, [325] and suggests that parents seek guidance and personal reassurance 
from the recruiter. The issue of disclosure is difficult for recruiters and trialists, since 
the patient may view ‘a hunch’ or a ‘personal opinion’ as an informed evidence-





Health professionals recruiting to all the trials under investigation in this thesis 
reported interpretation of eligibility criteria as a factor affecting recruitment to trial. 
Recruiters (particularly during the CONTRACT RCT) discussed feeling more 
comfortable when recruiting patients who presented within a certain subset of the 
eligibility criteria - those who had less severe symptoms. Previously this was 
described as, “the group in the ‘middle’ with unremarkable clinical and socio-
demographic features”. [262] [pg. 260] Those at either end of the eligibility spectrum 
had the potential to be excluded on ‘subjective’ or ‘softer’ grounds based on 
‘hunches’ and ‘bias’. Examples included - psychological issues in CFS/ME trials, or 
other co-morbid physical conditions when treating appendicitis. [262] Support for this 
finding is available in paediatric RCTs [260, 273] and in the wider theoretical 
literature. [31, 102, 274-277] 
 
Interviews with health professionals suggested they were committed to the RCTs to 
varying degrees, believing that they offered ‘an answer to the question’ and would 
move evidence-based practice forward in areas that required further exploration. 
However, my findings suggest that the severity of the condition under investigation, 
perceived trial or intervention burden, and the seriousness of outcome may be 
factors influencing both individual and collective team equipoise. This highlights the 
need for pre-trial and ongoing team meetings and discussions, where team members 
can openly raise issues or gain clarification in relation to trial eligibility criteria and 
trial intervention groups (see: Recommendations and implications for future 
research). The following conceptual model (Figure 6:1) provides a visual map of the 
way in which health professionals might act as gatekeepers to RCT research, 




patient, and determining risk versus reward on their behalf. At the same time a 
patient’s health status, attitudes and engagement with the health professional will 
influence their perceptions of risk versus reward in participating in the trial. 
 
Figure 6:1 Conceptual framework of factors influencing the decision to 
participate  
Hughes-Morley, Young, Waheed, Small and Bower (2015) 
 
6.2.6 How do these findings map on to an existing model of 
patient preference and decision-making? 
My findings highlight the complex and dynamic nature of preference for treatment 
and decision-making in the context of paediatric trial recruitment and participation. 
My findings can be ‘mapped’ onto the existing conceptual model of patient 





Figure 6:2 A model of patient preference and decision-making 
Bower, King, Nazareth, Lampe and Sibbald, 2005 [294] [pg. 69] 
 
Information and patient characteristics influenced the reasons provided by families 
for preferences. Information was provided by recruiters (about trial interventions) and 
came from other sources (e.g. discussions with wider family). Additional information 
sources used by parents in the trials reported in this thesis included drawing on their 
own or a close family member’s past experience of a ‘nasty’ appendicitis which 
resulted in rupture - this was a strong predictor of families declining the CONTRACT 
RCT. Medical history of patients, or that of a close family member have been cited 
as important factors in decision-making about trial participation. [280] Parents of 
children considering CFS/ME trials reported searching for evaluations of CFS/ME 




Patient characteristics might include length of illness, perceived level of pain, or 
belief that an intervention is ‘better suited’ to a patient’s personality. The patient’s 
evaluation of their own self-efficacy in relation to treatment outcomes and preference 
judgements is particularly relevant in trials which require adherence to a treatment 
protocol extending over several months. [78, 359, 360] This was an important factor 
in the CFS/ME trials, where some young people had negative perceptions (which 
may have been reinforced by parents) of their ability to engage in one of the 
intervention groups in the trials, e.g. group work, CBT and in particular physical 
activity (Graded Exercise Therapy in the MAGENTA RCT). These factors do not rely 
on ‘expectancies’ about treatment which may be more amenable to change via 
balanced information about trial groups. Instead, they rely on subjective evaluations 
which result in preferences which may differ in strength depending on the individual 
or family. 
 
The way in which utility is conceptualised in relation to preference is also considered 
as part of the preference model, with altruism highlighted as a potential source of 
utility for those considering trial participation. Parents and young people taking part 
in the four trials reported altruistic reasons for doing so, as previously reported in the 
paediatric literature when parents and young people consider trial participation. [172, 
326, 671] However, altruism was discussed alongside other motivating factors, 
including the hope for personal benefit as well as the benefit of others in the wider 
community in future. This links to research literature which suggests a more accurate 
way of discussing altruism and research (or specifically trial) participation is by 




participating - in most instances altruism will not be the primary motivating factor. 
[671] 
 
Non-utility sources of influence, such as ‘coercion’, were mentioned as problematic 
for those recruiting to the CONTRACT RCT, although in line with research literature 
CONTRACT families did not highlight coercion as an issue during interviews. [96] 
Training for health professionals recruiting to RCTs should include ways to explore 
preference for treatment with families and young people in an informative and non-
coercive way. Discussions between trialists and health professionals on ‘patient 
choice’, RCT participation, and access to treatment may also be useful during 
training sessions, particularly in RCTs which involve ongoing treatment over an 
extended period of time after randomisation. 
 
The value that parents and young people placed on altruism and perceived utility of 
other elements of the trial, such as focusing on one intervention, (e.g. activity 
management in the MAGENTA trial) as opposed to combining elements of Graded 
Exercise Therapy and activity management outside the RCT (see: More is better 
‘pick and mix’ approach) highlights the perceived ‘limited’ utility of RCT participation 
for some families. In contrast, the prospect of gaining access to an additional 
intervention (e.g. the Lightning Process) by participating in the SMILE RCT, 






6.2.7 Expanding the existing model of patient preference and 
decision-making 
A number of additional factors are pertinent when considering aspects of Bower et 
al’s four-stage model of preference development and operation within the context of 
paediatric trials. [294] The 2005 model is primarily based on RCTs consenting adult 
participants who are making the decision to participate for themselves, with 
additional but limited support from a clinical team and family members. In the context 
of paediatric RCTs, the interaction of multiple opposing or concurring preference 
views is likely to have important implications for decision-making and young peoples’ 
continued trial involvement. 
 
Findings from my thesis research demonstrate that young people and parents 
frequently report different preferences for treatment, (Conflicting parent-child 
preference) with potential for different preferences between parents (Conflicting 
parent-parent preference). This was also observed in a past (surgical) paediatric 
RCT, [66] however young people do value shared decision-making during times of ill 
health. [395, 399] Further investigation is needed to determine how conflicting 
preferences are negotiated during the course of recruitment consultations, how they 
are managed or resolved during long-term RCT treatment interventions, and whether 
or not negotiation occurs in collaboration with treating health professionals. 
 
My thesis research also found that preference is not static in participant or parent 
reports - preference for treatment can change for an individual, during the course of 




preference have been observed in a paediatric trial investigating different modes of 
treatment delivery, and more generally in a review of preference effects in adult 
RCTs. [289, 291] The fact that preferences for treatment may change over time has 
implications for behavioural interventions, particularly those that require ‘buy in’ from 
the patient, parent(s) and treating health professional(s). During the course of the 
present thesis research some health professionals reported changes in their 
preference for treatment as they interacted with families and were exposed to one or 
more (previously unfamiliar) interventions on a more regular basis. This in turn may 
influence families’ ongoing views and preferences. Measuring participant, parental or 
health professional preference before recruitment, and using this to predict and 
examine the effects of preference post-randomisation, may also therefore be difficult 
because of fluctuation and changes in preference over time. 
 
Finally, this thesis research highlights the way in which the 2005 model should be 
expanded to explore parental preferences and expectancies about treatment in 
relation to parental self-efficacy, and specifically the way in which parents influence 
their child’s self-efficacy. Parental self-efficacy is likely to be a very important factor 
in the context of paediatric RCTs, particularly those involving long term commitment 
to interventions for chronic health conditions. [145, 360, 658, 672] Treatment 
interventions for long term health conditions such as CFS/ME, obesity and diabetes 
nested within paediatric RCTs will include elements of self-efficacy, outcome 
expectancy, goal setting and behaviour change. [145, 295, 673-675] Preference 
judgements rely on expectancies about outcome which draw on patient evaluations 
of their own self-efficacy but are also likely to be informed by parent views of their 




Self-efficacy must also be considered on two levels, initially at the level of successful 
engagement with RCT processes, (e.g. participation in research discussions and the 
completion of outcome measures) and successful engagement with RCT 
interventions (e.g. is behaviour change attainable, can I commit to one of the RCT 
interventions?). When young people perceived that researchers proactively engaged 
them by inviting their questions and opinions, young people reported greater 
decisional self-efficacy. [676] However, the extent to which decisional self-efficacy 
relates to an individual’s confidence and belief in their ability to make changes to 
their behaviour and outcome expectancy (anticipated positive or negative 
consequences their actions produce) is not well understood in the context of wider 
health and RCTs. [677] 
 
These are important additional factors when considering this model in the paediatric 
context. It is important that the views of young people and children are heard in the 
context of RCT research. The tendency for parents to ‘dominate’ research 
consultations when both parents and young people are present has been reported 
previously and was also apparent in the current findings, (see: Complexity of triadic 
consultations and Conflicting parent-child preferences). [96] 
 
6.2.8 Ethical issues and participation in paediatric RCTs 
The FITNET-NHS and SMILE trial were similar in that both trials offered the 
opportunity of access to an intervention which was potentially otherwise unavailable 
(the Lightning Process course was unaffordable for many, and Online CBT modules 




specialist CFS/ME treatment outside the trial, (this included access to activity 
management, CBT and Graded Exercise Therapy) but eligible FITNET-NHS families 
may have had to travel a considerable distance to access this treatment. This is an 
important issue which should be considered carefully by recruiters exploring 
preferences for treatment, specifically because families may feel uncomfortable 
expressing their preferences if they feel treatment may be unavailable to them. An 
open and honest discussion of what treatment is available outside the RCT, and 
highlighting that trial interventions are currently both considered to be good options 
for eligible patients should also be discussed with care in these circumstances. 
 
Some families still consented to randomisation and trial participation despite 
preference(s) for treatment, (SMILE, MAGENTA, CONTRACT & FITNET-NHS). This 
has been observed in adult trials. [296] This is an important finding, because when 
participants make decisions about randomisation which conflict with their preference 
for treatment, their preference may still influence their engagement with the allocated 
intervention in the trial. It is important to consider the existing relationship that a 
recruiter has with the family. If a family is presented with trial information by a health 
professional who has provided a diagnosis and will continue to provide ongoing care, 
parents (and some young people depending on their age and maturity) may feel 
indebted to the health professional or clinical team. The line between clinical care 
and research involvement may be more blurred, as compared to families who are 
introduced to a trial by a research nurse they have never met before and will have no 





My thesis data highlights that paediatric recruitment consultations are more complex, 
because there are differences in how young people and their parents communicate 
preference. It also highlights that young people often have different preferences for 
treatment from their parents. Efforts should be made to explore the preferences of 
young people in accordance with their current health state and ability to be involved 
in an informed discussion. Communication in paediatric RCTs is more complex 
because young people and parents all play an active role in decision-making about 
trial participation. It was often difficult to gauge young people’s views about treatment 
and trial participation - this concurs with past paediatric trials research. [96] Future 
training for trialists and health professionals should take into consideration this 
additional complexity. 
 
Voluntariness of consent, assent and access to treatment is an important issue 
which requires consideration in any trial context. The current findings support past 
research which has found that parents are more likely to respond to ‘general’ 
questions if they are not specifically directed at young people, and that young 
people’s responses to questions directed at them were typically short. [391-393] 
Parents often interjected during CFS/ME recruitment consultations, with the intention 
of ‘helping their child out’ by giving their views or their perception of their child’s 
feelings or preferences. Many young people have reported that they value shared-
decision making during times of ill health, [395, 399] but more research is needed to 
establish ways of allowing young people to maintain autonomy. [678] Young people 




this may be particularly important in behavioural trials where treatment requires 
commitment to self-care interventions or activity programmes. [227, 678, 679] 
 
A longitudinal study examining the effect of choice on recruitment to family-based 
drug, tobacco and alcohol prevention programs found that those able to choose their 
intervention did not have better outcomes than those who were randomised. [650] 
This study measured satisfaction with intervention programs post intervention, rather 
than preference for an intervention at the beginning of the study. Findings were 
interesting since there were differences between the satisfaction levels reported by 
young people and their parents, with parents being more satisfied in the ‘choice’ 
condition as opposed to ’randomised’ condition. This highlights the added complexity 
when dealing with participation issues, preference issues prior to an intervention, 
and satisfaction post intervention in paediatric trials. 
 
 
6.3 Strengths and limitations 
6.3.1 Strengths 
The findings reported in this thesis are based on a large dataset, which drew on data 
from four different paediatric trial settings. A large dataset is not itself important when 
using qualitative approaches to data analysis but is a strength in the current context 
since findings are not limited to one trial site, context or paediatric condition. Three 
CFS/ME trials were included in the data analysis. Although investigating 




interventions offered in the trials and the availability of these interventions outside 
the trial. Families eligible for the MAGENTA and CONTRACT RCTs could easily 
access similar interventions outside of the trial, but for FITNET-NHS and SMILE 
families this was not the case. 
 
The data collection and analysis methods used in the four paediatric trials are a 
strength of this research. They allowed for a comparison of themes that were 
identified independently in each trial context (constant comparison methods), as well 
as comparing and contrasting themes across trials (framework analysis). Findings 
were discussed with my supervision team (EC, NM and BY) as well as colleagues 
working in each trial team at regular intervals during the data collection and analysis 
processes. [550, 680] 
 
Many qualitative research studies and those embedded in RCTs rely solely on 
interview data, and do not compare findings from two or more data collection 
methods. [461, 681] During this thesis I collected, and paired recruitment 
consultations and interview data, allowed for comparisons and analysis of real time 
recruitment practices, as well as retrospective reported practices from families and 
health professionals. [550] This added contextual information and allowed a more in-
depth and thorough understanding of the way in which preferences were discussed 
at the time the decision to participate was made, as well as retrospective reflections 
and rationale for treatment preferences, and is considered a particular strength. [463] 
 
This thesis research also included some analysis of issues relating to preference, 




the impact which preference for treatment had on their decision to discontinue 
treatment after several months, (MAGENTA) or requests to withdraw from treatment 
post-randomisation (CONTRACT) enabled an understanding of why families make 
such decisions in the context of each RCT. [463] 
 
Families were interviewed at more than one time point (e.g. before or after 
intervention delivery), therefore findings were not limited to one point in the trial 
process. Conducting interviews on three occasions during the SMILE RCT (before, 
after randomisation, and after the intervention) helped to facilitate rapport with 
families and highlighted the way in which preference for treatment may change over 
time. Although this approach was not used in the MAGENTA and FITNET-NHS trials 
(and was not feasible in an acute care setting), it demonstrates that the timing of 
qualitative research may be an important factor when investigating preference for 
treatment, specifically if the research team wish to gain families’ perspectives before 
they have made the decision to participate in an RCT. 
 
Participating health professionals delivered a range of interventions, in complex 
paediatric RCTs in acute and chronic care settings. Members of wider clinical teams 
were interviewed (e.g. those delivering ongoing care after randomisation) as well as 
those recruiting to the trials. Interviews also included a range of health professionals, 
including research nurses and those from a variety of specialties (occupational 
health, physiotherapy, surgery, psychology and specialist paediatric consultants) in 





The large data sample also reflects the fact that a high number of recruitment 
consultations were routinely recorded in each of the four RCTs, which demonstrates 
that recruiters were willing to record these interactions and allowed for the analysis 
of a wide range of consultations with varied outcomes (e.g. families who consented 
to and declined each RCT). Some recruiters initially felt uneasy about making 
recordings of recruitment consultations. However, high numbers of consultations 
were recorded in each trial, recruiters were engaged with the research team, 
reported that the training sessions were useful, and reported that the communication 
techniques discussed could be put into practice in future consultations. Analysis of 
recruitment consultations before and after training also allowed for a comparison of 
changes in dealing with preferences among other aspects of practice, and the way in 
which this impacted recruitment figures. 
 
Fathers were purposively sampled during the MAGENTA, FITNET-NHS and 
CONTRACT trials. The inclusion of fathers’ experiences and input in the decision-
making process is considered a strength of the current thesis findings. The research 
literature has often focused on mothers’ views and experiences (because mothers 
are often the primary carer). [108, 120, 204, 316, 507, 524] However fathers and 
other close family members also play an important role in decision-making when trial 







6.3.2 Limitations  
Interviews 
The preference data collected from interviews for this thesis was limited by the 
overall aims of the four main collaborating trials. Data collection for each trial 
focussed not only on preference for treatment (the focus of this thesis), each trial 
also collected more general data on a number of other feasibility issues explored by 
each nested qualitative study. Topic guides used in each trial contained a limited 
number of questions on preference for treatment as questions relating to all areas of 
trial feasibility had to be covered, thus time spent discussing preference in interviews 
was limited. As a result, preference data collected via interview was not as in-depth 
as it might have been had each interview solely focused on preference issues. 
 
Asking participants to think ‘retrospectively’ about preference for treatment may have 
influenced participants to feel they ‘should’ have had, or were being asked to 
‘construct’ preferences for treatment. Retrospective views about preference will be 
affected by the experience and satisfaction of young people and their parents with 
the intervention they received as part of the RCT, thus by asking questions about 
trial participation more generally expressions of strongly held views on preference 
could be and were raised by families and health professionals while discussing other 





It was not always possible to interview recruiters soon after specific recruitment 
consultations (where families had discussed preferences for treatment or declined 
the trial). Recruiters did not always remember the detail of consultations if they had 
taken place a number of weeks prior to the interview. Conversations about 
preference were often part of wider discussions about treatment and recruitment, 
therefore recruiters were usually only able to discuss specific ‘preference’ related 
aspects of consultations if they had taken place immediately before the interview. 
One advantage of a delayed interview was that thorough analysis of the related 
recruitment consultation could be carried out prior to interview. Preference related 
issues could then be raised by the interviewer and potentially discussed in more 
detail by the interviewee. 
 
Beliefs expressed at interview are co-constructed between the interviewer and the 
interviewee. Those conducting interviews across the four trials had varied levels of 
experience in the field of qualitative research interviewing, and this may have had an 
impact on the quality of the data collected. [685] Those with limited experience of 
qualitative interviewing asked more closed questions, and at times failed to use 
probing questions to explore treatment preferences. Feedback from those with more 
limited experience of collecting qualitative data highlighted worries about ‘changing 
the wording of questions’ and ‘not fitting all the questions into the interview’. 
 
Although telephone interviews may be convenient and less intrusive for both the 




cues - particularly useful when interviewing those with CFS/ME who may feel tired as 
the discussion progresses. Other information about the neighbourhood in which a 
family live and their homelife is also more apparent during face-to-face interviews in 
the participant’s home. Some young people were difficult to engage in telephone 
conversations, and face-to-face interviews tended to be more productive in terms of 
building rapport and gaining rich in-depth information. 
 
It was more difficult to arrange interviews with families who had declined the trials, 
despite these families indicating that they were happy to be contacted by a 
researcher - some did not respond to messages or cancelled interviews which had 
been arranged. During the CONTRACT trial some parents did not ask their child if 
they wished to participate in an interview because they might either not remember 
details of the trial because they were too ill, or they felt it was inappropriate and 
might make their child reflect upon distressing memories of being particularly unwell. 
 
Recruiters and health professionals were not routinely interviewed during recruitment 
to the SMILE RCT - this aspect of QRI methodology was developed after ethical 
approval for the trial had been obtained. It became clear after qualitative work was 
completed in the SMILE trial that feedback from recruiting health professionals and 
members of the wider CFS/ME team would have been useful, therefore this was 





Methodology and analysis 
Recruiters’ ability to constructively cede the floor and allow young people to 
contribute to recruitment consultations may have been exacerbated during 
recruitment to MAGENTA and FITNET-NHS as these consultations were conducted 
via telephone. Recruiters did not have the visual cues to anticipate whether 
individuals wanted more time to respond, at times relying on parent reports to 
determine young people’s feelings about treatment preference, e.g. “He’s screwing 
his face up”. Recruiters were advised to use a young person’s name to direct specific 
questions so that parents did not dominate conversations, but in a small number of 
conversations it became apparent that young people had ‘left the room to use the 
toilet’ and were not fully engaged with the conversation. 
 
Grounded theory works on the principle of an iterative analysis allowing for the 
testing of emerging theory. The fast-paced context of each RCT feasibility study did 
not always allow for extensive in-depth iterative analysis, and proved particularly 
difficult when analysing themes between the four RCTs. Framework analysis was 
used to manage and compare data due to the availability of a large amount of data 
across four different trials. However, this inevitably resulted in a loss of the iterative 
testing of findings and themes, which were relevant across and between the four 
trials but were identified too late to be ‘tested’ in the individual trial populations. 
 
It is important to recognise that my knowledge of the subject area and data analysis 




analysis in the CONTRACT and FITNET-NHS trials. [458] Analysing data from three 
CFS/ME trials means that these findings are not as broad as they would be if 
collaborations had been formed with trials in four different paediatric areas, e.g. a 
vaccination trial with a ‘well’ paediatric population, or a diabetes trial. Using content 
analysis to analyse ‘expressed’ preference allowed only for the aggregation of 
preference, it did not highlight important contextual factors such as availability of 
treatment outside of the RCT, and it was therefore not used to analyse recruitment 
consultation data from MAGENTA, FITNET-NHS or CONTRACT. 
 
 
6.4 Recommendations and implications for future 
research 
The current research findings improve RCT conduct and methodology in paediatric 
trials by highlighting issues of importance to families and health professionals during 
recruitment and participation in paediatric trials. These findings have already 
contributed to preliminary guidance documents for health professionals recruiting to 
paediatric trials, outlining strategies to identify and discuss treatment preference and 
equipoise in partnership with young people and their parents (see: Appendices 4, 5 
and 6: tips for recruitment, and Appendix 6: CONTRACT: Recruitment Flowchart). 
The CONTRACT trial recruited young people who had an unscheduled hospital 
admission, which is a setting where recruitment to research can be particularly 
challenging due to time limitations, the demanding clinical environment and the 




highlighted the lack of high-quality research investigating recruitment processes in 
RCTs which involved unplanned hospital admission, and the need for high quality 
verbal rather than written information in this trial context. [686] Further research in 
this area is required, particularly in RCTs where recruitment strategies or training 
programs are also randomised, in order to compare their effectiveness. [687] 
 
Future research based on Bower’s conceptual model could include an investigation 
of ‘global preference’ and the weighting given by young people and their parents to 
utility components of the model. These might include utility from participating (e.g. 
altruism and social exchange), availability of treatments outside the trial, and the 
probability of receiving a specific intervention in the trial. Exploration of these 
components of preference in a trial (with training for recruiters) might lead to a model 
of ‘informed expectancies’ specific to families’ decision-making on trial participation. 
Self-efficacy may hold more weight in complex trials requiring behavioural 
modification and commitment from participants over an extended period. The effect 
of self-efficacy on retention in behavioural trials is an area which requires further 
investigation. [688] Preference cannot be viewed as static - those who are initially 
disappointed when randomised to their non-preferred intervention group may later 
find the approach useful and effective. Thus, the measurement of preference before 
recruitment and its use to predict and examine the effect on retention may be 
unreliable. This thesis has found altruism or social exchange to be an important 
utility. It would also be important to consider potential benefit (faster recovery) and 
risk (treatment side effects) in relation to trial utility and preference for treatment. The 




consent to a trial when they are able to access the treatment externally is also 
important to consider when families make decisions about trial participation. 
 
A high proportion of conversations forming ‘part’ of recruitment consultations were 
not recorded during the CONTRACT RCT. This included initial conversations where 
the trial was introduced and final conversations where group allocation was given 
verbally to families. Although the research team routinely asked that all 
conversations about the trial be recorded, particularly those where families were 
given their group allocation, since parent or patient responses might display 
disappointment or excitement about the allocated intervention group. Recruiters 
either did not see the utility of recording these conversations, or felt unable 
practically and logistically to record them. 
 
Future research might look at innovative ways in which this type of information could 
be captured and used for research purposes with consent from families. This might 
include video recording the initial assessment appointment and would enable 
researchers to use conversation analysis to investigate specific sections of 
consultations where preference is discussed. The availability of visual as well as 
audio cues would enable a more in-depth analysis of the way in which families, 
recruiters or health professionals express or respond to preference, and possibly 
present a position of equipoise. These additional ‘mini’ consultations between health 
professionals and families prior to the ‘main’ recruitment consultation are likely to be 
important in terms of preference formation. It is not clear whether personal opinion 




Missing conversations from the consultation process). ‘Preference’ related data may 
have been lost from conversations which occurred before the main recruitment 
consultations, e.g. during the first FITNET-NHS phone call, or the eligibility 
assessment and initial clinical appointments in the SMILE and MAGENTA trials. The 
potential for communication about a trial to occur at multiple consultations has been 
noted in previous research in a paediatric setting, and more widely in research 
investigating decision-making in health care settings. [109, 689] 
 
A recent paper (2016) investigating parental reasons for declining participation in 
paediatric surgical trials found that the most common reason for doing so was 
preference for treatment (37%). [690] The authors state that better communication 
and explanation of trial rationale and treatment might be an effective way to tackle 
this issue. It is recommended that conversations to clarify and outline trial rationale 
should begin as early as possible in the consultation process, for example at the 
outpatient clinic stage for elective surgery, as early conversations may be key to the 
formation of preference for treatment. This indicates the importance of all 
conversations taking place between health professionals at all stages of the trial 
recruitment consultation process (see: Missing conversations from the consultation 
process). However, further research is required to determine the feasibility of making 
additional records of these conversations, particularly in an acute care setting where 
recorders may be stored securely in another area of the hospital. 
 
The effect of preference for treatment on the responses of young people and their 




not investigated in this thesis. This is important when considering satisfaction with 
treatment (particularly in behavioural trials), and the impact that treatment preference 
and/or satisfaction with treatment might have on missing data. The interaction 
between preference for treatment at trial outset and satisfaction with ongoing 
treatment as a trial progresses also requires further investigation. Further in-depth 
analysis of the complexity of paediatric trial consultations is needed, to understand 
the way in which the views and preferences of young people under the age of 16 are 
considered. Conversation analysis could be used to examine and explore turn-taking 
behaviour in paediatric recruitment consultations, particularly where both parents are 
present and participate in the decision-making process in collaboration with their 
child. 
 
Future research should explore the concepts of personal and collective equipoise 
with health professionals recruiting to trials, and those working with and treating 
young people post-randomisation. Pre-trial training should consider how health 
professionals view taking on the dual roles of clinician and recruiter. Issues relating 
to intervention groups and equipoise could be discussed by the teams who will be 
required to recruit to trials. It may also be important to consider treatment equipoise 
in place of treatment preference when developing future training and discussing trial 
rationale in partnership with families and health professionals. Rather than focusing 
on preference for treatment this training might focus instead on equipoise and 
treatment, thus exploring the way in which recruiters and wider team members view 





The way in which research teams and NHS clinical teams work together 
collaboratively could be improved using an ‘action learning’ and ‘action research’ 
approach so that all involved have an investment in the way in which data is 
collected and used. Pre-trial consultation meetings with clinical teams to discuss 
eligibility criteria and views on treatments should be investigated in future trials. The 
meetings should be audio-recorded where possible. Before trials commence 
interviews or focus groups with recruiters and wider teams delivering the 
interventions or care should be held. This will help to better understand team ‘mood’.  
These measures, and the continued inclusion of patient groups and their feedback 
are crucial to the acceptability of trial interventions during the planning and 
implementation phase of trials. 
 
Observed improvements in communication after training, and the effect of this on  
recruitment in different trial contexts is worthy of continued research and 
consideration. Although recruitment did not increase month on month, there 
appeared to be a ‘training effect’ in the three trials which used more structured forms 
of training for recruiters. Further research is needed in order to understand the 
‘active ingredient’, or way in which training influences recruitment, and how this 
training might be extended to wider clinical teams coming into contact with those 
considering trial participation or participating in continued clinical care as part of a 
trial. 
 
Greater transparency and consistency in the way in which recruitment processes are 




eligibility. Paediatric RCTs might benefit from using the SEAR framework to track the 
number of families: Screened, Eligible, Approached and Randomised. [417] 
Generalised phrases used to record reasons for non-participation e.g. ‘does not want 
to take part in research’ could be either a reflection on wider perceptions of research, 
or specific to one or more of the RCT interventions. Reason codes which are highly 
prescriptive particularly during the feasibility or internal pilot stage of a trial will not 
provide clinical teams or trialists with a clear view of the reasons why families decline 
a trial.  For example in CONTRACT only two reason codes were used for those who 




This thesis provides an increased understanding of treatment preference in 
paediatric RCTs. It has made a unique contribution in four areas: a) identifying that 
young people have treatment preferences, b) that young people and their families 
continue to consent to trials despite having preferences, c) that discussions of 
preference during recruitment can occur at any time, and d) that recruitment 
communication training can contribute to successful recruitment during feasibility and 
internal pilot paediatric RCTs. 
 
a) Preference for treatment is an important issue that should be explored when 
recruiting to paediatric trials which deliver complex behavioural or surgical 
interventions. This thesis has shown that young people and parents have treatment 




peoples’ preferences for treatment has not been prominent in past literature. The 
emotional and complex nature of preference discussions has also been identified: for 
parents wanting the best for their child; young people wanting to get better and help 
others; and health professionals balancing individual versus collective equipoise. 
 
b) Despite expressing preferences for treatment many families make the decision to 
participate in paediatric RCTs, therefore open discussions about preference are an 
important part of the informed consent process. This may be more prominent for 
RCTs delivering one or more interventions not available outside the RCT and could 
have further implications for retention and the completion of outcome measures. This 
is particularly relevant if trial interventions are ongoing over a prolonged period of 
time e.g. behavioural interventions. 
 
c) This thesis also identified that preference for treatment can arise in a number of 
different discussions between recruiters and families, not only during discussions 
specifically about the treatments offered in an RCT or discussions which occur 
immediately prior to consent. Preference for treatment can arise in discussions about 
trial processes, when families are discussing treatment, and post randomisation. 
 
d) Training recruiters to reflect on how they convey trial information improves 
communication about trial rationale, the exploration of treatment preferences, and 
discussions of equipoise between intervention groups. Training also appears to have 




The views and equipoise of those recruiting and treating RCT intervention 
participants influenced families at all stages of recruitment and intervention delivery 
and are likely to be an important influence on recruitment and retention as an RCT 
progresses. 
 
Further research is needed in paediatric settings to investigate the way in which 
health professionals discuss treatment options before and after the main recruitment 
consultation, including more transparency in relation to the way in which reasons for 
trial decline and discontinuation of interventions are sought and recorded. Future 
research should investigate the way in which a lack of health professional or family 





1. General Medical Council, 0–18 years: guidance for all doctors. Working with 
doctors. Working for patients. 2018, The GMC is a charity registered in 
England and Wales (1089278) and Scotland (SC037750). 
2. Cochrane. /glossary#letter-R. 2018; Available from: 
http://community.cochrane.org Accessed 10/05/2018. 
3. Howick, J. Oxford Centre for Evidence-based Medicine – Levels of Evidence. 
2009 Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, 
Sharon Straus, Brian Haynes, Martin Dawes: November 1998. ; Available 
from: https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-
levels-evidence-march-2009/. 
4. Evans, D., Hierarchy of evidence: a framework for ranking evidence 
evaluating healthcare interventions. J Clin Nurs, 2003. 12(1): p. 77-84. 
5. Muir Gray, J.A., et al., Transferring evidence from research into practice: 3. 
Developing evidence-based clinical policy. ACP J Club, 1997. 126(2): p. A14-
6. 
6. Sackett, D.L., Evidence-based medicine and treatment choices. Lancet, 1997. 
349(9051): p. 570; author reply 572-3. 
7. Patsopoulos, N.A., A.A. Analatos, and J. Ioannidis, Relative citation impact of 
various study designs in the health sciences. JAMA, 2005. 293(19): p. 2362-6. 
8. Cochrane, Handbook for Systematic Reviews of Interventions, T.C. 
Collaboration, Editor. 2011. 
9. Singal, A.G., P.D.R. Higgins, and A.K. Waljee, A Primer on Effectiveness and 
Efficacy Trials. Clinical and Translational Gastroenterology, 2014. 5(1): p. 
e45. 
10. Schwartz, D. and J. Lellouch, Explanatory and pragmatic attitudes in 
therapeutical trials. J Chronic Dis, 1967. 20(8): p. 637-48. 
11. Thorpe, K.E., et al., A pragmatic-explanatory continuum indicator summary 
(PRECIS): a tool to help trial designers. CMAJ, 2009. 180(10): p. E47-57. 
12. Sackett, D.L. and W.M. Rosenberg, The need for evidence-based medicine. J 
R Soc Med, 1995. 88(11): p. 620-4. 
13. British Broadcasting Corporation (BBC). The NHS: 'One of the greatest 
achievements in history' 1998  May 2018]. 
14. Department of Health, The health of the nation: a strategy for health in 
England. 1992, HMSO: London. 
15. Gabbay, J., The health of the nation. British Medical Journal, 1992. 
305(6846): p. 129-130. 
16. Hanney, S., et al., An assessment of the impact of NHS Health Technology 
Assessment Programme. Health Technol Assess 2007. 11(53). 
17. Department of Health, Assessing the Effects of Health Technologies: 
Principles, Practice, Proposals. 1992, London: Great Britain: NHS 
Management Executive: Advisory Group on Health Technology Assessment. 
18. NICE: National Institute for Health and Clinical Excellence. History of NICE. 
2018  May 2018]. 
19. European Commission, The Medicines for Human Use (Clinical Trials) 




20. Lehmann, B., Regulation (EC) No 1901/2006 on medicinal products for 
paediatric use & clinical research in vulnerable populations. Child Adolesc 
Psychiatry Ment Health, 2008. 2(1): p. 37. 
21. Donaldson, I.M.L. Ambroise Paré’s accounts of new methods for treating 
gunshot wounds and burns. JLL Bulletin: Commentaries on the history of 
treatment evaluation 2004; Available from: 
http://www.jameslindlibrary.org/articles/ambroise-pares-accounts-of-new-
methods-for-treating-gunshot-wounds-and-burns/. 
22. Donaldson, I.M.L., Van Helmont’s proposal for a randomised comparison of 
treating fevers with or without bloodletting and purging. . JLL Bulletin: 
Commentaries on the history of treatment evaluation 2016. 
23. Lind, J., Nutrition classics. A treatise of the scurvy by James Lind, MDCCLIII. 
Nutr Rev, 1983. 41(5): p. 155-7. 
24. Science Museum. Brought to Life: Exploring the History of Medicine. 2017  
[cited 2017 06/04/17]. 
25. Hrobjartsson, A., P.C. Gotzsche, and C. Gluud, The controlled clinical trial 
turns 100 years: Fibiger's trial of serum treatment of diphtheria. BMJ, 1998. 
317(7167): p. 1243-5. 
26. Hopkins, W.A., Patulin in the common cold. IV: Biological properties: 
extended trial in the common cold. . Lancet 1943. 2:: p. 631-635. 
27. Stuart-Harris, C.H., A.E. Francis, and J.M. Stansfeld, Patulin in the common 
cold. . Lancet 1943. 2:: p. 684. 
28. Clarke, M. The 1944 patulin trial of the British Medical Research Council: an 
example of how concerted common purpose can get reliable answers to 
important questions very quickly. JLL Bulletin: Commentaries on the history of 




29. Medical Research Council, STREPTOMYCIN treatment of pulmonary 
tuberculosis. Br Med J, 1948. 2(4582): p. 769-82. 
30. Crofton, J., The MRC randomized trial of streptomycin and its legacy: a view 
from the clinical front line. J R Soc Med, 2006. 99(10): p. 531-4. 
31. Hill, A.B., Medical ethics and controlled trials. Br Med J, 1963. 1(5337): p. 
1043-9. 
32. Antibiotic Combinations. 1956. 255(22): p. 1057-1059. 
33. Haarsager, J., Podolsky, S.H. The Antibiotic Era: Reform, Resistance, and the 
Pursuit of a Rational Therapeutics. Baltimore: Johns Hopkins University 
Press. 2015. 328 pp $34.95 ISBN 978-1-4214-1593-2. 2015. 37(8): p. 1391-
1392. 
34. Shen, W.W., A history of antipsychotic drug development. Compr Psychiatry, 
1999. 40(6): p. 407-14. 
35. Greene, J.A. and S.H. Podolsky, Reform, regulation, and pharmaceuticals--
the Kefauver-Harris Amendments at 50. The New England journal of 
medicine, 2012. 367(16): p. 1481-1483. 
36. National Institute for Biological Standards and Control (NIBSC). 1972  [cited 
2018 10/08/2018]. 
37. Medicines & Healthcare products Regulatory Agency (MHRA). Clinical trials 





38. Bothwell, L.E., et al., Assessing the Gold Standard--Lessons from the History 
of RCTs. N Engl J Med, 2016. 374(22): p. 2175-81. 
39. Jones, D.S. and S.H. Podolsky, The history and fate of the gold standard. The 
Lancet, 2015. 385(9977): p. 1502-1503. 
40. Lurie, P. and S.M. Wolfe, Unethical trials of interventions to reduce perinatal 
transmission of the human immunodeficiency virus in developing countries. N 
Engl J Med, 1997. 337(12): p. 853-6. 
41. Rothman, D.J., The shame of medical research. New York Rev Books, 2000. 
47(19): p. 60-4. 
42. Burdett, S., L.A. Stewart, and J.F. Tierney, Publication bias and meta-
analyses: a practical example. Int J Technol Assess Health Care, 2003. 19(1): 
p. 129-34. 
43. Zarin, D.A., et al., Issues in the registration of clinical trials. JAMA, 2007. 
297(19): p. 2112-20. 
44. Nuffield Council on Bioethics, Children and clinical research: ethical issues. 
2015, Nuffield Council on Bioethics: London ESP Colour Ltd. 
45. Deatrick, J.A., D.B. Angst, and C. Moore, Parents' views of their children's 
participation in phase I oncology clinical trials. J Pediatr Oncol Nurs, 2002. 
19(4): p. 114-21. 
46. Arain, M., et al., What is a pilot or feasibility study? A review of current 
practice and editorial policy. BMC Med Res Methodol, 2010. 10: p. 67. 
47. Eldridge, S.M., et al., Defining Feasibility and Pilot Studies in Preparation for 
Randomised Controlled Trials: Development of a Conceptual Framework. 
PLoS One, 2016. 11(3): p. e0150205. 
48. Avery, K.N., et al., Informing efficient randomised controlled trials: exploration 
of challenges in developing progression criteria for internal pilot studies. BMJ 
Open, 2017. 7(2): p. e013537. 
49. Guyatt, G.H., et al., A clinician's guide for conducting randomized trials in 
individual patients. CMAJ, 1988. 139(6): p. 497-503. 
50. Guyatt, G.H., et al., The n-of-1 randomized controlled trial: clinical usefulness. 
Our three-year experience. Ann Intern Med, 1990. 112(4): p. 293-9. 
51. Duan, N., R.L. Kravitz, and C.H. Schmid, Single-patient (n-of-1) trials: a 
pragmatic clinical decision methodology for patient-centered comparative 
effectiveness research. J Clin Epidemiol, 2013. 66(8 Suppl): p. S21-8. 
52. Lillie, E.O., et al., The n-of-1 clinical trial: the ultimate strategy for 
individualizing medicine? Per Med, 2011. 8(2): p. 161-173. 
53. Sung, L. and B.M. Feldman, N-of-1 trials: innovative methods to evaluate 
complementary and alternative medicines in pediatric cancer. J Pediatr 
Hematol Oncol, 2006. 28(4): p. 263-6. 
54. Nikles, C.J., A.M. Clavarino, and C.B. Del Mar, Using n-of-1 trials as a clinical 
tool to improve prescribing. Br J Gen Pract, 2005. 55(512): p. 175-80. 
55. Cook, D.J., Randomized trials in single subjects: the N of 1 study. 
Psychopharmacol Bull, 1996. 32(3): p. 363-7. 
56. Gallin, J.I. and F.P. Ognibene, Principles and Practice of Clinical Research 
Vol. (Third Edition). 2012: Academic Press is an Imprint of Elsevier. 
57. McNamara, D.G., A.R. Dickinson, and C.A. Byrnes, The perceptions and 
preferences of parents of children with tracheostomies in a study of 
humidification therapy. J Child Health Care, 2009. 13(3): p. 179-97. 
58. Brewin, C.R. and C. Bradley, Patient preferences and randomised clinical 




59. Olschewski, M., M. Schumacher, and K.B. Davis, Analysis of randomized and 
nonrandomized patients in clinical trials using the comprehensive cohort 
follow-up study design. Control Clin Trials, 1992. 13(3): p. 226-39. 
60. Howard, L. and G. Thornicroft, Patient preference randomised controlled trials 
in mental health research. Br J Psychiatry, 2006. 188: p. 303-4. 
61. Relton, C., et al., Rethinking pragmatic randomised controlled trials: 
introducing the "cohort multiple randomised controlled trial" design. BMJ, 
2010. 340: p. c1066. 
62. Torgerson, D.J., J. Klaber-Moffett, and I.T. Russell, Patient preferences in 
randomised trials: threat or opportunity? J Health Serv Res Policy, 1996. 1(4): 
p. 194-7. 
63. Britton, A., et al., Choosing between randomised and non-randomised 
studies: a systematic review. Health Technol Assess, 1998. 2(13): p. i-iv, 1-
124. 
64. Silverman, W.A. and D.G. Altman, Patients' preferences and randomised 
trials. Lancet, 1996. 347(8995): p. 171-4. 
65. Bond, J., et al., Protocol for north of England and Scotland study of 
tonsillectomy and adeno-tonsillectomy in children (NESSTAC). A pragmatic 
randomised controlled trial comparing surgical intervention with conventional 
medical treatment in children with recurrent sore throats. BMC Ear Nose 
Throat Disord, 2006. 6: p. 13. 
66. Lock, C., et al., North of England and Scotland Study of Tonsillectomy and 
Adeno-tonsillectomy in Children(NESSTAC): a pragmatic randomised 
controlled trial with a parallel non-randomised preference study. Health 
Technol Assess, 2010. 14(13): p. 1-164, iii-iv. 
67. Torgerson, D.J. and B. Sibbald, Understanding controlled trials. What is a 
patient preference trial? BMJ, 1998. 316(7128): p. 360. 
68. Cooper, K.G., A.M. Grant, and A.M. Garratt, The impact of using a partially 
randomised patient preference design when evaluating alternative 
managements for heavy menstrual bleeding. Br J Obstet Gynaecol, 1997. 
104(12): p. 1367-73. 
69. Klein, S., et al., Evaluating the effectiveness of a web-based intervention to 
promote mental wellbeing in women and partners following miscarriage, using 
a modified patient preference trial design: an external pilot. BJOG, 2012. 
119(6): p. 762-7. 
70. Zelen, M., Alternatives to classic randomized trials. Surg Clin North Am, 1981. 
61(6): p. 1425-32. 
71. Chang, R.W., et al., Prerandomization: an alternative to classic 
randomization. The effects on recruitment in a controlled trial of arthroscopy 
for osteoarthrosis of the knee. J Bone Joint Surg Am, 1990. 72(10): p. 1451-5. 
72. Snowdon, C., D. Elbourne, and J. Garcia, Zelen randomization: attitudes of 
parents participating in a neonatal clinical trial. Control Clin Trials, 1999. 
20(2): p. 149-71. 
73. O'Rourke, P.P., et al., Extracorporeal membrane oxygenation and 
conventional medical therapy in neonates with persistent pulmonary 
hypertension of the newborn: a prospective randomized study. Pediatrics, 
1989. 84(6): p. 957-63. 
74. Snowdon, C., J. Garcia, and D. Elbourne, Making sense of randomization; 
responses of parents of critically ill babies to random allocation of treatment in 




75. Schulz, K.F. and D.A. Grimes, Generation of allocation sequences in 
randomised trials: chance, not choice. Lancet, 2002. 359(9305): p. 515-9. 
76. Schulz, K.F. and D.A. Grimes, Blinding in randomised trials: hiding who got 
what. Lancet, 2002. 359(9307): p. 696-700. 
77. Yang, H., et al., Randomized trial of division versus nondivision of the short 
gastric vessels during laparoscopic Nissen fundoplication: 10-year outcomes. 
Ann Surg, 2008. 247(1): p. 38-42. 
78. Crawley, E., et al., Comparing specialist medical care with specialist medical 
care plus the Lightning Process for chronic fatigue syndrome or myalgic 
encephalomyelitis (CFS/ME): study protocol for a randomised controlled trial 
(SMILE Trial). Trials, 2013. 14: p. 444. 
79. Higgins, J.P.T., et al., The Cochrane Collaboration’s tool for assessing risk of 
bias in randomised trials. BMJ, 2011. 343. 
80. Treweek, S., et al., Strategies to improve recruitment to randomised trials. 
Cochrane Database Syst Rev, 2018. 2: p. MR000013. 
81. Hemminki, E., et al., Blinding decreased recruitment in a prevention trial of 
postmenopausal hormone therapy. J Clin Epidemiol, 2004. 57(12): p. 1237-
43. 
82. Avenell, A., et al., The effects of an open design on trial participant 
recruitment, compliance and retention--a randomized controlled trial 
comparison with a blinded, placebo-controlled design. Clin Trials, 2004. 1(6): 
p. 490-8. 
83. Powell, J.T., et al., Final 12-year follow-up of surgery versus surveillance in 
the UK Small Aneurysm Trial. Br J Surg, 2007. 94(6): p. 702-8. 
84. Cook, J.A., The challenges faced in the design, conduct and analysis of 
surgical randomised controlled trials. Trials, 2009. 10(1): p. 9. 
85. McCulloch, P., et al., Randomised trials in surgery: problems and possible 
solutions. BMJ, 2002. 324(7351): p. 1448-51. 
86. Devereaux, P.J., et al., Need for expertise based randomised controlled trials. 
BMJ, 2005. 330(7482): p. 88. 
87. Devereaux, P.J., et al., Participating surgeons' experience with and beliefs in 
the procedures evaluated in a randomized controlled trial. Clin Trials, 2004. 
1(225). 
88. Karanicolas, P.J., F. Farrokhyar, and M. Bhandari, Blinding: Who, what, when, 
why, how? Canadian Journal of Surgery, 2010. 53(5): p. 345-348. 
89. Blencowe, N.S., et al., Standardizing and monitoring the delivery of surgical 
interventions in randomized clinical trials. Br J Surg, 2016. 103(10): p. 1377-
84. 
90. Bowen, J. and S. Hirsch, Recruitment rates and factors affecting recruitment 
for a clinical trial of a putative anti-psychotic agent in the treatment of acute 
schizophrenia. Hum. Psychopharmacol. Clin. Exp., 1992. 7: p. 337–341. 
91. Kaur, G., R.L. Smyth, and P. Williamson, Developing a survey of barriers and 
facilitators to recruitment in randomized controlled trials. Trials, 2012. 13: p. 
218. 
92. Kaur, G., et al., A survey of facilitators and barriers to recruitment to the 
MAGNETIC trial. Trials, 2016. 17(1): p. 607. 
93. Rothmier, J.D., M.V. Lasley, and G.G. Shapiro, Factors Influencing Parental 





94. Sammons, H.M., et al., What motivates British parents to consent for 
research? A questionnaire study. BMC Pediatr, 2007. 7: p. 12. 
95. Peay, H.L., et al., Barriers and facilitators to clinical trial participation among 
parents of children with pediatric neuromuscular disorders. Clin Trials, 2018: 
p. 1740774517751118. 
96. Shilling, V., et al., Processes in recruitment to randomised controlled trials of 
medicines for children (RECRUIT): a qualitative study. Health technology 
assessment (Winchester, England), 2011. 15(15): p. 1-116. 
97. Caldwell, P.H., P.N. Butow, and J.C. Craig, Parents' attitudes to children's 
participation in randomized controlled trials. J Pediatr, 2003. 142(5): p. 554-9. 
98. Donovan, J., et al., Prostate Testing for Cancer and Treatment (ProtecT) 
feasibility study. Health Technol.Assess, 2003. 7(14): p. 1-88. 
99. Fernandez, C.V., et al., Barriers to the enrollment of children in the Children's 
Oncology Group study of very low risk Wilms tumor: a report from the 
Children's Oncology Group. J Pediatr Hematol Oncol, 2011. 33(7): p. 521-3. 
100. Hemming, K., et al., The stepped wedge cluster randomised trial: rationale, 
design, analysis, and reporting. BMJ, 2015. 350: p. h391. 
101. Berry, S.M., J.T. Connor, and R.J. Lewis, The platform trial: an efficient 
strategy for evaluating multiple treatments. JAMA, 2015. 313(16): p. 1619-20. 
102. Hill, A.B., The clinical trial. N Engl J Med, 1952. 247(4): p. 113-9. 
103. Nabulsi, M., Y. Khalil, and J. Makhoul, Parental attitudes towards and 
perceptions of their children's participation in clinical research: a developing-
country perspective. Journal of medical ethics, 2011. 37(7): p. 420-3. 
104. Kupst, M.J., et al., Clinical trials in pediatric cancer: parental perspectives on 
informed consent. J Pediatr Hematol Oncol, 2003. 25(10): p. 787-90. 
105. Kodish, E., et al., Communication of randomization in childhood leukemia 
trials. JAMA, 2004. 291(4): p. 470-5. 
106. Greenley, R.N., et al., Stability of parental understanding of random 
assignment in childhood leukemia trials: an empirical examination of informed 
consent. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology, 2006. 24(6): p. 891-7. 
107. Woolfall, K., et al., Parents' agendas in paediatric clinical trial recruitment are 
different from researchers' and often remain unvoiced: a qualitative study. 
PLoS One, 2013. 8(7): p. e67352. 
108. Eiser, C., et al., Mothers' attitudes to the randomized controlled trial (RCT): 
the case of acute lymphoblastic leukaemia (ALL) in children. Child Care 
Health Dev, 2005. 31(5): p. 517-23. 
109. Byrne-Davis, L.M., et al., Balancing high accrual and ethical recruitment in 
paediatric oncology: a qualitative study of the 'look and feel' of clinical trial 
discussions. BMC medical research methodology, 2010. 10: p. 101. 
110. Harvey, M., et al., 'We knew it was a totally at random thing': parents' 
experiences of being part of a neonatal trial. Trials, 2017. 18(1): p. 361. 
111. Wiley, F.M., et al., Parents' perceptions of randomization in pediatric clinical 
trials. Children Cancer Group. Cancer Pract, 1999. 7(5): p. 248-56. 
112. Vemulakonda, V.M. and J. Jones, Barriers to participation in surgical 
randomized controlled trials in pediatric urology: A qualitative study of key 
stakeholder perspectives. J Pediatr Urol, 2016. 12(3): p. 180.e1-7. 
113. Shilling, V. and B. Young, How do parents experience being asked to enter a 




114. Ward, F.R., Chaos, vulnerability and control: parental beliefs about neonatal 
clinical trials. J Perinatol, 2009. 29(2): p. 156-62. 
115. Glogowska, M., et al., Randomised controlled trial of community based 
speech and language therapy in preschool children. BMJ, 2000. 321(7266): p. 
923-6. 
116. Fried, E., The therapeutic misconception, beneficence, and respect. Account 
Res, 2001. 8(4): p. 331-48. 
117. Chappuy, H., et al., Children's views on their involvement in clinical research. 
Pediatric blood & cancer, 2008. 50(5): p. 1043-6. 
118. Dolan, L.A., et al., Preference assessment of recruitment into a randomized 
trial for adolescent idiopathic scoliosis. J Bone Joint Surg Am, 2008. 90(12): p. 
2594-605. 
119. Angiolillo, A.L., et al., Staged informed consent for a randomized clinical trial 
in childhood leukemia: impact on the consent process. Pediatr Blood Cancer, 
2004. 42(5): p. 433-7. 
120. Carvalho, A.A. and L.R. Costa, Mothers' perceptions of their child's enrollment 
in a randomized clinical trial: poor understanding, vulnerability and 
contradictory feelings. BMC Med Ethics, 2013. 14: p. 52. 
121. Shilling, V., et al., Communication about children's clinical trials as observed 
and experienced: qualitative study of parents and practitioners. PLoS One, 
2011. 6(7): p. e21604. 
122. Caldwell, P.H., P.N. Butow, and J.C. Craig, Pediatricians' attitudes toward 
randomized controlled trials involving children. J Pediatr, 2002. 141(6): p. 798-
803. 
123. Donovan, J., et al., Quality improvement report: Improving design and conduct 
of randomised trials by embedding them in qualitative research: ProtecT 
(prostate testing for cancer and treatment) study. Commentary: presenting 
unbiased information to patients can be difficult. BMJ, 2002. 325(7367): p. 
766-770. 
124. Paramasivan, S., et al., Key issues in recruitment to randomised controlled 
trials with very different interventions: a qualitative investigation of recruitment 
to the SPARE trial (CRUK/07/011). Trials, 2011. 12: p. 78. 
125. Mills, N., et al., Perceptions of equipoise are crucial to trial participation: a 
qualitative study of men in the ProtecT study. Control Clin Trials, 2003. 24(3): 
p. 272-82. 
126. Jepson, M., et al., An observational study showed that explaining 
randomization using gambling-related metaphors and computer-agency 
descriptions impeded randomized clinical trial recruitment. J Clin Epidemiol, 
2018. 99: p. 75-83. 
127. Jepson, M., et al., “It’s what we call a randomised control trial” exploring how 
randomisation is presented by recruiters in RCTs. Trials, 2015. 16((Suppl 
2):O36). 
128. Wilson, J.T., An update on the therapeutic orphan. Pediatrics, 1999. 104(3 Pt 
2): p. 585-90. 
129. Cohen, E., et al., An absence of pediatric randomized controlled trials in 
general medical journals, 1985-2004. J Clin Epidemiol, 2007. 60(2): p. 118-
23. 
130. Pritchard-Jones, K. and S. Europe, Clinical trials for children with cancer in 




European journal of cancer (Oxford, England : 1990), 2008. 44(15): p. 2106-
11. 
131. Cohen, E., et al., Child vs adult randomized controlled trials in specialist 
journals: a citation analysis of trends, 1985-2005. Arch Pediatr Adolesc Med, 
2010. 164(3): p. 283-8. 
132. Barst, R.J., Children deserve the same rights we do: the need for paediatric 
pulmonary arterial hypertension clinical drug development. Heart, 2010. 
96(17): p. 1337-8. 
133. Chalmers, I., et al., Key Concepts for Informed Health Choices: a framework 
for helping people learn how to assess treatment claims and make informed 
choices. BMJ Evidence-Based Medicine, 2018. 23(1): p. 29-33. 
134. Nuffield Council on Bioethics. Medicines research with children: Council 
welcomes EMA class waiver review. 2015  10/05/20018]; Available from: 
http://nuffieldbioethics.org/news/2015/promoting-medicines-research-children-
council-welcomes-emas-review. 
135. Wright, K. The Paediatric Regulation – a work in progress? 2016  10/05/18]; 
Available from: http://nuffieldbioethics.org/blog/2016/the-paediatric-regulation-
a-work-in-progress/. 
136. Smyth, R.L. and A.M. Weindling, Research in children: ethical and scientific 
aspects. Lancet, 1999. 354 Suppl 2: p. SII21-4. 
137. Simar, R., Pediatric Drug Development: The International Conference on 
Harmonization Focus on Clinical Investigations in Children. Drug Information 
Journal, 2000. 34: p. 809-819. 
138. Steinbrook, R., Testing medications in children. N Engl J Med, 2002. 347(18): 
p. 1462-70. 
139. Rheims, S., et al., Greater response to placebo in children than in adults: a 
systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS 
Med, 2008. 5(8): p. e166. 
140. Smyth, R.L., Research with children. Paediatric practice needs better 
evidence--gained in collaboration with parents and children. BMJ, 2001. 
322(7299): p. 1377-8. 
141. Roberts, R., et al., Pediatric drug labeling: improving the safety and efficacy of 
pediatric therapies. JAMA, 2003. 290(7): p. 905-11. 
142. Saint-Raymond, A., D. Brasseur, and N. Seigneuret, [Medicines for children: 
time to act!]. Arch Pediatr, 2005. 12(8): p. 1195-8. 
143. Saint Raymond, A. and D. Brasseur, Development of medicines for children in 
Europe: ethical implications. Paediatr Respir Rev, 2005. 6(1): p. 45-51. 
144. Conroy, S., et al., Survey of unlicensed and off label drug use in paediatric 
wards in European countries. European Network for Drug Investigation in 
Children. BMJ, 2000. 320(7227): p. 79-82. 
145. Crawley, E.M., et al., Clinical and cost-effectiveness of the Lightning Process 
in addition to specialist medical care for paediatric chronic fatigue syndrome: 
randomised controlled trial. Arch Dis Child, 2017. 
146. ME Association. The SMILE trial is published – with press release, science 
media centre ‘expert reactions’, and media coverage | 21 September 2017. 
2017 25 September 2017 May 2018]. 
147. Ginsberg, G.D., et al., Evaluation of child/adult pharmacokinetic differences 
from a database derived from the therapeutic drug literature. Toxicological 




148. Rocchi, F. and P. Tomasi, The development of medicines for children. Part of 
a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, 
Emilio Clementi, and Massimo Molteni. Pharmacol Res, 2011. 64(3): p. 169-
75. 
149. Sauer, P.J. and C.o.E.S.i.P. Ethics Working Group, Research in children. A 
report of the Ethics Working Group of the CESP. Eur J Pediatr, 2002. 161(1): 
p. 1-5. 
150. Crawley, E., The epidemiology of chronic fatigue syndrome/myalgic 
encephalitis in children. Arch Dis Child, 2014. 99(2): p. 171-4. 
151. Kessler, R.C., S. Avenevoli, and K. Ries Merikangas, Mood disorders in 
children and adolescents: an epidemiologic perspective. Biol Psychiatry, 
2001. 49(12): p. 1002-14. 
152. Weller, E.B. and R.A. Weller, Treatment options in the management of 
adolescent depression. J Affect Disord, 2000. 61 Suppl 1: p. 23-8. 
153. Barsness, K.A., et al., IL-1beta induces an exaggerated pro- and anti-
inflammatory response in peritoneal macrophages of children compared with 
adults. Pediatr Surg Int, 2004. 20(4): p. 238-42. 
154. Barsness, K.A., et al., Endotoxin induces an exaggerated interleukin-10 
response in peritoneal macrophages of children compared with adults. J 
Pediatr Surg, 2004. 39(6): p. 912-5; discussion 912-5. 
155. Bylund, D.B. and A.L. Reed, Childhood and Adolescent Depression: Why do 
Children and Adults Respond Differently to Antidepressant Drugs? 
Neurochemistry international, 2007. 51(5): p. 246-253. 
156. Farrell, R., et al., Barriers to participation in industry-sponsored clinical trials in 
pediatric type 2 diabetes. Pediatr Diabetes, 2017. 18(7): p. 574-578. 
157. Rudolf, M.C., et al., A search for the evidence supporting community 
paediatric practice. Arch Dis Child, 1999. 80(3): p. 257-61. 
158. Caldwell, P.H., et al., Clinical trials in children. Lancet, 2004. 364(9436): p. 
803-11. 
159. Bond, M.C. and S. Pritchard, Understanding clinical trials in childhood cancer. 
Paediatr Child Health, 2006. 11(3): p. 148-50. 
160. Ablett, S., C.R. Pinkerton, and G. United Kingdom Children's Cancer Study, 
Recruiting children into cancer trials--role of the United Kingdom Children's 
Cancer Study Group (UKCCSG). Br J Cancer, 2003. 88(11): p. 1661-5. 
161. Cancer Research UK. Children's cancer statistics. 2018; Available from: 
http://www.cancerresearchuk.org/health-professional/cancer-
statistics/childrens-cancers Accessed: 10/05/2018. 
162. Wishart, A., One in three: a son’s journey into the history of science and 
cancer 2006: London: Profile Books. 
163. Whelan, J.S. and L.A. Fern, Poor accrual of teenagers and young adults into 
clinical trials in the UK. Lancet Oncol, 2008. 9(4): p. 306-7. 
164. Tai, E., et al., Understanding and addressing the lack of clinical trial 
enrollment among adolescents with cancer. Pediatrics, 2014. 133 Suppl 3: p. 
S98-s103. 
165. Hough, R., et al., Are survival and mortality rates associated with recruitment 
to clinical trials in teenage and young adult patients with acute lymphoblastic 
leukaemia? A retrospective observational analysis in England. BMJ Open, 
2017. 7(10): p. e017052. 





167. Cancer Research UK, Race For Life. 2018. 
168. Nuffield Council on Bioethics, Statement of aspiration: improving research by 
involving children and young people. 2016. 
169. Regulation No 1901/2006, Regulation (EC) No 1901/2006 of the European 
Parliament and of the Council of 12 December 2006 on medicinal products for 
paediatric use and amending Regulation (EEC) No 1768/92, Directive 
2001/20/EC, Directive 2001/82/EC and Regulation (EC) No 726/2004. . 2006, 
Official J Eur Comm L 378/1: European Parliament  
170. European Medicines Agency. Stimulating the development of medicines for 
children. 2015  10/05/2018]. 
171. Gamble, C., et al., New European Union regulation of clinical trials is 
conflicting on deferred consent in emergency situations. BMJ, 2013. 346: p. 
f667. 
172. Luchtenberg, M., et al., Young People's Experiences of Participation in 
Clinical Trials: Reasons for Taking Part. Am J Bioeth, 2015. 15(11): p. 3-13. 
173. Healthtalk.org. Young people's experience: Clinical trials & medical research. 
2018; Available from: http://www.healthtalk.org/young-peoples-
experiences/clinical-trials-medical-research/topics. 
174. Bower, P., et al., Interventions to improve recruitment and retention in clinical 
trials: a survey and workshop to assess current practice and future priorities. 
Trials, 2014. 15: p. 399. 
175. Treweek, S., et al., Methods to improve recruitment to randomised controlled 
trials: Cochrane systematic review and meta-analysis. BMJ Open, 2013. 3(2). 
176. Healy, P., et al., Identifying trial recruitment uncertainties using a James Lind 
Alliance Priority Setting Partnership - the PRioRiTy (Prioritising Recruitment in 
Randomised Trials) study. Trials, 2018. 19(1): p. 147. 
177. Rooshenas, L., et al., Conveying Equipoise during Recruitment for Clinical 
Trials: Qualitative Synthesis of Clinicians' Practices across Six Randomised 
Controlled Trials. PLoS Med, 2016. 13(10): p. e1002147. 
178. Jerosch-Herold, C., et al., A questionnaire-based survey of participants' 
decisions regarding recruitment and retention in a randomised controlled trial - 
lessons learnt from the SCoRD trial. Contemp Clin Trials, 2011. 32(3): p. 363-
8. 
179. Ross, S., et al., Barriers to participation in randomised controlled trials: a 
systematic review. J Clin Epidemiol, 1999. 52(12): p. 1143-56. 
180. Howard, L., et al., Why is recruitment to trials difficult? An investigation into 
recruitment difficulties in an RCT of supported employment in patients with 
severe mental illness. Contemp Clin Trials, 2009. 30(1): p. 40-6. 
181. Toerien, M., et al., A review of reporting of participant recruitment and 
retention in RCTs in six major journals. Trials, 2009. 10: p. 52. 
182. Treweek, S., et al., Meeting the challenges of recruitment to multicentre, 
community-based, lifestyle-change trials: a case study of the BeWEL trial. 
Trials, 2013. 14: p. 436. 
183. McDonald, A.M., et al., What influences recruitment to randomised controlled 
trials? A review of trials funded by two UK funding agencies. Trials, 2006. 7: p. 
9. 
184. Schandelmaier, S., et al., Premature Discontinuation of Randomized Trials in 
Critical and Emergency Care: A Retrospective Cohort Study. Crit Care Med, 




185. Sully, B.G., S.A. Julious, and J. Nicholl, A reinvestigation of recruitment to 
randomised, controlled, multicenter trials: a review of trials funded by two UK 
funding agencies. Trials, 2013. 14: p. 166. 
186. Gul, R.B. and P.A. Ali, Clinical trials: the challenge of recruitment and 
retention of participants. J Clin Nurs, 2010. 19(1-2): p. 227-33. 
187. Walters, S.J., et al., Recruitment and retention of participants in randomised 
controlled trials: a review of trials funded and published by the United 
Kingdom Health Technology Assessment Programme. BMJ Open, 2017. 7(3): 
p. e015276. 
188. Kaur, G., Recruitment to Randomised Controlled Trials with Children, in 
Psychology. 2016, University of Liverpool. 
189. Huntington, C., et al., Lessons learned on recruitment and retention in hard-
to-reach families in a phase III randomised controlled trial of preparatory 
information for children undergoing general anaesthesia. BMC Oral Health, 
2017. 17(1): p. 122. 
190. Dufetelle, E., G.W. t Jong, and F. Kaguelidou, Randomized controlled trials in 
pediatric patients had higher completion rates than adult trials: a cross-
sectional study. J Clin Epidemiol, 2018. 100: p. 53-60. 
191. Amstutz, A., et al., Discontinuation and non-publication of randomised clinical 
trials supported by the main public funding body in Switzerland: a 
retrospective cohort study. BMJ Open, 2017. 7(7): p. e016216. 
192. Alturki, R., et al., Premature trial discontinuation often not accurately reflected 
in registries: comparison of registry records with publications. J Clin 
Epidemiol, 2017. 81: p. 56-63. 
193. Ioannidis, J.P., Clinical trials: what a waste. Bmj, 2014. 349: p. g7089. 
194. Chapman, S.J., et al., Discontinuation and non-publication of surgical 
randomised controlled trials: observational study. BMJ, 2014. 349: p. g6870. 
195. Ross, J.S., et al., Publication of NIH funded trials registered in 
ClinicalTrials.gov: cross sectional analysis. BMJ, 2012. 344: p. d7292. 
196. Ong, E.G., et al., Randomized clinical trial of glutamine-supplemented versus 
standard parenteral nutrition in infants with surgical gastrointestinal disease. 
Br J Surg, 2012. 99(7): p. 929-38. 
197. Smyth, R.M., et al., The natural history of conducting and reporting clinical 
trials: interviews with trialists. Trials, 2015. 16: p. 16. 
198. Stead, M., et al., Understanding the potential and challenges of adenoma 
treatment as a prevention opportunity: insights from the BeWEL formative 
study. Prev Med, 2012. 54(1): p. 97-103. 
199. Paramasivan, S., et al., A simple technique to identify key recruitment issues 
in randomised controlled trials: Q-QAT - Quanti-Qualitative Appointment 
Timing. Trials, 2015. 16: p. 88. 
200. Woolfall, K., et al., Doing challenging research studies in a patient-centred 
way: a qualitative study to inform a randomised controlled trial in the 
paediatric emergency care setting. BMJ Open, 2014. 4(5): p. e005045. 
201. De Salis, I., et al., Qualitative research to improve RCT recruitment: issues 
arising in establishing research collaborations. Contemp Clin Trials, 2008. 
29(5): p. 663-70. 
202. De Salis, I., et al., Using qualitative research methods to improve recruitment 
to randomized controlled trials: the Quartet study. J Health Serv Res Policy, 




203. Avery, K.N., et al., The feasibility of a randomized controlled trial of 
esophagectomy for esophageal cancer--the ROMIO (Randomized 
Oesophagectomy: Minimally Invasive or Open) study: protocol for a 
randomized controlled trial. Trials, 2014. 15: p. 200. 
204. Crawley, E., et al., The feasibility and acceptability of conducting a trial of 
specialist medical care and the Lightning Process in children with chronic 
fatigue syndrome: feasibility randomized controlled trial (SMILE study). Trials, 
2013. 14: p. 415. 
205. Robinson, L., et al., Identifying the participant characteristics that predict 
recruitment and retention of participants to randomised controlled trials 
involving children: a systematic review. Trials, 2016. 17(1): p. 294. 
206. Fletcher, B., et al., Improving the recruitment activity of clinicians in 
randomised controlled trials: a systematic review. BMJ Open, 2012. 2(1): p. 
e000496. 
207. Donovan, J.L., et al., Development of a complex intervention improved 
randomization and informed consent in a randomized controlled trial. J Clin 
Epidemiol, 2009. 62(1): p. 29-36. 
208. Lewin, S., C. Glenton, and A.D. Oxman, Use of qualitative methods alongside 
randomised controlled trials of complex healthcare interventions: 
methodological study. BMJ, 2009. 339: p. b3496. 
209. O'Cathain, A., et al., Maximising the value of combining qualitative research 
and randomised controlled trials in health research: the QUAlitative Research 
in Trials (QUART) study--a mixed methods study. Health Technol Assess, 
2014. 18(38): p. 1-197, v-vi. 
210. Houghton, C., et al., Factors that impact on recruitment to randomised trials in 
health care: a qualitative evidence synthesis (Protocol). Cochrane Database 
of Systematic Reviews, 2017. 
211. Rick, J., et al., Systematic techniques for assisting recruitment to trials 
(START): study protocol for embedded, randomized controlled trials. Trials, 
2014. 15(1): p. 407. 
212. Treweek, S., et al., Strategies to improve recruitment to randomised controlled 
trials. Cochrane Database Syst Rev, 2010(1): p. MR000013. 
213. Caldwell, P.H., et al., Strategies for increasing recruitment to randomised 
controlled trials: systematic review. PLoS Med, 2010. 7(11): p. e1000368. 
214. Parikh, Y., M. Mason, and K. Williams, Researchers' perspectives on pediatric 
obesity research participant recruitment. Clin Transl Med, 2016. 5(1): p. 20. 
215. Herbert, L.J., et al., Factors Associated with Recruitment and Retention in 
Randomized Controlled Trials of Behavioral Interventions for Patients with 
Pediatric Type 1 Diabetes. J Clin Psychol Med Settings, 2016. 23(2): p. 112-
25. 
216. Hein, I.M., et al., Why do children decide not to participate in clinical research: 
a quantitative and qualitative study. Pediatr Res, 2015. 78(1): p. 103-8. 
217. Weintraub, J.A. and C.E. Breland, Challenges, benefits, and factors to 
enhance recruitment and inclusion of children in pediatric dental research. Int 
J Paediatr Dent, 2015. 25(5): p. 310-6. 
218. Hoberman, A., et al., Factors that influence parental decisions to participate in 





219. Bhatnagar, S., et al., Development and impact of an intervention to boost 
recruitment in a multicenter pediatric randomized clinical trial. Clin Pediatr 
(Phila), 2014. 53(2): p. 151-7. 
220. Barratt, R., et al., Why families choose not to participate in research: feedback 
from non-responders. J Paediatr Child Health, 2013. 49(1): p. 57-62. 
221. Coutinho, M.T., et al., Factors associated with recruitment and retention of 
diverse children with asthma. Child Health Care, 2014. 43(2): p. 132-150. 
222. Tromp, K. and S. Vathorst, Gatekeeping by Professionals in Recruitment of 
Pediatric Research Participants: Indeed an Undesirable Practice. Am J 
Bioeth, 2015. 15(11): p. 30-2. 
223. Sharkey, K., et al., Clinician gate-keeping in clinical research is not ethically 
defensible: an analysis. J Med Ethics, 2010. 36(6): p. 363-6. 
224. Greenberg, R.G., et al., Parents' perceived obstacles to pediatric clinical trial 
participation: Findings from the clinical trials transformation initiative. Contemp 
Clin Trials Commun, 2018. 9: p. 33-39. 
225. O'Hara, C.B., et al., A qualitative feasibility study to inform a randomised 
controlled trial of fluid bolus therapy in septic shock. Arch Dis Child, 2018. 
103(1): p. 28-32. 
226. Volkening, L.K., et al., Recruitment Into a Pediatric Continuous Glucose 
Monitoring RCT. J Diabetes Sci Technol, 2017. 11(1): p. 100-107. 
227. Farrington, C., et al., Factors Affecting Recruitment of Participants for Studies 
of Diabetes Technology in Newly Diagnosed Youth with Type 1 Diabetes: A 
Qualitative Focus Group Study with Parents and Children. Diabetes Technol 
Ther, 2016. 18(9): p. 568-73. 
228. Tait, A.R., et al., Factors that influence parents' decisions to consent to their 
child's participation in clinical anesthesia research. Anesth Analg, 1998. 86(1): 
p. 50-3. 
229. Patterson, C.A., et al., Clinical Trial Decision Making in Pediatric Sickle Cell 
Disease: A Qualitative Study of Perceived Benefits and Barriers to 
Participation. J Pediatr Hematol Oncol, 2015. 37(6): p. 415-22. 
230. Barakat, L.P., et al., Initial development of a questionnaire evaluating 
perceived benefits and barriers to pediatric clinical trials participation. 
Contemp Clin Trials, 2013. 34(2): p. 218-26. 
231. Sauers-Ford, H.S., et al., Improving Recruitment and Retention Rates in a 
Randomized Controlled Trial. Pediatrics, 2017. 139(5). 
232. Zwaanswijk, M., et al., Young patients', parents', and survivors' 
communication preferences in paediatric oncology: results of online focus 
groups. BMC Pediatr, 2007. 7: p. 35. 
233. Caldwell, P.H., The Recruitment of Children to Randomised Controlled Trials, 
in Paediatrics and Child Health. 2003, University of Sydney. 
234. Breland-Noble, A.M., et al., "Mama just won't accept this": adult perspectives 
on engaging depressed African American teens in clinical research and 
treatment. J Clin Psychol Med Settings, 2011. 18(3): p. 225-34. 
235. May, D.E., et al., Factors associated with recruitment and screening in the 
Treatment for Adolescents With Depression Study (TADS). J Am Acad Child 
Adolesc Psychiatry, 2007. 46(7): p. 801-10. 
236. Breland-Noble, A.M., et al., Engaging depressed African American 
adolescents in treatment: lessons from the AAKOMA PROJECT. J Clin 




237. Bean, M.K., et al., Impact of motivational interviewing on engagement in a 
parent-exclusive paediatric obesity intervention: randomized controlled trial of 
NOURISH+MI. Pediatr Obes, 2019. 14(4): p. e12484. 
238. Nguyen, T.T., et al., Challenging recruitment of youth with type 2 diabetes into 
clinical trials. J Adolesc Health, 2014. 54(3): p. 247-54. 
239. Close, S., et al., Using information technology and social networking for 
recruitment of research participants: experience from an exploratory study of 
pediatric Klinefelter syndrome. J Med Internet Res, 2013. 15(3): p. e48. 
240. Wendler, D. and T. Jenkins, Children's and their parents' views on facing 
research risks for the benefit of others. Arch Pediatr Adolesc Med, 2008. 
162(1): p. 9-14. 
241. Franciscus, M., et al., Recruitment and retention of participants for an 
international type 1 diabetes prevention trial: a coordinators' perspective. Clin 
Trials, 2014. 11(2): p. 150-8. 
242. Banteka, M., V. Tailor, and A. Dahlmann-Noor, Delivering clinical trials and 
observational studies in child eye health: a nationwide survey in the United 
Kingdom. J Pediatr Ophthalmol Strabismus, 2015. 52(2): p. 106-12. 
243. Greenberg, R.G., et al., Perceived barriers to pediatrician and family 
practitioner participation in pediatric clinical trials: Findings from the Clinical 
Trials Transformation Initiative. Contemp Clin Trials Commun, 2018. 9: p. 7-
12. 
244. Powell, K., et al., Exceeding the recruitment target in a primary care paediatric 
trial: an evaluation of the Choice of Moisturiser for Eczema Treatment 
(COMET) feasibility randomised controlled trial. Trials, 2016. 17(1): p. 550. 
245. Djulbegovic, B., Uncertainty and equipoise: at interplay between 
epistemology, decision making and ethics. Am J Med Sci, 2011. 342(4): p. 
282-9. 
246. Donovan, J.L., et al., The intellectual challenges and emotional consequences 
of equipoise contributed to the fragility of recruitment in six randomized 
controlled trials. J Clin Epidemiol, 2014. 67(8): p. 912-20. 
247. Mills, N., et al., Training recruiters to randomized trials to facilitate recruitment 
and informed consent by exploring patients' treatment preferences. Trials, 
2014. 15: p. 323. 
248. Wasiewski, W.W. and K.C. Johnston, Clinical trials, devices, unproven 
treatments, and clinical equipoise. Stroke, 2009. 40(6): p. e441-2. 
249. Warshaw, M.G., et al., The interaction between equipoise and logistics in 
clinical trials: A case study. Clinical Trials, 2017. 14(3): p. 314-318. 
250. Hetherton, J., A. Matheson, and M. Robson, Recruitment by GPs during 
consultations in a primary care randomized controlled trial comparing 
computerized psychological therapy with clinical psychology and routine GP 
care: problems and possible solutions. Primary Health Care Research and 
Development 2004. 5: : p. 5–10. 
251. Freedman, B., Equipoise and the ethics of clinical research. N Engl J Med, 
1987. 317(3): p. 141-5. 
252. Hellman, S. and D.S. Hellman, Of mice but not men. Problems of the 
randomized clinical trial. N Engl J Med, 1991. 324(22): p. 1585-9. 
253. Lilford, R.J. and J. Jackson, Equipoise and the ethics of randomization. J R 




254. De Haan, E., et al., Prediction of outcome and early vs. late improvement in 
OCD patients treated with cognitive behaviour therapy and pharmacotherapy. 
Acta Psychiatr Scand, 1997. 96(5): p. 354-61. 
255. Gifford, F., Freedman's 'clinical equipoise' and sliding-scale all-dimensions-
considered equipoise'. J Med Philos, 2000. 25(4): p. 399-426. 
256. van der Graaf, R. and J.J. van Delden, Equipoise should be amended, not 
abandoned. Clin Trials, 2011. 8(4): p. 408-16. 
257. Baum, M., New approach for recruitment into randomised controlled trials: 
clinical trials are ethically impossible. Lancet, 1993. 341: p. 812-813. 
258. Charles, C., A. Gafni, and T. Whelan, Shared decision-making in the medical 
encounter: what does it mean? (or it takes at least two to tango). Soc Sci 
Med, 1997. 44(5): p. 681-92. 
259. Charles, C., A. Gafni, and T. Whelan, Decision-making in the physician-
patient encounter: revisiting the shared treatment decision-making model. Soc 
Sci Med, 1999. 49(5): p. 651-61. 
260. Morris, A.D., A.L. Zaritsky, and G. LeFever, Evaluation of ethical conflicts 
associated with randomized, controlled trials in critically ill children. Crit Care 
Med, 2000. 28(4): p. 1152-6. 
261. Hales, G., A. Beveridge, and D. Smith, The conflicting roles of clinicians 
versus investigators in HIV randomised clinical trials. Culture, Health & 
Sexuality, 2001. 3(1): p. 67-79. 
262. Ulucanlar, S., Randomised Controlled Trials and Equipoise, in Department of 
Social Medicine. 2010, University of Bristol. 
263. Ashcroft, R.E., et al., Implications of socio-cultural contexts for the ethics of 
clinical trials. Health Technol Assess, 1997. 1(9): p. i-iv, 1-65. 
264. Appelbaum, P.S., et al., Therapeutic misconception in research subjects: 
development and validation of a measure. Clin Trials, 2012. 9(6): p. 748-61. 
265. Dresser, R., The ubiquity and utility of the therapeutic misconception. Soc 
Philos Policy, 2002. 19(2): p. 271-94. 
266. Veatch, R.M., Why researchers cannot establish equipoise. Am J Bioeth, 
2006. 6(4): p. 55-7. 
267. Veatch, R.M., The irrelevance of equipoise. J Med Philos, 2007. 32(2): p. 167-
83. 
268. Jansen, L.A., A closer look at the bad deal trial: beyond clinical equipoise. 
Hastings Cent Rep, 2005. 35(5): p. 29-36. 
269. Sackett, D.L., Equipoise, a term whose time (if it ever came) has surely gone. 
CMAJ, 2000. 163(7): p. 835-6. 
270. Pletsch, P.K. and P.E. Stevens, Inclusion of children in clinical research: 
Lessons learned from mothers of diabetic children. Clinical Nursing Research, 
2001. 10: p. 140- 162. 
271. Hey, S.P., et al., Is the concept of clinical equipoise still relevant to research? 
BMJ, 2017. 359: p. j5787. 
272. Hey, S.P., et al., Research ethics for emerging trial designs: does equipoise 
need to adapt? BMJ, 2018. 360: p. k226. 
273. Garcia, J., D. Elbourne, and C. Snowdon, Equipoise: a case study of the 
views of clinicians involved in two neonatal trials. Clin Trials, 2004. 1(2): p. 
170-8. 
274. Ashcroft, R., Equipoise, knowledge and ethics in clinical research and 




275. Marquis, D., Leaving therapy to chance. Hastings Cent Rep, 1983. 13(4): p. 
40-7. 
276. Marquis, D., An argument that all prerandomized clinical trials are unethical. J 
Med Philos, 1986. 11(4): p. 367-83. 
277. Marquis, D., How to resolve an ethical dilemma concerning randomized 
clinical trials. N Engl J Med, 1999. 341(9): p. 691-3. 
278. Tomlin, Z., et al., Patient advocacy and patient centredness in participant 
recruitment to randomized-controlled trials: implications for informed consent. 
Health Expect, 2012. 
279. King, M., et al., Conceptual framework and systematic review of the effects of 
participants' and professionals' preferences in randomised controlled trials. 
Health technology assessment (Winchester, England), 2005. 9(35): p. 1-186, 
iii-iv. 
280. Harrop, E., et al., Why do patients decline surgical trials? Findings from a 
qualitative interview study embedded in the Cancer Research UK BOLERO 
trial (Bladder cancer: Open versus Lapararoscopic or RObotic cystectomy). 
Trials, 2016. 17(1): p. 35. 
281. Johnson, L.C., et al., Sampling bias and other methodological threats to the 
validity of health survey research. Int J Stress Mgmt, 2000. 7((4)): p. 247–67. 
282. Everitt, B.S., Analysis of drop-out data in treatment trials. Br J Psychiatry, 
1998. 173: p. 271. 
283. Mills, E.J., et al., Barriers to participation in clinical trials of cancer: a meta-
analysis and systematic review of patient-reported factors. Lancet Oncol, 
2006. 7(2): p. 141-8. 
284. McPherson, K. and A. Britton, The impact of patient treatment preferences on 
the interpretation of randomised controlled trials. Eur J Cancer, 1999. 35(11): 
p. 1598-602. 
285. Bell, M.L., et al., Differential dropout and bias in randomised controlled trials: 
when it matters and when it may not. BMJ, 2013. 346: p. e8668. 
286. Thorstensson, C.A., et al., Choosing surgery: patients' preferences within a 
trial of treatments for anterior cruciate ligament injury. A qualitative study. 
BMC Musculoskelet Disord, 2009. 10: p. 100. 
287. Steidtmann, D., et al., Patient treatment preference as a predictor of response 
and attrition in treatment for chronic depression. Depress Anxiety, 2012. 
29(10): p. 896-905. 
288. Torgerson, D. and J.K. Moffett, Patient preference and validity of randomized 
controlled trials. JAMA, 2005. 294(1): p. 41-2; author reply 42. 
289. Preference Collaborative Review Group, et al., Patients’ preferences within 
randomised trials: systematic review and patient level meta-analysis. Vol. 337. 
2008. 
290. Cook, T.D. and D.T. Campbell, Quasi-experimentation: design and analysis 
issues for field settings. 1979, Chicago: Rand McNally. 
291. Morgan-Trimmer, S., et al., Family preferences for home or hospital care at 
diagnosis for children with diabetes in the DECIDE study. Diabet Med, 2016. 
33(1): p. 119-24. 
292. King, M., et al., Impact of participant and physician intervention preferences 
on randomized trials: a systematic review. JAMA, 2005. 293(9): p. 1089-99. 
293. Kearney, A., et al., Development of an online resource for recruitment 
research in clinical trials to organise and map current literature. Clin Trials, 




294. Bower, P., et al., Patient preferences in randomised controlled trials: 
conceptual framework and implications for research. Soc Sci Med, 2005. 
61(3): p. 685-95. 
295. Bandura, A., Self-efficacy: the exercise of control. 1997, New York: : W.H. 
Freeman and Company. 
296. Ashok, P.W., et al., A randomized comparison of medical abortion and 
surgical vacuum aspiration at 10-13 weeks gestation. Hum Reprod, 2002. 
17(1): p. 92-8. 
297. Roland, M. and D. Torgerson, Understanding controlled trials: what outcomes 
should be measured? BMJ, 1998. 317(7165): p. 1075. 
298. Ghanizadeh, A., M.R. Mohammadi, and G.R. Dehbozorgi, Children and Their 
Parent's Perceptions of Symptom Severity and Treatment Preference for 
Tourette Syndrome. Iran J Psychiatry, 2010. 5(3): p. 93-6. 
299. Young, B., et al., Parents' experiences of their children's presence in 
discussions with physicians about Leukemia. Pediatrics, 2011. 127(5): p. 
e1230-8. 
300. Young, B., et al., Managing communication with young people who have a 
potentially life threatening chronic illness: qualitative study of patients and 
parents. BMJ, 2003. 326(7384): p. 305. 
301. Cahill, P. and A. Papageorgiou, Triadic communication in the primary care 
paediatric consultation: a review of the literature. Br J Gen Pract, 2007. 
57(544): p. 904-11. 
302. Nguyen, B., et al., Recruitment challenges and recommendations for 
adolescent obesity trials. J Paediatr Child Health, 2012. 48(1): p. 38-43. 
303. Taylor, K.M., R.G. Margolese, and C.L. Soskolne, Physicians' reasons for not 
entering eligible patients in a randomized clinical trial of surgery for breast 
cancer. N Engl J Med, 1984. 310(21): p. 1363-7. 
304. Kaas, R., A.A. Hart, and E.J. Rutgers, The impact of the physician on the 
accrual to randomized clinical trials in patients with primary operable breast 
cancer. Breast, 2005. 14(4): p. 310-6. 
305. Phillips, L.J., et al., Randomized controlled trial of interventions for young 
people at ultra-high risk of psychosis: study design and baseline 
characteristics. Aust N Z J Psychiatry, 2009. 43(9): p. 818-29. 
306. Young, B., Shilling, V., Hickey, H., Sowden, E., Smyth, R. L., & Williamson, P. 
R., What parents think about being approached about children’s trials, how 
this differs from what practitioners expect, and what this tells us about 
enhancing recruitment. Trials,, 2011. 12(Suppl 1), A116. 
307. Varma, S., T. Jenkins, and D. Wendler, How do children and parents make 
decisions about pediatric clinical research? . Journal of Pediatric Hematology 
2008. 30(823-828). 
308. Happ, M.B., et al., Parent and child perceptions of a self-regulated, home-
based exercise program for children with cystic fibrosis. Nurs Res, 2013. 
62(5): p. 305-14. 
309. Fogas, B.S., J.R. Oesterheld, and R.I. Shader, A retrospective study of 
children's perceptions of participation as clinical research subjects in a 
minimal risk study. J Dev Behav Pediatr, 2001. 22(4): p. 211-6. 
310. Wagner, K.D., M. Martinez, and T. Joiner, Youths' and their parents' attitudes 
and experiences about participation in psychopharmacology treatment 




311. Broome ME, R.D., Hall JM. , Children in Research: The Experience of Ill 
Children and Adolescents. J Fam Nurs, 2001. 7:: p. 32–49. 
312. Cherrill, J., et al., Clinical trials: the viewpoint of children. Arch Dis Child, 
2007. 92(8): p. 712-3. 
313. Cherrill, J., et al., Clinical trials: the viewpoint of children with a chronic illness 
compared with healthy children. Arch Dis Child, 2010. 95(3): p. 229-32. 
314. Wolthers, O.D., A questionnaire on factors influencing children's assent and 
dissent to non-therapeutic research. J Med Ethics, 2006. 32(5): p. 292-7. 
315. Stevens, P.E. and P.K. Pletsch, Ethical issues of informed consent: mothers' 
experiences enrolling their children in bone marrow transplantation research. 
Cancer Nurs, 2002. 25(2): p. 81-7. 
316. Masiye, F., et al., Why mothers choose to enrol their children in malaria 
clinical studies and the involvement of relatives in decision making: evidence 
from Malawi. Malawi Med J, 2008. 20(2): p. 50-6. 
317. Fisher, H.R., C. McKevitt, and A. Boaz, Why do parents enroll their children in 
research: a narrative synthesis. J Med Ethics, 2011. 37(9): p. 544-51. 
318. Vanhelst, J., et al., Effect of child health status on parents' allowing children to 
participate in pediatric research. BMC Med Ethics, 2013. 14: p. 7. 
319. Harth, S.C. and Y.H. Thong, Sociodemographic and motivational 
characteristics of parents who volunteer their children for clinical research: a 
controlled study. BMJ, 1990. 300(6736): p. 1372-5. 
320. van Stuijvenberg, M., et al., Informed consent, parental awareness, and 
reasons for participating in a randomised controlled study. Arch Dis Child, 
1998. 79(2): p. 120-5. 
321. Langley, J.M., et al., Parental willingness to enter a child in a controlled 
vaccine trial. Clin Invest Med, 1998. 21(1): p. 12-6. 
322. Tait, A.R., T. Voepel-Lewis, and S. Malviya, Factors that influence parents' 
assessments of the risks and benefits of research involving their children. 
Pediatrics, 2004. 113(4): p. 727-32. 
323. Glogowska, S.R., et al., Who's Afraid of the Randomised Controlled Trial? 
Parents' Views of an SLT Research Study. International Journal of Language 
& Communication Disorders, 2001. Vol. 36, No. s1: p. Pages 499-504. 
324. McCann, S.K., M.K. Campbell, and V.A. Entwistle, Reasons for participating 
in randomised controlled trials: conditional altruism and considerations for 
self. Trials, 2010. 11: p. 31. 
325. Woodgate, R.L. and R.A. Yanofsky, Parents' experiences in decision making 
with childhood cancer clinical trials. Cancer Nurs, 2010. 33(1): p. 11-8. 
326. Jollye, An exploratory study to determine how parents decide whether to enrol 
their infants into neonatal clinical trials. Journal of Neonatal Nursing, 2009. 15: 
p. 18-24. 
327. Gammelgaard, A., L.E. Knudsen, and H. Bisgaard, Perceptions of parents on 
the participation of their infants in clinical research. Arch Dis Child, 2006. 
91(12): p. 977-80. 
328. Hoehn, K.S., et al., What factors are important to parents making decisions 
about neonatal research? Arch Dis Child Fetal Neonatal Ed, 2005. 90(3): p. 
F267-9. 
329. Mason, S.A. and P.J. Allmark, Obtaining informed consent to neonatal 
randomised controlled trials: interviews with parents and clinicians in the 




330. Hayman, R.M., et al., Participation in research: informed consent, motivation 
and influence. J Paediatr Child Health, 2001. 37(1): p. 51-4. 
331. Fairhead, J., M. Leach, and M. Small, Public engagement with science? Local 
understandings of a vaccine trial in the Gambia. J Biosoc Sci, 2006. 38(1): p. 
103-16. 
332. Zupancic, J.A., et al., Determinants of parental authorization for involvement 
of newborn infants in clinical trials. Pediatrics, 1997. 99(1): p. E6. 
333. World Medical Organization, Declaration of Helsinki, in Ethical Principles for 
Medical Research Involving Human Subjects, W.M.A.D.o. Helsinki, Editor. 
1964. 
334. General Assembly of the World Medical, A., World Medical Association 
Declaration of Helsinki: ethical principles for medical research involving 
human subjects. J Am Coll Dent, 2014. 81(3): p. 14-8. 
335. Rothman, K.J., Declaration of Helsinki should be strengthened. BMJ, 2000. 
321(7258): p. 442-5. 
336. Lilford, R.J. and B. Djulbegovic, Declaration of Helsinki should be 
strengthened. Equipoise is essential principle of human experimentation. 
BMJ, 2001. 322(7281): p. 299-300. 
337. Levine, R.J. and K.A. Lebacqz, Ethical considerations in clinical trials. Clin 
Pharmacol Ther, 1979. 25(5): p. 728-41. 
338. Convention on the Rights of the Child., in UN GA Res 44/25. 1990. 
339. Nuffield Council on Bioethics. Children and clinical research: ethical issues: 
Stakeholder group meeting. 2014; Available from: 
http://nuffieldbioethics.org/news/2014/young-people-assess-progress-of-
council-s-project. 
340. Woolfall, K., et al., 15 minute consultation: an evidence-based approach to 
research without prior consent (deferred consent) in neonatal and paediatric 
critical care trials. Arch Dis Child Educ Pract Ed, 2015. 
341. Roper, L., et al., Children's views on research without prior consent in 
emergency situations: a UK qualitative study. BMJ Open, 2018. 8(6): p. 
e022894. 
342. ICH Guidelines for Good Clinical Practice E6(R1), T.I.C.f.H.o.T.R.f.P.f.H.U. 
(ICH), Editor. 1996. 
343. Beauchamp T and C. J., Principles of biomedical ethics. 5th ed. 2001, 
Oxford:: Oxford University Press. 
344. Leikin, S.L., Minors' assent or dissent to medical treatment. J Pediatr, 1983. 
102(2): p. 169-76. 
345. National Institute for Health Research Clinical Research Network, Introduction 
to good clinical practice (GCP): a practical guide to ethical and scientific 
quality standards in clinical research. , N.C.W. Development, Editor. 2012: 
Leeds: . 
346. Alderson, P., Competent children? Minors' consent to health care treatment 
and research. Soc Sci Med, 2007. 65(11): p. 2272-83. 
347. Broome, M.E., et al., Children in research: new perspectives and practices for 
informed consent. IRB, 2003. Suppl 25(5): p. S20-S23. 
348. Kodish, E., Informed consent for pediatric research: is it really possible? J 
Pediatr, 2003. 142(2): p. 89-90. 
349. Chappuy, H., et al., Parental consent in paediatric clinical research. Arch Dis 




350. Sammons, H.M., et al., Research with children and young people: not on 
them. Arch Dis Child, 2016. 101(12): p. 1086-1089. 
351. Tait, A.R., et al., Improving the readability and processability of a pediatric 
informed consent document: effects on parents' understanding. Arch Pediatr 
Adolesc Med, 2005. 159(4): p. 347-52. 
352. Caldwell, P.H., et al., Standard 1: consent and recruitment. Pediatrics, 2012. 
129 Suppl 3: p. S118-23. 
353. Solomon-Moore, E., et al., Roles of mothers and fathers in supporting child 
physical activity: a cross-sectional mixed-methods study. BMJ Open, 2018. 
8(1): p. e019732. 
354. Barkin, S.L., et al., Changing overweight Latino preadolescent body mass 
index: the effect of the parent-child dyad. Clin Pediatr (Phila), 2011. 50(1): p. 
29-36. 
355. Clarke, J.L., et al., Parent and child perceptions of school-based obesity 
prevention in England: a qualitative study. BMC Public Health, 2015. 15: p. 
1224. 
356. Hurling, R., et al., Automated coaching to help parents increase their 
children's brushing frequency: an exploratory trial. Community Dent Health, 
2013. 30(2): p. 88-93. 
357. Crawley, E., et al., Comparing specialist medical care with specialist medical 
care plus the Lightning Process for Chronic Fatigue Syndrome or Myalgic 
Encephalopathy (CFS/ME) Randomised Controlled Trial. SMILE – Specialist 
Medical Intervention & Lightning Evaluation. 2012, University of Bristol. 
358. Hutchings, N., et al., CONTRACT Study - CONservative TReatment of 
Appendicitis in Children (feasibility): study protocol for a randomised 
controlled Trial. Trials, 2018. 19(1): p. 153. 
359. Brigden, A., et al., Managed Activity Graded Exercise iN Teenagers and pre-
Adolescents (MAGENTA) feasibility randomised controlled trial: study 
protocol. BMJ Open, 2016. 6(7): p. e011255. 
360. Baos, S., et al., Investigating the effectiveness and cost-effectiveness of 
FITNET-NHS (Fatigue In Teenagers on the interNET in the NHS) compared 
to Activity Management to treat paediatric chronic fatigue syndrome 
(CFS)/myalgic encephalomyelitis (ME): protocol for a randomised controlled 
trial. Trials, 2018. 19(1): p. 136. 
361. Christie, D. and R. Viner, Adolescent development. BMJ, 2005. 330(7486): p. 
301-304. 
362. Ondrusek, N., et al., Empirical examination of the ability of children to consent 
to clinical research. J Med Ethics, 1998. 24(3): p. 158-65. 
363. Crain, W.C., Theories of Developmental Concepts and Applications. . 1980, 
Englewood Cliffs, NJ, Prentice-Hall   
364. Giedd, J.N., Structural magnetic resonance imaging of the adolescent brain. 
Ann N Y Acad Sci, 2004. 1021: p. 77-85. 
365. Tait, A.R., T. Voepel-Lewis, and S. Malviya, Participation of children in clinical 
research: factors that influence a parent's decision to consent. 
Anesthesiology, 2003. 99(4): p. 819-25. 
366. Modi, N., et al., Guidance on clinical research involving infants, children and 
young people: an update for researchers and research ethics committees. 




367. Royal College of Paediatrics Child Health: ethics advisory committee and D. 
Hull, Guidelines for the ethical conduct of medical research involving children. 
Arch.Dis.Child, 2000. 82: p. 177-1. 
368. Eder, M.L., et al., Improving informed consent: suggestions from parents of 
children with leukemia. Pediatrics, 2007. 119(4): p. e849-59. 
369. Yap, T.Y., et al., A physician-directed intervention: teaching and measuring 
better informed consent. Acad Med, 2009. 84(8): p. 1036-42. 
370. Johnson, L.M., et al., Practical communication guidance to improve phase 1 
informed consent conversations and decision-making in pediatric oncology. 
Cancer, 2015. 121(14): p. 2439-48. 
371. Woolfall, K., et al., How experience makes a difference: practitioners' views on 
the use of deferred consent in paediatric and neonatal emergency care trials. 
BMC Med Ethics, 2013. 14: p. 45. 
372. Woolfall, K.e.a., Research without prior consent (deferred consent) in trials 
investigating the emergency treatment of critically ill children: CONNECT 
study guidance. 2015. 
373. Young, B., et al., Examining the validity of the unitary theory of clinical 
relationships: comparison of observed and experienced parent-doctor 
interaction. Patient Educ Couns, 2011. 85(1): p. 60-7. 
374. Gamble, C., et al., What parents of children who have received emergency 
care think about deferring consent in randomised trials of emergency 
treatments: postal survey. PLoS One, 2012. 7(5): p. e35982. 
375. Scherer, D.G., The capacities of minors to exercise voluntariness in medical 
treatment decisions. Law Hum Behav, 1991. 15(4): p. 431-49. 
376. Abramovitch, R., et al., Children's capacity to agree to psychological research: 
knowledge of risks and benefits and voluntariness. Ethics Behav, 1995. 5(1): 
p. 25-48. 
377. Appelbaum, P.S., C.W. Lidz, and R. Klitzman, Voluntariness of consent to 
research: a conceptual model. Hastings Cent Rep, 2009. 39(1): p. 30-9. 
378. Mamotte, N. and D. Wassenaar, Measuring voluntariness of consent to 
research: an instrument review. J Empir Res Hum Res Ethics, 2015. 10(2): p. 
121-31. 
379. Gillies, K. and V.A. Entwistle, Supporting positive experiences and sustained 
participation in clinical trials: looking beyond information provision. J Med 
Ethics, 2012. 38(12): p. 751-6. 
380. Young, B., et al., Is communication guidance mistaken? Qualitative study of 
parent-oncologist communication in childhood cancer. Br J Cancer, 2013. 
109(4): p. 836-43. 
381. Sureshkumar, P., et al., Parental consent to participation in a randomised trial 
in children: associated child, family, and physician factors. Clin Trials, 2012. 
9(5): p. 645-51. 
382. Forsey, M., et al., Comparing doctors' and nurses' accounts of how they 
provide emotional care for parents of children with acute lymphoblastic 
leukaemia. Psychooncology, 2013. 22(2): p. 260-7. 
383. Unguru, Y., A.M. Sill, and N. Kamani, The experiences of children enrolled in 
pediatric oncology research: implications for assent. Pediatrics, 2010. 125(4): 
p. e876-83. 
384. General Medical Council. Good Practice in Research and Consent to 





385. Joseph, P.D., J.C. Craig, and P.H.Y. Caldwell, Clinical trials in children. British 
Journal of Clinical Pharmacology, 2013 (December 10). 
386. Brody, J.L., et al., Enrolling adolescents in asthma research: adolescent, 
parent, and physician influence in the decision-making process. J Asthma, 
2009. 46(5): p. 492-7. 
387. Tates, K., et al., Joking or Decision-Making? Affective and Instrumental 
Behaviour in Doctor-Parent-Child Communication. Psychol Health, 2002. 17: 
p. 281-295. 
388. Tates, K., et al., I've come for his throat': roles and identities in doctor-parent-
child communication. Child Care Health Dev, 2002. 28(1): p. 109-16. 
389. Tates, K., et al., Doctor-parent-child relationships: a 'pas de trois'. Patient 
Educ Couns, 2002. 48(1): p. 5-14. 
390. Wassmer, E., et al., How do paediatricians communicate with children and 
parents? Acta Paediatr, 2004. 93(11): p. 1501-6. 
391. Nova, C., E. Vegni, and E.A. Moja, The physician-patient-parent 
communication: a qualitative perspective on the child's contribution. Patient 
Educ Couns, 2005. 58(3): p. 327-33. 
392. Van Dulmen A, M., Children’s contribution to pediatric outpatient consultation. 
Pediatrics, 1998. 3:563–8. 
393. Tates, K. and L. Meeuwesen, 'Let mum have her say': turntaking in doctor-
parent-child communication. Patient Educ Couns, 2000. 40(2): p. 151-62. 
394. Coyne, I., Children's participation in consultations and decision-making at 
health service level: a review of the literature. International journal of nursing 
studies, 2008. 45(11): p. 1682-9. 
395. Coyne, I. and P. Gallagher, Participation in communication and decision-
making: children and young people's experiences in a hospital setting. J Clin 
Nurs, 2011. 20(15-16): p. 2334-43. 
396. Coyne, I., et al., Children's participation in shared decision-making: children, 
adolescents, parents and healthcare professionals' perspectives and 
experiences. Eur J Oncol Nurs, 2014. 18(3): p. 273-80. 
397. Tates, K. and L. Meeuwesen, Doctor-parent-child communication. A (re)view 
of the literature. Soc Sci Med, 2001. 52(6): p. 839-51. 
398. Blake, D., et al., Adolescent perspectives on informed assent for an HIV 
vaccine trial. . Journal of Adolescent Health, 2010. 46: p. S28. 
399. Coyne, I. and M. Harder, Children's participation in decision-making: 
balancing protection with shared decision-making using a situational 
perspective. J Child Health Care, 2011. 15(4): p. 312-9. 
400. Coyne, I., et al., Interventions for promoting participation in shared decision-
making for children with cancer. Cochrane Database Syst Rev, 2013. 6: p. 
Cd008970. 
401. O'Cathain, A., A Practical Guide to Using Qualitative Research with 
Randomized Controlled Trials. 2018, United Kingdom: Oxford University 
Press. 
402. O’Reilly, P., L. Martin, and G. Collins, Few patients with prostate cancer are 
willing to be randomised to treatment. BMJ : British Medical Journal, 1999. 
318(7197): p. 1556-1556. 
403. Livesey, J., et al., Trial of randomisation between radical prostatectomy and 




404. Donovan, J.L., et al., Development of a complex intervention improved 
randomization and informed consent in a randomized controlled trial. J.Clin 
Epidemiol., 2009. 62(1): p. 29-36. 
405. Mills, N., et al., Exploring treatment preferences facilitated recruitment to 
randomized controlled trials. J Clin Epidemiol, 2011. 64(10): p. 1127-36. 
406. Wade, J., et al., It's not just what you say, it's also how you say it: opening the 
'black box' of informed consent appointments in randomised controlled trials. 
Social science & medicine (1982), 2009. 68(11): p. 2018-28. 
407. Mills, N., et al., Addressing patient treatment preferences at trial recruitment, 
in Clinical Trials Methodology Conference 2011. 2011, Trials 2011. 
408. Donovan, J.L., et al., Optimising recruitment and informed consent in 
randomised controlled trials: the development and implementation of the 
Quintet Recruitment Intervention (QRI). Trials, 2016. 17(1): p. 283. 
409. Wade, J., et al., It's not just what you say, it's also how you say it: Opening the 
'black box' of informed consent appointments in randomised controlled trials. 
Soc.Sci.Med., 2009. 68(11): p. 2018-2028. 
410. Treweek, S., et al., Trial Forge Guidance 1: what is a Study Within A Trial 
(SWAT)? Trials, 2018. 19(1): p. 139. 
411. Clarke, M., et al., The SWAT (study within a trial) programme; embedding 
trials to improve the methodological design and conduct of future research. 
Trials, 2015. 16(Suppl 2): p. P209-P209. 
412. Smith, V., et al., SWAT-1: The effectiveness of a 'site visit' intervention on 
recruitment rates in a multi-centre randomised trial. Trials, 2015. 16: p. 211. 
413. Cockayne, S., et al., An optimised patient information sheet did not 
significantly increase recruitment or retention in a falls prevention study: an 
embedded randomised recruitment trial. Trials, 2017. 18(1): p. 144. 
414. Constantin, A. SWAT 36: Training in obtaining informed consent for clinical 
trials. (2016 MAR 13 1417) 2016. 
415. Jackson, C.J., et al., Women's views and experiences of a patient preference 
trial in surgery: a qualitative study of the CARPET1 trial. Clinical trials 
(London, England), 2010. 7(6): p. 696-704. 
416. Madsen, S.M., S. Holm, and P. Riis, Attitudes towards clinical research 
among cancer trial participants and non-participants: an interview study using 
a Grounded Theory approach. Journal of Medical Ethics, 2007. 33(4): p. 234. 
417. Wilson, C., et al., Development of a framework to improve the process of 
recruitment to randomised controlled trials (RCTs): the SEAR (Screened, 
Eligible, Approached, Randomised) framework. Trials, 2018. 19(1): p. 50. 
418. Hoddinott, P., J. Britten, and R. Pill, Why do interventions work in some 
places and not others: a breastfeeding support group trial. Soc Sci Med, 2010. 
70(5): p. 769-78. 
419. Farquhar, M., et al., The experience of using the SEIQoL-DW with patients 
with advanced chronic obstructive pulmonary disease (COPD): issues of 
process and outcome. Quality of Life Research, 2010. 19(5): p. 619-629. 
420. Ritchie, J. and J. Lewis, Qualitative research practice. A guide for social 
science students and researchers. 2nd Edition ed, ed. J.L. Edited by Jane 
Ritchie, Carol McNaughton Nicholls, & Rachel Ormston. 2003, London: Sage. 
421. Britten, N., Qualitative interviews in medical research. BMJ, 1995. 311(6999): 
p. 251-3. 
422. Braun, V. and V. Clarke, Successful Qualitative Research: A Practical Guide 




423. May, T., Social Research: Issues, Methods and Process. 2001: Maidenhead: 
Open University Press. Third Edition. 
424. Holstein, J.A. and J.F. Gubrium, The Active Interview. Research Methods. 
1995, London: Sage. 
425. Morse, J.M., Situating grounded theory within qualitative inquiry. Using 
grounded theory in nursing, ed. R.S.S. Edited by Schreiber, P.N. 2001, New 
York: Springer Publishing Company. 
426. Murray, S.A., et al., Use of serial qualitative interviews to understand patients’ 
evolving experiences and needs. BMJ, 2009. 339. 
427. Salmon, P., N. Mendick, and B. Young, Integrative qualitative communication 
analysis of consultation and patient and practitioner perspectives: towards a 
theory of authentic caring in clinical relationships. Patient Educ Couns, 2011. 
82(3): p. 448-54. 
428. O'Reilly, M. and N. Dogra, Interviewing Children and Young People for 
Research, ed. J. Seaman. 2017, London: Sage Publications Ltd. 
429. Kvale, S., Doing Interviews. The Sage Qualitative Research Kit, ed. U. Flick. 
2007, London: Sage Publications Ltd. 
430. Christensen, P.H., Children's participation in ethnographic research: Issues of 
power and representation. 2004. 18(2): p. 165-176. 
431. Goodenough, T., et al., Ethical protection in research: including children in the 
debate. . Researchers and their ‘subjects’, ed. W.E.e. In Smyth M. 2004, 
Bristol: Policy Press. 
432. Gallagher, M., ‘Power is not an evil’: rethinking power in participatory 
methods. Children's Geographies, 2008. 6(2): p. 137-150. 
433. Williams, B., Meaningful Consent to Participate in Social Research on the Part 
of People under the Age of Eighteen. Research Ethics Review 2006. Vol 2( 
No 1): p. 19–24. 
434. Masson, J., Researching children’s perspectives: legal issues. . Researching 
Children’s Perspectives ed. A. Lewis and G. Lindsay. 2000, Buckingham: 
Open University Press. 
435. Horsley, K. and A. McCabe. The Evaluator's Cookbook: Exercises for 




436. Thomas, N. and C. O'Kane, The ethics of participatory research with children. 
Children & Society, 2006. 12(5): p. 336-348. 
437. Irwin, L.G. and J. Johnson, Interviewing Young Children: Explicating Our 
Practices and Dilemmas. 2005. 15(6): p. 821-831. 
438. Minichiello, V., R. Aroni, and T. Hays, In-depth interviewing: Principles, 
techniques, analysis ed. T. Edition. 2008, Melbourne, VIC: Longman 
Cheshire. 
439. Silverman, D., Doing Qualitative Research: A Practical Handbook. Fourth 
Edition ed. 2013: Sage. 
440. Kanagasabai, P.S., et al., A Child-centered Method of Interviewing Children 
with Movement Impairments. Phys Occup Ther Pediatr, 2018. 38(3): p. 255-
268. 
441. Kara, H., Research and Evaluation for Busy Students and Practitioners: A 




442. Gardner, H. and D. Randall, The effects of the presence or absence of 
parents on interviews with children. Nurse Res, 2012. 19(2): p. 6-10. 
443. Redsell, S. and A.M. Hastings, Listening to Children and Young People in 
Healthcare Consultations. 2010: Radcliffe Publishing. 
444. Deakin, H. and K. Wakefield, Skype interviewing: reflections of two PhD 
researchers. Qualitative Research, 2014. 14(5): p. 603-616. 
445. Novick, G., Is there a bias against telephone interviews in qualitative 
research? Res Nurs Health, 2008. 31(4): p. 391-8. 
446. Holt, A., Using the telephone for narrative interviewing: a research note. 
Qualitative Research, 2010. 10(1): p. 113–121. 
447. Sturges, J.E. and K.J. Hanrahan, Comparing Telephone and Face-to-Face 
Qualitative Interviewing: a Research Note. 2004. 4(1): p. 107-118. 
448. Whale, K., et al., 'What does that mean?': a qualitative exploration of the 
primary and secondary clinical care experiences of young people with 
continence problems in the UK. BMJ Open, 2017. 7(10): p. e015544. 
449. Haig-Ferguson, A., et al., The use of Skype for delivering therapy in a 
Specialist Paediatric Chronic Fatigue Service; the dichotomy between 
restricting and enabling communication: a qualitative study. British Journal of 
Health Psychology [submitted for publication 2018]. 
450. Oltmann, S.M., Qualitative Interviews: A Methodological Discussion of the 
Interviewer and Respondent Contexts. Information Science Faculty 
Publications 
2016. 32. 
451. Hoser, B. and T. Nitschke, Questions on ethics for research in the virtually 
connected world. Social Networks, 2010. 32(3): p. 180–186. 
452. Hay-Gibson, N.V., Interviews via VoIP: benefits and disadvantages within a 
PhD study of SMEs. Library and Information Research, 2009. 33(105): p. 39–
50. 
453. O’Connor, H., et al., Internet-based interviewing. The SAGE Handbook of 
Online Research Methods. , ed. N. Fielding, N. Lee, and G. Blank. Vol. 271–
289. 2008, London: Sage. 
454. Garton, S. and F. Copland, ‘I like this interview; I get cakes and cats!’: the 
effect of prior relationships on interview talk. Qualitative Research, 2010. 
10(5): p. 533-551. 
455. McEvoy, P., Interviewing colleagues: addressing the issues of perspective, 
inquiry and representation. Nurse Res, 2001. 9(2): p. 49-59. 
456. McQueen, A., et al., Behind closed doors: physician-patient discussions about 
colorectal cancer screening. J Gen Intern Med, 2009. 24(11): p. 1228-35. 
457. Lawton, J., et al., Uncovering the emotional aspects of working on a clinical 
trial: a qualitative study of the experiences and views of staff involved in a 
type 1 diabetes trial. Trials, 2015. 16: p. 3. 
458. Hammersley, M. and P. Atkinson, Ethnography : principles in practice. 1989, 
London ; New York.: Routledge. 
459. McLeod, J., Qualitative Research in Counselling and Psychotherapy. 2001, 
London: Sage. 
460. Winter, G., A comparative discussion of the notion of validity in qualitative and 
quantitative research. The Qualitative Report, 2000. 4(3). 
461. Denzin, N.K., sociological methods: A sourcebook (2nd ed.) ed. 1978, New 




462. Barbour, R.S., Checklists for improving rigour in qualitative research: a case 
of the tail wagging the dog? BMJ, 2001. 322(7294): p. 1115-7. 
463. Tracy, S.J., Qualitative Quality: Eight “Big-Tent” Criteria for Excellent 
Qualitative Research. Qualitative Inquiry, 2010. 16(10): p. 837-851. 
464. Lincoln, Y.S. and E.G. Guba, Naturalistic inquiry. 1985, Newbury Park, CA: 
Sage. 
465. NICE: National Institute for Health and Clinical Excellence, Chronic fatigue 
syndrome/myalgic encephalomyelitis (or encephalopathy) Diagnosis and 
management of CFS/ME in adults and children., N.I.f.H.a.C. Excellence., 
Editor. 2007, Developed by the National Collaborating Centre for Primary 
Care: London. 
466. Carter, B.D., et al., Psychological symptoms in chronic fatigue and juvenile 
rheumatoid arthritis. Pediatrics, 1999. 103(5): p. 975-979. 
467. Van Middendorp, H., et al., Psychological adjustment of adolescent girls with 
chronic fatigue syndrome. Pediatrics, 2001. 107(3): p. E35. 
468. Crawley, E., L. Hunt, and P. Stallard, Anxiety in children with CFS/ME. 
Eur.Child Adolesc.Psychiatry, 2009. 
469. Bould, H., et al., Depression and anxiety in children with CFS/ME: cause or 
effect? Arch.Dis.Child, 2010. 
470. Bell, D.S., K. Jordan, and M. Robinson, Thirteen-year follow-up of children 
and adolescents with chronic fatigue syndrome. Pediatrics, 2001. 107(5): p. 
994-998. 
471. Crawley, E.M., A.M. Emond, and J.A. Sterne, Unidentified Chronic Fatigue 
Syndrome/myalgic encephalomyelitis (CFS/ME) is a major cause of school 
absence: surveillance outcomes from school-based clinics. BMJ Open, 2011. 
1(2): p. e000252. 
472. Rangel, L., et al., The course of severe chronic fatigue syndrome in childhood. 
J.R.Soc.Med., 2000. 93(3): p. 129-134. 
473. Joyce, J., M. Hotopf, and S. Wessely, The prognosis of chronic fatigue and 
chronic fatigue syndrome: a systematic review. QJM., 1997. 90(3): p. 223-
233. 
474. Rimes, K.A., et al., Incidence, prognosis, and risk factors for fatigue and 
chronic fatigue syndrome in adolescents: a prospective community study. 
Pediatrics, 2007. 119(3): p. e603-e609. 
475. Collin, S.M., et al., Chronic fatigue syndrome (CFS) or myalgic 
encephalomyelitis (ME) is different in children compared to in adults: a study 
of UK and Dutch clinical cohorts. BMJ Open, 2015. 5(10): p. e008830. 
476. Royal College of Paediatrics and Child Health, Evidence Based Guideline for 
the Management of CFS/ME (Chronic Fatigue Syndrome/Myalgic 
Encephalopathy) in Children and Young People. 2004: London. 
477. Loades, M., A. Brigden, and E. Crawley, Current treatment approaches for 
paediatric CFS/ME. Paediatr Child Health (Oxford), 2017. 27(9): p. 432-434. 
478. St Peter, S.D., et al., Single daily dosing ceftriaxone and metronidazole vs 
standard triple antibiotic regimen for perforated appendicitis in children: a 
prospective randomized trial. J Pediatr Surg, 2008. 43(6): p. 981-5. 
479. Rollins, K.E. and D.N. Lobo, Non-operative management of uncomplicated 
acute appendicitis in children: where is the evidence? Arch Dis Child, 2017. 
102(12): p. 1099-1100. 
480. NICE: National Institute for Health and Clinical Excellence. Appendicitis 2016  




481. Canty, T.G., Sr., et al., Laparoscopic appendectomy for simple and perforated 
appendicitis in children: the procedure of choice? J Pediatr Surg, 2000. 
35(11): p. 1582-5. 
482. Varadhan, K.K., K.R. Neal, and D.N. Lobo, Safety and efficacy of antibiotics 
compared with appendicectomy for treatment of uncomplicated acute 
appendicitis: meta-analysis of randomised controlled trials. BMJ, 2012. 344: p. 
e2156. 
483. Lee, S.L., et al., Does age affect the outcomes and management of pediatric 
appendicitis? J Pediatr Surg, 2011. 46(12): p. 2342-5. 
484. Mizrahi, I., et al., Comparison of pediatric appendectomy outcomes between 
pediatric surgeons and general surgery residents. J Surg Res, 2013. 180(2): 
p. 185-90. 
485. Tiboni, S., et al., Outcome of appendicectomy in children performed in 
paediatric surgery units compared with general surgery units. Br J Surg, 2014. 
101(6): p. 707-14. 
486. Hall, N.J., et al., Is interval appendicectomy justified after successful 
nonoperative treatment of an appendix mass in children? A systematic review. 
J Pediatr Surg, 2011. 46(4): p. 767-71. 
487. Armstrong, J., et al., Non-operative management of early, acute appendicitis 
in children: is it safe and effective? J Pediatr Surg, 2014. 49(5): p. 782-5. 
488. Svensson, J.F., et al., Recurrence of acute appendicitis after non-operative 
treatment of appendiceal abscess in children: a single-centre experience. 
Pediatr Surg Int, 2014. 30(4): p. 413-6. 
489. Georgiou, R., et al., Efficacy and Safety of Nonoperative Treatment for Acute 
Appendicitis: A Meta-analysis. Pediatrics, 2017. 139(3). 
490. Bowers, W.F., C.W. Hughes, and K.B. Bonilla, The treatment of acute 
appendicitis under suboptimal conditions. U S Armed Forces Med J, 1958. 
9(11): p. 1545-57. 
491. Vons, C., et al., Amoxicillin plus clavulanic acid versus appendicectomy for 
treatment of acute uncomplicated appendicitis: an open-label, non-inferiority, 
randomised controlled trial. Lancet, 2011. 377(9777): p. 1573-9. 
492. Styrud, J., et al., Appendectomy versus antibiotic treatment in acute 
appendicitis. a prospective multicenter randomized controlled trial. World J 
Surg, 2006. 30(6): p. 1033-7. 
493. Hansson, J., et al., Randomized clinical trial of antibiotic therapy versus 
appendicectomy as primary treatment of acute appendicitis in unselected 
patients. Br J Surg, 2009. 96(5): p. 473-81. 
494. Eriksson, S. and L. Granstrom, Randomized controlled trial of 
appendicectomy versus antibiotic therapy for acute appendicitis. Br J Surg, 
1995. 82(2): p. 166-9. 
495. Mason, R.J., Non-operative management of uncomplicated acute 
appendicitis: using antibiotics is effective and decreases morbidity. Evid 
Based Med, 2013. 18(2): p. 67-8. 
496. Liu, K. and L. Fogg, Use of antibiotics alone for treatment of uncomplicated 
acute appendicitis: a systematic review and meta-analysis. Surgery, 2011. 
150(4): p. 673-83. 
497. Turhan, A.N., et al., Comparison of operative and non operative management 
of acute appendicitis. Ulus Travma Acil Cerrahi Derg, 2009. 15(5): p. 459-62. 
498. Hall, N.J., et al., Active observation versus interval appendicectomy after 




study): an open-label, randomised controlled trial. Lancet Gastroenterol 
Hepatol, 2017. 2(4): p. 253-260. 
499. Nitecki, S., A. Assalia, and M. Schein, Contemporary management of the 
appendiceal mass. Br J Surg, 1993. 80(1): p. 18-20. 
500. Eriksson, S. and J. Styrud, Interval appendicectomy: a retrospective study. 
Eur J Surg, 1998. 164(10): p. 771-4; discussion 775. 
501. Puri, P., et al., Appendix mass in the very young child. J Pediatr Surg, 1981. 
16(1): p. 55-7. 
502. Freitas, M.S. and P.L. Glick, Interval appendectomy for acute appendicitis. J 
Pediatr Surg, 2009. 44(5): p. 1056-8. 
503. Svensson, J.F., et al., Nonoperative treatment with antibiotics versus surgery 
for acute nonperforated appendicitis in children: a pilot randomized controlled 
trial. Ann Surg, 2015. 261(1): p. 67-71. 
504. Minneci, P.C., et al., Feasibility of a nonoperative management strategy for 
uncomplicated acute appendicitis in children. J Am Coll Surg, 2014. 219(2): p. 
272-9. 
505. Gorter, R.R., et al., Initial antibiotic treatment for acute simple appendicitis in 
children is safe: Short-term results from a multicenter, prospective cohort 
study. Surgery, 2015. 157(5): p. 916-23. 
506. National Surgical Research Collaborative, Multicentre observational study of 
performance variation in provision and outcome of emergency 
appendicectomy. British Journal of Surgery, 2013. 100(9). 
507. Beasant, L., N. Mills, and E. Crawley, Adolescents and mothers value referral 
to a specialist service for chronic fatigue syndrome or myalgic encephalopathy 
(CFS/ME). Prim Health Care Res Dev, 2013: p. 1-9. 
508. ME Association. Complementary treatments. 2018; Available from: 
http://www.meassociation.org.uk/about/complementary-treatments/. 
509. White, P., et al., Comparison of adaptive pacing therapy, cognitive behaviour 
therapy, graded exercise therapy, and specialist medical care for chronic 
fatigue syndrome (PACE): a randomised trial. Lancet., 2011. 377(9768): p. 
823-836. 
510. Nijhof, S.L., et al., Effectiveness of internet-based cognitive behavioural 
treatment for adolescents with chronic fatigue syndrome (FITNET): a 
randomised controlled trial. Lancet, 2012. 379(9824): p. 1412-8. 
511. Barbour, R.S., The role of qualitative research in broadening the 'evidence 
base' for clinical practice. J Eval Clin Pract, 2000. 6(2): p. 155-63. 
512. Popper K, The Logic of Scientific Discovery. . 1959 London: Hutchinson. 
513. Clark, A.M., The qualitative-quantitative debate: moving from positivism and 
confrontation to post-positivism and reconciliation. J Adv Nurs, 1998. 27(6): p. 
1242-9. 
514. Guba, E.G. and Y.S. Lincoln, The Sage Handbook of Qualitative Research. 
3rd Edition ed. Chapter 8; Paradigmatic Controversies, contradictions and 
emerging confluences. 2005, london: Sage. 
515. Henwood, K. and N. Pidgeon, Beyond the qualitative paradigm: A framework 
for introducing diversity within qualitative psychology. Journal of Community 
and Applied Social Psychology, 1994. 4(4): p. 225-238. 
516. Burr, V., Social Constructionism. 2003, London: Routledge. 
517. Potter, J. and Wetherell, Discourse and social psychology: Beyond attitudes 




518. Madill, A., A. Jordan, and C. Shirley, Objectivity and reliability in qualitative 
analysis: realist, contextualist and radical constructionist epistemologies. Br J 
Psychol, 2000. 91 ( Pt 1): p. 1-20. 
519. Tebes, J.K., Community science, philosophy of science, and the practice of 
research. Am J Community Psychol, 2005. 35(3-4): p. 213-30. 
520. Beasant, L., et al., A systematic review and qualitative synthesis of literature 
reporting treatment preference in paediatric randomised controlled trials. . 
2015. 
521. Petticrew, M. and H. Roberts, Systematic Reviews in the Social Sciences A 
PRACTICAL GUIDE. 2006, 350 Main Street, Malden, MA 02148-5020, USA: 
Blackwell Publishing. 
522. Chappuy, H.F., A. C.; De Haut De Sigy, A., Parental comprehension and 
decision in informed consent in pediatric clinical trials. [French]. Revue 
d'Oncologie Hematologie Pediatrique, 2014. 2(2014376989): p. 65-69. 
523. Hissink Muller, P.C.E., et al., Parental preferences for treatment: Preliminary 
report from a randomised comparison of treatment strategies in (early) 
juvenile idiopathic arthritis (BeSt for Kids trial). Pediatric Rheumatology, 2011. 
9: p. 8. 
524. Hissink Muller, P.C.E., et al., Randomized clinical trial in pediatric 
rheumatology: Are parents and patients in equipoise? Arthritis and 
Rheumatism, 2012. 64: p. S849. 
525. Johnson, S.B., et al., Participant and parent experiences in the parenteral 
insulin arm of the diabetes prevention trial for type 1 diabetes. Diabetes Care, 
2007. 30(9): p. 2193-8. 
526. Johnson, S.B., et al., Participant and parent experiences in the oral insulin 
study of the Diabetes Prevention Trial for Type 1 Diabetes. Pediatr Diabetes, 
2009. 10(3): p. 177-83. 
527. Covidence, A product by Alfred Health. 2013. 
528. Gough, D., J. Thomas, and S. Oliver, Clarifying differences between review 
designs and methods. Syst Rev, 2012. 1: p. 28. 
529. Sandelowski, M., et al., Mapping the Mixed Methods-Mixed Research 
Synthesis Terrain. J Mix Methods Res, 2012. 6(4): p. 317-331. 
530. QSR International Pty Ltd, NVivo qualitative data analysis Software; Version 
10. 2012. 
531. Allmark, P. and S. Mason, Improving the quality of consent to randomised 
controlled trials by using continuous consent and clinician training in the 
consent process. J Med Ethics, 2006. 32(8): p. 439-43. 
532. Critical Appraisal Skills Program (CASP). Qualitative Research Checklist. 
2013  [cited 2013 31.05.13]; Available from: http://www.casp-uk.net/#!casp-
tools-checklists/c18f8. 
533. Dixon-Woods, M., et al., Appraising qualitative research for inclusion in 
systematic reviews: a quantitative and qualitative comparison of three 
methods. J Health Serv Res Policy, 2007. 12(1): p. 42-7. 
534. Malpass, A., et al., "Medication career" or "moral career"? The two sides of 
managing antidepressants: a meta-ethnography of patients' experience of 
antidepressants. Soc Sci Med, 2009. 68(1): p. 154-68. 
535. Noblit, G.H. and R.D. Hare, Meta-Ethnography: Synthesising Qualitative 
Studies. 1988, California  Newbury Park. 





537. Britten, N., et al., Using meta ethnography to synthesise qualitative research: 
a worked example. J Health Serv Res Policy, 2002. 7(4): p. 209-15. 
538. Atkins, S., et al., Conducting a meta-ethnography of qualitative literature: 
lessons learnt. BMC Med Res Methodol, 2008. 8: p. 21. 
539. Campbell, R., et al., Evaluating meta-ethnography: systematic analysis and 
synthesis of qualitative research. Health Technol Assess, 2011. 15(43): p. 1-
164. 
540. Donovan, J.L., et al., Clear obstacles and hidden challenges: understanding 
recruiter perspectives in six pragmatic randomised controlled trials. Trials, 
2014. 15: p. 5. 
541. Patton, M.Q., Qualitative Research & Evaluation Methods: Integrating Theory 
and Practice. 4th Edition ed. 2015, London: Sage Publications Ltd. 
542. Charmaz, K., Grounded Theory: Objectivist and Constructivist Methods. 2nd 
Edition ed. Handbook of Qualitative Research, ed. N.K. Denzin and Y.S. 
Lincoln. 2000, London: Sage Publications Inc. 
543. Glaser, B. and A. Strauss, The discovery of grounded theory: Strategies for 
qualitative research. 1999, New York: Aldine de Gruyter. 
544. Gale, N.K., et al., Using the framework method for the analysis of qualitative 
data in multi-disciplinary health research. BMC Med Res Methodol, 2013. 13: 
p. 117. 
545. Glaser & Strauss, The Discovery of Grounded Theory. 1967, USA: Aldine 
Transaction: New Brunswick, NJ; . 
546. Strauss and Corbin, Basics of Qualitative Research. 1998: Thousand Oaks 
CA: Sage Publications. 
547. Charmaz, K., Constructing Grounded Theory: A Practical Guide. . 2006: 
SAGE Publications Ltd. 
548. Braun, V. and V. Clarke, Using Thematic Analysis in Psychology. 
Qual.Res.Psych., 2006. 3: p. 77-101. 
549. Pigeon, N. and K. Henwood, Grounded Theory: The hadbook ofdata analysis. 
Vol. In M. Hardy A. Bryman (Eds). 2004, London: Sage. 
550. Mays, N. and C. Pope, Qualitative research in health care. Assessing quality 
in qualitative research. BMJ, 2000. 320(7226): p. 50-2. 
551. Sandelowski, M., Real qualitative researchers do not count: the use of 
numbers in qualitative research. Res Nurs Health, 2001. 24(3): p. 230-40. 
552. Elo, S. and H. Kyngas, The qualitative content analysis process. J Adv Nurs, 
2008. 62(1): p. 107-15. 
553. Hsieh, H.F. and S.E. Shannon, Three approaches to qualitative content 
analysis. Qual Health Res, 2005. 15(9): p. 1277-88. 
554. Prasad, B.D., Content Analysis. A method in Social Science Research, in 
Research Methods for Social Work., I.D.K.L.D. (ed). Editor. 2008, Rawat 
Publication.: New Delhi:. p. (pp.174-193). 
555. Cole, F.L., Content analysis: process and application. Clin Nurse Spec, 1988. 
2(1): p. 53-7. 
556. Krippendorff, K., Content Analysis: An introduction to its methodology. 1980, 
London: Sage. 
557. Denzin, N. and Y. Lincoln, Handbook of qualitative research. 2000: Sage: 
Thousand Oaks, CA. . 
558. Riach, K., Exploring Participant-centred Reflexivity in the Research Interview. 




559. Richards, H. and C. Emslie, The ‘doctor’ or the ‘girl from the University’? 
Considering the influence of professional roles on qualitative interviewing. 
Family Practice, , 2000. Volume 17(1): p. Pages 71–75. 
560. Fontana, A. and J.H. Frey, The Interview. From neutral stance to political 
involvement. . The Sage Handbook of Qualitative Research., ed. N.K.a.L. In 
Denzin, Y.S. (editors). Vol. Third Edition. 2005: London: Sage. . 
561. Mauthner, N.S. and A. Doucet, Reflexive Accounts and Accounts of 
Reflexivity in Qualitative Data Analysis. 2003. 37(3): p. 413-431. 
562. Barry, C.A., et al., Using Reflexivity to Optimize Teamwork in Qualitative 
Research. 1999. 9(1): p. 26-44. 
563. Mauthner, N.S., O. Parry, and K. Backett-Milburn, The Data are Out there, or 
are They? Implications for Archiving and Revisiting Qualitative Data. 1998. 
32(4): p. 733-745. 
564. Beasant, L. and F. Sherratt, Standard Operating Procedure (SOP) for the 
CONTRACT communication sub-study. 2017. 
565. Government document, Data Protection Act 1998, 
http://www.legislation.gov.uk/ukpga/1998/29/contents. 
566. Harris, P.A., et al., Research electronic data capture (REDCap)--a metadata-
driven methodology and workflow process for providing translational research 
informatics support. J Biomed Inform, 2009. 42(2): p. 377-81. 
567. Appleton, R.E., et al., The use of MElatonin in children with 
neurodevelopmental disorders and impaired sleep: a randomised, double-
blind, placebo-controlled, parallel study (MENDS). Health Technol Assess, 
2012. 16(40): p. i-239. 
568. Atkinson, M., et al., Comparison of oral amoxicillin and intravenous benzyl 
penicillin for community acquired pneumonia in children (PIVOT trial): a 
multicentre pragmatic randomised controlled equivalence trial. Thorax, 2007. 
62(12): p. 1102-6. 
569. Azzopardi, D.V., et al., Moderate hypothermia to treat perinatal asphyxial 
encephalopathy. N Engl J Med, 2009. 361(14): p. 1349-58. 
570. Balle, V., et al., Treatment of children with secretory otitis media (SOM) with 
amoxicillin and clavulanic acid (Spektramox) or penicillin-V (Primcillin). 
Bacteriological findings in the nasopharynx before and after treatment. Int J 
Pediatr Otorhinolaryngol, 1998. 45(1): p. 77-82. 
571. Craig, J.C., et al., Antibiotic prophylaxis and recurrent urinary tract infection in 
children. N Engl J Med, 2009. 361(18): p. 1748-59. 
572. Diabetes, C.C.T.R., Group., et al., The effect of intensive treatment of 
diabetes on the development and progression of long-term complications in 
insulin-dependent diabetes mellitus. N Engl J Med, 1993. 329(14): p. 977-86. 
573. UK Collaborative ECMO Trial Group, UK collaborative randomised trial of 
neonatal extracorporeal membrane oxygenation. The Lancet, 1996. 
348(9020): p. 75-82. 
574. Hissink Muller, P.C., et al., A comparison of three treatment strategies in 
recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results 
of the BeSt for Kids-study. Pediatr Rheumatol Online J, 2017. 15(1): p. 11. 
575. Lenney, W., et al., Management of Asthma in School age Children On 
Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel 
study of efficacy and safety. Health Technol Assess, 2013. 17(4): p. 1-218. 
576. Mitchell, C.D., et al., Benefit of dexamethasone compared with prednisolone 




Research Council ALL97 randomized trial. Br J Haematol, 2005. 129(6): p. 
734-45. 
577. Moreira, T.A., et al., Combined oral midazolam-ketamine better than 
midazolam alone for sedation of young children: a randomized controlled trial. 
Int J Paediatr Dent, 2013. 23(3): p. 207-15. 
578. Van Asperen, P.P., et al., A multicentre randomized placebo-controlled 
double-blind study on the efficacy of Ketotifen in infants with chronic cough or 
wheeze. J Paediatr Child Health, 1992. 28(6): p. 442-6. 
579. van Wijk, R.M., et al., Helmet therapy in infants with positional skull 
deformation: randomised controlled trial. BMJ, 2014. 348: p. g2741. 
580. Vora, A., et al., Treatment reduction for children and young adults with low-
risk acute lymphoblastic leukaemia defined by minimal residual disease 
(UKALL 2003): a randomised controlled trial. Lancet Oncol, 2013. 14(3): p. 
199-209. 
581. Wake, M., et al., Outcomes and costs of primary care surveillance and 
intervention for overweight or obese children: the LEAP 2 randomised 
controlled trial. BMJ, 2009. 339: p. b3308. 
582. Wang, W.C., et al., Hydroxycarbamide in very young children with sickle-cell 
anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet, 
2011. 377(9778): p. 1663-72. 
583. Ng, S.M., et al., An explanatory randomised placebo controlled trial of 
levothyroxine supplementation for babies born <28 weeks' gestation: results 
of the TIPIT trial. Trials, 2013. 14: p. 211. 
584. Cunningham, S., et al., In search of the sample: recent experiences of a trial 
team in orthodontics. Contemp Clin Trials, 2011. 32(4): p. 530-4. 
585. Levi, R.B., et al., Diagnosis, disclosure, and informed consent: learning from 
parents of children with cancer. J Pediatr Hematol Oncol, 2000. 22(1): p. 3-12. 
586. Allen, J., et al., Is a randomised controlled trial of a maternity care intervention 
for pregnant adolescents possible? An Australian feasibility study. BMC Med 
Res Methodol, 2013. 13: p. 138. 
587. Banks, J., et al., Evaluating the transferability of a hospital-based childhood 
obesity clinic to primary care: a randomised controlled trial. Br J Gen Pract, 
2012. 62(594): p. e6-12. 
588. Bauchner, H., et al., Therapy for acute otitis media. Preference of parents for 
oral or parenteral antibiotic. Arch Pediatr Adolesc Med, 1996. 150(4): p. 396-
9. 
589. Blickman, J.G., et al., Child life services in pediatric radiology: A randomized 
controlled trial. Pediatric Radiology, 2013. 43: p. S573-S574. 
590. Duncan, B., et al., Parental perceptions of the therapeutic effect from 
osteopathic manipulation or acupuncture in children with spastic cerebral 
palsy. Clin Pediatr (Phila), 2004. 43(4): p. 349-53. 
591. Forsander, G., Family attitudes to different management regimens in diabetes 
mellitus. Practical Diabetes International, 1995. 12(2): p. 80-85. 
592. Miner, J.R., et al., Randomized clinical trial of nebulized fentanyl citrate versus 
i.v. fentanyl citrate in children presenting to the emergency department with 
acute pain. Acad Emerg Med, 2007. 14(10): p. 895-8. 
593. Payne, K., et al., Day-case anaesthesia: What would the patient prefer? 
Clinician in Management, 2004. 12(3): p. 133-139. 
594. Paediatric European Network for Treatment of AIDS (PENTA), Parents' 




trial: the PENTA 1 trial. Paediatric European Network for Treatment of AIDS. 
HIV Medicine, 1999. 1: p. 25-31. 
595. Rovers, M.M., et al., The effect of ventilation tubes on language development 
in infants with otitis media with effusion: A randomized trial. Pediatrics, 2000. 
106(3): p. E42. 
596. Sandler, J., et al., Effectiveness of 3 methods of anchorage reinforcement for 
maximum anchorage in adolescents: A 3-arm multicenter randomized clinical 
trial. Am J Orthod Dentofacial Orthop, 2014. 146(1): p. 10-20. 
597. Sartain, S.A., et al., Randomised controlled trial comparing an acute 
paediatric hospital at home scheme with conventional hospital care. Arch Dis 
Child, 2002. 87(5): p. 371-5. 
598. Schuttelaar, M.L., et al., A randomized controlled trial in children with eczema: 
nurse practitioner vs. dermatologist. Br J Dermatol, 2010. 162(1): p. 162-70. 
599. Sederberg-Olsen, J., et al., Problems in recruiting patients to controlled trials 
on children with secretory otitis media: a demographic comparison of 
excluded versus included patients. Int J Pediatr Otorhinolaryngol, 1998. 43(3): 
p. 229-33. 
600. Spandorfer, P.R., et al., Oral versus intravenous rehydration of moderately 
dehydrated children: a randomized, controlled trial. Pediatrics, 2005. 115(2): 
p. 295-301. 
601. Tercyak, K.P., Jr., et al., Offering a randomized trial of intensive therapy for 
IDDM to adolescents. Reasons for refusal, patient characteristics, and 
recruiter effects. Diabetes Care, 1998. 21(2): p. 213-5. 
602. Willey, S.E., D.M. Griffiths, and J.J. Nightingale, Prospective randomised 
controlled trial comparing rectal versus oral paracetamol and diclofenac in 
children following appendicectomy. Acute Pain, 2005. 7(1): p. 33-35. 
603. Williams, K.G., et al., A randomized controlled trial of cast versus splint for 
distal radial buckle fracture: an evaluation of satisfaction, convenience, and 
preference. Pediatr Emerg Care, 2013. 29(5): p. 555-9. 
604. Wright, J.G., et al., Treatments for paediatric femoral fractures: a randomised 
trial. Lancet, 2005. 365(9465): p. 1153-8. 
605. Wynn, L., et al., Recruitment of infants with sickle cell anemia to a Phase III 
trial: data from the BABY HUG study. Contemp Clin Trials, 2010. 31(6): p. 
558-63. 
606. Young, B.J., et al., Pretreatment attrition and childhood social phobia: 
Parental concerns about medication. J Anxiety Disord, 2006. 20(8): p. 1133-
47. 
607. Gowers, S.G., et al., A randomised controlled multicentre trial of treatments 
for adolescent anorexia nervosa including assessment of cost-effectiveness 
and patient acceptability - the TOuCAN trial. Health Technol Assess, 2010. 
14(15): p. 1-98. 
608. Paradise, J.L., et al., Efficacy of tonsillectomy for recurrent throat infection in 
severely affected children. Results of parallel randomized and nonrandomized 
clinical trials. N Engl J Med, 1984. 310(11): p. 674-83. 
609. Paradise, J.L., et al., Efficacy of adenoidectomy for recurrent otitis media in 
children previously treated with tympanostomy-tube placement. Results of 





610. Reddihough, D.S., et al., Efficacy of programmes based on Conductive 
Education for young children with cerebral palsy. Dev Med Child Neurol, 
1998. 40(11): p. 763-70. 
611. Rovers, M.M., et al., Generalisability of clinical trials in otitis media with 
effusion. Int J Pediatr Otorhinolaryngol, 2001. 60(1): p. 29-40. 
612. van Wijk, R.M., et al., Parents' decision for helmet therapy in infants with skull 
deformation. Childs Nerv Syst, 2014. 30(7): p. 1225-32. 
613. Mattila, P.S., et al., Prevention of otitis media by adenoidectomy in children 
younger than 2 years. Arch Otolaryngol Head Neck Surg, 2003. 129(2): p. 
163-8. 
614. Weinstein, S.L., et al., Effects of bracing in adolescents with idiopathic 
scoliosis. N Engl J Med, 2013. 369(16): p. 1512-21. 
615. Moher, D., et al., Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. BMJ, 2009. 339: p. b2535. 
616. Rovers, M.M., et al., Generalizability of trial results based on randomized 
versus nonrandomized allocation of OME infants to ventilation tubes or 
watchful waiting. J Clin Epidemiol, 2001. 54(8): p. 789-94. 
617. Dixon-Woods, M., et al., Conducting a critical interpretive synthesis of the 
literature on access to healthcare by vulnerable groups. BMC Med Res 
Methodol, 2006. 6: p. 35. 
618. Sandelowski, M., S. Docherty, and C. Emden, Focus on qualitative methods. 
Qualitative metasynthesis: issues and techniques. Res Nurs Health, 1997. 
20(4): p. 365-71. 
619. Walter, S., et al., Beyond the treatment effect: Evaluating the effects of patient 
preferences in randomised trials. Stat Methods Med Res, 2014. 26(1): p. 489-
507. 
620. Schulz, K.F., et al., CONSORT 2010 Statement: updated guidelines for 
reporting parallel group randomised trials. Trials, 2010. 11: p. 32. 
621. Moher, D., et al., CONSORT 2010 explanation and elaboration: updated 
guidelines for reporting parallel group randomised trials. BMJ, 2010. 340: p. 
c869. 
622. Wulf, F., Krasuska, M. and Bullinger, M. , Determinants of decision-making 
and patient participation in paediatric clinical trials: A literature review. Open 
Journal of Pediatrics, 2012. 2: p. 1-17. 
623. Snethen, J.A., et al., Family patterns of decision-making in pediatric clinical 
trials. Res Nurs Health, 2006. 29(3): p. 223-32. 
624. Lees, A., et al., Positioning Children's Voice in Clinical Trials Research: A 
New Model for Planning, Collaboration, and Reflection. Qual Health Res, 
2017. 27(14): p. 2162-2176. 
625. Ashcroft, R., et al., Children's consent to research participation: social context 
and personal experience invalidate fixed cutoff rules. Am J Bioeth, 2003. 3(4): 
p. 16-8. 
626. Siminoff, L.A., J.H. Fetting, and M.D. Abeloff, Doctor-patient communication 
about breast cancer adjuvant therapy. J Clin Oncol, 1989. 7(9): p. 1192-200. 
627. Centre for Reviews and Dissemination Systematic Reviews: CRD's guidance 
for undertaking systematic reviews in health care. 2009.  DOI: 
97811900640473. 
628. Harman, N., et al., Development of an online resource for recruitment 




629. Selva, A.S.I., et al., Development and use of a content search strategy for 
retrieving studies on patients' views and preferences. Health Qual Life 
Outcomes., 2017. Aug 30;15(1):126. 
630. van Hoorn, R., et al., The development of PubMed search strategies for 
patient preferences for treatment outcomes. BMC Med Res Methodol, 2016. 
16: p. 88. 
631. Galton, F., Regression towards mediocrity in hereditary stature. . Journal of 
the Anthropological Institute 1886. 15: p. 246-63. 
632. Morton, V. and D.J. Torgerson, Effect of regression to the mean on decision 
making in health care. BMJ, 2003. 326(7398): p. 1083-4. 
633. O’Cathain A, T.K., Rudolph A, Drabble SJ, Hewison J. , What can qualitative 
research do for randomised controlled trials? A systematic mapping review. 
BMJ Open 2013;3:e002889., 2013. 
634. Alliance for Clinical Trials in Oncology, A Randomized Trial of Radical 
Prostatectomy Versus Brachytherapy for Patients With T1c or T2a N0 M0 
Prostate Cancer. 2001. 
635. NCIC Clinical Trials Group, A Phase III Study of Active Surveillance Therapy 
Against Radical Treatment in Patients Diagnosed With Favourable Risk 
Prostate Cancer [START]. 2007. 
636. Crook, J.M., et al., Comparison of health-related quality of life 5 years after 
SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. 
J Clin Oncol, 2011. 29(4): p. 362-8. 
637. Wilt, T.J., et al., Radical prostatectomy versus observation for localized 
prostate cancer. N Engl J Med, 2012. 367(3): p. 203-13. 
638. Schandelmaier, S., et al., Premature Discontinuation of Pediatric Randomized 
Controlled Trials: A Retrospective Cohort Study. J Pediatr, 2017. 184: p. 209-
214 e1. 
639. Wade, J., et al., How informed is your consent? Techniques to facilitate 
informed consent in trial recruitment [abstract]. in Clin Trials, 2010. 2010. 
640. Avery, K.N.L.M., C.; Berrisford R.; Barham C, Donovan, J.L.; Elliott, J.; Falk, 
S.J.; Goldin, R.; Hanna, G.; Hollowood, A.; Krysztopik, R.; Noble, S.; Sanders, 
G.; Streets, CG.; Titcomb, DR.; Wheatley, T.; Blazeby, J.M., The feasibility of 
a randomized controlled trial of esophagectomy for esophageal cancer - the 
ROMIO (Randomized Oesophagectomy: Minimally Invasive or Open) study: 
protocol for a randomized controlled trial. Trials., 2014. Jun 2;(15:): p. 200. 
641. Townsend, D., et al., A systematic review of training programmes for 
recruiters to randomised controlled trials. Trials, 2015. 16(1): p. 432. 
642. Mills, N., et al., Training health professionals to recruit into challenging 
randomized controlled trials improved confidence: the development of the 
QuinteT randomized controlled trial recruitment training intervention. J Clin 
Epidemiol, 2018. 95: p. 34-44. 
643. Lane, J.A., et al., Active monitoring, radical prostatectomy, or radiotherapy for 
localised prostate cancer: study design and diagnostic and baseline results of 
the ProtecT randomised phase 3 trial. Lancet Oncol, 2014. 15(10): p. 1109-
18. 
644. Bradley, C., Designing medical and educational intervention studies. A review 
of some alternatives to conventional randomized controlled trials. Diabetes 




645. Feine, J.S., M.A. Awad, and J.P. Lund, The impact of patient preference on 
the design and interpretation of clinical trials. Community Dent Oral Epidemiol, 
1998. 26(1): p. 70-4. 
646. Sammons, H.M., et al., British and Canadian views on the ethics of paediatric 
clinical trials. Eur J Clin Pharmacol, 2007. 63(5): p. 431-6. 
647. Kerr, C.E.P., et al., The impact of describing clinical trial treatments as new or 
standard. Patient Education and Counseling, 2004. 53(1): p. 107-113. 
648. Adamson, S.J., D.J. Sellman, and G.M. Dore, Therapy preference and 
treatment outcome in clients with mild to moderate alcohol dependence. Drug 
Alcohol Rev, 2005. 24(3): p. 209-16. 
649. Ananworanich, J., et al., A feasibility study of immediate versus deferred 
antiretroviral therapy in children with HIV infection. AIDS Res Ther, 2008. 5: p. 
24. 
650. Byrnes, H.F., et al., Implementation fidelity in adolescent family-based 
prevention programs: relationship to family engagement. Health Educ Res, 
2010. 25(4): p. 531-41. 
651. George, S.Z. and M.E. Robinson, Preference, expectation, and satisfaction in 
a clinical trial of behavioral interventions for acute and sub-acute low back 
pain. J Pain, 2010. 11(11): p. 1074-82. 
652. Aalborg, A.E., et al., Implementation of adolescent family-based substance 
use prevention programs in health care settings: Comparisons across 
conditions and programs. Health Educ J, 2012. 71(1): p. 53-61. 
653. Bishop, M.D., et al., The influence of clinical equipoise and patient 
preferences on outcomes of conservative manual interventions for spinal pain: 
an experimental study. J Pain Res, 2017. 10: p. 965-972. 
654. Kearney, A., et al., Reducing attrition within clinical trials: The communication 
of retention and withdrawal within patient information leaflets. PLoS One, 
2018. 13(10): p. e0204886. 
655. Thompson, E.A., et al., The feasibility of a pragmatic randomised controlled 
trial to compare usual care with usual care plus individualised homeopathy, in 
children requiring secondary care for asthma. Homeopathy, 2011. 100(3): p. 
122-30. 
656. Hissink Muller, P.C.E., et al., Participation in a single-blinded pediatric 
therapeutic strategy study for juvenile idiopathic arthritis: are parents and 
patient-participants in equipoise? BMC Med Ethics, 2018. 19(1): p. 96. 
657. Anderson, E., et al., Testing the feasibility of recruiting adolescents with 
CFS/ME to Internet-delivered therapy: Internal pilot within a randomised 
controlled trial investigating online Cognitive Behavioural Therapy (Fatigue In 
Teenagers on the interNET in the NHS – “FITNET-NHS”) compared to Skype-
delivered Activity Management for adolescents with CFS/ME. [draft October 
2019]. 
658. Brigden, A., Results of the feasibility phase of the Managed Activity Graded 
Exercise iN Teenagers and Pre-Adolescents (MAGENTA) Randomised 
Controlled Trial of treatments for Chronic Fatigue Syndrome/ Myalgic 
Encephalomyelitis. Pilot and Feasibility Studies, [submitted for publication 
August 2019]. 
659. Hall, N.J., et al., CONservative TReatment of Appendicitis in Children – a 





660. Eborall, H.C., et al., The face of equipoise--delivering a structured education 
programme within a randomized controlled trial: qualitative study. Trials, 2014. 
15: p. 15. 
661. Spillane, A.J. and G.B. Mann, Surgeon knows best versus breast cancer 
surgical clinical trial equipoise: a plea for the sake of future trials. ANZ J Surg, 
2017. 87(3): p. 111-112. 
662. Radley, A. and M. Billig, Accounts of health and illness: Dilemmas and 
representations. Sociology of Health & Illness, 1996. 18(2): p. 220-240. 
663. May, V., On being a 'good' mother: The moral presentation of self in written 
life stories. Sociology-the Journal of the British Sociological Association, 2008. 
42(3): p. 470-486. 
664. Comwell, J., Hard-Eamed Lives: Accounts of Health and Illness from East 
London. 1984, London: Tavistock. 
665. Nelson, P.A., et al., 'Doing the "right" thing': how parents experience and 
manage decision-making for children's 'normalising' surgeries. Soc Sci Med, 
2012. 74(5): p. 796-804. 
666. Lock, C., et al., Childhood tonsillectomy: who is referred and what treatment 
choices are made? Baseline findings from the North of England and Scotland 
Study of Tonsillectomy and Adenotonsillectomy in Children (NESSTAC). Arch 
Dis Child, 2010. 95(3): p. 203-8. 
667. Blair, R.L., et al., The Scottish tonsillectomy audit. Audit Sub-Committee of the 
Scottish Otolaryngological Society. J Laryngol Otol, 1996. 110 Suppl 20: p. 1-
25. 
668. Ellington, M., Jr., et al., Child health status, neurodevelopmental outcome, 
and parental satisfaction in a randomized, controlled trial of nitric oxide for 
persistent pulmonary hypertension of the newborn. Pediatrics, 2001. 107(6): 
p. 1351-6. 
669. Plank, R.M., et al., A randomized trial of Mogen clamp versus Plastibell for 
neonatal male circumcision in Botswana. J Acquir Immune Defic Syndr, 2013. 
62(5): p. e131-7. 
670. Janevic, M.R., et al., The role of choice in health education intervention trials: 
a review and case study. Soc Sci Med, 2003. 56(7): p. 1581-94. 
671. Locock, L. and L. Smith, Personal benefit, or benefiting others? Deciding 
whether to take part in clinical trials. Clin Trials, 2011. 8(1): p. 85-93. 
672. Brigden, A., et al., How are behavioural interventions delivered to children (5-
11-year olds): A systematic mapping review. BMJ Paediatrics Open, 2019 [In 
press]. 
673. Reilly, K.C., et al., "C.H.A.M.P. Families": Description and Theoretical 
Foundations of a Paediatric Overweight and Obesity Intervention Targeting 
Parents-A Single-Centre Non-Randomised Feasibility Study. Int J Environ 
Res Public Health, 2018. 15(12). 
674. Ng, C.Y., et al., Theory-Based Health Behavior Interventions for Pediatric 
Chronic Disease Management: A Systematic Review. JAMA Pediatr, 2018. 
172(12): p. 1177-1186. 
675. Michie, S., et al., Developing and Evaluating Digital Interventions to Promote 
Behavior Change in Health and Health Care: Recommendations Resulting 
From an International Workshop. J Med Internet Res, 2017. 19(6): p. e232. 
676. Miller, V.A., C. Feudtner, and A.F. Jawad, Children's Decision-Making 




Fairness and Self-Efficacy. J Empir Res Hum Res Ethics, 2017. 12(2): p. 87-
96. 
677. Bandura, A., Health promotion by social cognitive means. Health Educ Behav, 
2004. 31(2): p. 143-64. 
678. Weinger, K., K.A. O'Donnell, and M.D. Ritholz, Adolescent views of diabetes-
related parent conflict and support: a focus group analysis. J Adolesc Health, 
2001. 29(5): p. 330-6. 
679. Dixon-Woods, M., B. Young, and D. Heney, Partnerships with children. BMJ, 
1999. 319(7212): p. 778-80. 
680. Mays, N. and C. Pope, Rigour and qualitative research. BMJ, 1995. 
311(6997): p. 109-12. 
681. O’Cathain A, T.K., Drabble SJ, Rudolph A, Goode J, Hewison J., Maximising 
the value of combining qualitative research and randomised controlled trials in 
health research: the QUAlitative Research in Trials (QUART) study – a mixed 
methods study. . Health Technol Assess. , 2014. Jun; 18((38): ): p. 1-197. . 
682. Liaschenko, J. and S.M. Underwood, Children in Research: Fathers in Cancer 
Research—Meanings and Reasons for Participation. Journal of Family 
Nursing, 2001. 7(1): p. 71-91. 
683. Macfadyen, A., et al., Involving fathers in research. 2011. 16(3): p. 216-219. 
684. Swallow, V., et al., Fathers and mothers developing skills in managing 
children's long-term medical conditions: how do their qualitative accounts 
compare? Child Care Health Dev, 2011. 37(4): p. 512-23. 
685. Murphy, E. and R. Dingwall, Qualitative Methods and Health Policy Research. 
2003, New York: Walter de Gruyter, Inc. 
686. Rowlands, C., et al., Detailed systematic analysis of recruitment strategies in 
randomised controlled trials in patients with an unscheduled admission to 
hospital. BMJ Open, 2018. 8(2). 
687. Leira, E.C., et al., Extending acute trials to remote populations: a pilot study 
during interhospital helicopter transfer. Stroke, 2009. 40(3): p. 895-901. 
688. Gillies, K., et al., Systematic Techniques to Enhance rEtention in Randomised 
controlled trials: the STEER study protocol. Trials, 2018. 19(1): p. 197. 
689. Kukla, R., Conscientious autonomy: displacing decisions in health care. 
Hastings Cent Rep, 2005. 35(2): p. 34-44. 
690. Gonzalez, K.W., et al., Understanding parental refusal of permission for child 
participation in surgical prospective trials. Pediatr Surg Int, 2016. 32(5): p. 
505-8. 
691. Jenkins, V., et al., Discussing randomised clinical trials of cancer therapy: 
evaluation of a Cancer Research UK training programme. BMJ, 2005. 
330(7488): p. 400. 
692. Blazeby, J., et al., Optimising recruitment into RCTs in surgery. A focused 






Appendix 1: Ethical Approvals  
Ethical approval for my PhD project incorporating qualitative data from all four trials 
was obtained via the Research and Enterprise Development (RED) Team University 
of Bristol, (Study 2374). All work was undertaken with the financial support of the 
MRC ConDuCT-II (Collaboration and innovation for Difficult and Complex 
randomised controlled Trials In Invasive procedures) Hub for Trials Methodology 
Research (MR/K025643/1). Good Clinical Practice (GCP) training, Disclosure and 
Barring Service (DBS formerly CRB) checks, research passports and local NHS 
letters of access were also obtained for each qualitative study within each trial.  
 
Overall trial findings from the MAGENTA, FITNET-NHS and CONTRACT RCTs were 
not known to me at the time of writing this thesis. Findings from the SMILE RCT 
were published in July 2017. 
 
Ethical approval was obtained for each RCT as detailed below: 
Study name and acronym: Specialist Medical Intervention & Lightning Evaluation: 
SMILE 
Ethics committee: South West 2 Local Research Ethics Committee 
REC reference: 10/H0206/32  






Study name and acronym: Managed Activity Graded Exercise in Teenagers and 
Pre-Adolescents: MAGENTA 
Ethics committee: NRES Committee South West – Frenchay 
REC reference: 15/SW/0124 
Approval granted: Feasibility: REC: 3rd July 2015. NHS Trust: 13th August 2015  
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to the ethics committee concerning this, and the ethics committee’s re-review of 




Study name and acronym: Investigating the effectiveness and cost-effectiveness of 
using FITNET-NHS (Fatigue In Teenagers on the interNET in the NHS) compared to 
activity management to treat CFS/ME in the United Kingdom: FITNET-NHS 
Ethics committee: South West Frenchay Research Ethics committee 
REC reference: 16/SW/0268 
Approval granted:  REC: 10th October 2016 HRA:13th October 2016 
 
Study name and acronym: CONservative TReatment of Appendicitis in Children a 
randomised controlled Trial: CONTRACT 
Ethics committee: South Central Hampshire A Research Ethics Committee 
REC reference: 16/SC/0596  




Appendix 2: Systematic Review 
Eligibility and Inclusion Criteria 
Participants/population: 
Inclusion: Children and young people aged 0 – 17.99yrs at trial entry.  
Exclusion: adult RCT participants aged 18 plus.  
Interventions: 
Inclusion: Any intervention, combination of interventions. 
Exclusion: None. 
Comparators: 
Inclusion: Any comparative intervention. 
Exclusion: None. 
Outcomes: 
Inclusion: Any clinical outcome, this review is not seeking to review clinical 
outcome, instead it will review the expressed treatment preferences of children, 
young people and their parents in relation to their randomisation allocation.  
Include if 'Preference' for treatment group is reported by patient/parent before or 
after randomisation/intervention, this could be expressed as preference for one or 
more treatment groups in relation to allocation and/or treatment/outcome OR a 
'non-preference' or dislike for particular treatment group(s). 
Exclusion: If 'Satisfaction' is reported by patient/parent after 
randomisation/intervention, it is satisfaction with outcome/a received treatment 
NOT a ‘preference’ between treatment groups. Use reasons: 'Reports patient OR 
parent satisfaction with treatment outcome’.  
Context:  
Inclusion: The first RCT paper was published in 1948, therefore database 
searches will be limited to the time period 1950-2014 inclusive. 
Exclusion: Any study prior to the year 1950.  
Study design:  
Inclusion: RCTs with prospectively recruited children and young people where 
there is randomisation including, (complete or partial) and treatment preference is 
reported for all, (or some) of the participants. Qualitative studies that report 
treatment preference in RCTs.  





MEDLINE Search Strategy 
Database: Medline 1950 to present 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     adolescent/ or exp child/ (2516113) 
2     minors/ (2367) 
3     Pediatrics/ (42050) 
4     (pediatri$ or paediatri$ or teenager$ or young person$ or young people).ti,ab. 
(245419) 
5     (adolesc$ or boy$ or girl$ or child$ or juvenil$ or schoolchild$).ti,ab. 
(1213948) 
6     or/1-5 (2862052) 
7     (exp adult/ or adult.ti.) not (pediatri$ or paediatri$ or teenager$ or adolesc$ or 
young person$ or young people or boy$ or girl$ or child$ or juvenil$ or 
schoolchild$).ti,ab. (5590793) 
8     6 not 7 (1740500) 
-------------------------------------------------------------------------------- 
9     exp Clinical Trials as Topic/ (295653) 
10     ((random* or crossover* or control* or cross-sectional or observational or 
longitudinal or clinical) adj4 (trial or trials or design or study or studies)).ti,ab. 
(1026721) 
11     9 or 10 (1187255) 
-------------------------------------------------------------------------------- 
12     ((patient$ or participant$ or parent$ or mother$ or father$ or child$ or carer$ 
or caregiver$ or care-giver$ or personal) adj3 (view or views or priorit$ or 
perception$ or prefer$ or belief$ or expectation$ or choice$ or perspective$ or 
satisfact$ or experience or experiences or opinion$ or concern or concerns or 
feeling$)).ti,ab. (189786) 
13     exp patient satisfaction/ (65985) 
14     professional-family relations/ or professional-patient relations/ or physician-
patient relations/ or researcher-subject relations/ (97784) 





16     8 and 11 and 15 (6445) 
-------------------------------------------------------------------------------- 
17     letter/ (857062) 
18     editorial/ (358231) 
19     news/ (165244) 
20     exp historical article/ (333331) 
21     Anecdotes as topic/ (4682) 
22     comment/ (581752) 
23     case report/ (1739336) 
24     (letter or comment$).ti. (91081) 
25     or/17-24 (3403060) 
-------------------------------------------------------------------------------- 
26     randomized controlled trial/ or Randomized Controlled Trials as Topic/ or 
random$.ti,ab. (848254) 
27     25 not 26 (3371992) 
-------------------------------------------------------------------------------- 
28     animals/ not humans/ (4004886) 
29     exp Animals, Laboratory/ (764211) 
30     exp Animal Experimentation/ (6725) 
31     exp Models, Animal/ (447357) 
32     exp rodentia/ (2802604) 
33     (rat or rats or mouse or mice).ti. (1119422) 
34     or/27-33 (7983465) 
-------------------------------------------------------------------------------- 
35     16 not 34 (6323) 
Medline search carried out 6th January 2015 retrieved 6323 records 
EMBASE 8th January 2015 retrieved 9296 records 
CINHAL 13th January 2015 retrieved 1977 records 





MEDLINE = 4813 
EMBASE = 5204 
CINAHL = 1824 
COCHRANE = 5094 





Title and abstract screening: Inclusion criteria 
1. FACTOR/ASSESSMENT 1. a. Published 1950 –2014?  (y/n) 
2. FACTOR/ASSESSMENT 1. b. RCT               (y/n/unclear) 
3. FACTOR/ASSESSMENT 2. Age?                (add age 
range) 
4. FACTOR/ASSESSMENT 3a. Reports TP quantitative?  (y/n) 
5. FACTOR/ASSESSMENT 3b. Reports TP qualitative?             (y/n) 
6. FACTOR/ASSESSMENT 3c. Reports TP descriptively?  (y/n) 
7. COVIDENCE REASONS FOR EXCLUSION   
Include/Exclude:  
a. Wrong study design  
b. Adult population 
c. Wrong patient population 
d. Reports patient OR parent satisfaction with treatment outcome not 
preference between intervention groups 
e. No discussion of preference between intervention groups 
f. study protocol & no indication that treatment preference between groups 
will be measured 
g. study protocol & hand search will be carried out for full trial results paper 
h. Full text not available 
i. Duplicate 
j. Abstract or poster & hand search will be carried out on author for full 
publication(s) in relation to trial 
k. Data analysis not separated by age for those under/over 18yrs 




Data extraction fields 
Data extraction fields: 
Author 
Primary outcome or secondary paper 
Country 
RCT type (full, feasibility, preference, comprehensive cohort) 
RCT aim 
Area of study & Description of interventions  
Participant age (months/years) 
Is preference expressed by patient/parent prior to randomisation  
Is preference expressed by patients (in addition to parents)   
Number of eligible participants consenting to randomised groups 
Number of eligible patients not randomised because of treatment preference n (%) 
Post randomisation drop-out due to preference 
Total: withdrawn/discontinued treatment/crossed over/lost to follow up 
Further information reported on preference (included: preference of parent 
different from young person, preference groups added, early trial closure, 
extension required and trial terminated early) 
Additional qualitative data extraction fields: 
Number of qualitative participants (parents/ participants) 
Qualitative aim 
Qualitative data collection method(s) 












Example: meta-ethnography – second order constructs 
 
 





Five themes with preference related data: 2nd order constructs (themes) and author’s 















Author 1st order constructs (original papers)
2nd order constructs (Theme names 
original papers)*
Overarching 3rd order construct and sub-themes (translation/synthesis)
Carvalho_2013
"Relieved. I feel like jumping for joy. That is great." [kisses the child] 
[laughs] [Mother’s expectation prior to randomisation: Sedation. 
Group assigned: Sedation] 
Mothers' feelings before and after the 
drawing: after the drawing
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability, Relief and Happiness
Carvalho_2013
"We feel relief, knowing he will not feel the treatment so much." 
[Mother’s expectation prior to randomisation: General anesthesia. 
Group assigned: Sedation] 
Mothers' feelings before and after the 
drawing: after the drawing
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and Relief
Carvalho_2013
"We would like to have gotten the general anesthesia . . . Now we have 
to do it with the sheet [passive restraint]." [Mother’s expectation prior 
to randomisation: General anesthesia. Group assigned: Physical 
restraint] 
Mothers' feelings before and after the 
drawing: after the drawing
An emotional response to randomisation and expressions of preference for 
treatment: Disappointment
Carvalho_2013
"Oh, no!" [Mother’s expectation prior to randomisation: Physical 
restraint. Group assigned: General anesthesia] 
Mothers' feelings before and after the 
drawing: after the drawing
An emotional response to randomisation and expressions of preference for 
treatment: Disappointment
Carvalho_2013
no quotation [Mother cried]  [Mother’s expectation prior to 
randomisation: General anesthesia. Group assigned: Physical restraint] 
Mothers' feelings before and after the 
drawing: after the drawing
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and Disappointment
Eiser_2005
"we would have wanted the old one but if it helps others it's OK. They 
pick you at random and we got picked (for the new drug)".  [new 
treatment/negative]
Preference for different arms of the trial
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and Disappointment
Eiser_2005
"We were glad to get the old  treatment. It means if she relapses we  
can still have the new treatment"  [standard treatment/positive]
Preference for different arms of the trial
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and Relief
Eiser_2005
"We are not bothered about being on the old treatment as they only 
give the best, don’t they?" [standard treatment/positive]
Preference for different arms of the trial
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability, Hopes and Fears
Eiser_2005
"Treatment is excellent anyway and anything they offer can only be 
better. I am all for research"  [new treatment/positive]
Preference for different arms of the trial
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability, Hopes and Fears
Eiser_2005
"We were disappointed. You go through all that talking and decision 
making and then you get the old treatment anyway"
Understanding of the trial: Aims and 
Randomisation
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and Disappointment
Eiser_2005
 "I can’t remember what it was about. Was it we could choose whether 
it was one drug we had or another, or whether we could be put in a 
trial and then the people running the trial would choose the drug for us 
and then we wouldn’t know which we were on? We agreed but were 
not happy about the computer deciding" 
Understanding of the trial: Aims and 
Randomisation
Parents’ preferences for treatment: expressed while making sense and asking 
questions about the RCT - Understanding of trial processes (nature of RCT, 
randomisation, equipoise)
Glogowska_2001
"I was told yes, he had a problem and he needed help and I think now, 
well, I’ve got to wait ... to get any help" 
Parents understanding of the nature of the 
trial
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and Disappointment (Access to treatment)
Glogowska_2001
"It was a case of if his name came out of the box ... then he was lucky 
enough to go on it ... which I think is wrong ... but then I suppose it’s all 
the cutbacks"
Parents understanding of the nature of the 
trial
Parents’ preferences for treatment: expressed while making sense and asking 
questions about the RCT - Understanding of trial processes (nature of RCT, 
randomisation, equipoise) Fate and luck
Glogowska_2001
"If she’d [the therapist] seen something ... and thought ... this is 
something really serious well then he wouldn‘t have been put on that 
sort of waiting group."
Parents' motivation for taking part
Parents’ preferences for treatment: expressed while making sense and asking 
questions about the RCT (Access to treatment)
Glogowska_2001
 "I don ’t mind answering the questions ... and assessing him ... but it’s 
just the fact ... I wish it was ... therapy a lot more"
Parents' motivation for taking part
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability, Hopes and Disappointment (Access to treatment)
Glogowska_2001
"I couldn’t justify saying O.K. we'll go along with this research group 
and wait for a year because he needed help then"
The meaning of participation to the parents
An emotional response to randomisation and expressions of preference for 






Author 1st order constructs (original papers)
2nd order constructs (Theme names 
original papers)*
Overarching 3rd order construct and sub-themes (translation/synthesis)
Jollye_2009
"You associate a blood transfusion with someone being sick, really 
sick." [blood transfusion trial] 
Contemplating the research trial - risks and 
benefits
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and Responsibility (Understanding of treatment groups )
Jollye_2009 [child might not be randomised to the] "right" arm [Ventilation trial] 
Contemplating the research trial - risks and 
benefits
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy
Lock_2010
"If it come to the 10 month up and he didn’t need it done, my wife says, 
‘Oh I might get it done anyway, just in case" 
Management of recurrent sore: Having a 
tonsillectomy ‘just in case’
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Management of condition and practical implications
Lock_2010
"Yeah his brother had his took out and he’s been brilliant since he got 
his done … it was the best thing I could have done for him … that’s why 
we are trying to push to get his done because it’s just recurring all the 
time, every couple of months or so and it’s not fair on the bairn and it’s 
not fair on his education either because he’s having to have the time 
off school because he’s just, well he wouldn’t be any good at school"
Management of recurrent sore: Using the 
experience of other & Requesting 
tonsillectomy
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Perceived benefits and risks (Management of condition & 
practical implications).
Shilling_2011
"Her only real way of getting it is to go and take part in the trial 
because then, I’ve got sort of a 50/50 chance of either she gets the drug 
or she gets the placebo. But she wouldn’t be getting it otherwise"
Communication as observed - Mismatches and 
misunderstandings
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Perceived benefits and risks (Access to treatment 
medication or therapy)
Shilling_2011
"getting the right medication"                                                                                                                              
Doctor: "So we are running this study for the last year now, where I’m 
afraid half the [babies] get the supplement and half the [babies] 
doesn’t get it"
Communication as observed - Mismatches and 
misunderstandings
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy
Shilling_2011
"We’d already made our mind up that we were going to. Before we’d 
even got the information …] we just weren’t getting sleep […] it’s like, 
we have to do something" 
Communication as observed - Mismatches and 
misunderstandings
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy (Management of 
condition and practical implications)
Shilling_2011
Doctor: "We’ve been using it for […] ten years or so […] and the whole 
idea of this study is to do it properly and to get the proof that it works 
so that we can use it more widely and for many more doctors to 
prescribe it, if it, if it is successful"  [recorded recruitment consultation] 
"in order to get that tablet he has to participate in the trial"   [interview 
with mother who declined the RCT]            
Communication as observed - Mismatches and 
misunderstandings
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy
Shilling_2011
Doctor: "The hormone is given through err … an infusion. It’s called err 
a syringe pump basically, which is, you know, puts medicine to the 
veins. Um and we will give it once a day"                                        Mother: 
"OK"                                                                                                                                                        
Doctor: All these procedures won’t cause distress to your baby […] if 
your baby is not getting fully milk feeds, then we will use the lines. Once 
a baby is going on to full or milk feeds, then we will give drops and 
things […] so it won’t cause any distress" [recorded recruitment 
consultation]
Communication as observed - Mismatches and 
misunderstandings
Parents’ preferences for treatment: expressed while making sense and asking 







Author 1st order constructs (original papers)
2nd order constructs (Theme names 
original papers)*
Overarching 3rd order construct and sub-themes (translation/synthesis)
Shilling_2011
"I didn’t see why I […] could say ‘no’ to it. Because I thought, well it’s, 
you know, a 50/50 chance of her getting […] this additional help which 
she might need"
What influences decision making: Benefits to 
the child, the family and others
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy (Hopes and 
fears)
Shilling_2011
"Maybe he might get [the trial drug], maybe he mightn’t. Maybe, if he 
does get it, it might help him in some way and if he doesn’t get it then, 
you know, at least I tried to help [you] with the study" 
What influences decision making: Benefits to 
the child, the family and others
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy (Responsibility)
Shilling_2011
"What my question is, if they say he’s gonna take the placebo, […], the 
dummy one what is he going to benefit from the study?"
Communication as observed - Parents 
interactivity in the trial discussion
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy (Understanding 
of treatment groups and unanswered questions)
Snowdon_1997
"I suppose what they're saying is that er if at the end of the day 
conventional really really really isn't going to work for him then that 
[ECMO] would be absolutely ideal because... the chances are maybe he 
would be picked."                                                                                                                                                                                                                                                                                                                                             
What were parents' understanding of the basis 
of treatment decisions 
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy (Understanding 
of treatment groups and unanswered questions)
Snowdon_1997
"I thought that the doctor had entered Timothy for the trial as he was 
perfect for the ECMO treatment."
What were parents' understanding of the basis 
of treatment decisions 
Parents’ preferences for treatment: expressed while making sense and asking 
questions about the RCT - Understanding of trial processes (nature of RCT, 
randomisation, equipoise)
Snowdon_1997
"I just felt there could have been ten other babies with exactly the same 
problems as him and now there is nine sets of parents who are now 
being told that their baby's not being accepted onto the trial. And I did 
feel a bout of guilt for that but I could have gone out and...danced on 
water...when I got told that he'd been accepted." [Robert ECMO].
What were parents' perceptions of why 
randomization was used: Clinical resources
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy (Vulnerability, 
Relief, Happiness)
Snowdon_1997
"unfair" [Janet: Coventional Management and Gary: ECMO], "hard" 
[Mary: ECMO], "tough" [Alan: ECMO], and "heartless" [Angela: 
Coventional Management]. 
Acceptance of Randomization
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and responsibility
Snowdon_1997
"I feel desperately sorry for parents who, you know, were turned down 
particularly if their child doesn't live. I think it would be hard but I can 
see that it is necessary in case ...the research shows that ECMO is 
actually detrimental to children" [Mary: ECMO]
Acceptance of Randomization
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - A difficult decision 
Snowdon_1997
"I suppose trials have to be a bit heartless, but you'd think that when 
the baby looks like they're dying, you'd think they'd just say... Oh hell 
you know... let's try the ECMO, see if it saves this baby... but with that 
sort of a trial they can't do that can they? They have to say, Well look, 
this baby looks like it's dying but l'm sorry it's getting conventional 
treatment and that's that." [Angela: Coventional Management]. 
Acceptance of Randomization
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - A difficult decision 
Snowdon_1997 "lucky" [mentioned by a number of participants] Acceptance of Randomization
An emotional response to randomisation and expressions of preference for 






Author 1st order constructs (original papers)
2nd order constructs (Theme names 
original papers)*
Overarching 3rd order construct and sub-themes (translation/synthesis)
Snowdon_1997
"it's not something that you would expect because when you go into a 
hospital you think right, it's a baby, they are going to do whatever is 
necessary for the baby, you know." [Fatima: Coventional 
Management].                                                                                                                                          
"anybody eligible for it should use it." [Fatima: Coventional 
Management].       
Rejection of Randomization
Parents’ preferences for treatment: expressed while making sense and asking 
questions about the RCT - Understanding of trial processes (nature of RCT, 
randomisation, equipoise)
Snowdon_1997
"I think any parent wants to try anything, you know, they don't sit 
down and think it's research, there could be side effects or there could 
be abnormalities that might come up. I think as parents...your first 
instinct is to save your baby." [Fatima: Coventional Management]. 
Rejection of Randomization
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and responsibility
Snowdon_1997
"they ought to have known which... [was] best"  ... "He almost made it 
come across as it's the only thing we've got left to try and to me they 
ought to have tried it... [if it was] their opinion that he should have 
gone, then he should have gone, but if they thought, well he's better 
off staying here, then he should have stayed here" [Nick: Coventional 
Management].        
Rejection of Randomization
Parents’ preferences for treatment: expressed while making sense and asking 
questions about the RCT - Understanding of trial processes (nature of RCT, 
randomisation, equipoise) (Anger)
Snowdon_1997
"Yes, by randomization and that--that annoyed me. It didn't annoy me 
at the time because we got it (ECMO) but since then the very thing 
that's stuck in my mind all the time is who gives them the right to play 
God with babies" lives? And why the hell have we got it on trial when 
it's been in the States and it's got an 89% success rate or whatever...? 
Why is the National Health playing around with this? You know they 
wouldn't play around if America suddenly came up with a cure for 
cancer... Why are they playing around with babies' lives? Er, you know 
who gives them the right to sit there with say 10 babies and think well 
this--this one here you know will--will suit the trial, you know. Why not 
all 10 of them? Why isn't it available everywhere so everybody has a 
fair chance?" [Robert: ECMO].
Rejection of Randomization
Parents’ preferences for treatment: expressed while making sense and asking 
questions about the RCT - Understanding of trial processes (nature of RCT, 
randomisation, equipoise) (Anger)
Snowdon_1997
"Even if she had been randomized out that bed would still have been 
available, wouldn't it? I couldn't come to terms with that at all. Now by 
all means fill the beds up and if babies come along that can't get into 
the beds then that is fine but this randomization of having a bed and a 
team and not being able to get into the bed was er--well I just couldn't 
come to terms with that which is why I would question.., the system of 
randomization." [Gary: ECMO]. 
Rejection of Randomization
Parents’ preferences for treatment: expressed while making sense and asking 










Author 1st order constructs (original papers)
2nd order constructs (Theme names 
original papers)*
Overarching 3rd order construct and sub-themes (translation/synthesis)
Snowdon_1997
"I knew it was random. I mean this is the whole thing about the Fate 
thing. I tell you it's kind of going through [your] whole life without 
following religion or anything like that but at that time you cling on to 
anything really and I thought there is only one decision here and it has 
to be Fate... I thought well if there is any justice in the world then the 
decision will come through right and as far as I'm concerned I mean 
that's what happened. He stayed and had traditional treatment and 
the fact that he didn't go to the ECMO as far as I'm concerned the 
decision was right. Fate played its hand" [Neil: Coventional 
Management]. "God's hand" [Andrea describing Robert's view: 
Coventional Management]. "justice" [Pascal: ECMO, and Neil: 
Coventional Management]. "very deep faith in God." [Mary: ECMO 
described her own and her husband's faith].
Rejection of Randomization
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and Responsibility / Fate and Luck
Snowdon_1997
"It probably would have killed me if l had known that it was a 
randomized test and if they had turned around and said she couldn't 
go on, urn, you know...because I knew the ventilator wasn't helping 
her which meant...as good as "I am sorry there is nothing else we can 
do but wait for her to die." [Fatima: Coventional Management]. 
Rejection of Randomization
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and Responsibility
Snowdon_1997
"We went back to the ward. The nurses said "Oh, he hasn't got the 
ECMO, he's staying here" and them saying that we thought, oh dear, 
you know, we've had the wrong one or something. We felt 
disappointed." [Paul: Coventional Management]. 
Rejection of Randomization







Author 1st order constructs (original papers)
2nd order constructs (Theme names 
original papers)*
Overarching 3rd order construct and sub-themes (translation/synthesis)
Woodgate_2010
"I’m sure if he had been chosen for any other arm except for the 
difficult one, I would not have given it another great thought. But it all 
came down to the fact that he got chosen for the one with so much 
more intravenous and lumbar puncture medication, then it threw me 
for a loop and I went through a very touch period. Not the initial period 
because you have 56 days before you get randomized. So you have a 
long time before you get randomized. I would have been fine if they 
had put him on the easier arms of the study. But the minute that it hit 
me full in the face was when we got chosen for the tough arm that hit 
me like a lead brick." (randomised to active treatment)                                                                                 
Coming to terms with my decision
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and Responsibility
Woodgate_2010
"She (the doctor) said had it been her child and this was chosen 
(standard treatment) for him probably she would do exactly as I am 
doing, and that was enough to make me calm I She too agreed with 
what I’m saying and feels that it’s a wise decision. That was enough to 
make me at peace again. And now whatever happens with [child's] 
treatment, relapse or whatever, I will never look back and say I’ve 
made a poor decision. I will not do that." (randomised to active 
treatment)
Coming to terms with my decision
An emotional response to randomisation and expressions of preference for 
treatment: Vulnerability and Responsibility
Woolfall_2013
‘‘I’ve got sort of a 50/50 chance of either she gets the drug or she gets 
the placebo. But she wouldn’t be getting it otherwise.’’
Parents' agenda items: Access to medication
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy 
Woolfall_2013
"I’d heard about , [name of trial drug] and I’d read a few things on the 
internet, because of , [child’s] sleeping, and I just thought, right I’m 
going to ask if he can have it."
Parents' agenda items: Access to medication
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy 
Woolfall_2013
 ‘‘if he does get the ,[name of trial drug] on this trial it will help him 
have a good night’s sleep.’’
Parents' agenda items: Clinical benefit 
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Management of condition and practical implications
Woolfall_2013 ‘‘I was just thinking I hope he gets the, [Name of trial drug] one.’’ Parents' agenda items: Clinical benefit 
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy 
Woolfall_2013
‘‘We had to weigh it up against the fact that…. it could be a placebo 
anyway, it might not be the trial medication."
Parents' agenda items: Randomisation 
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Access to treatment, medication or therapy 
Woolfall_2013
"I wonder who does actually makes the decision, who goes on what 
and who doesn’t"
Misunderstandings linked to agenda items: 
Randomisation
Parents’ preferences for treatment: expressed while making sense and asking 
questions about the RCT - Understanding of trial processes (nature of RCT, 
randomisation, equipoise)
Woolfall_2013
"We’d already made our mind up that we were going to. Before we’d 
even got the information […] we just weren’t getting sleep […] it’s like, 
we have to do something."
Parents’ misunderstandings Linked to Agenda 
Items: Access to medication
Parents’ preferences for treatment: expressed motivations and reservations about 
taking part in an RCT - Perceived benefits and risks / facilitators and barriers to trial 
participation
Woolfall_2013
"It’s called err a syringe pump basically, which is, you know, puts 
medicine to the veins." [recorded recruitment consultation]                                                                                                                  
"[Doctor] told me, I think, they’re going to put like kind of a small tube 
inside him…I just didn’t like the idea from the beginning so I didn’t give 
it more attention." [interview with mother who declined the RCT]  
Parents’ misunderstandings Linked to Agenda 
Items: Practical implications of trial procedures
Parents’ preferences for treatment: expressed while making sense and asking 
questions about the RCT - Understanding of treatment groups and unanswered 







Author 1st order constructs (original papers)
2nd order constructs (Theme names 
original papers)*
Overarching 3rd order construct and sub-themes (translation/synthesis)
Lock_2010
"I was a bit disappointed actually because I just wanted to get rid of it 
[sore throat] straight away." [Participant, age 15].
Management of recurrent sore
throats: Requesting tonsillectomy
An emotional response to randomisation and expressions of preference for 
treatment: Disappointment
Shilling_2011
"I was thinking, this could be really good for me but what if it’s the 
placebo then, um, it’s like I’m doing it for nothing basically." 
[Participant:11–14 years, interview].
Participants’ preferences for treatment: expressed motivations and reservations 
about taking part in an RCT - Access to treatment, medication or therapy 
Shilling_2011
"You just think like ‘oh […] what are we gonna have to do’ like, ‘what 
medicines are we gonna take’ and then obviously […] ‘what will 
happen as a consequence of the medicine" (F57, 11–14 years)
Participants’ preferences for treatment: expressed while making sense and asking 
questions about the RCT: Understanding of treatment groups and unanswered 
questions
Shilling_2011
"It would benefit me and other children in the future for like if they 
have the same thing they can get medicine and not have to do the 
study but like get it straight away because I helped" [Participant:11–14 
years, interview].
Participants’ preferences for treatment: expressed motivations and reservations 
about taking part in an RCT  - Perceived benefits and risks (facilitators and barriers 
to trial participation)
Shilling_2011
"They basically said that some people would get the real thing and 
others needed to get the placebo" [Participant:11–14 years, interview].
Young people’s experiences of the trial 
approach
Participants’ preferences for treatment: expressed motivations and reservations 
about taking part in an RCT - Access to treatment, medication or therapy 
Shilling_2011
‘Even though one of them might not work for the bones and things will 
it do some good for me?’ [Participant:11–14 years, recruitment 
consultation].
Young people’s interactivity in the trial 
discussion
Participants’ preferences for treatment: expressed motivations and reservations 
about taking part in an RCT  - Perceived benefits and risks (facilitators and barriers 
to trial participation)
Young peoples' data
*Findings and discussion points from original papers were analysed but are not included in this table.
What influences decision making: young 
people - what is important to young people 




Appendix 3: SMILE  
[Reference: Crawley, E., et al., Comparing specialist medical care with specialist 
medical care plus the Lightning Process for chronic fatigue syndrome or myalgic 
encephalomyelitis (CFS/ME): study protocol for a randomised controlled trial (SMILE 
Trial). Trials, 2013. 14: p. 444. http://www.ncbi.nlm.nih.gov/pubmed/24370208]] 
 
SMILE: Inclusion/exclusion criteria 
Inclusion criteria 
Children will be included if they have been diagnosed with CFS/ME (made using 
NICE guidance*) and are between 12 and 18 years old inclusive.  
 
[*NICE: National Institute for Health and Clinical Excellence, Chronic fatigue 
syndrome/myalgic encephalomyelitis (or encephalopathy) Diagnosis and 
management of CFS/ME in adults and children., N.I.f.H.a.C. Excellence., Editor. 
2007, Developed by the National Collaborating Centre for Primary Care: London]. 
 
Exclusion criteria 
Children will be excluded if: they are too severely affected to attend hospital 
appointments (defined as children and young people that do not regularly leave 
their house), or if they or their parents have insufficient English to either 
understand the Patient Information Leaflet (PIL) and consent form to take part in 





SMILE: Eligibility assessment  
Eligible young people were identified by health professionals at their initial clinical 
appointment with the specialist CFS/ME team. The initial clinical appointment 
included: an assessment of symptoms, diagnosis, treatment plan and an introduction 
to the SMILE trial, it lasted approximately 90 minutes. The specialist multi-
disciplinary team included paediatricians, occupational therapists, physiotherapists 
and clinical psychologists providing a satellite service from several hospitals and 
health centres in the South-West of the UK. 
 
Young patients were initially assessed for CFS/ME symptoms, and those that were 
given a diagnosis of CFS/ME and were eligible for the trial were informed about 
potential participation in a feasibility RCT at the end of their clinical appointment. 
These families were given a brief verbal overview of the RCT, and the relevant 
patient and parent information leaflets were given to families who were interested in 
finding out more about the trial. The health professional also asked families if they 
were willing to be contacted by a researcher (LB) and a recruiter working on the 
SMILE research team. Consent to contact was obtained from families who were 
willing to hear more about the trial. If families were willing to provide reasons for 
declining contact from the research team these were recorded and passed on 





SMILE: Integrated qualitative aims and objectives  
 
1. To assess the recruitment process, including views and experiences of the 
initial assessment/eligibility appointment, recruitment to trial appointment, 
provision and acceptability of patient information, and reasons for accepting or 
declining participation in the trial. 
2. To explore prior exposure, beliefs, expectations and preferences about 
specialist medical care and Lightning Process interventions before 
assignment, post-randomisation, and experiences and acceptability of the 
intervention and outcome after having received it. 
3. To investigate appropriate patient-reported outcome measures for the RCT, 
including views and experiences of completing the Hospital Anxiety and 
Depression Scale (HADS), the Profile of Mood States (POMS), and the 
Spence Children’s Anxiety Scale (SCAS). 
4. To observe the delivery of both interventions to provide data on setting, 





SMILE: Trial flow 
Participant flow through trial related interventions and data collection procedures.  
 
 
[Reference: Crawley et al 2012, Comparing specialist medical care with specialist 
medical care plus the Lightning Process for Chronic Fatigue Syndrome or Myalgic 
Encephalopathy (CFS/ME) Randomised Controlled Trial. SMILE – Specialist Medical 





SMILE: Data collection and randomisation 
Allocation (ratio 1:1) was concealed and minimised by age (categories 12-15 or 16-
18 years) and gender. A telephone-based interactive voice response system was 
used to randomise participants. This was maintained by the Bristol Randomised 
Trials Collaboration. Because of the nature of the interventions, it was not practical to 
blind either the family or the clinical service to treatment allocation. 
After allocation the recruiter informed the clinical service of the patient’s allocation, 
(by phone or email) to enable the clinical team to send a letter with details of the 
patient’s next follow-up appointment. When relevant, the recruiter also informed the 
Lightning Process group (via telephone) so that a Lightning Process introductory 
book could be sent out to the participant, and a Lightning Process practitioner could 
make contact with the family. The participant’s GPs was informed via letter, that their 
patient was participating in the SMILE trial, and which intervention the young person 
had been allocated. 
 
Recording of first clinical appointment 
A sample of initial assessment appointments were audio-recorded by the research 
team to document the interaction between health care professionals and potentially 
eligible families, specifically the way in which the SMILE trial was introduced to 
families. All Lightning Process courses were audio-recorded and a researcher (LB) 
observed the delivery of 25% of the LP courses. Data from Lightning Process 
courses was not used in the current thesis but some data from initial clinical 
appointments was used during the qualitative data analyses to provide contextual 




SMILE: Intervention groups 
Specialist medical care leaflets for paediatric CFS/ME patients 
The link below provides current versions of the CFS/ME specialist medical care 
program leaflets. These have been updated since the SMILE RCT but the 




• Activity, rest, and sleep diary 
• CBT leaflet 
• Energy management 
• Exam Stress 
• Exercise Chart 
• Information for Schools and Colleges 
• Managing feelings 
• Sleep & Relaxation 
 





In the community Lightning Process courses would be available to participants of 
any age with a range of conditions (including: CFS/ME, fibromyalgia, depression, 
anxiety and obsessive-compulsive disorder). The Lightning Process course is a 
mixture of theory and practical sessions involving both group and individual 
discussions with those participating (3-5 participants per group during the SMILE 
RCT). In the theory sessions, SMILE participants learned about stress and its 
physical effects, how the mind and body interact and how thought processes can be 
helpful and unhelpful. In the practical sessions, they identified goals they wished to 
achieve (e.g. walking for longer) and were given different ways to think about and 
prepare for this. They then had the chance to practise this on the course with the 
Lightning Process practitioner there to support them. Participants were given up to 
30 minutes of homework each day so they could continue to practise the skills they 
had learnt, using a goal they identified during that day’s session.  The Lightning 
Process was not a treatment offered by the specialist paediatric CFS/ME service 
outside the trial, but if parents wished they could access this treatment by paying for 
the course which cost approximately £620 if accessed privately (course cost when 
the SMILE protocol was published 2013). The Lightning Process course was (and is 
currently) not offered or paid for by the NHS outside of the SMILE trial. During the 
SMILE trial it was made clear to families that they were free to access this course 





SMILE: Patient Information Leaflet (12-18yrs)  
v9 May 2011 
 
  
CFS/NHS/PAEDIATRICS - Specialist help for ME.   
   
  
        
SMILE  
Specialist Medical Intervention & Lightning Evaluation 
 
Feasibility randomised controlled trial for Chronic Fatigue Syndrome/ME 
 
INFORMATION LEAFLET FOR TEENAGERS 
 
We would like to invite you to take part in a research study which will tell us whether it is 
possible to study specialist medical care compared to specialist medical care plus the 
Lightning Process as interventions (ways to help) for Chronic Fatigue Syndrome or Myalgic 
encephalopathy (CFS/ME) in teenagers. 
Before you decide to take part it is important for you to understand why the study is being 
done and what it will involve.  Please read this leaflet carefully.  You can talk about it with 
your family, friends, doctor, or us if you want to. We would like to go through this information 
with you and we think this will take about 20 to 30 minutes. The leaflet is divided in to two 
parts. Part 1 tells you about the study and what will happen to you if you take part. Part 2 
gives details about how the study will be run. 
Ask us if there is anything you don’t understand or if you want more information.  Take time 
to decide whether or not you want to join in.   
Thank you for reading this! 
 
Part 1 
Why are we doing this study? 
1. We want to find out whether it is possible to do a study investigating specialist medical 
care with or without the Lightning Process. To do this, we need to know whether young 
people will take part. 
2. We also want to find out more about the differences between the Lightning Process and 
specialist medical care. We are particularly interested in your views of both 
interventions. 
3. As part of this study, we will also try and study the cost of the illness to families and 
measure the cost of treatment.  
4. We know that the questionnaires we are using don’t always suit teenagers with CFS/ME 
so we are going to use this study to understand more about what you think about the 
questionnaires we use. 
What is Specialist Medical Care?  
Specialist Medical Care is the current treatment teenagers normally receive if they have 
CFS/ME. They normally have a follow up phone call at 2 weeks followed by individual family 
based sessions with a member of the Bath Specialist CFS/ME team. This could be a 
physiotherapist, psychologist or occupational therapist depending on your goals and where 
you would like to receive follow up. You will be offered either activity management, Cognitive 
Behavioural Therapy (CBT), graded exercise or a mixture of all three depending on your 




average, most teenagers have three or four follow up sessions, spread out over 3 to 
6 months usually at 6 weeks and then every 6 weeks. 
What is the Lightning Process? 
The Lightning Process is based on the idea that the body and mind work together to 
affect your health. It is a training programme, run as a course on three consecutive 
days (for 3 hours 45 minutes a day) in a group with up to five other young people 
aged between 12 and 18 years old. The course is run by a Lightning Process 
Practitioner. Lightning Process Practitioners are trained in Neuro Linguistic 
Programming (NLP), life coaching, clinical hypnotherapy and the Lightning Process – 
they are not medically trained.  The courses will be held somewhere near you, either 
in a clinic or hospital, or in a hotel or community hall. Where ever it is held, it will be 
suitable for the course and for young people your age.  
There are regular breaks throughout the course and a mixture of group and 
individual discussions. Each day the course will include a theory session and a 
practical session. In the theory session, teenagers learn about stress and its physical 
effects, how the mind-body interacts and how thought processes can be helpful and 
unhelpful. In the practical session, teenagers identify goals they wish to achieve (for 
example, standing for longer) and are given different ways to think about and 
prepare for this. They then have the chance to practise this on the course with the 
Lightning Process practitioner there to support them.  
A parent can attend and a researcher may be present to watch the session. 
Teenagers are given up to 30 minutes homework each day so they can continue to 
practise the skills they have learnt using a goal they identified on the course.  
Why have I been asked to take part? 
You have been asked if you want to take part because you are between 12 and 18 
years of age, have CFS/ME and have attended an assessment at the Bath Specialist 
CFS/ME service.  
We do not think you should take part if you are severely affected (cannot leave the 
house) or if you do not speak English. You should not take part if there is one 
intervention you don’t want to do for example, if you aren’t comfortable working in 
groups. 
Do I have to take part? 
You do not have to take part in this study. If you agree to meet the researcher who 
will ask you about your views about the interventions or the nurse who will explain 
more about the study, this will not commit you to taking part in the study.  
If you decide to take part but change your mind later, we will continue to follow you 
up like we do other teenagers who are not part of the study unless you tell us you 
don’t want us to You can withdraw from the study at any point and if you want us to 
we will take out the information collected at interview at any point before we carry out 




We hope that up to 90 young people and their parents will take part in this study but 
it is up to you to decide whether or not to take part. If you decide not to take part or 
decide to withdraw at any time, this will not affect the standard of specialist medical 
care you would normally receive.  
What are we asking you to do? 
First stage:  
If you agree to take part in this study, a researcher may arrange a time to interview 
you in the next two weeks at a place and time that is convenient for you and your 
family to find out what you know about the Lightning Process and what your views 
are about the different types of intervention. The interview will be audio-recorded 
with your permission and will last for around 20 minutes.  
If you (and your parent if you are under 16) agree to proceed, a research nurse will 
then arrange to visit you at home (or a location of your choice), spend some time 
with you to discuss the two different interventions and explain more about the study. 
If you are willing to take part, you will be randomly allocated (in other words, by 
chance) to one of two intervention groups: either specialist medical care or specialist 
medical care plus the Lightning Process. As this study is trying to find out whether 
we can compare both groups, it will not be possible for you to choose the group. The 
group that you will be part of will be determined by computer at random. This is the 
same as rolling a dice.  
Second stage: In the second stage you will be part of group 1 which is Specialist 
Medical Care) or group 2 which is Specialist Medical Care plus the Lightning 
Process. 
Group 1: Specialist Medical Care 
If you are in group 1, you will receive specialist medical care. 
Group 2: Specialist Medical Care plus the Lightning Process 
If you are in group 2, you will receive specialist medical care and the Lightning 
Process. In addition to the specialist medical care described above, you will be 
asked to read the “Introduction to the Lightning Process” book (140 pages) or listen 
to the audio book before you attend the lightning process course.  Your 
parents/guardian will be asked to read or listen to the Lightning Process book as 
well. You will then need to complete an assessment form asking about what goals 
you have set and what you have learnt from reading the book/listening to the audio 
book.  
After this, the Lightning Process Practitioner will phone and talk to you and your 
parents/guardian to check that having found out more about what is going to happen 
you are still happy with attending the course. They will discuss your goals and the 
content of the book you have read with you and your parent/guardian. This is an 




If you or your parents need more time to talk to the Lightning Process Practitioner, 
you can arrange other phone calls with them.  
If you are happy to attend the course, you will be booked on to the Lightning Process 
course which will run on three consecutive days (for 3 hours 45 minutes a day). You 
will be in a group with up to five other young people aged between 12 and 18 years 
old who are also involved in the study. After the Lightning Process course, you will 
be offered two follow up phone calls at 2 and 4 weeks at a time that is convenient for 
you. This will be in addition to the specialist medical follow up sessions as above. 
You can cancel follow up sessions at any stage if you feel you do not need or want 
them.  
Group 1 and Group 2 
After you know which intervention group you are in, we may interview you (if you 
haven’t already been interviewed) to find out what you felt about the process of 
randomisation or we may interview you after the intervention to find out what you feel 
about it and how you found completing study questionnaires. We will only interview 
you once. Interviews will take approximately 20 minutes and will be held at your 
home or a location of you and your parents/guardians choice.  
We want to find out more about both interventions. The intervention sessions will be 
audio-recorded and for about half the interventions, the researcher will also observe 
the session.  
Whether you take part in this study or not, you will receive questionnaires by post at 
6 months and a year to check how you are doing. Each pack of questionnaires takes 
about ten minutes to complete. If you take part in this study, you will receive two 
more questionnaires at each time point, than teenagers who do not take part in the 
study. These questionnaires are to help us understand more about which 
questionnaires we should use and to find out more about the cost of treatment and 
the cost of the illness. They will take you an extra five minutes (or so) to complete. 
We will also send questionnaires to you at 3 months after the intervention. 
We will ask your school with your permission about how much you have been at 
school when we first see you and at follow up.  
Do I have to take part? 
You do not have to take part in this study. If you agree to meet the researcher who 
will ask you about your views about the interventions, or the nurse, who will explain 
more about the study, this will not commit you to taking part in the study.  
We hope that up to 90 young people and their parents will take part in this study but 
it is up to you to decide whether or not to take part. If you decide not to take part or 
decide to withdraw at any time, this will not affect the standard of specialist medical 
care you would normally receive.  




You may need to spend time talking to a researcher for about 20 minutes so we can 
understand what you think about the study and the sessions either before or after 
you have them. You will need to spend 20 minutes talking to the research nurse 
about the study. If you take part, you will need to complete questionnaires at 3 
months after the interventions as well as the normal time points (6 months and 
annually). You will also need to complete 2 more questionnaires at each time point 
that we think will take about 5 minutes to complete. You may not find the intervention 
arm you have been offered helps you. This could be true for both interventions. 
Teenagers with CFS/ME can get worse with any intervention offered. There is no 
data in teenagers, see tables 1 and 2 for data in adults. Some parents of children 
who receive Specialist Medical Care and the Lightning Process have told us that 
they find the two approaches and the language used is different. If this is a problem 
for you, we will talk about it with you and offer support.   
Are there any side effects of the interventions? 
We do not think there are any side effects of the interventions but because the 
Lightning Process has not been tested before, we will be monitoring all interventions 
and closely following up all young people who take part. 
Benefits of joining in 
There are no specific benefits for you in taking part in this study. If we understand 
more about the interventions, taking part in this study may help other teenagers with 
CFS/ME in the future.  
What happens when the research study stops?   
After the study stops, you will continue to access specialist medical care if you still 
need it. You will also continue to receive follow up questionnaires, like the teenagers 
who did not take part in the study. 
What if there is a problem? 
We will try and deal with any problem you have during this study. Detailed 
information is given in part 2. 
Will my details be kept private? 
Yes. Your privacy is important to us and all your details will be handled in 






At clinic assessment: 
Eligible for study?
Consent for contact?
Research Nurse Information session 
Consent to study?
Randomisation
Read Lightning Process book
Specialist CFS/ME treatment
Questionnaires received: 6 weeks, 3 months, 6 months and annually
Parent +/- young person
interview








Phone call: Lightning Practitioner



















Specialist CFS/ME treatment 
plus Lightning Process
Specialist CFS/ME treatment : Follow up 2 weeks, 6 weeks and 6 weekly



























If the information in Part 1 has interested you and you are considering taking 
part in this study, please read the additional information in Part 2 before 
making any decision. 
What if new information becomes available? 
Sometimes during the course of a research study, new information becomes 
available about the interventions that are being studied. If this happens, we will tell 
you about it and discuss with you whether you want to continue in the study.  
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any point and this will not affect the care that we 
give you. We will keep the information that we have collected up to the time you 
leave the study but this is completely private and nobody will know it is you. You will 
continue to receive the follow up questionnaires that other teenagers receive who 
are not part of the study but you can tell us if you do not want these and we will stop 
sending them to you. 
What should I do if I have a problem with this study?  
If you have any problems with this study, please speak to PI DETAILS or any 
member of the clinical team that you know. You would be able to complain to the 
NHS in the usual way if you were not happy with the study through the Patient 
Advice and Liaison services (PALS) 01225 473424. 
In the event that something does go wrong and you are harmed during the research 
and this is due to someone being careless then you may be able to take legal action 
to get repayment from the hospital but your parents may need to pay a lawyer to 
help you. You can also use the normal National Health Service system for 
complaints if you want to.  
Does everybody involved in the study have the appropriate police checks? 
Yes. All those working in the study have had the necessary police checks to make 
sure they are safe to work with children and young people.  
Your privacy 
It is very important that all the information you give us is completely private. We will 
write down the things that you say from the audio-recording and take out any details 
linking the recording to you so that nobody will know that it was you. We may use 
small bits of what you say when we report the study, but the quotes will be 
completely anonymised so nobody will know it was you. The recording will be 
encrypted and password protected (so no-one else can listen to it) before it is stored 
on a secure university server.  The copy of what you said in the interview (the 
transcript) will be linked to you and your parents via a code. All personal details or 
lists that could identify you will be kept secure in locked cabinets in locked offices or 




All questionnaires that you fill out are anonymised before they are given to you. We 
will give you a 13-digit identification code that will be on the top of the 
questionnaires. A list of names and corresponding identification numbers are kept 
separately and securely on a password protected NHS server. 
If you tell us something that makes us worried about your safety, we may have to 
discuss this with somebody else as we need to be sure you are safe. This means, 
what you say would not be kept completely private. We would do the same if you told 
us something in clinic. 
Data protection 
All data is completely anonymised and is kept on secure encrypted password 
protected University Servers. 
Consent 
We have to be absolutely certain that you are happy to join in this study, so if you 
say you are, we will ask you to sign our consent form. We will also ask you to sign a 
consent form if we interview you. Even if you do sign the forms, you will be free to 
withdraw at any point. Just tell us if this is the case. Whether or not you wish to 
participate, you will continue to receive the same care from the clinical team. 
Who will know I am taking part in the study? 
We think your GP should know that you are taking part in this study because they 
need to know what happens to you and we will ask your permission to let your GP 
know. 
What will happen to the results of the study? 
This study will give us information about how much young people with CFS/ME use 
health services and will tell us more about which questionnaires we think we should 
use. We aim to publish these results in journals to help other people seeing 
teenagers with CFS/ME. If young people take part in this study, we will use the 
results to plan for a larger study to look at whether the Lightning Process is helpful or 
not. 
Who is organising and funding the study? 
This research is organised by Dr Esther Crawley who is the Clinical Lead for the 
Bath specialist CFS/ME service at the RNHRD and leads the Paediatric CFS/ME 
Research team at the University of Bristol. Dr Crawley is working with a group of 
researchers at the University of Bristol who are helping her with this study. The study 
is funded by The Linbury Trust and The Ashden Trust. 






The study has been approved by the South West 2 Research Ethics Committee. It 
has also been checked and approved by the RNHRD research committee. 
Table 1. Data taken from Action for ME (AfME) and Association of Young people 
with ME (AYME) joint report “M.E. 2008: What progress”. 2763 people answered this 
survey (7% were children and young people) 
Intervention Helpful (%) No change (%) Made worse (%) 
GET 45 21 34 
CBT 50 38 12 
Lightning Process 53 31 16 
*GET = Graded Exercise Therapy. CBT = Cognitive Behavioural Therapy. 
For the full report:  
http://www.actionforme.org.uk/Documents/get-
informed/Survey%20Summary%20Report%202008.pdf 
Also reported in Parliamentary enquiry found here:  
http://www.actionforme.org.uk/Documents/get-
informed/APPG%20Report%20FINAL.pdf 
Table 2. Data taken from 2008 MEA survey of 4217 people (<5% where children and 













GET 906 3.4 18.7 21.4 23.4 33.1 
CBT 997 2.8 23.1 54.6 11.6 7.9 
LP 101 25.7 18.8 34.7 7.9 12.9 
*GET = Graded Exercise Therapy. CBT = Cognitive Behavioural Therapy. LP = 
Lightning Process 
For the full report:  
http://www.meassociation.org.uk/wp-content/uploads/2010/09/2010-survey-report-lo-
res10.pdf 
Also reported in Parliamentary enquiry found here:  
http://www.actionforme.org.uk/Documents/get-
informed/APPG%20Report%20FINAL.pdf 
Contact / Further Information:  
XXX  Or if you want to talk to somebody independent please contact XXX 
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CFS/NHS/PAEDIATRICS - Specialist help for ME.   
   
         
 
SMILE  
Specialist Medical Intervention & Lightning Evaluation 
 
Feasibility randomised controlled trial for Chronic Fatigue Syndrome/ME 
 
INFORMATION LEAFLET FOR PARENTS 
 
We would like to invite you to take part in a research study which will tell us whether it is 
possible to study specialist medical care compared to specialist medical care plus the 
Lightning Process as interventions for Chronic Fatigue Syndrome or Myalgic encephalopathy 
(CFS/ME) in children. 
Before you decide to take part it is important for you to understand why the study is being 
done and what it will involve.  Please read this leaflet carefully.  You can talk about it with 
your family, friends, doctor, or us if you want to. We would like to go through this information 
with you and we think this will take about 20 to 30 minutes. The leaflet is divided in to two 
parts. Part 1 tells you about the study and what will happen to you and your child if you take 
part. Part 2 give details about the conduct of the study.  
Ask us if there is anything you don’t understand or if you want more information.  Take time 
to decide whether or not you want to join in.   
Thank you for reading this! 
 
Part 1 
Why are we doing this study? 
1. We want to find out whether young people will take part in a study comparing specialist 
medical care with or without the Lightning Process.  
2. We also want to find out about the differences between the Lightning Process and 
specialist medical care and your views them. 
3. We will study the cost of the illness to families and measure the cost of treatment.  
4. We know that the questionnaires we are using don’t always suit children and young 
people with CFS/ME so we are going to use this study to understand more about what 
your child thinks about the questionnaires we use. 
What is Specialist Medical Care?  
Specialist Medical Care is the current treatment children normally receive if they have CFS/ME. 
After their assessment, they will have a follow up phone call at 2 weeks followed by individual 
sessions with a member of the Bath Specialist CFS/ME team. This could be a physiotherapist, 
psychologist or occupational therapist depending on your child’s goals and where you would 
like to receive follow up. They will be offered either activity management, cognitive behavioural 
therapy (CBT), graded exercise or a mixture of all three depending on the goals and needs of 
your child. The timing and number of the sessions depends on your child’s needs but on 
average, most young people have three or four follow up sessions, spread out over 3 to 6 








What is the Lightning Process? 
The Lightning Process is based on the idea that the body and mind work together to affect 
your health. It is a training programme, run as a course on three consecutive days (for 3 
hours 45 minutes a day) in a group with up to five other young people aged between 12 and 
18 years old. The course is run by a Lightning Process Practitioner. Lightning Process 
Practitioners are trained in Neuro Linguistic Programming (NLP), life coaching, clinical 
hypnotherapy and the Lightning Process – they are not medically trained.  The courses will 
be held somewhere near you, either in a clinic or hospital, or in a hotel or community hall.  
There are regular breaks throughout the course and a mixture of group and individual 
discussions. The daily seminars will include a theory session and a practical session. In the 
theory session, children learn about stress, how the mind-body interacts and how thought 
processes can be helpful and unhelpful. In the practical session children and young people 
identify goals they wish to achieve (for example, standing for longer) and are given 
alternative ways to think about and prepare for this. They then have the opportunity to 
practise this on the course with the Lightning Process practitioner there to support them.  
A parent can attend and a researcher may be present to observe the session. Young people 
are given up to 30 minutes homework each day so they can continue to practise the skills 
they have learnt using a goal identified by the young person on the course.  
 
Why has my child been asked to take part? 
You child has been asked if they want to take part because they are between 12 and 18 
years of age, have CFS/ME and have attended an assessment at the Bath Specialist 
CFS/ME service.  
We do not think your child should take part if they are severely affected (cannot leave the 
house) or if they do not speak English. Your child should not take part if there is one 
intervention they do not want to do, for example, if they don’t feel comfortable working in 
groups.  
 
Does my child have to take part? 
Your child does not have to take part in this study. If you agree to meet the researcher who 
will ask you about your views about the interventions or the nurse who will explain more 
about the study, this will not commit you to taking part in the study. 
If you decide to take part but withdraw later, we will continue to follow up your child as if they 
were not in the study unless you tell us you don’t want us to. Your child can withdraw at any 
point in the study. Your child can withdraw their information collected at interview at any point 
in the study before analysis  
We hope that up to 90 young people and their parents will take part in this study but it is up to 
you and your child to decide whether or not to take part. If you decide not to take part or 
decide to withdraw at any time, this will not affect the standard of specialist medical care you 








What are we asking you to do.  
First stage:  
If you agree to take part in this study, a researcher may arrange a time to interview you in the 
next two weeks and during the study (on no more than three occasions) at a place and time 
that is convenient for you. This is to find out what you know about the Lightning Process and 
about your experience of each type of intervention.  The interviews will be audio-recorded 
with your permission and will last between 20 minutes to an hour. Your child will be 
interviewed at one of these time points for approximately 20 minutes. 
If you and your child agree to proceed, a research nurse will arrange to visit you at a location 
of your choice, to discuss the two different intervention options and explain more about the 
study. If you are willing to take part, your child will be randomly allocated to one of two 
intervention groups: either specialist medical care or specialist medical care plus the 
Lightning Process. As this study is trying to find out whether we can compare both groups, it 
will not be possible for you to choose the group for your child. The group that your child will 
be part of will be determined by computer at random (in other words, by chance).  
Second stage:  
In the second stage you child will be part of group 1 which is Specialist Medical Care) or 
group 2 which is Specialist Medical Care plus the Lightning Process 
 
Group 1: Specialist Medical Care 
If your child is in group 1, they will receive specialist medical care. While your child is in this 
intervention arm, we will ask them not to access the Lightning Process outside the study.  
Group 2: Specialist Medical Care plus the Lightning Process 
If you child is in group 2, they will receive specialist medical care and the Lightning Process 
intervention. In addition to the specialist medical care described above, young people in this 
group will be asked to read the “Introduction to the Lightning Process” book (140 pages) or 
listen to the audio book before they attend the lightning process course.  You will be asked to 
read or listen to the Lightning Process book as well. Your child will then complete an 
assessment form asking about what goals they have set themselves and what they learnt 
from reading the book/listening to the audio book.  
After this, the Lightning Process Practitioner will phone and talk to you and your child to 
check that having found out more about what is going to happen they are still happy with 
attending the course. They will discuss your child’s goals with both of you and the content of 
the book you have read. This is an opportunity for you or your child to ask questions, and find 
out more about the Lightning Process. You and your child may feel you need more time to 
discuss the Lightning Process with the Lightning Process Practitioner and you can arrange 
more telephone calls if you want to.  
If you and your child are happy to attend a Lightning Process course, your child will be 
booked on to the Lightning Process course which will run on three consecutive days (for 3 
hours 45 minutes a day) in a group with up to five other young people aged between 12 and 
18 years old who are also involved in the study. After the Lightning Process course, you will 
have two follow up phone calls at 2 and 4 weeks at a time that is convenient for you. This will 
be in addition to the specialist medical follow up sessions as above. You and your child can 







Group 1 and Group 2 
The intervention sessions will be audio-recorded and for approximately half the interventions, 
the researcher will also observe the session.  
Children in both groups (and those who do not take part) will receive questionnaires by post 
at 6 weeks, 6 months and a year to check how they are doing. Each pack of questionnaires 
takes about ten minutes to complete. If your child takes part in this study, they will receive 
two more questionnaires at each time point than children who do not take part in the study, 
which will take an extra five minutes (or so) to complete. These questionnaires are to help us 
understand more about which questionnaires we should use and to find out more about the 
cost of treatment and the cost of the illness. If you child takes part in this study, they will also 
receive questionnaires at 3 months (in addition to 6 weeks, 6 months and annually).  
We will also contact your child’s school at assessment and at each of these follow up time 
points to find out how much school they are attending.  
If your child takes part in the study, we will also ask you to fill in three questionnaires at the 
start and two at follow-up, so we can understand more about the cost of this illness to your 
family and the cost of treatment. We estimate that these questionnaires will take you less 
than 10 minutes to complete.  
 
Are there any disadvantages of taking part in this study? 
You may need to spend time talking to us on three different occasions. We think this will take 
about 20 minutes each time but may take longer (no more than an hour). You will need to 
spend 20 minutes talking to the research nurse about the study. Your child may be 
interviewed as well but only at one time point and for no more than 20 minutes. If your child 
takes part, they will need to complete questionnaires at 3 months after the interventions as 
well as the normal time points (6 weeks, 6 months and annually). They will also need to 
complete two more questionnaires at each time point that we think will take about 5 minutes 
(or so) to complete.  
You will need to complete three more questionnaires at the start and two questionnaires at 
follow up. This will take 10 to 20 minutes each time.  
Your child may not find the intervention arm they have been offered helps them. This could 
be true for both interventions. Teenagers with CFS/ME can get worse with any intervention 











re there any side effects of the interventions? 
We do not think there are any side effects of the interventions but because the Lightning 
Process has not been evaluated before, we will be monitoring all interventions and closely 
following up all young people who take part. 
 
Benefits of joining in 
There are no specific benefits for you or your child taking part in this study although some 
parents may find it helpful to talk to others about their experiences. If we understand more 
about the interventions, taking part in this study may help other children and young people 
with CFS/ME in the future.  
 
What happens when the research study stops?   
After the study stops, your child will continue to access specialist medical care if they still 
need it. They will also continue to receive follow up questionnaires like the young people who 
did not take part in the study. 
 
What if there is a problem? 
We will try and deal with any problem you or your child has during this study. Detailed 
information is given in part 2. 
 
Will my details be kept private? 
Yes. Your privacy is important to us and all your details will be handled in confidence. The 





At clinic assessment: 
Eligible for study?
Consent for contact?
Research Nurse Information session 
Consent to study?
Randomisation
Read Lightning Process book
Specialist CFS/ME treatment
Questionnaires received: 6 weeks, 3 months, 6 months and annually
Parent +/- young person
interview








Phone call: Lightning Practitioner



















Specialist CFS/ME treatment 
plus Lightning Process
Specialist CFS/ME treatment : Follow up 2 weeks, 6 weeks and 6 weekly





























If the information in Part 1 has interested you and you are considering taking part in 
this study, please read the additional information in Part 2 before making any decision. 
 
What if new information becomes available? 
If new information becomes available, we will tell you about it and discuss whether you and 
your child want to continue in the study. If the study stops for any reason, we will tell you and 
your child and arrange continuing care for your child. 
What will happen if I don’t want to carry on with the study? 
Your child can withdraw from the study at any point and this will not affect the care that we 
give them. We will keep the information that we have collected up to the point of withdrawal 
but this is completely anonymous and nobody will know it is your child. Your child will 
continue to receive the follow up questionnaires that other young people receive who are not 
part of the study but you can tell us if you do not want to complete this as well and we will 
stop sending them to your child. 
What should I do if I have a problem with this study?  
If you have any problems with this study, please speak to Dr Esther Crawley (01225 465941. 
esther.crawley@bristol.ac.uk) or any member of the clinical team that you know. You 
would be able to complain to the NHS in the usual way if you were not happy with the study 
by contacting the Patient Advice and Liaison services (PALS) 01225 473424. 
In the event that something does go wrong and you are harmed during the research and this 
is due to someone’s negligence then you may have grounds for legal action for 
compensation against the RNHRD, but you may have to pay your legal costs. The normal 
National Health Service complaints mechanism will still be available to you (if appropriate).  




It is very important that all the information you and your child give us is completely private. 
We will write down the things that you and your child say from the audio-recording and take 
out any details linking the recording to you or your child so that nobody will know that it was 
you. We may use small bits of what you say when we report the study, but your quotes will be 
anonymised and nobody will know it was you. The recording will be encrypted and password 
protected (so nobody else can listen to it) before it is stored on a secure university server. 
The copy of what you said in the interview (the transcript) will be linked to you and your child 
via a code. All personal details or lists that could identify you will be kept secure in locked 
cabinets in locked offices or password protected on secure NHS computers.  
All questionnaires that you fill out are anonymised before they are given to you. We will give 
you a 13 digit identification code that will be on the top of the questionnaires. A list of names 
and corresponding identification numbers are kept separately and securely on a password 
protected NHS server.  
As with any child being seen in clinic, if we have concerns over your child’s welfare, we may 
have to break confidentiality. In some cases, we may have to discuss your child with another 








All data is completely anonymised and is kept on secure encrypted password protected 
University Servers.  
 
Consent 
We have to be absolutely certain that you are happy to join in this study, so if you say you 
are, we will ask you and your child to sign our consent form. We will also ask you to sign a 
consent form if we interview you, to check you are still happy. Even if you do sign the consent 
forms, you and your child will be free to withdraw at any point. Just tell us if this is the case. 
Whether or not you wish to participate, your child will continue to receive the same care from 
the clinical team.  
 
Who will know I am taking part in the study? 
We think your GP should know about the interventions your child receives and we will ask 
your permission to let your GP know.  
 
What will happen to the results of the study? 
This study will give us information about how much families use health services and will tell 
us more about which questionnaires we should use. We aim to publish these results in 
journals to help other health professionals. If it is possible to recruit young people into this 
study, we will use the results to plan for a larger study to look at whether the Lightning 
Process is helpful or not.  
 
Who is organising and funding the study? 
This research is organised by Dr Esther Crawley who is the Clinical Lead for the Bath 
specialist CFS/ME service at the RNHRD and leads the Paediatric CFS/ME Research team 
at the University of Bristol. Dr Crawley is working with a group of researchers at the 
University of Bristol who are helping her with this study. The study is funded by the Linbury 
Trust and The Ashden Trust.  




The study has been approved by the South West 2 Research Ethics Committee. It has also 




The details below were added to v9 of the young person and parent PIL due to trial 
controversy: The recruiter discussed families’ feelings about the controversy that 
had surrounded the SMILE trial, and specifically discussed the following tables: 
 
Table 1. Data taken from Action for ME (AfME) and Association of Young people 
with ME (AYME) joint report “M.E. 2008: What progress”. 2763 people answered this 
survey (7% were children and young people) 
Intervention Helpful (%) No change (%) Made worse (%) 
GET 45 21 34 
CBT 50 38 12 
Lightning Process 53 31 16 
*GET = Graded Exercise Therapy. CBT = Cognitive Behavioural Therapy. 
For the full report: 
http://www.afme.org.uk/res/img/resources/Survey%20Summary%20Report%202008
.pdf 
Also reported in Parliamentary enquiry found here: 
http://www.afme.org.uk/res/img/resources/APPG%20Report%20FINAL.pdf 
Table 2. Data taken from 2008 MEA survey of 4217 people (<5% where children and 













GET 906 3.4 18.7 21.4 23.4 33.1 
CBT 997 2.8 23.1 54.6 11.6 7.9 
LP 101 25.7 18.8 34.7 7.9 12.9 
*GET = Graded Exercise Therapy. CBT = Cognitive Behavioural Therapy. LP = 
Lightning Process 
For the full report:  
http://www.meassociation.org.uk/wp-content/uploads/2010/09/2010-survey-report-lo-
res10.pdf 
Also reported in Parliamentary enquiry found here: 
http://www.afme.org.uk/res/img/resources/APPG%20Report%20FINAL.pdf 
Contact / Further Information:  
XXX Or if you want to talk to somebody independent please contact XXX 




SMILE: Interview Topic Guide  
v2 May 2010 
These questions will be used as prompts to ensure all important areas are covered  
Welcome, introduction, stress confidentiality. Discuss consent, sign form or check continues to 
be happy with consent. 
 
After assessment & before randomisation 
1. Can you talk me through your initial appointment with the research nurse? 
Prompts: What was said, did you understand what was being said? Feelings? 
2. What were your initial thoughts about the study? 
Prompts: What did you think when you were told about it? Feelings? Worries? 
Expectations? 
3. Did you know anything about the Lightning Process before this initial appointment 
(for first interview only)? 
Prompts: How/ who? What did you think? What information?  
4. What did you think about the information you were given about the study?  
Prompts: What information did you get – oral and written? Did you read it? Understand 
it? Did it give you enough information/too much? Were there things you thought they had 
forgotten to include? 
5. Have you found out any information about the Lightning Process since? 
Prompts: Why? How? What did you find? What did you think?  
6. What are your thoughts at this stage on taking part or not? Why? 
NB - Stress that they’re not being asked at this stage but that we want to gauge their 
thoughts, stress also that it makes no difference to the interviewer 
7. If you were to take part, would you have a preference for one of the interventions?  
Prompts: Why?  Issues over participation? Engagement? What would you do if allocated 
the other intervention? 
8. What do you think about having treatments allocated at random, i.e. by chance?  
Prompts: Why is it done? How do you feel about this way of deciding what treatment 
 you’ll get? Is there a better way? Do you think you’ll be happy to be randomised? 
Do  you think you’re likely to get one intervention rather than the other? Why? 
9. You have now done some questionnaires at follow up. What did you/your child 
think about the questions you were asked?  
Prompts: Were there any particularly difficult ones? What did you think about the HADS/ 





After randomisation & before interventions 
1. Can you tell me what happened when the research nurse visited and   
explained about randomisation? 
Prompts: What did she say? Understandable? What did you think? Did you understand 
what was going to happen? 
2.  What did you think before randomisation? 
Prompts: Were you happy with the process? Did you understand what was going to 
happen and why?  
3.  Did you agree to randomisation or not? Why? 
4.  What did you think when you got your intervention allocation? 
Prompts: How did you feel? Was it what you expected/wanted? Expectations of 
intervention? What have you done since then?  
5.  You have now done some questionnaires at follow up. What did you/your child 
think about the questions you were asked?  
Prompts: Were there any particularly difficult ones? What did you think about HADS 
/POMS inventory? Would you leave some out? Other areas that should be covered? 
 
After intervention 
1. Tell me about the intervention you received? 
Prompts: What happened? What was good/bad? What would you change? Venue? 
Structure of sessions? Language used? Was it as expected? 
2. Do you think you/your child have/has learnt anything from it, if so what?  
Prompts: About CFS/ME, themselves, self-management?  
3. What has happened after the intervention? 
Prompts: How have you/they done? What are you/they doing? Feeling?  
4. What do you think now about being randomised? 
Prompts: Would you do it again? What do you think about the study for others?  
5. You have now done some questionnaires at follow up. What did you/your 
child think about the questions you were asked?  
Prompts: Were there any particularly difficult ones? What did you think about the HADS/ 






SMILE: Recruitment training methods 
During the SMILE RCT a clinical CFS/ME team provided a brief introduction to 
SMILE and gaining ‘consent to contact’ from families at the end of the patient initial 
assessment appointment. The research team would then contact families to discuss 
the RCT in full, usually at a face-to-face meeting in their home. During the SMILE 
RCT rates of recruitment were not formally monitored in conjunction with recruiter 
training. 
Initial one-to-one training sessions were provided for recruiters shortly after they 
joined the research team. These training sessions included informal discussions with 
the qualitative lead (NM) and the qualitative researcher, (LB) in relation to best 
practice and recruitment strategies used in the ProtecT trial. [123] Training 
discussions focussed on communication strategies that might facilitate informed 
consent, including; providing evidence-based information and emphasising the 
equivalence of all treatments offered in the RCT, spending a similar amount of time 
explaining each intervention arm, ceding the floor to allow patients/parents to 
express their views and preferences, and discussing preferences. An existing 
generic ‘Tips for recruitment’ document developed by the lead qualitative researcher 
(NM) was also given to recruiters, (see: SMILE: Tips for Recruitment and informed 
consent) and was used for the duration of the RCT. 
During the three months after each recruiter joined the SMILE RCT, the qualitative 
lead provided tailored feedback to recruiters, by listening to and reviewing two 
randomly selected transcribed sections of their audio-recorded recruitment 
consultations. Verbal feedback relating to good practice was provided via informal 




notes from analyses of the audio-recordings were provided for recruiters ongoing 
reference. When new recruiters joined the research team they ‘shadowed’ the 
existing recruiter, firstly by observing a consultation, then conducting one themselves 
with the experienced recruiter present to provide support where required. New 
recruiters then went on to conduct consultations alone. Recruitment consultations 
were routinely transcribed and analysed so that further feedback on best practice 
could be provided on an ongoing basis. This training was delivered on an ad-hoc 
basis if qualitative researchers felt it necessary to highlight communication issues, 
















SMILE: Content analysis checklist 
*Adapted from N. Mills ProtecT (Prostate Testing for Cancer and Treatment)  
Information Appointments Oct-Dec 2005. 
 
1. Young person: Preference at outset  
2. Parent: Preference at outset 
Preference expressed at outset?  - State ‘yes’ if the preference is expressed fairly early on in the 
consultation i.e. prior to a discussion of the two treatments. If the preference is first expressed later 
in the consultation then please state “Yes (but after a discussion of 1 or 2 treatments)” or whatever 
is appropriate. 
Preference expressed at outset may also be a ‘non-preferred’ intervention - i.e. if they express not 
wanting a particular treatment. Please make this clear if so then treat as you would a preference. 
 
3. Young person: Key reasons for preference 
4. Parent: Key reasons for preference 
If reason(s) for preference provided, please record. 
(e.g., knew someone who had treatment in the past.) 
 
5. Young person: Preference: definite, probable, or no evidence / preference not stated 
6. Parent: Preference: definite, probable, or no evidence / preference not stated 
 
• ‘Definite' if they repeat their preference at various points throughout the consultation and/or 
they have definite reasons for preferring this treatment – i.e. their initial preference seems 
to be quite strong/sure/grounded.  
 
• 'Probable' if they express a preference but then don't follow this up, seem pretty unsure, 
change their mind, don't give reasons for their preference etc - i.e. their initial preference 
seems weak/unsupported/not definite but they did single out a treatment.  
 
• ‘No evidence / preference not stated’ do not provide verbal response to questions relating 
to preference / preferences not explored during recruitment discussion. 
 
7. Young person: Entrenched or dispensed with as consultation proceeds 
8. Parent: Entrenched or dispensed with as consultation proceeds 
Entrenched or dispensed with as consultation proceeds? 
 
• State whether their preference is strengthened (entrenched) or 
weakened/dissipated/dissolved (dispensed) as a result of the discussion with the recruiter.  
 





Appendix 4: MAGENTA 
[Reference: Brigden, A., et al., Managed Activity Graded Exercise iN Teenagers and 
pre-Adolescents (MAGENTA) feasibility randomised controlled trial: study protocol. 
BMJ Open, 2016. 6(7): p. e011255.] 
 
MAGENTA: Inclusion/exclusion criteria 
Inclusion criteria 
Children and adolescents will be eligible for inclusion if they are given a diagnosis 
of CFS/ME (made using NICE guidance*) and aged between 8 and 17 years 
inclusive. 
 
[*NICE: National Institute for Health and Clinical Excellence, Chronic fatigue 
syndrome/myalgic encephalomyelitis (or encephalopathy) Diagnosis and 
management of CFS/ME in adults and children., N.I.f.H.a.C. Excellence., Editor. 
2007, Developed by the National Collaborating Centre for Primary Care: London]. 
Exclusion criteria 
Children and adolescents will be excluded if they are severely affected. NICE 
defines severe CFS/ME as individuals who are unable to do activity for 
themselves, or carry out minimal daily tasks only, they have severe cognitive 
difficulties and depend on wheelchair for mobility or are referred for CBT at their 





MAGENTA: Eligibility assessment 
Eligible young people were identified by health professionals at their initial 
assessment appointment with the specialist CFS/ME team. Patients diagnosed with 
CFS/ME who met the eligibility criteria were informed about potential participation in 
a feasibility RCT at the end of their first clinical appointment. Families were given a 
brief verbal overview of the RCT, and the relevant patient and parent information 
leaflets were given to families who were interested in finding out more about the trial. 
The health professional asked families if they were willing to be contacted at a later 
date by a research nurse responsible for recruitment, and written assent/consent to 
contact was obtained from families who were willing to hear more about the trial and 





MAGENTA: Integrated qualitative aims and objectives 
During the feasibility stage integrated qualitative methodology was used to assess 
the feasibility and acceptability of trial conduct, specifically to understand issues that 
would relate to the successful design and implementation of a full-scale RCT. 
1. To investigate the recruitment process including eligibility assessment, the 
recruitment consultation and the views of children and parents, clinical and 
recruitment staff about the recruitment process. 
2. Assess the number of eligible children, the number of children approached, 
the number recruited, and the number retained in the first 6 months of the 
study. 
3. To assess issues of retention and interview those who cross-over or drop-out 
of the trial. 
4. Assess the acceptability (satisfaction and compliance) of Graded Exercise 
Therapy and activity management. 
5. Assess the feasibility and acceptability of using accelerometers to measure 
physical activity in children with CFS/ME. 
6. Evaluate whether the two treatments are distinct and being delivered in a 





MAGENTA: Trial flow 







MAGENTA: Data collection and randomisation 
Randomisation and allocation outcome 
The recruiter randomised those who provided assent/consent to participate. 
Randomisation was carried out via a web-based randomisation system, operated by 
the Bristol Randomised Trials Collaboration, (telephone randomisation was used on 
occasions when the web-based system was unavailable). Allocation to the two 
treatment groups of either Graded Exercise Therapy or activity management (ratio 
1:1) used minimisation to facilitate balance between treatment groups by age 
(categories: 8-12-years and 13-17-years) and gender. A random component was 
retained to prevent accurate prediction of allocation.  Because of the nature of the 
intervention, it was not practical to blind either the family or the clinical service to 
treatment allocation. 
 
Families were given their randomisation outcome either at the end of the recruitment 
consultation, or at an agreed time after the call on occasions when the randomisation 
website was not accessible. Recruiters were asked to leave the audio-recorder on 
until after the participant was given their group allocation, so that young person and 
parent reactions to the allocation was captured on the recording. After allocation the 
recruiter informed the clinical service of the patient’s allocation, so that a letter could 
be sent to the family with their follow-up appointment details. The participant’s GPs 






Recording of follow-up appointment 
Follow-up appointments were routinely audio-recorded by the research team to 
document the interaction between health care professionals and participants in 
receipt of Graded Exercise Therapy and activity management in the MAGENTA trial. 
These recordings were recorded to determine intervention fidelity and were not 
include in the analyses of this project. 
 
MAGENTA: Intervention groups 
Graded Exercise Therapy: Intervention Overview 
Young people were offered advice that was focused on exercise with detailed 
assessment of current physical activity and a programme including timed daily 
exercise. Young people were asked to record the amount of exercise they did and 
were taught to use a heart rate monitor with target heart rates to avoid over-exertion. 
They were able to choose whether they wanted text reminders to do exercise. The 
exercise programme was negotiated and agreed at each appointment between the 
health professional, young person and parent/carer. Health professionals delivered 
interventions in both groups were encouraged to offer routine advice about sleep, 
medication use and symptom control. 
 
Young people, their parents/carers and the health professional who provided the 
intervention chose the number of follow up sessions (between eight & 12) and the 
frequency of appointments (every two to six weeks) with a maximum length of 
treatment of one year. The number, frequency and length of follow up sessions for 




Participants who developed anxiety or depression that require treatment during the 
trial follow-up period were offered up to 12 sessions of CBT. Individual CBT sessions 
were delivered every two weeks by a clinical psychologist who specialised in 
CFS/ME. Participants were able to cross-over after six months (the primary outcome 
point) Participants were free to withdraw from either the intervention or the trial at 
any time. If participants wanted to cross-over before six months, their decision was 
recorded and they were asked if they would be willing to continue to provide 





GET Intervention Monitoring: Ongoing Intervention 
Research ID: 
Date of Appointment:        6 Month Due: 
Session Number:       *Please use 6-month form if applicable 
Mandatory                                           Tick if discussed                           Reason if not discussed 
Has initial exercise target been achieved for everyday for 1-2weeks?                             Y  /   N                       
if yes: 
Child advised to increase exercise slowly by 10-
20% a week 
  
Is the child doing 30 minutes of gentle exercise each day                                                  Y  /   N                       
if yes: 
Child advised to increase exercise intensity such 
that participants start doing aerobic exercise 
  
The aerobic component will then be slowly 
increased as the total amount of exercise is 
increased 
  
Participants will be encouraged to continue to 
increase exercise to achieve Department of Health 
recommended levels of 60 minutes a day of a 
mixture of moderate/vigorous intensity aerobic 




For all participants: 
Child advised to continue to time and record their 
exercise 
  
Diary reviewed to help young people ensure their 
exercise is the same every day 
  
Did the child use the diary?                                                                                                       Y  /   N                        
Child advised to continue to monitor their heart rate 
using a heart rate monitor. Target set.  
  
Has child been using heart rate monitor                                                                                    Y  /   N                        
Managing setbacks discussed prior to discharge in 





should be reduced and when they should start to 




Prohibited                                          Tick if discussed                                    Reason if discussed 
Advice on cognitive activity   
Discussion about the different types of cognitive 
activities 
  
Instructions to record the cognitive activities   
Flexible                                               Tick if discussed                                                      
Assessment of range of movement.   
Advice on length of time at school (full /half days, 
one lesson a day) and support increasing time at 
school. 
  
Advice over exams   
Young people can be shown how to do stretches   
They can also be offered a strengthening 
programme if this is one of their goals 
  
 
Referred to CBT                                            Y    /    N 
Has an Adverse even been reported         Y    /    N  (if yes, please find adverse event form at the 






Activity management: Intervention Overview 
Activity management converted a “boom-bust” pattern of activity to a manageable 
amount that could be achieved consistently every day (baseline). The activity 
management intervention in the MAGENTA RCT focused only on cognitive activities: 
school, school work, reading, socialising, and screen time (phone, laptop, TV, 
games). Those allocated to this group received advice about the total amount of 
daily activity, excluding physical activity, they did not receive specific advice about 
their use of exercise, increasing exercise or timed physical exercise. Health 
professionals delivered interventions in both groups were encouraged to offer routine 
advice about sleep, medication use and symptom control. 
 
Young people, their parents/carers and the health professional who provided the 
intervention chose the number of follow up sessions (between eight & 12) and the 
frequency of appointments (every two to six weeks) with a maximum length of 
treatment of one year. The number, frequency and length of follow up sessions for 
each participant was recorded, along with data recorded on activity charts. 
Participants who developed anxiety or depression that require treatment during the 
trial follow-up period were offered up to 12 sessions of CBT. Individual CBT sessions 
were delivered every two weeks by a clinical psychologist who specialised in 
CFS/ME. Participants were able to cross-over after six months (the primary outcome 
point) Participants were free to withdraw from either the intervention or the trial at 
any time. If participants wanted to cross-over before six months, their decision was 
recorded and they were asked if they would be willing to continue to provide 






Date of Appointment:        6 Month Due: 
Session Number:       *Please use 6-month form if applicable 
Mandatory                                                           Tick if discussed               Reason if not discussed 
Has the participants managed the baseline for 1-2 weeks?                             Y  /   N    if yes: 
Increase this baseline by 10-20% each week.   
Participants will continue to increase activity until they are 
able to do at least 8 hours of cognitive activity a day. 
  
All participants: 
The different types of cognitive activity (high concentration 
and low concentration) which will vary according to age 
Cognitive activities include time at school or doing school 
work, reading, some craft/hobbies, socialising and screen 
time (phone, laptop, TV, computer, other devices) 
  
Advise participants to record the total number of minutes 
spent each day doing high-energy cognitive activities using 
paper diaries/ “ActiveME” app. Recording activity is used to 
help participants understand whether they are doing the 
same each day or varying their activity and whether the 
baseline has been set at the correct level. 
  
Therapists will discuss problems encountered by 
participants and provide possible solutions. Managing 
setbacks will be discussed (how much to reduce school and 
other cognitive activity and for how long). 
  
Prohibited                                                           Tick if discussed               Reason if discussed 
Discussion about number of steps, minutes of exercise etc.    
Aerobic, versus non-aerobic activity   
No discussion about increasing physical activity (only 
discussion about increasing overall activity) 
  
No advice on exercises or using a strengthening programme   




Flexible                                                                         Tick if discussed                                                      
Advice on PE in school (no PE, half a lesson, full lesson)   
Attendance at sporting events (do not attend, attend limited 
period of time) 
  
Young people can record physical activity within the total 
cognitive activity but are not required to do so 
  
 
Referred to CBT                                            Y    /    N 
Has an Adverse even been reported         Y    /    N  (if yes, please find adverse event form at the 






MAGENTA: Information leaflet for young people (8-11yrs)  




















MAGENTA: Information leaflet for young people (12-17yrs) 


























MAGENTA: Information leaflet for parents 



























MAGENTA: Interview Topic Guide 
v0.1 16/09/2015  
Possible questions for parents/carers/young people. 
 
We will undertake in-depth discussions with young patients and their parents/carers 
to understand their views and experiences of trial processes.  
Discussions will take place at 2 time points: After randomisation/before intervention 
& during the intervention. 
Ice breaker: 
1. Can you talk me through [Name’s] initial appointment with the specialist service? 
Prompts: What was said, did you understand what was being said? Feelings? 
 
Provision and acceptability of patient information & recruitment process: 
2. What were your initial thoughts about the research study? 
Prompts: What did you think when you were told about it? Feelings? Worries? Expectations? 
 
3. What did you think about the information you were given about the study?  
Prompts: What information did you get – oral and written (PIS)? Did you read it? Understand 
it? Did it give you enough information/too much? Were there things you thought they had 
forgotten to include?  
 
4. Can you talk me through the conversation you had with the research nurse?  
Prompts: What was said, did you understand what was being said? Feelings? 
 
5. What did you find out about activity management from the research nurse?  
Prompts: What did she say? What did you already know? When/Where did you find this out? 
What did you think?  
 
6. What did you find out about graded exercise therapy from the research nurse? 
Prompts: What did she say? What did you already know? When/Where did you find this out? 
What did you think?  
 
7. Can you tell me what you thought when the research nurse explained about 
randomisation? 
Prompts: What did she say? Understandable? What did you think? Did you understand what 
was going to happen next? 
 
8. What did you think when you were told you got [AM/GET]? 







Reasons for accepting or declining participation: 
Use depending on whether or not the family declined or accepted to take part in 
MAGENTA. 
9. What did you think about having treatments allocated at random, i.e. by chance?  
Prompts: How do you feel about this way of deciding what treatment you get? Were you 
happy to be randomised? Did you wonder why this is done? Is there a better way? Did you 
think you were likely to get one treatment rather than the other? Why? 
 
10. What did you think about when deciding whether or not to take part in the study?  
Prompts: Feelings? Expectations? Worries? Treatments offered? Randomisation? What did 
you already know? Favoured a particular treatment? 
 
11. Why did you choose [not] to take part in the study?  
Prompts: Feelings? Expectations? Worries? Treatments offered? Randomisation? Favoured 
a particular treatment? What did you already know? 
 
12. Why did you decide [not] to accept the [intervention] allocated to [name] at 
randomisation? Feelings? Expectations? Worries? Treatments offered? Randomisation? 
Favoured a particular treatment? What did you already know? 
 
13. Why did you decide to stop participating in the study [drop-out] after randomisation?  
Feelings? Expectations? Worries? Treatments offered? Randomisation?  
Favoured a particular treatment? What did you already know? 
 
Acceptability of GET/AM: 
14. What do you think about the treatments [GET/AM] offered in this study?  
Prompts: What would you have done if allocated the other treatment?  Issues over 
participation? Engagement? 
 
15. Tell me about the [GET/AM] you are receiving? 
Prompts: What has happened? What is good/bad? What would you change? Structure of 
sessions? How is it explained to you? Is it as you expected? Is it age appropriate?  
 
16. What has happened next? 
Prompts: How are you/they doing? What are you/they doing? Feeling?  Expectations? 
Worries? 
 
17. Tell me about the effect that GET/AM has had on you/your child?  
Prompts: Their CFS/ME, themselves, self-management? School? Life in general?  
 
Acceptability of the use of the accelerometer: 
18. What were your initial thoughts about using an accelerometer? 
Prompts: How do you feel about wearing it? How do you find using it? Is it age appropriate? 
Any technical problems? Any benefits? Worries? Visibility? 
 
19. Are there any things we need to consider for people your age when using it? 




Acceptability of the use of the heart monitor [GET only]: 
20. What did you think about using a heart monitor/taking your pulse? 
Prompts: Feelings? Worries? Expectations? Do you think using the heart monitor/taking your 




21. What do you think now about being involved in the MAGENTA study? 
Prompts: Would you do it again? Would you recommend it to a friend of they had CFS/ME? 
What do you think about the study for others your age?  
 
22. Is there anything else you would like to tell me? 
Prompts: About the study? Randomisation? Taking part in research in general?  
 
Thank you for taking part in the MAGENTA study! 
 
 
Example change to preference question: 
From: SMILE topic guide (parents/young people) 
If you were to take part, would you have a preference for one of the 
interventions?  
Prompts: Why?  What would you do if allocated the other intervention?  
Issues over participation? Engagement? 
 
To: MAGENTA (parents/young people) 
What were your initial thoughts about the research study? 
Prompts: What did you think when you were told about it? Feelings? 
Worries? Expectations? 
 
What did [recruiter] tell you about the treatments? 
Prompts: What did she say? What did you already know? When/Where 
did you find this out? What did you think? Depending on which 






MAGENTA: Recruitment training methods 
During the MAGENTA RCT three clinical CFS/ME teams provided a brief 
introduction to MAGENTA and gaining ‘consent to contact’ from families at the end of 
the patient initial assessment appointment. Research nurses would then contact 
families to discuss the RCT in full via telephone. Research nurses conducted all 
recruitment consultations and took online consent/assent when families wished to 
participate in the RCT. Members of the research team carried out recruitment 
consultations only when research nurses were on leave. 
Initial training sessions were informed by methodology developed in the QRI 
intervention (see: Section 2.2 Qualitative research and adult randomised controlled 
trials). [408] Good practice from the SMILE RCT also informed initial MAGENTA 
training sessions, and a structured approach to training was undertaken prior to the 
MAGENTA trial opening to recruitment. All initial training sessions lasted 
approximately 1.5 hours and were led by the qualitative researcher (LB). Initial face-
to-face (site 1) or telephone (sites 2 and 3) training sessions were carried out with 
recruiters on a one-to-one basis. Recruiters were also provided with a training pack 
prior to recruitment: 
1. A list of questions about confidence and recruiting to RCTs. [691]  
2. Key points for difficult trials. [692] 
3. Mills 2014 peer reviewed article. [247] 
4. ‘Tips for Recruitment and informed consent’ document. 
The ‘Tips for Recruitment’ document (see: MAGENTA: Tips for recruitment and 
informed consent) provided tailored information specific to communicating 




discussion of: the study, procedures, randomisation, and included a recruitment 
checklist outlining key points to cover in the recruitment consultation (e.g. right to 
withdrawal and data protection). Because some recruiters had no experience of 
recruiting to RCTs, role-play ‘practice’ recruitment consultations were also conducted 
prior to the RCT opening to recruitment. Role play consultations were conducted via 
telephone between the trainer (LB) and recruiters, with the trainer acting as a parent 
or participant. 
MAGENTA trial rates of recruitment were then monitored on a monthly basis, (see: 
The impact of communication training on recruitment figures) in conjunction with 
monthly trial management group meetings and ongoing training and analyses of 
audio-recorded recruitment consultations. Analyses of recruitment consultations was 
conducted by the qualitative researcher (LB) on an ongoing basis, with support from 
the qualitative lead (NM). Feedback was provided for recruiters during three further 
training sessions, (site 1 only, conducted by LB) during months three, six and 12 of 
the RCT. The final training session was delayed until month twelve because the 
CFS/ME at site 1 service moving to a new location in month 11 of the feasibility RCT. 
Follow-up training included examples from previous months audio recruitment 
consultations. Examples included good practice, and areas where changes could be 
made to improve communication and the process of informed consent. Written 
feedback was provided for recruiters, should they wish to refer to it at a later date. 
The MAGENTA ‘Tips for Recruitment’ document was developed further in month six, 
to incorporate findings from analyses of recruitment consultations and feedback from 





Activity Management (AM): 
• - Assessment of cognitive activity:  high concentration, low concentration 
(e.g. school work, screen time & hobbies)  
• - Find activity baseline & slowly increase activity  
(by 10-20% each week) 
• - Complete paper diaries / ActiveME app 
• - Focus: daily cognitive activities, no detailed discussion of physical 
activities 
Graded Exercise Therapy (GET): 
• - Assessment of physical activity: how far they can walk in 2 minutes  
(e.g. range and type of exercise used) 
• - Find exercise baseline & slowly increase their exercise 
(by 10-20% each week) 
• - Complete paper exercise diaries / ActiveME app 
• - Child taught to monitor their heart rate 
• - Focus: daily exercise, no detailed discussion of cognitive activities 
 
The following text was added to remind recruiters to highlight the lack of evidence 
base, because some families believing that activity management already had an 
evidence-base but graded exercise therapy did not: 
“Reassure the family that these two treatment routes can be used to treat 
CFS/ME, are currently used by the specialist service but we need to carry 



















Appendix 5 FITNET-NHS 
[Reference: Baos, S., et al., Investigating the effectiveness and cost-effectiveness of 
FITNET-NHS (Fatigue In Teenagers on the interNET in the NHS) compared to 
activity management to treat paediatric chronic fatigue syndrome (CFS)/myalgic 
encephalomyelitis (ME): protocol for a randomised controlled trial. Trials, 2018. 
19(1): p. 136.] 
 
FITNET-NHS: Inclusion/exclusion criteria 
Inclusion criteria 
1) Children aged 11 to 17 years  
2) Children with CFS/ME (defined using NICE guidance*)  
3) Children with no local specialist CFS/ME service 
 
[*NICE: National Institute for Health and Clinical Excellence, Chronic fatigue 
syndrome/myalgic encephalomyelitis (or encephalopathy) Diagnosis and 
management of CFS/ME in adults and children., N.I.f.H.a.C. Excellence., Editor. 
2007, Developed by the National Collaborating Centre for Primary Care: London]. 
Exclusion criteria 
1) Children not disabled by fatigue 
2) Children whose fatigue is due to another cause  
3) Children or parents unable to complete video calls (e.g. Skype) or FITNET-
NHS modules (e.g. unable to read FITNET-NHS material, or significant 
development problems, or limited internet access, unwilling/unable to set up 
personal email address/video call (e.g. Skype) account) 






FITNET-NHS: Eligibility assessment 
Young people without a local CFS/ME service were referred to the specialist 
paediatric CFS/ME service via their local primary care services. The eligibility 
assessment was carried out by a recruiter (health professionals from the specialist 
CFS/ME team) via telephone. Two telephone calls were made by the recruiter, an 
initial 10-minute call to establish whether the family were still interested in 
participating in the trial. If interested the family were then sent all relevant trial related 
documentation via email, including: PILs, consent to contact form and the Revised 
Children’s Anxiety and Depression Scale questionnaire (RCADS*). After consent to 
contact and RCADS forms were returned, a decision was made in relation to trial 
eligibility. In addition to using RCADS scoring criteria, recruiters were able to seek 
additional guidance and clarification from a Clinical Psychologist if necessary when 
assessing for eligibility. After the assessment of eligibility was established, a second 
call was made by the recruiter to firstly screen for a diagnosis of CFS/ME using NICE 
guidelines and secondly complete a recruitment consultation if a young person was 
given a diagnosis of CFS/ME. 
[Reference: *Chorpita, B.F., C. Ebesutani, and S.H. Spence. Revised Children’s 
Anxiety and Depression Scale questionnaire (RCADS). 2015. Available from: 
https://www.childfirst.ucla.edu/resources/.] 
























[Reference: Chorpita 2015, Revised Children’s Anxiety and Depression Scale 
questionnaire (RCADS) Publisher: Child FIRST – Focus on Innovation and Redesign 






FITNET-NHS: Integrated qualitative aims and objectives 
Integrated qualitative methodology was used to assess the feasibility and 
acceptability of conducting the FITNET-NHS RCT, specifically to understand issues 
that would relate to the successful design and implementation of a full-scale RCT in 
the UK, (the original FITNET trial* was conducted in the Netherlands).  During the 
internal pilot phase qualitative methodology aimed to: 
1. Examine whether it was feasible to recruit to FITNET-NHS (online delivery versus 
activity management (skype delivery) from a specialist service  to patients in different 
regions of the UK. 
2. Examine whether FITNET-NHS and activity management are acceptable 
interventions for children in different regions of the UK. 
[Reference: * Nijhof, S.L., et al., Effectiveness of internet-based cognitive 
behavioural treatment for adolescents with chronic fatigue syndrome (FITNET): a 





FITNET-NHS: Trial flow 
Participant flow through trial related interventions and data collection procedures.  
Recruitment consultation 
+/- randomisation 
Clinical nurse ascertains interest in study 
and provides trial information 
Activity Management FITNET-NHS  
Referral from primary care to CFS/ME 
Specialist Service 
Assessment of referral appropriateness. Is 
this a referral for CFS/ME?  
Routine screening blood results collated and 
assessed 
Appointment made 
Clinical assessment (~ 90 minutes): review 
of questionnaires, activity, fatigue, history, 
+/- examination 
Advice given on activity/sleep, symptoms 
Follow up appointments:  
Skype or face-to face (~60 minutes)  
0-6 follow up appointments depending on 
funding and ability to travel 
Child is sent battery of postal questionnaires 
to assess fatigue, mood, disability 
Child completes battery of questionnaires to 
assess fatigue, mood, disability 
Current treatment pathway for ‘Choose 
and Book” out-of-region referrals  
Treatment pathway for “Choose and 
Book” out-of-region referrals after 
FITNET-NHS introduced  
Referral from primary care to CFS/ME 
Specialist Service 
Routine screening blood results collated 
and assessed 
Child completes mood (RCADS) 
questionnaire  
Nurse specialist phone call: check 
paediatric assessment, screening bloods 
are normal, discuss fatigue, mood and 
disability to determine whether child has 
CFS/ME 
Child completes battery of questionnaires 
(except RCADS) 
3 appointments:  
1 x 90 minute assessment 
and treatment 
























































Child/parent does not 
want to take part 
Follow up treatment by 
local team supported by 
Specialist Service 
Follow up treatment by local team supported 











FITNET-NHS: Data collection and randomisation 
Randomisation and allocation outcome 
The recruiter randomised those who provided assent/consent to participate. 
Randomisation was carried out via a web-based randomisation system, operated by 
the Bristol Randomised Trials Collaboration, (telephone randomisation was used on 
occasions when the web-based system was unavailable). Allocation to the two 
treatment groups of either FITNET-NHS (online CBT) or activity management via 
skype (allocation ratio 1:1). Minimisation was used to facilitate balance between 
treatment groups by age and gender. A random component was retained to prevent 
accurate prediction of allocation.  Because of the nature of the intervention, it was 
not practical to blind either the family or the clinical service to treatment allocation. 
 
FITNET-NHS: Intervention groups 
FITNET-NHS Online CBT: Intervention Overview  
(Protocol v1.0) 
Participants first complete the psycho-educational components then work through 19 
interactive modules over 6 months. Parent modules explore and address parent’s 
beliefs and behaviours towards their child with CFS/ME focusing on their role as 
carers. The modules for participants introduce CBT, present CFS/ME as a multi-
factorial model, discuss the role of the family and develop treatment goals. The CBT 
modules focus on cognitive behavioural strategies with instructions on exercises for 
identifying, challenging and changing cognitive processes. Modules 1, 2 and 4 
introduce CBT and explain the role of therapists, present CFS/ME as a multifactorial 




the family. Modules 3 and 5 focus on treatment goals including the goal of full-time 
education. Modules 6 to 19 focus on cognitive behavioural strategies with 
instructions on exercises on identifying, challenging and changing cognitive 
processes that contribute to CFS/ME. Young people will be asked to do homework 
(answer questions and complete diaries). Whilst young people are able to complete 
the modules at their own pace, they will be encouraged to work on and complete 
modules before the next appointment. 
 
After parents complete the psycho-educational sections, they separately complete 
19 CBT modules. These explore and address parent’s beliefs and behaviours 
towards their child with CFS/ME. In children younger than 15 years, parents are 
supported to act as a coach. In those older than 15, parents are encouraged to step 
back and support their child taking responsibility for their treatment. Parents 
complete diaries and questionnaires and there is a review function of all completed 
modules. 
 
The FITNET-NHS clinical psychologists will make appointments and provide e-
consultations. E-consultations are an email exchange between the therapist and the 
participants which functions only on the FITNET-NHS platform. In addition, 
participants and parents are required to complete homework (for example, sleep-
wake, and thoughts and feelings diaries). These will be discussed in the e-
consultations and used to support behaviour change. The therapist works with 
parents and young people separately and responding together is discouraged. 




consultations, usually every 2 weeks, unless the participant/parent and therapist feel 
the need for this to be different. Participants and parents will be asked to complete 
homework/tasks within specified time frames. Therapists will also respond to 
participants parents within the specified time frame. A chat function will be provided 
within working hours to answer simple questions. 
 
Activity management via Skype: Intervention Overview 
(Protocol v1.0) 
Participants allocated to activity management will have up to three Skype 
appointments (one assessment and two follow-up). Parent/carer attendance is 
optional. Participants will then be discharged to their local service providers with up 
to 3 support phone calls. Activity management aims to convert a “boom-bust” pattern 
to a baseline with the same daily amount. For children/teenagers with CFS/ME these 
are almost entirely cognitive activities: school, schoolwork, reading, socialising, and 
screen time (phone, laptop, TV, games) but may also include some physical 
activities. Those allocated to this arm will receive advice about the total amount of 
daily activity, including physical activity, but will not receive specific advice about 
feelings, beliefs and behaviour change. Therapists treating children in both arms will 
be encouraged to offer routine advice about sleep, medication use and symptom 
control. 
 
Young people, their parents/carers and the health professional providing the 




frequency of appointments (every 2-6 weeks). The baseline assessment should take 
around 90 minutes. The follow up assessment should take 60 minutes each. We will 
collect the number, frequency and duration of initial/follow up sessions for each 
participant. This data will be used in the FITNET-NHS cost-effectiveness analysis. 
Participants will not be able to cross-over to the other treatment arm. 
 
Following the set of video calls the therapists will hand-over care to the local 
nominated health professional in primary/secondary care. Therapists will discuss the 
case by phone/letter (as normal clinical practice), ask for a review within six-eight 
weeks and offer up to three telephone calls to advise on treatment options, 
overcoming barriers and symptom control. The activity management Intervention 
Monitoring: Follow Up form can be used as a guide for the discussion with the local 
team and this can be stapled to the phone call discussion and placed in the medical 
notes. Local providers mostly offer face-to-face follow-up, some may use telephone. 
Research team contact details: 




A randomised controlled trial of Fatigue In Teenagers on the interNET (FITNET-
NHS) compared to Activity management (AM) to treat paediatric CFS/ME 
 
 
Activity Management Intervention Monitoring: Follow Up 
 
 
Patient name: ______________________________________Research ID: __ __ __ __ __ __  
Follow up session (circle):  1    2    3    4    5    or          




Mandatory                                                                        Tick if discussed                   Reason 
if not discussed 
Has the participants managed the baseline for 1-2 weeks?           Y  /   N                       if yes: 
Increase this baseline by 10-20% each week.   
Participants will continue to increase activity until they are able to 
do up to 8 hours of cognitive and physical activity a day. 
  
All participants: 
Discuss different types of activity, both cognitive and physical, 
which vary according to age.  
  
Discuss different types of cognitive activities (high and low 
concentration). 
  
Discuss physical activities, which vary according to severity (e.g. 
severely affected-sitting up in bed, mildly affected- running). 
  
Advise on how to record the total number of minutes spent each 
day doing high-energy activities using paper diaries/ “ActiveME” 
app or other methods. Discuss levels of activity and whether the 
baseline has been set at the correct level. 
  
Discuss problems and possible solutions, managing setbacks.   
Advice on sleep.   
 
Flexible                                                                            Tick if discussed                         Reason 
(if applicable) 
Advice on exercise: no. steps, mins. exercise, aerobic vs. non-
aerobic activity, advice on exercises or using a strengthening 
programme (e.g. PE in school, attendance at sporting events, 
recording physical activity within total cognitive activity).  
  
Discuss anxiety and/or depression.   




Advice on symptom control (if required).   
 
Prohibited                                                                      Tick if discussed                             Reason 
if discussed 
Detailed discussion of feelings, beliefs and how they change.   
Diaries on feelings and their relationship with behaviour.   
 
Has an Adverse event been reported        Y    /    N     (if yes, please notify the research team and 
complete AE/SAE form)                                                                               
Does patient need ActiveME App              Y    /    N     (if yes, please notify the research team) 
 
Duration of session (circle appropriate):  
          0 – 30 minutes                30 – 60 minutes       60 – 90 minutes 
 
Name of assessor: ________________________________     
Today’s date:       __ __ / __ __ / __ __ __ __  
(BLOCK CAPITALS) 
 
Signature: _______________________________________     
 
 






FITNET-NHS: Information Leaflet for young people (11-15yrs)  

























FITNET-NHS: Information Leaflet for young people (16-17yrs)  































FITNET-NHS: Information leaflet for parents  







































FITNET-NHS: Interview Topic Guide Young People 
v0.2 09/02/2017  
 
Introduction 
 Introduce research: We want to talk to families who are taking part in the trial 
about: their experience so far, the information they were given and how they are 
finding the treatment. What families tell us is used to understand if the treatment is 
acceptable and improve the trial. 
 
 Procedures: Usually done over Skype or the telephone. Chat to child and parent 
separately or together if they prefer, 20-40 mins- can stop when you want to, audio 
record, everything will be anonymised.  
 
 Separate from treatment 
 
 Questions, happy? 
 
  Sign Consent Forms (REDCap) (Child Assent (12-15), Consent (16-18), Parent 
Consent for Child (12-18), Parent Consent) 
 
Demographics (Child) 
Male    Female  
Age:              
School attendance:            
Diagnosis/ length of illness:                  
     
Trial Arm:  FITNET   Activity Management 
How far through treatment (FITNET modules (/19)/ Skype calls (/3):   
  




Interviewed:  Skype   Telephone   Home  
Child & Parent:  Together  Separately 
 
Interview 
1. Can you tell me a bit about your chronic fatigue? 
Prompts: Impact on your life? Journey before the specialist service?  
Previous treatment/ management to help it- what worked/ didn’t work? 
 
Provision and acceptability of patient information & recruitment process: 
2. How did you hear about the study? 
Prompts: What did you think when you were told about it? What kinds of 
things did you like about it? What kind of things were you/they worried about?  
 
3. What did you think about the information you were given about the 
study?  
Prompts: PIS?- read it?, understand it?, enough information/too much? 
Things missing? Seek information elsewhere (what)? How did you find the 
phone calls with the research team?- things missing, did not understand? 
 
4. What were you told about the treatments?  
Prompts: Both FITNET & AM- what did you think? What did you already know 
(from where)? Did you understand? Understand what was going to happen 
next? Feelings? 
 
5. What were the most important messages told to you by the research 
team? 
Prompts: Treatment plan? Benefits/risks? Recordings? Recovery?  
 
6. What did you think about having treatments allocated by randomisation, 
i.e. by chance?  
Prompts: How do you feel about this way of deciding your treatment? Happy? 
Did you wonder why this is done? Did you think you were likely to get one 
treatment rather than the other? Is there a better way? Why? 
 
7. Did you discuss the study with anyone else e.g. your/their GP?  
Prompts: Local CFS/ME specialist? Are you getting any advice about 
your/their CFS/ME from anyone else? E.g. Online? Other sources of 
information? 
 
Reasons for accepting participation: 




Prompts: How did you feel? Was it what you expected/wanted? Favoured a   
treatment? What would you have done if allocated the other treatment? 
Worries? 
 
9. What did you think about when deciding whether or not to take part in 
the study?  
Prompts: Treatments offered? Randomisation? What did you already know? 
Favoured a particular treatment? Helping other people or not? Worries? 
 
Acceptability of FITNET-NHS: 
10. What were your first thoughts about following an online treatment 
programme? 
Prompts: Did you think it would work? Any worries? 
 
11. Tell me about the FITNET treatment you are/were receiving? 
Prompts: What you expected? What has happened? What is good/bad about 
it? Would you change anything about it (what)? How are you/they doing (is it 
working)? 
 
12. How are you getting on with the FITNET-NHS online chapters? 
Prompts: How do you find using it? Is it age appropriate? Any technical 
problems? Any benefits? Worries? What do you think about modules? How 
do you feel about the frequency of the e-consultations? How do you feel about 
the advice you get? How do you feel about the homework you are asked to 
do? Do the modules make you feel more or less anxious, or about the same? 
 
13. Are there any things we need to consider for people your age when 
using it? 
Prompts: Text, Chapters? E-consultations? Homework? Advice? 
 
Acceptability of the AM Skype Calls: 
14. What were your initial thoughts about speaking to a doctor/ being 
treated using Skype?  
Prompts: Did you think it would work? Any worries?  
 
15. Tell me about the AM you are/were receiving? 
Prompts: What you expected? What has happened? What is good/bad about 
it? Would you change anything about it (what)? How are you/they doing (is it 
working)? 
 
16. How are you getting on with the video (e.g. Skype) calls? 
Prompts: How do you find using it? Is it age appropriate? Any technical 




(e.g. Skype) calls? How do you feel about the frequency of the video calls? 
How do you feel about the advice you get? How do you feel about the 
homework you are asked to do? 
 
17. Are there any things we need to consider for people your age when 
using it? 
Prompts: Calls? Assessments? Advice? 
 
And finally: 
18. What do you think now about being involved in the FITNET-NHS study? 
Prompts: Would you do it again? Would you recommend it to a friend of they 
had CFS/ME? What do you think about the study for others your age?  
 
19. Is there anything else you would like to tell me? 
Prompts: About the study? Things we need to improve/ change? Taking part 





FITNET-NHS: Interview Topic Guide Parents/Carers 
v0.2 09/02/2017  
 
Introduction 
 Introduce research: We want to talk to families who are taking part in the trial 
about: their experience so far, the information they were given and how they are 
finding the treatment. What families tell us is used to improve the trial. 
 
 Procedures: Usually done over Skype. Chat to child and parent separately, 
short-20 mins- can continue if you want to, audio record, everything will be 
anonymised, stop at any time.  
 
 Separate from treatment 
 
 Questions, happy? 
 
  Sign Consent Forms (REDCap) (Child Assent (12-15), Consent (16-18), Parent 
Consent for Child (12-18), Parent Consent) 
 
Demographics (Child) 
Male    Female  
Age:              
Ethnicity:             
School attendance:            
Diagnosis/ length of illness:                  
     
Hometown:             
Trial Arm:  FITNET   Activity Management 





Interview Date:   
Interviewed:  Skype   Home Child & Parent:  Together  
Separately 
Interview 
1. What led to [child] being referred to the CFS/ME specialist service?  
Prompts: Did CFS/ME have an impact on your child’s life? If so, did you/they 
do anything to manage it in any way or not? What things were you doing to 
help it before you started to see the specialist service? 
 
2. Can you talk me through [child’s] initial appointment with the specialist 
service? 
Prompts: What was said, did you understand what was being said? Feelings? 
 
Provision and acceptability of patient information & recruitment process: 
3. What were your initial thoughts about the research study? 
Prompts: What did you think when you were told about it? What kinds of 
things did you like about it? What kind of things were you/they worried about?  
 
4. What did you think about the information you were given about the 
study?  
Prompts: What information did you get – verbal and written (PIS)? Did you 
read it? Understand it? Did it give you enough information/too much? Were 
there things you thought they had forgotten to include? Did you supplement 
this information with that from other sources or not? If so, what 
information/which sources? 
 
5. What did the research team tell you about the treatments?  
Prompts: What did they say? What did you already know? When/Where did 
you find this out? What did you think? Depending on which treatment they talk 
about first: What did [they] mention about the other [FITNET-NHS/AM] 
treatment? Did you understand what was being said? What did you think? Did 
you understand what was going to happen next? Feelings? 
 
6. What were the most important messages conveyed to you during the 
discussion with [name - the research nurse] about the research study? 
Prompts: Treatment plan? Benefits/risks? Recordings? Recovery?  
 
7. What did you think about having treatments allocated by randomisation, 
i.e. by chance?  
Prompts: How do you feel about this way of deciding what treatment you get? 
Were you happy to be randomised? Did you wonder why this is done? Did 
you think you were likely to get one treatment rather than the other? Is there a 




8. Did you discuss the study with anyone else e.g. your/their GP?  
Prompts: Local CFS/ME specialist? Are you getting any advice about 
your/their CFS/ME from anyone else? E.g. Online? Other sources of 
information? 
 
Reasons for accepting participation: 
 
9. What did you think about when deciding whether or not to take part in 
the study?  
Prompts: Treatments offered? Randomisation? What did you already know? 
Favoured a particular treatment? Did you think about the study in terms of 
helping other people or not? [Altruism? EC interested] only if chose to take 
part and not mentioned yet. Worries? 
 
10. What did you think when you were told your child got [FITNET-
NHS/AM]? 
Prompts: How did you feel? Was it what you expected/wanted? What do you 
think about the treatments [FITNET-NHS/AM] offered in this study? Why did 
you decide [not] to accept the [treatment] allocated to [name] at 
randomisation? What would you have done if allocated the other treatment? 
Favoured a particular treatment? What did you already know? 




Acceptability of FITNET-NHS/AM: 
11. Do you think the FITNET-NHS/AM had an effect on you/your child or 
not?  
Prompts: Their CFS/ME, themselves, how you/they manage their CFS/ME? 
School? Life in general?  
 
12. Tell me about the [FITNET-NHS/AM] you are/were receiving? 
Prompts: What has happened? What is good/bad about it? Would you change 
anything about it? If so what?  Structure of sessions? How was it explained to 
you? What did you expect it to be like? Is it age appropriate? How are 
you/they doing? What are you/they doing? What kind of things have you/they 
been worried about? How do you feel after a follow up session/module 
completion? 
 
Acceptability of the FITNET-NHS online modules: 
13. What were your initial thoughts about following an online treatment 
programme? 
Prompts: How do you find using it? Is it age appropriate? Any technical 




14. How are you getting on with the FITNET-NHS online modules? 
Prompts: What do you think about modules? How do you feel about the 
frequency of the e-consultations? How do you feel about the advice you get? 
How do you feel about the homework you are asked to do? Do the modules 
make you feel more or less anxious, or about the same? 
 
15. Are there any things we need to consider for children your child age or 
parents when using it? 
Prompts: Modules? E-consultations? Homework? Advice? 
 
Acceptability of the AM Skype Calls: 
16. What were your initial thoughts about your child speaking to a doctor/ 
being treated using Skype?  
Prompts: How do you find using it? Were you on the call? Is it age 
appropriate? Any technical problems? Any benefits? Worries?  
 
17. How are you getting on with the video (e.g. Skype) calls? 
Prompts: What do you think about video (e.g. Skype) calls? How do you feel 
about the frequency of the video calls? How do you feel about the advice 
given? How do you feel about the homework? Do the modules make you feel 
more or less anxious, or about the same? 
 
18. Are there any things we need to consider for people your child’s age 
when using it? 
Prompts: Calls? Assessments? Advice? 
 
And finally: 
19. What do you think now about being involved in the FITNET-NHS study? 
Prompts: Would you do it again? Would you recommend it to a friend of they 
had CFS/ME? What do you think about the study for other families?  
 
20. Is there anything else you would like to tell me? 
Prompts: About the study? Randomisation? Taking part in research in 





FITNET-NHS Recruitment training methods 
Members of a clinical CFS/ME team were responsible for eligibility screening and 
conducted all recruitment consultations during the FITNET-NHS RCT. Rates of 
recruitment were also monitored on a monthly basis during the FITNET-NHS trial, as 
they had been during the MAGENTA RCT (see: The impact of communication 
training on recruitment figures). 
The ‘MAGENTA: Tips for Recruitment and informed consent’ document was adapted 
to support FITNET-NHS recruiters (FITNET-NHS: Tips for Recruitment and informed 
consent). All FITNET-NHS recruiters had previously recruited to paediatric RCTs 
(including MAGENTA). An initial face-to-face group training session (lasting 
approximately 1.5 hours) was led by two qualitative researchers, (by LB & RP) in 
month three of the FITNET-NHS trial. Training drew upon analyses of recruitment 
consultations conducted in the first three months of the trial. 
Relevant sections of recruitment consultations were routinely recorded and analysed 
by the FITNET-NHS qualitative researcher (RP) on an ongoing basis, as had been 
the case in the MAGENTA RCT. Samples of recruitment consultations were also 
listened to in full and analysed by LB and NM, these consultations were discussed 
with RP to develop ongoing tailored group training. Follow-up training was conducted 
at the beginning of months six, nine and 12 (each 1 hour in duration). Examples from 
previous months recruitment consultations were used to highlight good practice, and 
areas where changes could be made to improve communication about the RCT. 
Written feedback was provided for recruiters, (by LB & RP) should they wish to refer 
to it at a later date. The FITNET-NHS ‘tips for recruitment’ document was developed 




consultations. Further information was added highlighting similarities between the 
two intervention arms, (e.g. sleep advice was provide in both intervention arms) to 
emphasise that both were active treatments, and that both arms offered treatment 





















Appendix 6 CONTRACT 
[Reference: Hutchings, N., et al., CONTRACT Study - CONservative TReatment of 
Appendicitis in Children (feasibility): study protocol for a randomised controlled Trial. 
Trials, 2018. 19(1): p. 153.] 
 
CONTRACT: Inclusion/exclusion criteria 
Inclusion/exclusion criteria 
Inclusion Criteria 
1. Child age 4 – 15 years (<16 years and >3 years) 
2. Clinical diagnosis, either with or without radiological assessment, of 
acute appendicitis which prior to study commencement would be treated 
with appendicectomy 
3. Written informed parental consent, with child assent if appropriate 
 
Exclusion Criteria 
1. Clinical signs or radiological findings to suggest perforated appendicitis 
2. Presentation with appendix mass 
3. Previous episode of appendicitis or appendix mass treated non-
operatively 
4. Major anaesthetic risk precluding allocation to the appendicectomy arm 
5. Known antibiotic allergy preventing allocation to non-operative 
treatment arm 
6. Antibiotic treatment started at referring institution (defined as 2 or more 
doses administered) 
7. Cystic fibrosis (there is a higher background incidence of appendicitis in 
this population and they are at an increased risk of recurrence. 
Therefore, there is a lack of equipoise between treatment arms for this 
group of children) 
8. Positive pregnancy test 




CONTRACT: Eligibility assessment 
Eligible participants were identified by surgeons when diagnosed with acute 
appendicitis. The trial was explained to parents and young people via recruitment 
consultations conducted by surgeons and supported by research nurses. Age 
appropriate information sheets and a short video presentation were available to 
support the verbal discussion (recruitment consultation) of the trial provided by 
surgeons. Consent for trial participation was obtained from parents within four hours 
of first discussing the trial. Young people aged 12-years or older were asked to 
provide assent if they felt well enough to do so. At this time, written consent was also 
obtained for use of the audio-recorded recruitment consultation for research 
purposes. 
 
CONTRACT: Integrated qualitative aims and objectives 
Integrated qualitative methodology was a key element in the CONTRACT feasibility 
trial and was used to assess the feasibility and acceptability of conducting a future 
trial. The CONTRACT Communication Sub-Study (CCSS) aimed to: 
1. Monitor and optimise recruitment and informed consent during the feasibility 
stage of trial, to inform the design and conduct of a future trial. 
2. Investigate the acceptability to families of the recruitment consultation, trial 
interventions and wider trial processes. 






CONTRACT Trial flow 
From the CONTRACT parent information leaflet version 2.1:  
 
 
From the CONTRACT Health Technology Application: Submitted 17/09/15:  
 
  
Antibiotics not working  
Children receiving non-operative treatment who, in the opinion of the consultant 
surgeon in charge of their care have clinically deteriorated such that immediate 
appendicectomy is mandated, will undergo appendicectomy at any stage. A formal 
review will be performed at 24 hours following randomisation and any child deemed to 
have significantly deteriorated will undergo appendicectomy. Those who are stable or 
clinically improving will continue with non-operative treatment. Those who are not 
showing clinical signs of improvement at 48 hours following randomisation will undergo 
appendicectomy. These decision points will be made based on the clinical judgement of 
the treating consultant as is current practice rather than on any predefined set of criteria 
for which evidence does not currently exist. Children who require appendicectomy for 
failure of non-operative treatment will be treated post-operatively according to a 
standardised treatment regime already in use at our institutions and identical to that to 




CONTRACT: Data collection and randomisation 
Recording of recruitment to trial consultations 
Surgeons and research nurses sought verbal permission to record recruitment 
consultations with all families of young people eligible for the trial. A digital recorder 
and instructions on use were available at each participating site (D, E and F). Health 
professionals were advised to store the digital recorder in an accessible but secure 
location. Recruitment consultations were conducted in accident and emergency 
departments and inpatient wards at participating sites. Recruitment consultations 
included information in relation to the CONTRACT trial, and interventions, potential 
risks and benefits of taking part and answered any questions raised by the families. 
 
Randomisation and allocation outcome 
The CONTRACT protocol stated that informed consent and randomisation to the trial 
should happen within four hours of the initial trial consultation. After randomisation, 
the appropriate treatment pathway was administered immediately. Allocation to the 
two treatment groups of either antibiotics or surgery, (allocation ratio 1:1) used 
minimisation to ensure similarity between the groups in factors associated with 
diagnostic accuracy and outcome of treatment.  Randomisation was carried out via 
an online system available 24-hours per day with telephone back-up provided by the 
relevant Clinical Trials Unit. Because of the nature of the interventions, it was not 
practical to blind either the family or the clinical service to treatment allocation. 
Families were given their randomisation outcome immediately and the appropriate 





CONTRACT: Intervention groups 
Non-operative intervention (antibiotics) 
Non-operative participants were monitored regularly and remained nil by mouth for a 
minimum 12-hour period. When participants had been afebrile for 24-hours they 
changed to oral antibiotics. Criteria for discharged home was based on: vital signs 
within normal limits for age, afebrile for >24 hours, tolerating light diet orally, 
mobilising and adequate oral pain relief. Participants received a total course of 10 
days of antibiotics following randomisation. Parents were provided with information 
about the risk of recurrence and what to do should they feel they require further 
advice about their child’s condition from the clinical team. The definition of recurrent 
acute appendicitis was based on histopathological evidence of acute appendicitis 
following readmission during the 6-month follow-up period. Readmitted participants 
were recorded and treated at the discretion of the clinical team to whom they 
present. These participants were not eligible for re-enrolment in the study. 
Operative intervention (appendectomy) 
A peritoneal microbiology swab was taken from each participant and sent for 
microbiological culture. Standardised treatment pathways at participating institutions 
were used to determine the duration of post-operative antibiotic regimes. These were 
based on histopathological evidence obtained from the removed organ, participants 
with a macroscopically normal appendix or simple acute appendicitis received no 
further antibiotics. Participants with a gangrenous or perforated appendix continued 
to receive intravenous antibiotics for a minimum of 3-5 days, (intravenous and oral). 
Criteria for discharge home was identical to those in the non-operative treatment 
group. Readmitted participants (due to surgical complications or infection) were 




CONTRACT: Information Leaflet for young people (8-11yrs)  













CONTRACT: Information Leaflet for teenagers (12-15yrs)  













CONTRACT: Information leaflet for parents  





























CONTRACT: Interview Topic Guide parents/carers 
v8.0 05/12/2017  
 
CONTRACT Communication Sub-Study – Possible questions for 
parents/carers. 
 
The list of questions below are just indications of the sorts of topics we plan to 
explore. We will always tailor questions for each person depending on their situation 
(e.g. whether the family participated in CONTRACT or not) and what is important for 
them as an individual.   
 
As we interview more people over the course of the study and learn what questions 
are the most important to ask, we will usually refine or change questions.   
 
 Setting the scene  
 
1. What led to [child’s name] being brought in to hospital?  
 
Prompts: Symptoms? Duration? How child was in themselves? How did you manage this? 
What happened next? Feelings? Did you take the child go to the GP/walk in centre/A&E? 
What did the GP/staff you spoke to advise? Did the GP/staff indicate what treatment for 
appendicitis might involve? 
 
2. Can you talk me through what happened when you got to the hospital?  
 
Prompts: What was said, did you understand what was being said? Who did you speak to? 
How you/your child was feeling at this point? What else was being done to help? What was 
said about treatments? Thoughts/feelings? 
 
 Thoughts about the CONTRACT study 
 
3. What were your initial thoughts about the CONTRACT research study?  
 
Prompts: Who first mentioned the study/how did you first hear about it? What did you 
think/feel when you were first heard about it? Was there anything you/child liked about it – 






How staff explained the study and acceptability of patient information & recruitment 
process: 
 
4. What did you think about how the study was explained?  
 
Prompts: What was said about it? Was there anything unclear or surprising? What questions 
did you have/did you ask these/were they answered? Did you feel people were able to take 
the time you/your child needed? Were they interested in what you/your child thought? What 
other information did you get about the study – verbal and written (PIS/IPAD video)? Did you 
read/watch it? What did you think of it? Did it give you the information you needed: enough 
information/too much? Were there things you thought they had forgotten to include? Did you 
have a chance to ask to about/look for information from other sources or not? If so, what 
information/which sources?  
 
5. What did the [nurse/surgeon/doctor] tell you about the two treatments in 
CONTRACT?  
 
Prompts: When/Where did you find this out? What did they say? What did you already 
know? What did you think? Depending on which treatment they talk about first: What did 
[they] mention about the other treatment? What there anything said that wasn’t very clear?  
What did you think? Was it explained what was going to happen next? Feelings? Did you 
discuss the possibility of antibiotics not working? What was your understanding of this? What 
did you think about this? (Prompt: if discussed as same, prompt a bit further. Was your 
concern that they wouldn’t work to treat [child] now or did you worry the appendicitis might 
come back in future?) 
 
6. What were the most important messages conveyed to you during the 
discussion with [nurse/surgeon/doctor] about the research study?  
 
Prompts: Treatment plan? Benefits? Risks? Recordings? Recovery? Did you feel it was 
you/your child’s decision? Was there ever a sense of pressure? 
 
7. What did you think about having treatments allocated by randomisation, i.e. by 
chance?  
 
Prompts: How do you feel about this way of deciding what treatment you get? Were you 
okay to be randomised? Did you wonder why this is done? Did you think you were likely to 
get one treatment rather than the other? Did you feel like the team may have preferred one 
treatment over another for your child? Why? Is there a better way – could you tell me about 










8. What did you think about when deciding whether or not to take part in the 
study?  
 
Prompts: Treatments offered? Randomisation? What did you already know? Favoured a 
particular treatment? Worries? Benefits? Time pressures? Any other pressures? Wider 
family views? Did you think about the study in terms of helping other people or not?  
 
What do you think (recruiter) thought about the study? Did you get an impression 
whether (recruiter) thought one treatment or another would be more/less suited to 
(child)? 
 
9. Could I ask about how you decided not to take part in the study?  
 
Prompts: Would you tell me about what influenced your decision? Timing of request to take 
part? Timing of study? Treatments offered? Randomisation? Favoured a particular 
treatment? What did you already know? Feelings? Expectations? Worries?  
 
10. What did you think when you were told you got [allocated group]?  
 
Prompts: How did you feel? Was it what you expected/wanted? What do you think about the 
treatments [allocated group] offered in this study?  
 
Use depending on whether or not the family dropped out shortly after randomisation 
I understand you decided to withdraw at randomisation – could you tell me about that 
decision? What would you have done if allocated the other treatment? Favoured a particular 
treatment? What did you already know? Randomisation? Expectations? Worries? Issues 
over participation? Engagement?  
 
Use if family withdrew some hours or days after randomisation 
 
11. Could I ask about how you decided to stop participating in the study 
[withdraw]?  
 
Prompts: Would you tell me about what influenced your decision? Feelings? Expectations? 
Worries? Treatments offered? Randomisation? Favoured a particular treatment? What did 







Experience of treatment over time and recovery 
 
12. Tell me about the treatment you/your child received?  
 
Prompts: How was the [child’s name] in the hours after the operation/the antibiotics were 
started. What was been good/bad about the treatment during that time? Would you change 
anything about it? If so what? How was it explained to you about what to expect? Is the 
treatment appropriate for someone of your/your child’s age? 
 
 
IF ANTIBIOTIC FAILURE… 
Why did [child’s name] have surgery after being randomised to antibiotics? Did you request 
surgery or did the doctor/nurse suggest that it would be best? What was the reason for this? 
What did you/they look out for when deciding to operate? How long between randomisation 
to antibiotics and the decision to operate? How long did you wait for an operation after it had 
been decided? 
 
13. What has happened since the [surgery/antibiotic administration]?  
 
Prompts: How was the [child’s name] in the days after the operation/the antibiotics were 
started. What is good/bad about it in the longer term? Would you change anything about it? 
If so what? What did you expect recovery to be like? What were the main ways appendicitis 
affected you/your child? How did you know/what did you look out for to tell if the treatment 
was helping you/your child (symptoms/condition/life)? If you were telling someone who has 
never had appendicitis before what it’s like to have it/have a child with appendicitis how 
would you describe it? How are they doing now – any problems? Are there any activities that 
s/he is not yet able to do? How will you know when they are fully recovered? What kind of 
things have you/they been worried about? Did the doctor explain that families that participate 
in CONTRACT will be followed up? Do you remember what was explained? How do 




14. What do you think now about being involved in the CONTRACT study?  
 
Prompts: Now a bit of time has passed, would you make the same decision again? Would 
you recommend it to a friend/family in the same situation? What do you think about the study 
for other children of your child’s age? Thoughts on being recorded? 
 
15 Is there anything else you would like to tell me?  
 
Prompts: About the study? Randomisation? Taking part in research in general? Are there 
any questions you would like to ask?  
 




CONTRACT: Interview Topic Guide Adapted for children (8-11yrs) 
and young people (12-15yrs) 


























CONTRACT communication (qualitative) sub-study 
Topic Guide children (8-11yrs) / young people (12-15yrs) 
 
v6.0 05/12/2017  
Introductions, icebreakers & 5 minutes general chat. 
Colouring or would they like to draw a picture?  
 
Pass [adapted topic guide] to participant (age 8-11yrs) so they can write/draw in 
booklet and either keep it or hand it back to the researcher at the end of the 
interview.  
 
 Thoughts about the CONTRACT study  
 
1. What did you think when you were first told about the CONTRACT 
research study?  
 
Prompts: When were you told about it? How were you feeling when you were told 
about it? Was there anything you liked about it – tell me about this? Was there 
anything you didn’t like? Was there anything that worried you about it?  
 
2. What did the doctor or nurse tell you about the two treatments in the 
study?  
 
Prompts: When/Where did you find this out? What did they say? What did you 
already know? What did you think? Depending on which treatment they talk about 
first: What did [they] mention about the other treatment? What there anything said 
that wasn’t very clear?  What did you think? Was it explained what was going to 
happen next? Feelings?  
 
 
3. What did you think about how the CONTRACT research study was 
explained to you? If they struggle to remember ask if you can show the 
video] 
 
Prompts: What was said about it? Was there anything unclear or surprising? What 
questions did you have/did you ask these/were they answered? Did you feel you had 
enough time to decide? Were they interested in what you thought? What other 
information did you get about the study – verbal and written (PIS/IPAD video)? Did 
you read/watch it? What did you think of it? What did it tell you? Did it give you the 
information you needed: enough information/too much? Were there things you 
thought they had forgotten to include? Is there anything we could do to improve how 






4. What did you think about when deciding to take part or not?  
 
Prompts: Treatments offered? Randomisation? What did you already know? 
Favoured a particular treatment? Worries? Benefits? Time pressures? Any other 
pressures? Wider family views? Did you think about the study in terms of helping 
other people or not? What do you think the most important message was? 
 
5. What did you think when you were told you were having antibiotics/an 
operation?  
 
Prompts: How did you feel? Was it what you expected/wanted? What do you think 
about the treatments [allocated group] offered in this study? I understand you 
decided to withdraw at randomisation – could you tell me about that decision? What 
would you have done if allocated the other treatment? Favoured a particular 
treatment? Did you feel like the team may have preferred one treatment over another 
for you? Why? What did you already know? Randomisation? Expectations? 
Worries? Issues over participation? Engagement?  
 
6. Can you tell me about the treatment you had?  
 
Prompts: What has been good/bad about it? Would you change anything about it? If 
so what? How was it explained to you? Is the treatment appropriate for someone of 
your/your child’s age? 
 
7. What has happened since you had your treatment]?  
 
Prompts: What is good/bad about it? Would you change anything about it? If so 
what? What did you expect recovery to be like?  
What were the main ways it affected you? How did you know/what did you look out 
for to tell if the treatment was helping you (symptoms/condition/life)? If you were 
telling someone who has never had appendicitis before what it’s like to have it how 
would you describe it? How are you/they doing now? How will you know when 
you/they are fully recovered? What kind of things have you/they been worried about? 
Any side effects? Did the doctor explain that families that participate in CONTRACT 
will be followed up with a few more appointments to see how you’re getting on? Do 
you remember what was explained? How do you feel about follow up? School? 
Home life? Life in general? 
 
8. What do you think now about being involved in the CONTRACT research 
study?  
 
Prompts: Would you do it again? Would you recommend it to a friend/family in the 
same situation? What could we do to improve the study & make it better? What do 




Further questions depending on age and maturity 
 
9. What were the most important messages that the [doctor or nurse] told 
you about the study?  
 
Prompts: Treatment plan? Benefits? Risks? Recordings? Recovery? Did you make 
this decision with your parent(s)/carer(s) or did they decide for you? Did you sign 
something, (assent) what did you think about this? 
 
10. What did you think about having treatments chosen by randomisation? 
[explain randomisation as 50:50 chance of being in one group or the 
other] 
 
Prompts: How do you feel about this way of deciding what treatment you get? Were 
you okay with this? Is there a better way we could explain this to you? Did you 
wonder why this is done? Did you think you were likely to get one treatment rather 
than the other? 
 
11. Could I ask about how you decided not to take part in the study?  
 
Prompts: Would you tell me about what influenced your decision? Timing of request 
to take part? Timing of study? Treatments offered? Randomisation? Favoured a 
particular treatment? What did you already know? Feelings? Expectations? Worries?  
 
12. Could I ask about how you decided to stop participating in the study 
[drop-out]?  
 
Prompts: Would you tell me about what influenced your decision? Feelings? 
Expectations? Worries? Treatments offered? Randomisation? Favoured a particular 
treatment? What did you already know? Timing of dropout from study? 
 
13. Is there anything else you would like to tell me?  
 
Prompts: About the study? Randomisation? Taking part in research in general? Are 
there any questions you would like to ask?  
 






CONTRACT: Recruitment training methods 
Members of three surgical teams were responsible for recruiting to the CONTRACT 
RCT. The total number of surgeons recruiting into the trial was not known by the 
qualitative team, because study consent forms were only sent to the research team 
when families also opted into the nested qualitative communication study. Three 
initial face-to-face group training session was carried out with 29 surgeons and 
research nurses supporting recruitment. Recruiters’ past experience of recruiting to 
RCTs was not known. Recruitment was split into three ‘phases’ during the 
CONTRACT RCT, with each of the three training sessions conducted at the 
beginning of either, phase one, two or three of recruitment: 
Phase one of recruitment months 1-4. 
Phase two of recruitment months 5-8. 
Phase three of recruitment months 9-12. 
Phase one training included a generic PowerPoint presentation, informal group 
discussions, and role-play activities. Phases two and three included tailored 
PowerPoint presentations, and specific examples from previous months recruitment 
consultations: 
Generic training topics: Phase 1 
Recruitment issues for RCTs 
Public perceptions of RCT research 
Discussing RCTs with families and exploring treatment 
preferences 
Group work 
Role play / demonstration 
Overview of CONTRACT Communication study 
Communication study: How will it work? 
Digital recorders 
Questions 




Tailored training topics: Phase 2 
Recruitment to CONTRACT: How are we doing so far?  
CONTRACT Communication study quiz (terminology) 
Consultations exemplary in terms of…   
Is there room to be a bit more positive about research and 
about CONTRACT? Words suggestive of burden 
Participation positives 
More balanced language for treatment arms… 
Terminology for study arms 
Exploring reasons and beliefs underlying preferences   
Balancing treatment preferences 
Past experience: Previous bad experience of appendicitis 
Randomisation: Examples of good explanations 
Families’ questions 
Introducing the recording… 
Questions 
 
Tailored training topics: Phase 3 
Feasibility Study Progress 
Thank you to recruiters 
Communication Study Progress 
Health professional feedback leads to change 
Consultations exemplary in terms of…   
R.C.T. Fortunes! 
CONTRACT Consultation Process 
Describing randomisation 
Antibiotics: Recurrence & managing expectations 
Surgery: Surgical risks are often neglected 
Words have power (terminology) 
Exploring treatment preferences   




Recruiters were again provided with a ‘Hints and Tips’ document (CONTRACT: Tips 
for Recruitment and informed consent) adapted and developed for use, drawing 
upon good practice from the SMILE, MAGENTA and FITNET-NHS RCTs. After the 
second training session a second document was developed (see: CONTRACT: 
Recruitment Flowchart) because surgeons reported that they also wanted a step by 
step guide of the documents and equipment needed to conduct the consultation, 




should conduct each task (e.g. introducing the RCT, verbal consent, recording the 
discussion, showing the iPad video). Many surgeons recruited to the RCT 
infrequently, so wanted all this information in one document. The flowchart also 
provided information on the inclusion/exclusion criteria, and how to explore negative 
past experience of appendicitis, because this was a common reason provided by 






























Appendix 7: CONSORT Diagrams 






SMILE: Declined after consent to contact  
(When recruiter made contact by telephone) 
 
 
Reason for decline Returned consent to contact: Declined
Perceived study burden 9
Preference for treatment 9
Too much at moment 8












FITNET-NHS: CONSORT diagram 
 
Of those potentially eligible (n=201) participants were excluded from the RCT at 
three time points due to ineligibility/no funding (n = 53). Therefore, the total number 
of eligible participants = 148 
 
All referrals to the service: 553
Potentially eligible referrals (region/age): 201
6 Incorrectly excluded (missed)
33 Not eligible/ no funding
11 Declined
6 Pending 1st phone call, of which:
4 are awaiting blood results from GP
1st phone call (willing to consider study): 145
13 Not eligible / no funding
24 Declined
5 Pending eligibility assessment, of which:


















% of those 
not in trial
% of total 
referrals
TOTAL NOT IN TRIAL (ANY REASON): 50 37 20 107 100% 53%
TOTAL EXCLUSIONS 33 13 7 53 50% 26%
EXCLUSION: Local specialist service 9 9 2 20 19% 10%
EXCLUSION: Referred for diagnosis/ second opinion (req face to face) 4 2 0 6 6% 3%
EXCLUSION: Diagnosis: Not CFS (includes other cause for fatigue) 3 0 3 6 6% 3%
EXCLUSION: Diagnosis: Not disabled by fatigue 0 0 1 1 1% 0%
EXCLUSION: No bloods - Needlephobic 2 0 0 2 2% 1%
EXCLUSION: No bloods - none returned within 6 weeks of request 1 0 0 1 1% 0%
EXCLUSION: Unable to do FITNET modules/ Skype - give reason (e.g. no computer/ not computer literate - parent or child/ learning difficulties) 0 0 1 1 1% 0%
EXCLUSION: Pregnant at assessment 0 0 0 0 0% 0%
EXCLUSION: Age 7 1 0 8 7% 4%
EXCLUSION: Not funded 5 0 0 5 9% 2%
OTHER exclusion/decline (give reason)**** 2 1 0 3 3% 1%
OTHER: Inapproriately excluded 6 0 0 6 6% 3%
TOTAL DECLINED 11 24 13 48 45% 24%
DECLINED: Want face to face appt 7 10 7 24 22% 12%
DECLINED: Perceived study burden 0 2 0 2 2% 1%
OTHER: Family/patient away 0 1 0 1 1% 0%
DECLINED: Declined TRIAL - other reason (please state if known)** 0 7 1 8 7% 4%
DECLINED: Declined TREATMENT (give reason if known)*** 4 4 5 13 12% 6%




CONTRACT CONSORT diagram 
 
[Reference: Moher, D., et al., CONSORT 2010 explanation and elaboration: updated 
guidelines for reporting parallel group randomised trials. BMJ, 2010. 340: p. c869.]  





Not Eligible N=146 
 
Suggested perforated appendix – 105 
Appendix Mass – 20 
Already started antibiotic treatment at site – 16 
Appendix abscess - 1 
Previous non-operative treatment of appendicitis – 4* 




Did not consent N=58 
 
Preference for surgery – 35 
Did not want to take part in research - 22 







Withdrew – 2 (7%) 
Switched to appendicectomy – 8 (28%): 
Simple acute appendicitis – 4 
Perforated appendix – 4 
Appendicectomy after discharge – 7 (24%): 
Perforated appendix – 2 
Appendicitis – 1 
Appendix Mass – 1 
SAA – 3 
Discharged as per protocol – 19 (66%)  
Post-discharge outcomes:  





Withdrew – 1 (4%) 
Simple acute appendicitis – 17 
Perforated appendix - 8 
Normal appendix – 2* 
*one of these had subsequent wound 
inflammation and dehiscence 
Not Approached N=16 
 
Language barrier – 5 
No staff available to consent - 3 






Appendix 8: Monthly recruitment Figures  
MAGENTA 
Month Recruited Declined all  Total by month Cumulative 
1 7 3 10 10 
2 3 5 8 18 
3 9 3 12 30 
4 8 5 13 43 
5 5 7 12 55 
6 3 4 7 62 
7 12 3 15 77 
8 7 5 12 89 
9 8 8 16 105 
10 7 10 17 122 
11 8 14 22 144 
12 3 14 17 161 
13 8 3 11   











Total by month Cumulative 
1 1 5 6 6 
2 6 9 15 21 
3 7 5 12 33 
4 10 2 12 45 
5 11 6 17 62 
6 3 1 4 66 
7 8 1 9 75 
8 13 3 16 91 
9 8 7 15 106 
10 7 2 9 115 
11 3 1 4 119 
12 6 6 12 131 
13 9 4 13   












Approached Recruited % Approached Recruited % Approached Recruited % Approached Recruited % Approached Recruited
1 2 2 100% 7 3 43% 5 2 40% 14 7 50 14 7
2 3 1 33% 1 1 100% 1 0 0% 5 2 40 19 9
3 4 2 50% 4 0 0% 1 0 0% 9 2 22 28 11
4 5 3 60% 1 0 0% 3 0 0% 9 3 33 37 14
5 6 3 50% 2 1 50% 4 3 75% 12 7 58 49 21
6 6 1 17% 3 2 67% 2 0 0% 11 3 27 60 24
7 7 3 43% 3 2 67% 4 3 75% 14 8 57 74 32
8 5 2 40% 1 1 100% 1 1 100% 7 4 57 81 36
9 3 0 0% 5 2 40% 1 1 100% 9 3 33 90 39
10 5 2 40% 3 3 100% 0 0 0% 8 5 63 98 44
11 2 2 100% 7 6 86% 2 0 0% 11 8 73 109 52
12 4 4 100% 0 0 0% 2 1 50% 6 5 83 115 57
52 25 48% 37 21 57% 26 11 42% 115 57 50% 115 57
Month
Cumulative Total Total [Sites D,E&F]Site FSite ESite D
Site D Site E Site F Total
Preference for surgery 21 3 5 29
Does not want to take part in research 3 11 7 21
Other  – patient in distress 0 1 0 1
Randomised 17 12 10 39
Unable to provide informed consent due to 
language barrier
3 1 1 5
No staff available 2 0 0 2
Clinician decision not to approach 1 2 2 5
47 30 25 102




Appendix 9: Qualitative interview samples all trials (Family interviews) 
SMILE: Family interview sample 







status in trial Treatment group Site ID 
Young person 
S4 Mum S4 
Male 12 7 77 Recruited Specialist Medical Care  S 
Young person 
S88 Mum S88 
Female 17 10 13 Recruited Specialist Medical Care  S 
Young person 
S2 Mum S2 
Female 14 6 63 Recruited Specialist Medical Care  S 
Mum S33 Female 15 3 135 
Crossed to 
Lightning Process 
Specialist Medical Care  S 
Young person 
S35 Mum S35 
Female 12 10 20 Recruited Specialist Medical Care  S 
Young person 
S38 Mum S38 
Female 16 10 26 Recruited Specialist Medical Care  S 
Young person 
S5 Mum S5 
Female 13 5 273 Recruited 
Specialist Medical Care 
plus Lightning Process 
S 
Young person 
S36 Mum S36 
Female 13 4 137 Recruited 
Specialist Medical Care 
plus Lightning Process 
S 
Young person 
S9 Mum S9 
Female 12 4 99 Recruited 
Specialist Medical Care 
plus Lightning Process 
S 
Young person 
S12 Mum S12 
Female 15 5 223 Recruited 
Specialist Medical Care 
plus Lightning Process 
S 
Young person 
S7 Mum S7 
Male 13 4 79 Recruited 
Specialist Medical Care 












status in trial Treatment group Site ID 
Young person 
S34 Mum S34 
Male 15 9 108 Recruited 
Specialist Medical Care 
plus Lightning Process 
S 
Young person 
S8 Mum S8 
Female 16 3 58 Recruited 
Specialist Medical Care 




MAGENTA: Family interview sample 








Status in trial Treatment group 
Site 
ID 
Young person M35 
Mum M35                  
Dad M35 
Female 17 9 36 
Crossed to Graded Exercise 
Therapy 
 Activity management M 
Young person M51 
Mum M51 
Female 14 10 105 
Crossed to Graded Exercise 
Therapy 
 Activity management M 
Young person M65 
Mum M65 
Male 8 3 30 Recruited  Activity management M 
Young person M9 
Dad M9 
Male 14 5 154 Recruited  Activity management M 
Mum M23 Male 12 6 70 Recruited  Activity management M 
Young person M72 
Mum M72 












Status in trial Treatment group 
Site 
ID 
Young person M88 
Mum M88 
Female 13 4 182 Recruited  Activity management M 
Young person  
M99 
Female 16 9 173 Recruited  Activity management M 
Young person 
M60, Mum M60 
Female 17 10 69 Recruited  Activity management M 
Young person 
M11, Mum M11 
Female 11 6 86 Recruited  Activity management M 
Young person 
M129 Mum M129 
Male 15 9 76 Recruited  Activity management M 
Young person M93 
Mum M93 
Female 13 5 38 Recruited  Activity management M 
Young person M29 
Mum M29 
Male 15 6 244 Withdrew from treatment  Activity management M 
Young person M2 
Mum M2 
Female 17 8 25 Withdrew from treatment & trial  Activity management M 
Young person 
M108 Mum M108 
Female 14 10 39 Withdrew from treatment & trial  Activity management M 
Mum M52 Female 15 6 106 Declined Care outside RCT M 
Young person M61 
Mum M61 
Female 15 10 9 Declined Care outside RCT M 
Mum M87 Female 17 4 13 Declined Care outside RCT M 
Mum M110 Female 12 3 8 Declined Care outside RCT M 












Status in trial Treatment group 
Site 
ID 
Young person M34 
Mum M34 
Male 15 6 99 





Young person M25 
Mum M25 




Young person M5 
Mum M5 




Young person M3 
Mum M3 




Young person M16 
Mum M16 




Young person M20 
Mum M20 




Young person M43 
Mum M43 




Young person M49 
Mum M49 





M115 Mum M115 




Young person M1 
Mum M1 





M109 Mum M109 




Young person M64 
Mum M64 








FITNET-NHS: Family interview sample 






Status in trial Treatment group Site ID 
Young Person 
F3 Mum F3 
Male 15 10 80 Recruited Skype activity management  F 
Young Person 
F1 Mum F1 
Female 12 7 75 Recruited Skype activity management F 
Young Person 
F15 Mum F15 
Female 12 6 189 Recruited Skype activity management F 
Mum F9 Male 16 8 231 Recruited Skype activity management F 
Young Person 
F22 
Female 11 7 141 Recruited Skype activity management F 
Mum F11 Female 13 4 131 Recruited Skype activity management F 
Young Person 
F20 Mum F20 
Female 13 6 121 Recruited Skype activity management F 
Young Person 
F13 Mum F13 
Female 15 8 97 Recruited Skype activity management F 
Young Person 
F23 Mum F23 
Female 16 8 83 Recruited FITNET Online CBT F 
Young Person 
F25 Mum F25 










Status in trial Treatment group Site ID 
Young Person 
F18 Mum F18 
Male 13 8 229 Recruited FITNET Online CBT F 
Young Person 
F27 Mum F27           
Dad 27 
Female 14 7 174 Recruited FITNET Online CBT F 
Young Person 
F6 Mum F6 
Female 13 9 210 Recruited FITNET Online CBT F 
Young Person 
F10 Mum F10 
Female 16 10 69 Recruited FITNET Online CBT F 
Young Person 
F28 Mum F28                
Dad F28 
Female 15 4 132 Recruited FITNET Online CBT F 
Young Person 
F21 Mum F21 
Male 11 10 117 Recruited FITNET Online CBT F 
Young Person 
F26 Mum F26 
Male 11 5 140 Recruited FITNET Online CBT F 
Young Person 
F24 Mum F24 
Female 17 5 226 Recruited FITNET Online CBT F 
Young Person 
F12 Dad F12 
Female 16 8 126 Recruited FITNET Online CBT F 
Young Person 
F19 Mum F19 





CONTRACT: Family interview sample 













CE6 Mum CE6 
Male 11 1 28 Recruited Antibiotics CE 
Young person 
CF20 Dad CF20 
Male 7 7 25 Recruited Antibiotics CF 
Young person 
CD9 Mum CD9                  
Dad D9 
Male 12 2 56 Recruited Antibiotics CD 
Young person 
CE7 Mum CE7 
Male 14 10 32 
Recruited - Recurrence: 
Continued with antibiotics 
Antibiotics CE 
Young person 
CE4 Mum CE4                  
Dad CE4 
Male 10 8 38 
Recruited - Recurrence: 
Continued with antibiotics 
Antibiotics CE 
Young person 
CE5 Mum CE5                  
Dad CE5 
Female 9 10 33 
Recruited - Recurrence: 
Revert to surgery 
Antibiotics CE 
Young person 
CD1 Mum CD1 
Female 10 3 34 
Recruited - Treatment 
failure: Revert to surgery 
Antibiotics CD 
Young person 
CD15 Dad CD15 
Female 12 9 35 
Recruited - Treatment 
failure: Revert to surgery 
Antibiotics CD 
Young person 
CD10 Mum CD10 
Male 6 9 20 
Recruited - Treatment 


















CD21 Mum CD21 
Male 7 5 48 
Recruited - Withdrew from 
trial as felt child was 
getting worse 
Antibiotics  CD 
Young person 
CE19 Dad CE19 
Male 11 3 55 Recruited Appendectomy CE 
Young person 
CE23 Mum CE23 
Male 8 3 34 Recruited Appendectomy CE 
Young person F9 
Mum CF9                  
Dad CF9 
Female 8 10 51 Recruited Appendectomy CF 
Young person 
CF13 Dad CF13 
Male 7 9 88 Recruited Appendectomy CF 
Young person 
CF19 Mum CF19 
Female 6 8 43 Recruited Appendectomy CF 
Young person 
CF11 Dad CF11 
Male 13 5 117 Recruited Appendectomy CF 
Young person 
CD2 Dad CD2 
Female 11 2 39 Recruited Appendectomy CD 
Young person 
CD5 Mum CD5 
Male 9 10 49 Recruited Appendectomy CD 
Young person 
CD18 Mum CD18 
Male 9 8 28 Recruited Appendectomy CD 
Young person 
CE10 Mum CE10 




















CE9 Mum CE9 





CF18 Mum CF18 





CF15 Mum CF15 





CF21 Mum CF21 





CD11 Dad CD11 





CD8 Mum CD8 





CD12 Mum CD12                  
Dad CD12 





CD4 Mum CD4                  
Dad CD4 















Standard operating procedure for designated persons supporting fieldworkers 
























Appendix 11: Transfer of digital recordings 
STANDARD OPERATING PROCEDURE: 
Transfer of digital recordings  
1. INTRODUCTION, BACKGROUND & PURPOSE: 
The purpose of the following SOP is to describe the procedure for downloading 
files from a digital device (Olympus DS-3400) to an NHS or University of Bristol 
PC (e.g., after recruitment/randomisation / interview discussion & intervention 
session). 
2. ABBREVIATIONS  
University of Bristol: UoB 
3. SCOPE 
All discussions about recruitment/randomisation, between family members and 
the recruiter will be routinely recorded and need to be transferred onto secure 
University of Bristol servers for analysis.  
All interview discussions between family members and the qualitative researcher 
will be routinely recorded and need to be transferred onto secure University of 
Bristol servers for analysis. 
All follow up intervention sessions for participants recruited to the trial will be 
routinely recorded for analysis by members of the clinical team delivering 
treatments and need to be transferred onto secure University of Bristol servers 
for analysis. 
4. RESPONSIBILITIES 
The recruiters, qualitative researchers, and members of the clinical teams 
delivering follow up sessions will be responsible for storing and transferring files 
holding identifiable patient information. The project co-ordinator & principal 
investigator, (PI) will be responsible for overseeing this process, ensuring that all 
staff are transferring audio-recordings in a timely and secure manner.  
PI: [Removed] Project Co-ordinator:[Removed] Recruitment: [Removed] 
Qualitative discussion:[Removed] Recording Clinical sessions:[Removed] 
5. PROCEDURES 
a. Load Olympus dictation software onto your PC if it’s not already available, 





b. Ensure the Olympus DS3400 digital recorder is fully encrypted with the 
following passwords: The machine pin for all is: XXXX Folders: XXXXXX 
 
c. Click on ‘Dictation Module’ on the program start menu to access the Olympus 
DSS Pro Dictation Module OR connect the digital recorder to the PC via the 
lead and the dictation module should open automatically. 
 
d. Attach the digital recorder to your PC (you will need to enter the encryption 
code to open the recorder: xxxx) to view recorded file & click into any of the 
‘device manager’ folders with labelled A-E (see screen shot below – bottom 
left) 
e. Select ‘download all’ to transfer your files from the device (folders in bottom 
left of screen) to folders in the dictation tray: 
f. Right click on the relevant audio file and select – decrypt – input the 
decryption password (XXXXX) 
g. Once decrypted copy and paste the file into your named folder on the shared 
data drive:Shared drive: Z:\sftp\uploads\xxxx\Audio Recordings\XXXX 
h. File names cannot be changed on NHS computers so leave the file name 
assigned by the digital recorder and the research team will amend file names 
using the consent/research ID and date read out at the beginning of the 
recording. 
i. As soon as the research team confirm receipt of the audio file & that they 
have checked that transfer has been successful (e.g., it is openable) the 
original audio file saved on the device can be deleted. 
 
6. RELATED SOPS, WORK INSTRUCTIONS AND DOCUMENTS  




7. FORMS/TEMPLATES TO BE USED (if applicable) N/A 
8. REFERENCES (if applicable) N/A 
9. APPENDICES (if applicable) N/A 






Appendix 12: Patient and Public Involvement (PPI) 
SMILE 
During the development phase of the SMILE trial, (prior to this PhD research project) 
PPI was used to inform the design of the RCT. Representatives from the Association 
of Young people with ME (AYME) read and suggested changes to the protocol, and 
provided feedback in relation to patient consent forms, information leaflets and the 
interview topic guide. Teenagers’ views on trial involvement and the concept of 
equipoise were also discussed with healthy school students at a Social and 
community Medicine departmental Young Persons’ Advisory Group (YPAG) meeting. 
 
MAGENTA and FITNET-NHS 
Prior to the MAGENTA RCT (2014) a YPAG of past and current patients who had 
experienced symptoms of CFS/ME was set-up by Professor Crawley at the 
University of Bristol. This advisory group advised and commented on various 
aspects of each RCT as they were developed and set-up. Points relevant to the 
current PhD project included; the acceptability of patient information leaflets, the 
interview topic guide, mode of interview (home, skype or telephone) and using an 
online consent/assent system. The CFS/ME YPAG met twice a year to discuss the 
MAGENTA and FITNET-NHS RCTs, advising on recruitment, RCT processes and 
further changes to patient information sheets, including advice about the inclusion of 
a statement highlighting that young people may not get better with any type of 




young people would receive core specialist treatment about sleep and symptoms in 
both arms during the FITNTE-NHS RCT. 
 
CONTRACT 
Prior to the CONTRACT RCT a PPI work stream was formed, this included a parent 
co-investigator who contributed to drafting the grant proposal and was involved at 
several points throughout the research program. It also included a Study Specific 
Advisory Group, (SSAG) of children who had experienced acute uncomplicated 
appendicitis, children who had not, and parents. The SSAG provided feedback in 
relation to patient/parent information leaflets and the interview topic guide, the 











Study Specific Advisory Group (SSAG) outcomes: PIL & Interview topic guide 
PIL 
1. The group felt we were not getting across the important message of ‘why’ we were doing the 
trial, particularly in the ‘Things you need to do’ section, and we need to highlight the fact that 
we want feedback from participants about how we can make the study better. 
 
[We amended the PIL for young people to reflect this ] 
 
‘Why have I been asked to take part?’ 
We are asking you because your option about how we can make the study better is very 
important to us & a doctor already discussed the main CONTRACT study with you or your 
family. 
 
‘Things you need to know’  
We are interested in your views on how we can improve the CONTRACT study.  
 
 
2. In the ‘what will happen if I take part’ section there were issues with the fact that we specify 
how long the conversation with the researcher will take; ’30 minutes’. They felt this was 
unnecessary and should be removed. 
 
[We amended the PIL for young people to reflect this] 
 
Interview topic guide 
3. The group didn’t like Q1, too abrupt and too soon in the conversation:  
Can you tell me a bit about what happened when you began to feel ill with your 
appendicitis?  
Preferred more general Introductions, get to know each other. 
‘Normal conversation’ questions; hobbies, what they’ve been doing lately, where I’m from, 
what I like doing. ‘Ground rules’ for conversation e.g., confidentiality, not discussed with 
clinical team. 
 
Perhaps use: What did you think when you were first told about the CONTRACT 
research study?  
Take into consideration the fact that they may not want to ‘think back’ to when they were very 
ill/scared, may not remember. 
 
 
 
